0001737995
false
0
0
0.81
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
0001737995
2023-01-01
2023-06-30
0001737995
dei:BusinessContactMember
2023-01-01
2023-06-30
0001737995
2022-12-31
0001737995
2021-12-31
0001737995
2023-06-30
0001737995
2022-01-01
2022-12-31
0001737995
2021-01-01
2021-12-31
0001737995
2023-04-01
2023-06-30
0001737995
2022-04-01
2022-06-30
0001737995
2022-01-01
2022-06-30
0001737995
us-gaap:PreferredStockMember
2020-12-31
0001737995
us-gaap:CommonStockMember
2020-12-31
0001737995
STSS:CommonStockSubscriptionReceivableMember
2020-12-31
0001737995
us-gaap:AdditionalPaidInCapitalMember
2020-12-31
0001737995
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-12-31
0001737995
us-gaap:RetainedEarningsMember
2020-12-31
0001737995
2020-12-31
0001737995
us-gaap:PreferredStockMember
2021-12-31
0001737995
us-gaap:CommonStockMember
2021-12-31
0001737995
STSS:CommonStockSubscriptionReceivableMember
2021-12-31
0001737995
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001737995
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-12-31
0001737995
us-gaap:RetainedEarningsMember
2021-12-31
0001737995
us-gaap:PreferredStockMember
2022-12-31
0001737995
us-gaap:CommonStockMember
2022-12-31
0001737995
STSS:CommonStockSubscriptionReceivableMember
2022-12-31
0001737995
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001737995
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-12-31
0001737995
us-gaap:RetainedEarningsMember
2022-12-31
0001737995
us-gaap:PreferredStockMember
2023-03-31
0001737995
us-gaap:CommonStockMember
2023-03-31
0001737995
STSS:CommonStockSubscriptionReceivableMember
2023-03-31
0001737995
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001737995
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-03-31
0001737995
us-gaap:RetainedEarningsMember
2023-03-31
0001737995
2023-03-31
0001737995
us-gaap:PreferredStockMember
2022-03-31
0001737995
us-gaap:CommonStockMember
2022-03-31
0001737995
STSS:CommonStockSubscriptionReceivableMember
2022-03-31
0001737995
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001737995
us-gaap:RetainedEarningsMember
2022-03-31
0001737995
2022-03-31
0001737995
us-gaap:PreferredStockMember
2021-01-01
2021-12-31
0001737995
us-gaap:CommonStockMember
2021-01-01
2021-12-31
0001737995
STSS:CommonStockSubscriptionReceivableMember
2021-01-01
2021-12-31
0001737995
us-gaap:AdditionalPaidInCapitalMember
2021-01-01
2021-12-31
0001737995
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-01-01
2021-12-31
0001737995
us-gaap:RetainedEarningsMember
2021-01-01
2021-12-31
0001737995
us-gaap:PreferredStockMember
2022-01-01
2022-12-31
0001737995
us-gaap:CommonStockMember
2022-01-01
2022-12-31
0001737995
STSS:CommonStockSubscriptionReceivableMember
2022-01-01
2022-12-31
0001737995
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-12-31
0001737995
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-01-01
2022-12-31
0001737995
us-gaap:RetainedEarningsMember
2022-01-01
2022-12-31
0001737995
us-gaap:PreferredStockMember
2023-01-01
2023-03-31
0001737995
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001737995
STSS:CommonStockSubscriptionReceivableMember
2023-01-01
2023-03-31
0001737995
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001737995
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-01-01
2023-03-31
0001737995
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001737995
2023-01-01
2023-03-31
0001737995
us-gaap:PreferredStockMember
2023-04-01
2023-06-30
0001737995
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001737995
STSS:CommonStockSubscriptionReceivableMember
2023-04-01
2023-06-30
0001737995
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001737995
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-04-01
2023-06-30
0001737995
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001737995
us-gaap:PreferredStockMember
2022-01-01
2022-03-31
0001737995
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001737995
STSS:CommonStockSubscriptionReceivableMember
2022-01-01
2022-03-31
0001737995
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001737995
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001737995
2022-01-01
2022-03-31
0001737995
us-gaap:PreferredStockMember
2022-04-01
2022-06-30
0001737995
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001737995
STSS:CommonStockSubscriptionReceivableMember
2022-04-01
2022-06-30
0001737995
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001737995
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001737995
us-gaap:PreferredStockMember
2023-06-30
0001737995
us-gaap:CommonStockMember
2023-06-30
0001737995
STSS:CommonStockSubscriptionReceivableMember
2023-06-30
0001737995
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001737995
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-06-30
0001737995
us-gaap:RetainedEarningsMember
2023-06-30
0001737995
us-gaap:PreferredStockMember
2022-06-30
0001737995
us-gaap:CommonStockMember
2022-06-30
0001737995
STSS:CommonStockSubscriptionReceivableMember
2022-06-30
0001737995
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001737995
us-gaap:RetainedEarningsMember
2022-06-30
0001737995
2022-06-30
0001737995
us-gaap:IPOMember
2022-04-17
2022-04-19
0001737995
us-gaap:IPOMember
2022-04-19
2022-04-19
0001737995
us-gaap:BuildingMember
2022-12-31
0001737995
us-gaap:MachineryAndEquipmentMember
srt:MinimumMember
2022-12-31
0001737995
us-gaap:MachineryAndEquipmentMember
srt:MaximumMember
2022-12-31
0001737995
STSS:WebsiteMember
2022-12-31
0001737995
STSS:StockOptionsAndWarrantsMember
2022-01-01
2022-12-31
0001737995
us-gaap:BuildingMember
2023-06-30
0001737995
us-gaap:MachineryAndEquipmentMember
srt:MinimumMember
2023-06-30
0001737995
us-gaap:MachineryAndEquipmentMember
srt:MaximumMember
2023-06-30
0001737995
STSS:WebsiteMember
2023-06-30
0001737995
STSS:StockOptionsAndWarrantsMember
2023-01-01
2023-06-30
0001737995
us-gaap:LandMember
2022-12-31
0001737995
us-gaap:LandMember
2021-12-31
0001737995
us-gaap:BuildingMember
2021-12-31
0001737995
us-gaap:MachineryAndEquipmentMember
2022-12-31
0001737995
us-gaap:MachineryAndEquipmentMember
2021-12-31
0001737995
STSS:WebsiteMember
2021-12-31
0001737995
us-gaap:LandMember
2023-06-30
0001737995
us-gaap:MachineryAndEquipmentMember
2023-06-30
0001737995
us-gaap:StockOptionMember
2022-01-01
2022-12-31
0001737995
us-gaap:StockOptionMember
2022-01-01
2022-06-30
0001737995
STSS:SharePurchaseAgreementMember
2022-07-05
2022-07-06
0001737995
STSS:SharePurchaseAgreementMember
us-gaap:CommonStockMember
2022-07-05
2022-07-06
0001737995
STSS:SharePurchaseAgreementMember
us-gaap:CommonStockMember
2022-07-06
0001737995
STSS:SharePurchaseAgreementMember
us-gaap:StockOptionMember
2022-07-05
2022-07-06
0001737995
STSS:SharePurchaseAgreementMember
STSS:StockOptionOneMember
2022-07-05
2022-07-06
0001737995
STSS:SharePurchaseAgreementMember
2022-01-01
2022-12-31
0001737995
STSS:SharePurchaseAgreementMember
2021-01-01
2021-12-31
0001737995
STSS:SafegardMedicalIncMember
2022-07-06
0001737995
STSS:SafegardMedicalIncMember
2022-07-05
2022-07-06
0001737995
us-gaap:FiniteLivedIntangibleAssetsMember
2022-12-31
0001737995
STSS:SharePurchaseAgreementMember
2022-04-01
2022-06-30
0001737995
STSS:SharePurchaseAgreementMember
2022-01-01
2022-06-30
0001737995
us-gaap:FiniteLivedIntangibleAssetsMember
2023-06-30
0001737995
STSS:NotePurchaseAgreementMember
STSS:UnrelatedThirdPartyPurchasersMember
2021-12-14
0001737995
STSS:NotePurchaseAgreementMember
2021-12-14
0001737995
STSS:NotePurchaseAgreementMember
STSS:UnrelatedThirdPartyPurchasersMember
2021-12-13
2021-12-14
0001737995
STSS:NotePurchaseAgreementMember
2022-12-31
0001737995
STSS:NotePurchaseAgreementMember
2022-01-01
2022-12-31
0001737995
STSS:NotePurchaseAgreementMember
2021-01-01
2021-12-31
0001737995
STSS:NotePurchaseAgreementMember
2021-12-31
0001737995
STSS:NotePurchaseAgreementMember
2022-04-19
0001737995
STSS:NotePurchaseAgreementMember
2022-04-17
2022-04-19
0001737995
STSS:NotePurchaseAgreementMember
us-gaap:NoteWarrantMember
2022-01-01
2022-12-31
0001737995
STSS:NotePurchaseAgreementMember
us-gaap:NoteWarrantMember
2022-12-31
0001737995
STSS:NotePurchaseAgreementMember
us-gaap:NoteWarrantMember
2021-12-31
0001737995
STSS:NotePurchaseAgreementMember
2022-06-30
0001737995
STSS:NotePurchaseAgreementMember
2022-01-01
2022-03-31
0001737995
STSS:NotePurchaseAgreementMember
2022-03-31
0001737995
STSS:NotePurchaseAgreementMember
2022-04-19
2022-04-19
0001737995
STSS:NotePurchaseAgreementMember
us-gaap:NoteWarrantMember
2023-01-01
2023-06-30
0001737995
2017-12-11
0001737995
2019-04-18
0001737995
2022-03-19
2022-03-22
0001737995
2022-03-22
0001737995
2022-03-21
0001737995
us-gaap:WarrantMember
2022-04-11
2022-04-13
0001737995
us-gaap:WarrantMember
2022-04-13
0001737995
us-gaap:IPOMember
2022-04-12
2022-04-14
0001737995
2022-04-14
0001737995
2022-04-12
2022-04-14
0001737995
us-gaap:PrivatePlacementMember
us-gaap:CommonStockMember
2021-01-01
2021-12-31
0001737995
us-gaap:PrivatePlacementMember
us-gaap:CommonStockMember
2021-12-31
0001737995
STSS:TradingWarrantsMember
2022-04-21
2022-04-30
0001737995
STSS:OverAllotmentWarrantsMember
2022-04-21
2022-04-30
0001737995
us-gaap:IPOMember
2022-12-31
0001737995
us-gaap:WarrantMember
2022-01-01
2022-12-31
0001737995
us-gaap:NoteWarrantMember
2022-04-18
2022-04-19
0001737995
us-gaap:NoteWarrantMember
2022-12-31
0001737995
us-gaap:NoteWarrantMember
2022-01-01
2022-12-31
0001737995
STSS:PurchaseAgreementMember
2023-02-01
2023-02-03
0001737995
STSS:PurchaseAgreementMember
2023-02-03
0001737995
2023-02-13
0001737995
2023-02-12
2023-02-13
0001737995
us-gaap:WarrantMember
2022-04-19
0001737995
2022-04-01
2022-12-31
0001737995
STSS:NotePurchaseAgreementMember
2022-04-01
2022-12-31
0001737995
STSS:NonTradingWarrantsMember
2023-04-01
2023-04-30
0001737995
us-gaap:NoteWarrantMember
2023-06-30
0001737995
2023-04-01
2023-04-30
0001737995
STSS:NonTradingWarrantsMember
2023-02-01
2023-02-28
0001737995
STSS:NonTradingWarrantsMember
2023-02-28
0001737995
STSS:NonTradingWarrantsMember
2023-06-30
0001737995
STSS:NonTradingWarrantsMember
2023-04-01
2023-06-30
0001737995
STSS:NonTradingWarrantsMember
2023-01-01
2023-06-30
0001737995
STSS:TradingWarrantsMember
2022-04-01
2022-04-30
0001737995
us-gaap:OverAllotmentOptionMember
2022-04-01
2022-04-30
0001737995
STSS:TradingWarrantsMember
2022-04-30
0001737995
STSS:TradingWarrantsMember
2022-12-31
0001737995
STSS:TradingWarrantsMember
2023-04-01
2023-06-30
0001737995
STSS:TradingWarrantsMember
2023-01-01
2023-06-30
0001737995
STSS:TradingWarrantsMember
2022-04-01
2022-06-30
0001737995
us-gaap:NoteWarrantMember
2022-01-01
2022-06-30
0001737995
us-gaap:NoteWarrantMember
2022-04-19
2022-04-19
0001737995
us-gaap:NoteWarrantMember
2022-04-19
0001737995
us-gaap:NoteWarrantMember
us-gaap:WarrantMember
2022-01-01
2022-12-31
0001737995
STSS:NoteWarrantsMember
2023-04-01
2023-06-30
0001737995
STSS:NoteWarrantsMember
2023-01-01
2023-06-30
0001737995
STSS:NoteWarrantsMember
2023-06-30
0001737995
STSS:NoteWarrantsMember
2022-01-01
2022-06-30
0001737995
STSS:NoteWarrantsMember
2022-04-01
2022-06-30
0001737995
us-gaap:IPOMember
2023-06-30
0001737995
us-gaap:IPOMember
2023-01-01
2023-06-30
0001737995
us-gaap:SeriesAPreferredStockMember
srt:DirectorMember
STSS:AlanBlackmanMember
2018-02-18
0001737995
us-gaap:SeriesAPreferredStockMember
srt:DirectorMember
us-gaap:IPOMember
STSS:AlanBlackmanMember
2022-04-15
0001737995
us-gaap:SeriesAPreferredStockMember
us-gaap:IPOMember
STSS:AlanBlackmanMember
2022-04-15
0001737995
us-gaap:SeriesAPreferredStockMember
srt:DirectorMember
STSS:AlanBlackmanMember
2021-12-31
0001737995
us-gaap:SeriesAPreferredStockMember
srt:DirectorMember
us-gaap:IPOMember
STSS:AlanBlackmanMember
2021-12-31
0001737995
us-gaap:SeriesAPreferredStockMember
us-gaap:IPOMember
STSS:AlanBlackmanMember
2018-02-28
0001737995
STSS:NoteWarrantsMember
2022-12-31
0001737995
STSS:TradingAndOverallotmentWarrantsMember
2022-12-31
0001737995
STSS:TradingAndOverallotmentWarrantsMember
2023-06-30
0001737995
STSS:OfferingWarrantsMember
2023-06-30
0001737995
STSS:WarrantsIssuedForServiceManagementMember
2023-06-30
0001737995
us-gaap:GeneralAndAdministrativeExpenseMember
2022-01-01
2022-12-31
0001737995
us-gaap:ResearchAndDevelopmentExpenseMember
2022-01-01
2022-12-31
0001737995
us-gaap:GeneralAndAdministrativeExpenseMember
2021-01-01
2021-12-31
0001737995
us-gaap:ResearchAndDevelopmentExpenseMember
2021-01-01
2021-12-31
0001737995
STSS:TwoThousandTwentyThreeEquityIncentivePlanMember
2023-01-01
2023-06-30
0001737995
STSS:TwoThousandTwentyThreeEquityIncentivePlanMember
2023-06-30
0001737995
srt:ChiefExecutiveOfficerMember
2023-01-01
2023-06-30
0001737995
srt:DirectorMember
2023-01-01
2023-06-30
0001737995
STSS:EmployeesAndConsultantMember
2023-01-01
2023-06-30
0001737995
STSS:TwoThousandTwentyTwoEquityIncentivePlanMember
STSS:EmploymentAgreementMember
2023-02-01
2023-02-28
0001737995
STSS:TwoThousandTwentyThreeEquityIncentivePlanMember
2023-01-25
0001737995
us-gaap:GeneralAndAdministrativeExpenseMember
2023-04-01
2023-06-30
0001737995
us-gaap:GeneralAndAdministrativeExpenseMember
2023-01-01
2023-06-30
0001737995
us-gaap:GeneralAndAdministrativeExpenseMember
2022-04-01
2022-06-30
0001737995
us-gaap:GeneralAndAdministrativeExpenseMember
2022-01-01
2022-06-30
0001737995
us-gaap:ResearchAndDevelopmentExpenseMember
2022-04-01
2022-06-30
0001737995
us-gaap:ResearchAndDevelopmentExpenseMember
2022-01-01
2022-06-30
0001737995
STSS:ExercisePriceRangeOneMember
2022-01-01
2022-12-31
0001737995
STSS:ExercisePriceRangeOneMember
2022-12-31
0001737995
STSS:ExercisePriceRangeTwoMember
2022-01-01
2022-12-31
0001737995
STSS:ExercisePriceRangeTwoMember
2022-12-31
0001737995
STSS:ExercisePriceRangeThreeMember
2022-01-01
2022-12-31
0001737995
STSS:ExercisePriceRangeThreeMember
2022-12-31
0001737995
STSS:ExercisePriceRangeFourMember
2022-01-01
2022-12-31
0001737995
STSS:ExercisePriceRangeFourMember
2022-12-31
0001737995
STSS:ExercisePriceRangeFiveMember
2022-01-01
2022-12-31
0001737995
STSS:ExercisePriceRangeFiveMember
2022-12-31
0001737995
STSS:ExercisePriceRangeSixMember
2022-01-01
2022-12-31
0001737995
STSS:ExercisePriceRangeSixMember
2022-12-31
0001737995
STSS:ExercisePriceRangeSevenMember
2022-01-01
2022-12-31
0001737995
STSS:ExercisePriceRangeSevenMember
2022-12-31
0001737995
srt:MinimumMember
2022-01-01
2022-12-31
0001737995
srt:MaximumMember
2022-01-01
2022-12-31
0001737995
srt:MinimumMember
2021-01-01
2021-12-31
0001737995
srt:MaximumMember
2021-01-01
2021-12-31
0001737995
srt:MinimumMember
2023-01-01
2023-06-30
0001737995
srt:MaximumMember
2023-01-01
2023-06-30
0001737995
STSS:OfficersAndDirectorsMember
2022-12-31
0001737995
STSS:OfficersAndDirectorsMember
2021-12-31
0001737995
STSS:OfficersAndDirectorsMember
2023-06-30
0001737995
us-gaap:FairValueInputsLevel1Member
2022-12-31
0001737995
us-gaap:FairValueInputsLevel2Member
2022-12-31
0001737995
us-gaap:FairValueInputsLevel3Member
2022-12-31
0001737995
us-gaap:FairValueInputsLevel1Member
2023-06-30
0001737995
us-gaap:FairValueInputsLevel2Member
2023-06-30
0001737995
us-gaap:FairValueInputsLevel3Member
2023-06-30
0001737995
STSS:RoyaltyAgreementMember
STSS:BarryBerlerMember
2017-07-01
2017-07-31
0001737995
STSS:RoyaltyAgreementMember
STSS:BarryBerlerMember
2018-09-01
2018-09-30
0001737995
STSS:RoyaltyAgreementMember
STSS:BarryBerlerMember
2018-09-30
0001737995
STSS:RoyaltyAgreementMember
STSS:BarryBerlerMember
2019-05-01
2019-05-31
0001737995
STSS:EmploymentAgreementMember
2022-07-30
2022-08-01
0001737995
STSS:EmploymentAgreementMember
2022-08-31
2022-09-01
0001737995
STSS:Mr.BlackmanMember
2022-06-30
0001737995
STSS:Mr.BlackmanMember
us-gaap:SubsequentEventMember
2023-01-01
2023-03-26
0001737995
STSS:EmploymentAgreementMember
2022-01-01
2022-12-31
0001737995
STSS:ServiceAgreementMember
2022-10-01
2022-10-31
0001737995
STSS:Mr.BlackmanMember
2023-01-01
2023-01-01
0001737995
STSS:EmploymentAgreementMember
2022-09-30
2022-09-30
0001737995
2023-02-08
2023-02-09
0001737995
2023-02-09
0001737995
us-gaap:SubsequentEventMember
STSS:ChiefExecutiveOfficerAndDirectorMember
2023-01-25
2023-01-25
0001737995
us-gaap:SubsequentEventMember
STSS:ChiefExecutiveOfficerAndDirectorMember
2023-01-25
0001737995
us-gaap:SubsequentEventMember
srt:ChiefExecutiveOfficerMember
2023-01-25
2023-01-25
0001737995
us-gaap:SubsequentEventMember
srt:ExecutiveOfficerMember
2023-01-25
2023-01-25
0001737995
us-gaap:SubsequentEventMember
srt:DirectorMember
2023-01-25
2023-01-25
0001737995
us-gaap:SubsequentEventMember
STSS:TwoThousandTwentyThreeEquityIncentivePlanMember
2023-01-25
0001737995
us-gaap:SubsequentEventMember
2023-02-08
2023-02-09
0001737995
us-gaap:SubsequentEventMember
2023-02-09
0001737995
us-gaap:SubsequentEventMember
STSS:PurchaseAgreementMember
2023-02-01
2023-02-03
0001737995
us-gaap:SubsequentEventMember
STSS:PurchaseAgreementMember
2023-02-03
0001737995
STSS:ExercisePriceRangeOneMember
2023-01-01
2023-06-30
0001737995
STSS:ExercisePriceRangeOneMember
2023-06-30
0001737995
STSS:ExercisePriceRangeTwoMember
2023-01-01
2023-06-30
0001737995
STSS:ExercisePriceRangeTwoMember
2023-06-30
0001737995
STSS:ExercisePriceRangeThreeMember
2023-01-01
2023-06-30
0001737995
STSS:ExercisePriceRangeThreeMember
2023-06-30
0001737995
STSS:ExercisePriceRangeFourMember
2023-01-01
2023-06-30
0001737995
STSS:ExercisePriceRangeFourMember
2023-06-30
0001737995
STSS:ExercisePriceRangeFiveMember
2023-01-01
2023-06-30
0001737995
STSS:ExercisePriceRangeFiveMember
2023-06-30
0001737995
STSS:ExercisePriceRangeSixMember
2023-01-01
2023-06-30
0001737995
STSS:ExercisePriceRangeSixMember
2023-06-30
0001737995
STSS:ExercisePriceRangeSevenMember
2023-01-01
2023-06-30
0001737995
STSS:ExercisePriceRangeSevenMember
2023-06-30
0001737995
STSS:ExercisePriceRangeEightMember
2023-01-01
2023-06-30
0001737995
STSS:ExercisePriceRangeEightMember
2023-06-30
0001737995
STSS:ExercisePriceRangeNineMember
2023-01-01
2023-06-30
0001737995
STSS:ExercisePriceRangeNineMember
2023-06-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
Registration
No. 333-______
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
S-1
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
Sharps
Technology, Inc.
(Exact
name of registrant as specified in its charter)
Nevada |
|
3841 |
|
82-3751728 |
(State
or other jurisdiction of
incorporation
or organization) |
|
(Primary
Standard Industrial
Classification
Code Number) |
|
(I.R.S.
Employer
Identification
Number) |
Sharps
Technology, Inc.
105
Maxess Road, Ste. 124
Melville,
New York 11747
(631)
574 -4436
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Robert
M. Hayes
Chief
Executive Officer
Sharps
Technology, Inc.
105
Maxess Road, Ste. 124
Melville,
New York 11747
(631)
574 -4436
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Copies
to:
Arthur
Marcus, Esq.
Sichenzia
Ross Ference LLP
1185
Avenue of the Americas
New
York, NY 10036
(212)
930-9700
Approximate
date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box. ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller
reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large
accelerated filer ☐ |
Accelerated
filer ☐ |
|
Non-accelerated
filer ☒ |
Smaller
reporting company ☒ |
|
|
Emerging
growth company ☒ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant will file a further amendment which specifically states that this registration statement will thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement will become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
The
registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date
as the Commission, acting pursuant to said Section 8(a), may determine.
The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
PRELIMINARY
PROSPECTUS |
|
SUBJECT
TO COMPLETION |
|
OCTOBER
16,
2023 |
11,331,482
Shares of Common Stock Offered by the Selling
Stockholders
This
prospectus relates to the offering and resale by the selling stockholders identified herein of up to 11,331,482 shares of common
stock issued or issuable to such selling stockholders including (i) 2,581,479 shares of our common stock issuable upon exercise
of pre-funded warrants, (ii) 8,750,003 shares of common stock issuable upon the exercise of outstanding warrants (“SS
Warrants”, as defined in the Selling Stockholders’ section, beginning on page [49] of this
prospectus);. The shares described in the preceding sentence, under (i) and (ii) shall collectively be referred to as the “Common
Units”. Please see “Private Placement of Pre-funded Warrants and Warrants” beginning on page [48] of
this prospectus.
We
will not receive any proceeds from the selling stockholders. Upon the cash exercise of the warrants however, we will receive the exercise
price of such warrants, for an aggregate of approximately $5.6 million.
The
selling stockholders may sell all or a portion of the shares of common stock beneficially owned by them and offered hereby from time
to time directly or through one or more underwriters, broker-dealers or agents. Please see the section entitled “Plan of Distribution”
on page [51] of this prospectus for more information. For information on the selling stockholders, see the section entitled “Selling
Stockholders” on page [49] of this prospectus. We will bear all fees and expenses incident to our obligation to register
the shares of common stock.
Our
common stock is quoted on the Nasdaq Capital Market under the symbol “STSS.” On October 13, 2023, the last reported
sale price per share of our common stock was $0.44.
We
may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire
prospectus and any amendments or supplements carefully before you make your investment decision.
Investing
in our common stock involves a high degree of risk. See “Risk Factors” beginning on page [8] of this prospectus for
a discussion of information that you should consider before investing in our securities.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The
date of this prospectus is October 16, 2023
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
You
may only rely on the information contained in this prospectus or that we have referred you to. We have not authorized anyone to provide
you with different information. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities
other than the common stock offered by this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an
offer to buy any common stock in any circumstances in which such offer or solicitation is unlawful. Neither the delivery of this prospectus
nor any sale made in connection with this prospectus shall, under any circumstances, create any implication that there has been no change
in our affairs since the date of this prospectus. For investors outside the United States: Neither we nor the selling stockholders have
done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that
purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must
inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of
this prospectus outside the United States.
Unless
the context otherwise requires, references to “we,” “our,” “us,” or the “Company” in
this prospectus mean Sharps Technology, Inc., a Nevada corporation and its subsidiaries.
GENERAL
MATTERS
Unless
otherwise indicated, all references to “dollars,” “US$,” or “$” in this prospectus are to United
States dollars.
This
prospectus contains various company names, product names, trade names, trademarks and service marks, all of which are the properties
of their respective owners.
Unless
otherwise indicated or the context otherwise requires, all information in this prospectus assumes no exercise of the over-allotment option.
Unless
otherwise indicated, all references to “GAAP” in this prospectus are to United States generally accepted accounting principles.
Information
contained on our websites, including sharpstechnology.com, shall not be deemed to be part of this prospectus or incorporated herein by
reference and should not be relied upon by prospective investors for the purposes of determining whether to purchase the securities offered
hereunder.
For
investors outside the United States, neither we nor any of our agents have done anything that would permit this offering or possession
or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You
are required to inform yourself about and to observe any restrictions relating to this offering and the distribution of this prospectus.
USE
OF MARKET AND INDUSTRY DATA
This
prospectus includes market and industry data that has been obtained from third party sources, including industry publications, as well
as industry data prepared by our management on the basis of its knowledge of and experience in the industries in which we operate (including
our management’s estimates and assumptions relating to those industries based on that knowledge). Management’s knowledge
of such industries has been developed through its experience and participation in those industries. Although our management believes
such information to be reliable, neither we nor our management have independently verified any of the data from third party sources referred
to in this prospectus or ascertained the underlying economic assumptions relied upon by such sources. Furthermore, references in this
prospectus to any publications, reports, surveys or articles prepared by third parties should not be construed as depicting the complete
findings of the entire publication, report, survey or article. The information in any such publication, report survey or article is not
incorporated by reference in this prospectus.
TRADEMARKS
We
own or have rights to various trademarks, service marks and/or trade names that we use in connection with the operation of our business.
This prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of their respective
owners. Our use or display of third parties’ trademarks, service marks and trade names or products in this prospectus is not intended
to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks
and trade names referred to in this prospectus may appear without the ®, TM or SM symbols, but the
omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.
PROSPECTUS
SUMMARY
This
summary highlights selected information that is presented in greater detail elsewhere in this prospectus. This summary does not contain
all of the information you should consider before investing in our securities. You should read this entire prospectus carefully, including
the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results
of Operations” and our financial statements and the related notes included elsewhere in this prospectus, before making an investment
decision. Unless the context otherwise requires, the terms “the Company,” “Sharps,” ‘Sharps Technology,”
“we,” “us” and “our” in this prospectus refer to Sharps Technology, Inc.
Company
Overview
Sharps
Technology, Inc. is a medical device company that has designed and patented various safety syringes which we are seeking to commercialize
and other syringe products currently marketable.
Our
safety syringes products, which we refer to as the Sharps Provensa™ and Securgard™, are ultra-low waste and have safety
features, which we believe will provide us a competitive advantage over other syringes. Sharps Provensa is a patented and FDA-cleared
safety syringe addressing the important needs of the global healthcare market. We received FDA clearance for the Sharps Provensa on June
12, 2006, for subcutaneous and intramuscular injections into the human body.
Reincorporation
and Reverse Split
Prior
to March 22, 2022, we were a Wyoming corporation and on March 22, 2022, we reincorporated (the “Reincorporation”) as a Nevada
corporation (“Sharps Nevada”) pursuant to a merger into a newly formed Nevada corporation which was approved by our board
of directors and the holders of the majority of our outstanding shares of common stock.
Corporate
Information
The
Company was incorporated in the State of Wyoming on December 16, 2017. On March 22, 2022, we reincorporated as a Nevada corporation.
Our principal business address is 105 Maxess Road, Melville, New York 11747. We maintain our corporate website at sharpstechnology.com.
The reference to our website is an inactive textual reference only. The information that can be accessed through our website is not part
of this prospectus, and investors should not rely on any such information in deciding whether to purchase our securities.
THE
OFFERING
Issuer |
|
Sharps
Technology, Inc. |
|
|
|
Securities
Offered by the Selling Stockholders |
|
11,331,482
shares of our common stock, including 2,581,479
shares of our common stock issuable upon the exercise of pre-funded warrants, and 8,750,003 shares of common stock
issuable upon the exercise of warrants. |
|
|
|
Trading
Market |
|
The
common stock offered in this prospectus is quoted on the Nasdaq Capital Market under the symbol “STSS”. |
|
|
|
Common
Stock Outstanding Before this Offering |
|
15,274,457
shares |
|
|
|
Common
Stock Outstanding After this Offering |
|
26,605,939
shares (1) |
|
|
|
Use
of Proceeds |
|
We
will not receive any of the proceeds from the sale of the shares of our common stock being offered for sale by the selling
stockholders. Upon the exercise of the warrants for an aggregate of 8,750,003 shares of common stock by payment of cash
however, we will receive the exercise price of the warrants, or an aggregate of approximately $5.6 million
from the investors in the September 2023 Private Placement before offering expenses (the “September 2023 Private
Placement”). |
|
|
|
Plan
of Distribution |
|
The
selling stockholders may sell all or a portion of the shares of common stock beneficially owned by them and offered hereby from time
to time directly or through one or more underwriters, broker-dealers or agents. Registration of the common stock covered by this
prospectus does not mean, however, that such shares necessarily will be offered or sold.
See
“Plan of Distribution.” |
|
|
|
Risk
Factors |
|
Please
read “Risk Factors” and other information included in this prospectus for a discussion of factors you should carefully
consider before deciding to invest in the securities offered in this prospectus. |
1 |
The
number of shares of common stock shown above to be outstanding after this offering is based on 15,274,457 shares outstanding prior
to the offering, which excludes the issuance of any shares issuable upon the exercise of any pre-funded warrants, any warrants or
options outstanding. |
Emerging
Growth Company under the JOBS Act
We
qualify as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging
growth company, we have elected to take advantage of reduced reporting requirements and are relieved of certain other significant requirements
that are otherwise generally applicable to public companies. As an emerging growth company:
|
● |
we
may present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis
of Financial Condition and Results of Operations; |
|
|
|
|
● |
we
are exempt from the requirement to obtain an attestation and report from our auditors on whether we maintained effective internal
control over financial reporting under the Sarbanes-Oxley Act; |
|
|
|
|
● |
we
are permitted to provide less extensive disclosure about our executive compensation arrangements; and |
|
|
|
|
● |
we
are not required to give our stockholders non-binding advisory votes on executive compensation or golden parachute arrangements. |
We
may take advantage of these provisions until December 31, 2027 (the last day of the fiscal year following the fifth anniversary of our
initial public offering) if we continue to be an emerging growth company. We would cease to be an emerging growth company if we have
more than $1.235 billion in annual revenue, have more than $700 million in market value of our shares held by non-affiliates or
issue more than $1.0 billion of non-convertible debt over a three-year period. We may choose to take advantage of some but not all of
these reduced burdens. We have elected to provide two years of audited financial statements. Additionally, we have elected to take advantage
of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for
complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier
of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition
period provided in Section 7(a)(2)(B) of the Securities Act.
SUMMARY
CONSOLIDATED FINANCIAL AND OTHER DATA
The
following tables present our summary financial data and should be read together with our unaudited financial statements and audited financial
statements and accompanying notes and information in “Management’s Discussion and Analysis of Financial Condition and Results
of Operations” appearing elsewhere in this prospectus. Our financial statements are prepared and presented in accordance with U.S.
generally accepted accounting principles (“GAAP”). Our historical results are not necessarily indicative of our future results.
Balance
Sheet Data
| |
December 31, | | |
December 31, | | |
June 30, | |
| |
2021 | | |
2022 | | |
2023 | |
| |
| | |
| | |
(unaudited) | |
Assets | |
| | | |
| | | |
| | |
Total current assets | |
$ | 1,609,155 | | |
$ | 4,423,450 | | |
$ | 4,110,441 | |
Total assets | |
$ | 5,902,350 | | |
$ | 11,839,656 | | |
$ | 11,794,135 | |
Liabilities and Stockholders’ Equity | |
| | | |
| | | |
| | |
Total current liabilities | |
$ | 2,766,153 | | |
$ | 2,006,522 | | |
$ | 2,912,866 | |
Total liabilities | |
| 2,766,153 | | |
| 2,198,522 | | |
| 3,104,866 | |
Total stockholders’ equity | |
| 3,136,197 | | |
| 9,641,134 | | |
| 8,689,269 | |
Total liabilities and stockholders’
equity | |
$ | 5,902,350 | | |
$ | 11,839,656 | | |
$ | 11,794,135 | |
Statement
of Operations Data
| |
For
the Years Ended December
31, | | |
For
the Six Months Ended June
30, 2023 | |
| |
2021 | | |
2022 | | |
(unaudited) | |
Revenue | |
$ | - | | |
$ | - | | |
$ | | |
Total operating expenses | |
| (4,4,497,666 | ) | |
| (8,738,793 | ) | |
| (4,850,135 | ) |
Loss from operations | |
| (4,497,666 | ) | |
| (8,738,793 | ) | |
| (4,850,135 | )) |
Other income (expense) | |
| | | |
| 25,636 | | |
| (38,368 | ) |
Interest (expense)income | |
| (166,746 | ) | |
| (1,320,416 | ) | |
| 76,871 | |
FMV gain adjustment for derivatives | |
| | | |
| 5,392,911 | | |
| 93,977 | |
Net loss | |
$ | (4,664,412 | ) | |
$ | (4,639,662 | ) | |
$ | (4,717,655 | ) |
RISK
FACTORS
Investing
in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together
with all of the other information in this prospectus, including the section titled “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” and our financial statements and related notes, before making a decision to invest
in our securities. Our business, financial condition, results of operations and prospects could be adversely affected by these risks.
In that event, the market price of our common stock could decline, and you could lose part or all of your investment.
Risks
Related to Our Technology, Business, and Industry
We
are an early-stage company with a history of losses.
We
incurred net losses of $4,717,655 and $4,639,662 for the six months ended June 30, 2023 and for the year ended December
31, 2022, respectively. We have not generated any revenue to date, and we had accumulated deficit of 20,025,021 as of June
30, 2023. We have developed our Sharps Provensa product line but there can be no assurance that it will be commercially successful.
Our potential profitability is dependent upon a number of factors, many of which are beyond our control. If we are unable to achieve
and sustain profitability, the value of our business and common stock may significantly decrease.
We
have a limited operating history and we may not succeed.
We
have a limited operating history, and we may not succeed. We have not yet commercialized our Sharps Provensa or other products. You
should consider, among other factors, our prospects for success in light of the risks and uncertainties encountered by companies that,
like us, are in their early stages. For example, unanticipated expenses, problems, and technical difficulties may occur and they may
result in material challenges to our business. We may not be able to successfully address these risks and uncertainties or successfully
implement our operating strategies. If we fail to do so, such failure could have a material adverse effect on our business, financial
conditions and results of operation. We may never generate significant revenues or achieve profitability.
We
may not succeed in commercializing Sharps Provensa or any future product.
We
may face difficulties or delays in the commercialization of Sharps Provensa or any future products, which could result in our inability
to timely offer products or services that satisfy the market. We may, for example, encounter difficulties due to:
|
● |
our
inability to adequately market our products; |
|
● |
our
inability to effectively scale manufacturing as needed to maintain an adequate commercial supply of our products; |
|
● |
our
inability to attract and retain skilled support team, marketing staff and sales force necessary to increase the market for our products
and to maintain market acceptance for our products; and |
|
● |
the
difficulty of establishing brand recognition and loyalty for our products. |
In
addition, to increase our production capacity, we will need to build inventory, which will require that we purchase certain additional
equipment, including molding machines and molds. We have not received any orders to date. Even if we succeed in building inventory, and
increasing our production capacity, there is no assurance we will receive any orders for our Sharps Provensa or any future products.
We
may encounter significant competition and may not be able to successfully compete.
There
are many medical device companies offering safety syringes, and more competitors are likely to arrive. Some of our competitors have considerably
more financial resources than us. As a result, we may not be able to successfully compete in our market, which could result in our failure
to successfully commercialize Sharps Provensa, or otherwise fail to successfully compete. We anticipate that our major domestic competitors
will include Retractable Technologies, Inc., Becton, Dickinson & Company, Medtronic Minimally Invasive Therapies, Terumo Medical
Corp., Smiths Medical, and B Braun. There can be no assurances that we will be able to compete successfully in this environment.
We
are vulnerable to new technologies.
Because
we have a narrow focus on particular product lines and technology (currently, safety needle products), we are vulnerable to the development
of superior or similar competing products and to changes in technology which could eliminate or reduce the need for our products. If
a superior or similar technology is created, the demand for our products could be adversely affected.
We
are subject to product liability risk.
As
a manufacturer and provider of safety needle products, we will face an inherent business risk of exposure to product liability claims.
Additionally, our success will depend on the quality, reliability, and safety of our products and defects in our products could damage
our reputation. If a product liability claim is made and damages are in excess of our product liability coverage (which is currently
$5 million, and which we may increase as we commence and increase sales of our products), our competitive position could be weakened
by the amount of money we could be required to pay to compensate those injured by our products. In the event of a recall, we have recall
insurance.
Our
business may be affected by changes in the health care regulatory environment.
In
the U.S. and internationally, government authorities may enact changes in regulatory requirements, reform existing reimbursement programs,
and/or make changes to patient access to health care, all of which could adversely affect the demand for our products and/or put downward
pressure on our prices. Future healthcare rulemaking could affect our business. We cannot predict the timing or impact of any future
rulemaking or changes in the law.
The
approval process for medical device products outside the United States varies among countries and may limit our ability to develop, manufacture
and sell our products internationally. Failure to obtain marketing and regulatory approval in international jurisdictions would prevent
our products from being marketed abroad.
In
order to market and sell our Sharps Provensa product line and any additional medical device products we may develop in the future in
the European Union and many other jurisdictions, we, and our collaborators, must obtain separate marketing approvals and comply with
numerous and varying regulatory requirements. We have not yet received approval or clearance to sell our products in any jurisdiction
outside the United States. The approval procedure varies among countries and may involve additional testing. We may conduct clinical
trials for, and seek regulatory approval to market, our product candidates in countries other than the United States. If we or our collaborators
seek marketing approval for a product candidate outside the United States, we will be subject to the regulatory requirements of health
authorities in each country in which we seek approval. With respect to marketing authorizations in Europe, we will be required to submit
a European Marketing Authorisation Application, or MAA, to the European Medicines Agency, or EMA, which conducts a validation and scientific
approval process in evaluating a product for safety and efficacy. The approval procedure varies among regions and countries and may involve
additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval or clearance. In addition,
marketing approval or clearance by the FDA does not ensure approval or clearance by the health authorities of any other country.
Ongoing
regulation of our products may limit how we market our products, which could materially impair our ability to generate revenue.
Approval
or clearance of a medical device product may carry conditions that limit the market for the product or put the product at a competitive
disadvantage relative to alternative products. For instance, a regulatory approval or clearance may limit the indicated uses for which
we can market a product or the patient population that may utilize the product. These restrictions could make it more difficult to market
any product effectively. Accordingly we expect to continue to expend time, money and effort in all areas of regulatory compliance.
We
are dependent on our management, without whose services our business operations could cease.
At
this time, our management is wholly responsible for the development and execution of our business plan. If our management should choose
to leave us for any reason before we have hired additional personnel, our operations may fail. Even if we are able to find additional
personnel, it is uncertain whether we could find qualified management who could develop our business along the lines described herein
or who would be willing to work for compensation the Company could afford. Without such management, the Company could be forced to cease
operations and investors in our common stock or other securities could lose their entire investment.
We
may not be able to raise capital as needed to develop our products or maintain our operations.
We
expect that we will need to raise additional funds to execute our business plan and expand our operations. Additional financing may not
be available to us on favorable terms, or at all. If we cannot raise needed funds on acceptable terms, the Company’s business and
prospects may be materially adversely affected.
Health
care crises could have an adverse effect on our business.
Particularly
during 2020, several states and local jurisdictions imposed, and others in the future may impose, “shelter-in-place” orders,
quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. Although
the manufacturing facility we operate has continued to operate during the 2020-2021 COVID-19 pandemic due to its status as an essential
business, we continue to monitor the evolving situation and cannot guarantee that the situation would be the same for any future pandemic.
In the future, we may elect or be required to close temporarily which would result in a disruption in our activities and operations.
Our supply chain, including transportation channels, may be impacted by any such restrictions as well. Any such disruption could impact
our sales and operating results.
Widespread
health crises also negatively affect economies which could affect demand for our products. While we plan to market our Sharps Provensa
and other products for use for injecting medicines as well as Covid-19 and other vaccines, in the event of a resurgence of COVID-19 or
in the case of any future pandemic, there is no guarantee that revenues from syringes needed for vaccines would offset the effects to
our business in a global economic decline.
Health
systems and other healthcare providers in our markets that provide procedures that may use our products have suffered financially and
operationally and may not be able to return to pre-pandemic levels of operations. Travel and import restrictions may also disrupt our
ability to manufacture or distribute our devices. Any import or export or other cargo restrictions related to our products or the raw
materials used to manufacture our products could restrict our ability to manufacture and ship products and harm our business, financial
condition, and results of operations.
Our
key personnel and other employees could still be affected by COVID-19 or any future pandemic, which could affect our ability to operate
efficiently.
Our
business may be adversely affected by uncertainties in obtaining and enforcing intellectual property rights.
We
believe our main competitive strength is our technology, including patent protection and trade secrets relating to the manufacture and
design of our products. We are dependent on patent rights to prevent unlawful copying of our products, and if the patent rights are invalidated
or circumvented, our business would be adversely affected. We consider patent protection to be of material importance in the design,
development, and marketing of our products.
Our
patent pending applications may not issue as patents, which may have a material adverse effect on our ability to prevent others from
commercially exploiting products similar to ours.
We
have three issued patents, three pending patent applications in the United States, and one PCT (Patent Cooperation Treaty) patent application.
We cannot be certain that we are the first inventor of the subject matter to which we have filed a particular patent application, or
if we are the first party to file such a patent application. If another party has filed a patent application to the same subject matter
as we have, we may not be entitled to the protection sought by the patent application. Further, the scope of protection of issued patent
claims is often difficult to determine. As a result, we cannot be certain that the patent applications that we file will issue, or that
our issued patents will be broad enough to protect our proprietary rights or otherwise afford protection against competitors with similar
technology. In addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Our competitors
may challenge or seek to invalidate our issued patents, or design around our issued patents, which may adversely affect our business,
prospects, financial condition or operating results. Also, the costs associated with enforcing patents, confidentiality and invention
agreements, or other intellectual property rights may make aggressive enforcement impracticable.
Illegal
distribution and sale by third parties of counterfeit versions of our products could have a negative impact on us.
Third
parties may illegally distribute and sell counterfeit versions of our products which do not meet our rigorous manufacturing and testing
standards. Our reputation and business could suffer harm as a result.
Risks
Related to This Offering and Our Securities
Our
common stock could be subject to extreme volatility.
The
trading price of our common stock may be affected by a number of factors, including events described in the risk factors set forth in
this prospectus, as well as our operating results, financial condition and other events or factors. In addition to the uncertainties
relating to future operating performance and the profitability of operations, factors such as variations in interim financial results
or various, as yet unpredictable, factors, many of which are beyond our control, may have a negative effect on the market price of our
common stock. In recent years, broad stock market indices, in general, and smaller capitalization companies, in particular, have experienced
substantial price fluctuations. In a volatile market, we may experience wide fluctuations in the market price of our common stock and
wide bid-ask spreads. These fluctuations may have a negative effect on the market price of our common stock. In addition, the securities
market has, from time to time, experienced significant price and volume fluctuations that are not related to the operating performance
of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.
We
have never paid common stock dividends and have no plans to pay dividends in the future, as a result our common stock may be less valuable
because a return on an investor’s investment will only occur if our stock price appreciates.
Holders
of shares of our common stock are entitled to receive such dividends as may be declared by our Board of Directors. To date, we have paid
no cash dividends on our shares of common stock and we do not expect to pay cash dividends on our common stock in the foreseeable future.
We intend to retain future earnings, if any, to provide funds for operations of our business. Therefore, any return investors in our
common stock will be in the form of appreciation, if any, in the market value of our shares of common stock. There can be no assurance
that shares of our common stock will appreciate in value or even maintain the price at which our stockholders have purchased their shares.
Our
shares will be subject to potential delisting if we do not maintain the listing requirements of the Nasdaq Capital Market.
This
offering constitutes the selling stockholders’ offering of our shares. We have listed the shares of our common stock on the Nasdaq
Capital Market, or Nasdaq.
Nasdaq
has rules for continued listing, including, without limitation, minimum market capitalization and other requirements. Failure to maintain
our listing, or de-listing from Nasdaq, would make it more difficult for shareholders to dispose of our common stock and more difficult
to obtain accurate price quotations on our common stock. This could have an adverse effect on the price of our common stock. Our ability
to issue additional securities for financing or other purposes, or otherwise to arrange for any financing we may need in the future,
may also be materially and adversely affected if our common stock is not traded on a national securities exchange.
We
will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time
to compliance with our public company responsibilities and corporate governance practices.
As
a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company, which we
expect to further increase after we are no longer an “emerging growth company.” The Sarbanes-Oxley Act, the Dodd-Frank Wall
Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Capital Market, and other applicable securities rules
and regulations impose various requirements on public companies. Our management and other personnel will devote a substantial amount
of time to compliance with these requirements. Moreover, these rules and regulations will increase our legal and financial compliance
costs and will make some activities more time-consuming and costly. We cannot predict or estimate the amount of additional costs we will
incur as a public company or the specific timing of such costs.
As
a result of being a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting,
and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a
result, the value of our common stock.
We
will be required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness
of our internal control over financial reporting as of the end of the fiscal year that coincides with the filing of our second annual
report on Form 10-K. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal
control over financial reporting. In addition, our independent registered public accounting firm will be required to attest to the effectiveness
of our internal control over financial reporting in our first annual report required to be filed with the SEC following the date we are
no longer an “emerging growth company.” We have not yet commenced the costly and time-consuming process of compiling the
system and processing documentation necessary to perform the evaluation needed to comply with Section 404, and we may not be able to
complete our evaluation, testing and any required remediation in a timely fashion once initiated. Our compliance with Section 404 will
require that we incur substantial expenses and expend significant management efforts. We currently do not have an internal audit group,
and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting
knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404.
Our
current controls and any new controls that we develop may become inadequate because of changes in conditions in our business. In addition,
changes in accounting principles or interpretations could also challenge our internal controls and require that we establish new business
processes, systems and controls to accommodate such changes. Additionally, if these new systems, controls or standards and the associated
process changes do not give rise to the benefits that we expect or do not operate as intended, it could adversely affect our financial
reporting systems and processes, our ability to produce timely and accurate financial reports or the effectiveness of internal control
over financial reporting. Moreover, our business may be harmed if we experience problems with any new systems and controls that result
in delays in their implementation or increased costs to correct any post-implementation issues that may arise.
Any
failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition
or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, we could lose
investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and
we could be subject to sanctions or investigations by the SEC or other regulatory authorities. Failure to remedy any material weakness
in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies,
could also restrict our future access to the capital markets.
Future
sales of our common stock in the public market could cause the market price of our common stock to decline.
Sales
of a substantial number of shares of our common stock in the public market following the completion of this offering, or the perception
that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through
the sale of additional equity securities. Some of our existing equity holders have substantial unrecognized gains on the value of the
equity they hold based upon the price of this offering, and therefore, they may take steps to sell their shares or otherwise secure the
unrecognized gains on those shares. We are unable to predict the timing of or the effect that such sales may have on the prevailing market
price of our common stock.
If
we fail to comply with the continued listing requirements of NASDAQ, specifically, Nasdaq Listing Rule 5550(a)(2), as we’ve received
a notice from the Staff of the Listing Qualifications Department on July 12, 2023, we may face possible delisting, which would result
in a limited public market for our shares and make obtaining future debt or equity financing more difficult for us.
As
previously reported, on July 12, 2023, the Company received a letter from the Listing Qualifications
Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to maintain
a minimum bid price of $1.00 over the previous 30 consecutive business days dated May 26, 2023, to July 11, 2023. If the Company
does not comply with the NASDAQ rules in the future, Nasdaq will provide notice that the Company’s Common Stock will be subject
to delisting. The Rules provide the Company a compliance period of 180 calendar days in which to
regain compliance. If at any time during this 180 day period the closing bid price of the Company’s security is at least $1 for
a minimum of ten consecutive business days, the Staff will provide written confirmation of compliance. The Company would then
be entitled to appeal that determination to a Nasdaq hearings panel. There can be no assurance that the Company will regain compliance
with the Minimum Bid Price Requirement.
Our
stock price may be volatile, and the value of our common stock may decline.
We
cannot predict the prices at which our common stock will trade. The initial public offering price of our units will be determined by
negotiations between us and the underwriters and may not bear any relationship to the market price at which our common stock will trade
after this offering or to any other established criteria of the value of our business and prospects, and the market price of our common
stock following this offering may fluctuate substantially and may be lower than the initial public offering price. In addition, the trading
price of our common stock following this offering is likely to be volatile and could be subject to fluctuations in response to various
factors, some of which are beyond our control. These fluctuations could cause you to lose all or part of your investment in our common
stock as you might be unable to sell your shares at or above the price you paid in this offering. Factors that could cause fluctuations
in the trading price of our common stock include the following:
|
● |
actual
or anticipated fluctuations in our financial condition or results of operations; |
|
|
|
|
● |
variance
in our financial performance from expectations of securities analysts; |
|
|
|
|
● |
changes
in our projected operating and financial results; |
|
|
|
|
● |
changes
in laws or regulations applicable to our products; |
|
|
|
|
● |
announcements
by us or our competitors of significant business developments, acquisitions or new products; |
|
|
|
|
● |
sales
of shares of our common stock by us or our shareholders, as well as the anticipation of lock-up releases; |
|
|
|
|
● |
our
involvement in litigation; |
|
|
|
|
● |
future
sales of our common stock by us or our stockholders,; |
|
|
|
|
● |
changes
in senior management or key personnel; |
|
|
|
|
● |
the
trading volume of our common stock; |
|
|
|
|
● |
changes
in the anticipated future size and growth rate of our market; |
|
|
|
|
● |
general
economic and market conditions; and |
|
|
|
|
● |
other
events or factors, including those resulting from war, incidents of terrorism, global pandemics or responses to these events. |
Broad
market and industry fluctuations, as well as general economic, political, regulatory and market conditions, may also negatively impact
the market price of our common stock. In the past, companies who have experienced volatility in the market price of their securities
have been subject to securities class action litigation. We may be the target of this type of litigation in the future, which could result
in substantial expenses and divert our management’s attention.
If
securities or industry analysts do not publish research or publish unfavorable or inaccurate research about our business, the market
price and trading volume of our common stock could decline.
The
market price and trading volume of our common stock following the completion of this offering will be heavily influenced by the way analysts
interpret our financial information and other disclosures. We do not have control over these analysts. If few securities analysts commence
coverage of us, or if industry analysts cease coverage of us, our stock price could be negatively affected. If securities or industry
analysts do not publish research or reports about our business, downgrade our common stock, or publish negative reports about our business,
our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly,
demand for our common stock could decrease, which might cause our stock price to decline and could decrease the trading volume of our
common stock.
Management
will have broad discretion as to the use of the proceeds from this offering and may not use the proceeds effectively.
Our
management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways
that may not improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively
could have a material adverse effect on our business and cause the price of our common stock to decline.
We
do not intend to pay dividends on our common stock for the foreseeable future.
We
have paid no dividends on our common stock to date and we do not anticipate paying any dividends to holders of our common stock in the
foreseeable future. While our future dividend policy will be based on the operating results and capital needs of the business, we currently
anticipate that we will retain any earnings to finance our future expansion and for the implementation of our business plan. Investors
should take note of the fact that a lack of a dividend can further affect the market value of our common stock and could significantly
affect the value of any investment in the Company.
Our
articles of incorporation allow for our board to create new series of preferred stock without further approval by our stockholders, which
could adversely affect the rights of the holders of our common stock.
Our
board of directors has the authority to fix and determine the relative rights and preferences of preferred stock. Our board of directors
has the authority to issue up to 1,000,000 shares of our preferred stock without further stockholder approval. 1 share of preferred stock
is designated Series A Preferred Stock and is outstanding. Our board of directors could authorize the creation of additional series of
preferred stock that would grant to holders of preferred stock the right to our assets upon liquidation, or the right to receive dividend
payments before dividends are distributed to the holders of common stock. In addition, subject to the rules of any securities exchange
on which our stock is then listed, our board of directors could authorize the creation of additional series of preferred stock that has
greater voting power than our common stock or that is convertible into our common stock, which could decrease the relative voting power
of our common stock or result in dilution to our existing stockholders.
The
holder of our Series A Preferred Stock will have 29.5% of the voting power of our stockholders for the election of directors and will
have certain senior rights upon sale of our Company under certain conditions.
There
is 1 share of Series A Preferred Stock issued and outstanding, which is held by our former co-chairman and chief operating officer,
Alan Blackman. The Series A Preferred Stock entitles the holder to 29.5% of the voting power of the Company’s stockholders only
as it relates to the elections of directors. As a result, Mr. Blackman was able to exert substantial influence over the election
of directors to the Board. However, as discussed above, Mr. Blackman resigned from the Board of the company effective July 27, 2023.
Additionally, in connection with Mr. Blackman’s resignation, once his severance payments are satisfied, Mr. Blackman shall return
the Series A Preferred Stock to the Company for cancellation.
Further,
the Series A Preferred Stock, provides that in the event the Company is sold during the two year period following completion of this
offering at a price per share of more than 500% of the initial offering price per Common Unit in this offering, the Series A Preferred
Stock will entitle the holder to 10% of the total purchase price. This may reduce the value of our common stock, as other holders, in
the event of such an acquisition, will be entitled to a lower price per share than they would otherwise receive.
Our
executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly
influence all matters submitted to stockholders for approval.
Our
executive officers, directors and principal stockholders in the aggregate, beneficially own approximately 11% of our common stock.
Such persons acting together, will have the ability to control or significantly influence all matters submitted to our stockholders for
approval, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring
or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging
a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction
would benefit other stockholders.
Additional
stock offerings in the future may dilute then-existing shareholders’ percentage ownership of the Company.
Given
our plans and expectations that we will need additional capital and personnel, we anticipate that we will need to issue additional shares
of common stock or securities convertible or exercisable for shares of common stock, including convertible preferred stock, convertible
notes, stock options or warrants. The issuance of additional securities in the future will dilute the percentage ownership of then current
stockholders.
We
are an “emerging growth company,” and we cannot be certain if the reduced reporting and disclosure requirements applicable
to emerging growth companies will make our common stock less attractive to investors.
We
are an “emerging-growth company,” as defined in the JOBS Act, and we have elected to take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,”
including the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, or Section 404, reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Pursuant to
Section 107 of the JOBS Act, as an emerging growth company, we have elected to use the extended transition period for complying with
new or revised accounting standards until those standards would otherwise apply to private companies. As a result, our consolidated financial
statements will not be comparable to the financial statements of issuers who are required to comply with the effective dates for new
or revised accounting standards that are applicable to public companies, which may make our common stock less attractive to investors.
In addition, if we cease to be an emerging growth company, we will no longer be able to use the extended transition period for complying
with new or revised accounting standards.
We
will remain an emerging-growth company until the earliest of: (1) the last day of the fiscal year following the fifth anniversary of
this offering; (2) the last day of the first fiscal year in which our annual gross revenue is $1.07 billion or more; (3) the date on
which we have, during the previous rolling three-year period, issued more than $1 billion in non-convertible debt securities; and (4)
the date we qualify as a “large accelerated filer,” with at least $700 million of equity securities held by non-affiliates.
We
cannot predict if investors will find our common stock less attractive as a result of choosing to rely on these exemptions. For example,
if we do not adopt a new or revised accounting standard, our future results of operations will not be as comparable to the results of
operations of certain other companies in our industry that adopted such standards. If some investors find our common stock less attractive
as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus contains, in addition to historical information, forward-looking statements. These statements are based on our management’s
beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained principally
under the headings “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of
Financial Condition and Results of Operations,” “Use of Proceeds” and “Business.” Forward-looking statements
include statements concerning:
|
● |
our
possible or assumed future results of operations; |
|
|
|
|
● |
our
business strategies; |
|
|
|
|
● |
our
ability to attract and retain customers; |
|
|
|
|
● |
our
ability to sell products to customers; |
|
|
|
|
● |
our
cash needs and financing plans; |
|
|
|
|
● |
our
competitive position; |
|
|
|
|
● |
our
industry environment; |
|
|
|
|
● |
our
potential growth opportunities; |
|
|
|
|
● |
the
effects of future regulation; and |
|
|
|
|
● |
the
effects of competition. |
All
statements in this prospectus that are not historical facts are forward-looking statements. We may, in some cases, use terms such as
“anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,”
“may,” “plans,” “potential,” “predicts,” “projects,” “should,”
“will,” “would” or similar expressions that convey uncertainty of future events or outcomes to identify forward-looking
statements.
The
outcome of the events described in these forward-looking statements are subject to known and unknown risks, uncertainties and other factors
that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements
expressed or implied by the forward-looking statements. These important factors include our financial performance and the other important
factors we discuss in greater detail in “Risk Factors.” You should read these factors and the other cautionary statements
made in this prospectus as applying to all related forward-looking statements wherever they appear in this prospectus. Given these factors,
you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s
beliefs and assumptions only as of the date on which the statements are made. We undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law. You should read this prospectus
and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus
is a part, completely and with the understanding that our actual future results may be materially different from what we currently expect.
USE
OF PROCEEDS
We
will not receive any of the proceeds from the sale of the shares of our common stock being offered for sale by the selling stockholders.
Upon the exercise of the 8,750,003 Common Warrants by payment of cash, we will
receive the exercise price of the Common Warrants, or an aggregate of approximately $5.6 million from the investors in the September 2023 Private
Placement. We will bear all fees and expenses incident to our obligation to register the shares of common stock. Brokerage
fees, commissions and similar expenses, if any, attributable to the sale of shares offered hereby will be borne by the selling stockholder.
There
is no assurance the warrants or pre-funded warrants will be exercised for cash. We intend to use such proceeds, if any, for general
corporate, working capital purposes and capital expenditures.
DIVIDEND
POLICY
We
have never declared or paid any cash dividends on our common stock. We do not anticipate paying any cash dividends to stockholders in
the foreseeable future. In addition, any future determination to pay cash dividends will be at the discretion of the board of directors
and will be dependent upon our financial condition, results of operations, capital requirements, and such other factors as the Board
of Directors deem relevant. There are no restrictions in our articles of incorporation or bylaws that restrict us from declaring dividends.
CAPITALIZATION
The
following table sets forth our cash and our capitalization as of June 30, 2023, on:
|
● |
an
actual basis; and |
|
|
|
|
● |
on
a pro forma as adjusted basis to give effect to (i) the sale of 4,418,521 shares and pre-funded warrants under the Shelf registration
on Form S-3 and the sale by us of 2,581,479 Common Units in this offering, at $1.073 per Common Unit, after deducting underwriting
discounts and commissions and estimated offering expenses payable by us, |
You
should read this table in conjunction with “Use of Proceeds,” “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” and our unaudited financial statements for the six months ended June 30, 2023
and the related notes thereto, included in this prospectus.
| |
Actual | | |
Pro forma as adjusted | |
Cash | |
$ | 2,924,019 | | |
$ | 7,806,345 | |
Total Assets | |
$ | 11,794,135 | | |
$ | 16,676,461 | |
| |
| | | |
| | |
Total liabilities | |
| 3,104,866 | | |
| 4,213,616 | |
Stockholders’ equity: | |
| | | |
| | |
Preferred Stock, $0.0001 par value: 1,000,000 shares authorized, 1 share issued and outstanding | |
| | | |
| | |
Common Stock, $0.0001 par value: 100,000,000 shares authorized; 11,655,936 shares issued and outstanding,
actual; 15,274,457, shares issued and outstanding, pro forma as adjusted* | |
| 1,166 | | |
| 1,528 | |
Additional paid-in capital | |
| 28,154,012 | | |
| 32,070,107 | |
Accumulated other comprehensive income | |
| 559,112 | | |
| 559,112 | |
Accumulated deficit | |
| (20,025,021 | ) | |
| (20,167,902 | ) |
Total stockholders’ equity | |
$ | 8,689,269 | | |
$ | 12,462,845 | |
Total Liabilities and Stockholders’ Equity | |
$ | 11,794,135 | | |
$ | 16,676,461 | |
*Does not include any
exercise of the pre-funded warrants.
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You
should read the following discussion and analysis of financial condition and results of operations in conjunction with our financial
statements and related notes appearing elsewhere in this prospectus. In addition to historical information, the following discussion
and analysis includes forward looking statements that involve risks, uncertainties and assumptions. Our actual results and the timing
of events could differ materially from those anticipated in these forward looking statements as a result of a variety of factors, including
those discussed in “Risk Factors” and elsewhere in this prospectus. See the discussion under “Special Note Regarding
Forward Looking Statements” beginning on page 16 of this prospectus.
Forward-Looking
Statements
The
information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities
Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act,
which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited
to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and
plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “may,” “plans,” “projects,” “will,” “would” and similar
expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying
words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should
not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions
and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties
that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation,
the risks set forth in our filings with the SEC. The forward-looking statements are applicable only as of the date on which they are
made, and we do not assume any obligation to update any forward-looking statements.
Overview
Since
our inception in 2017, we have devoted substantially all of our resources to the research and development of our safety syringe products.
To date, we have generated no revenue. We have incurred net losses in each year of $4,639,662 and $4,664,412 for the years ended December
31, 2022 and 2021, respectively. Substantially all of our net losses resulted from costs incurred in connection with our research and
development efforts, payroll and consulting fees, stock compensation and general and administrative costs associated with our operations,
including costs incurred for being a public company since April 14, 2022. See below Initial Public
Offering, Liquidity and Capital Resources and Notes to Consolidated Financial Statements
We
classify our operating expenses as research and development, and general and administrative expenses. We maintain a corporate office
located in Melville, New York, but employees and consultants in the US work remotely and will continue to do so indefinitely. In June
2020, in connection with the agreement to acquire Safegard, a former syringe manufacturing facility in Hungary, which was completed on
July 6, 2022, we were contractually provided the exclusive use of the facility for research and development and testing in exchange for
payment of the seller’s operating costs, including among others, use of Safegard’s work force, utility costs and other services.
In
order to compete in the market, we must build inventory. Commencing in the 4th Quarter of 2022 we have started building inventory.
We require commercial quantities of inventory to secure orders. Delivery is expected shortly after receiving orders.
Research
and Development
Research
and development expense consists of expenses incurred while performing research and development activities for our various syringe products.
We recognize research and development expenses as they are incurred. Our research and development expense primarily consist of:
● |
Manufacturing
and testing costs and related supplies and materials; |
|
|
● |
Consulting
fees paid for our Chief Technology Officer; |
● |
Operating
costs paid to Safegard, through the acquisition date for use of Safegard’s workforce, utilities and other services, relating
to the facility being utilized; and |
|
|
● |
Third-party
costs, including engineering, incurred for development and design. |
Substantially
all of our research and development expenses to date have been incurred in connection with our syringe products. We expect our research
and development expenses to increase for the foreseeable future as we continue to enhance our product to meet the market requirements
for our Sharps Provensa product line for its various intended uses throughout the world.
On
September 29, 2022, Sharps Technology entered into an agreement (the “Nephron Agreement”) with InjectEZ, LLC (“InjectEZ”),
Nephron Pharmaceuticals Corporation (“NPC”), Nephron SC, Inc. (“NSC”), and Nephron Sterile Compounding Center
LLC (“Sterile”) (NPC, NSC, and Sterile are sometimes collectively referred to as “Nephron”), pursuant to which
Sharps was to provide technical advice and assistance to support manufacturing by InjectEZ, purchase certain quantities of syringes as
they may order or require, and collaborate with Nephron on certain related business endeavors. The Nephron Agreement is for a period
of four (4) years, expiring on September 28, 2026 and continues thereafter for successive one (1) year periods. The Agreement includes
provisions for collaborations in the areas of Manufacturing and Supply, a Pharma Services Program, and Distribution. NPC is a West Columbia,
S.C.-based company that develops and produces safe, affordable generic inhalation solutions and suspension products. NPC also operates
an industry-leading 503B Outsourcing Facility division, which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV
bags for hospitals across America, in an effort to alleviate drug shortage needs. NPC launched a CLIA-certified diagnostics lab in 2020
where it tests people for COVID-19 and administers vaccinations.
The
Agreement also allows for further expansion of manufacturing capabilities by Sharps Technology working with Nephron to support future
industry and customer demand of pre-fillable systems as detailed in the Agreement. See “Recent Developments” below.
Additionally,
Sharps entered into a Pharma Services Program (PSP) with Nephron that will create new business development growth opportunities for both
companies. These opportunities will include the development and sale of next generation drug delivery systems that will be produced by
Sharps and can be purchased by the healthcare industry, pharmaceutical markets, as well as by Nephron.
On
December 8, 2022, Sharps entered into a distribution agreement (the “Distribution Agreement”) with Nephron Pharmaceuticals
pursuant to which the Sharps Technology appointed Nephron as its exclusive distributor for the sale and distribution of the products
subject to the Distribution Agreement in and throughout the United States. Pursuant to the Distribution Agreement, the price of shipping
products will be based on the cost of delivery to Nephron’s warehouse and the Company will pay for the cost of delivery to Nephron.
The Distribution Agreement has a term of two years and will continue in effect unless either party notifies the other party of its desire
to terminate. At any time and for any reason, either party can terminate the Distribution Agreement after thirty (30) days’ notice
and in the event of a breach of any of the Distribution Agreement’s terms and provisions, either party can terminate the Distribution
Agreement by providing 90 days written notice. The Company has the right to terminate the Distribution Agreement with 60 days written
notice if certain conditions are met as set forth in the Distribution Agreement.
The
Company’s collaboration will include the creation of a Pharma Services Program (PSP) designed to support Healthcare customers
that need innovative solutions and products to support their business. This program will create new business development growth opportunities
for both companies. We believe that these opportunities for the Company will include the development and sale of next generation drug
delivery systems for Nephron products, the healthcare industry, and pharmaceutical markets. The development of the program will help
create new fill/finish project opportunities that will utilize innovative packaging solutions developed by the Company. These new customer
projects will help create a future pipeline of growth for both companies working together. Initial, and currently confidential, projects
have been identified and will be further developed through the collaboration efforts of Nephron and the Company. The opportunity to create
new innovative technologies to support Nephron and the healthcare industry would be transformative for the Company and its future.
The
Company recently entered into an Asset Purchase Agreement to purchase the Inject EZ facility and a Purchase Agreement to supply Nephron
with all of its required copolymer prefilled syringes which will significantly broaden our relationship with Nephron described above.
See “Recent Developments”
We
continue to be in discussions with healthcare companies and distributors for sales of our disposable syringe products. We intend to market
these products to the US and foreign governments. In certain situations, we will also look to sell our disposable syringe products to
hospitals and clinician offices as opportunities present themselves.
We
expect that the Sharps Securegard product line will represent our initial disposable syringe platform to be commercially available to
the market. The Securegard platform has an advanced set of features and benefits to support the needs of the market along with a high
level of readiness for manufacturing and the ability to provide large commercial quantities for customers.
There
have been delays in the commercialization of the Sharps Provensa product line. The Provensa product’s combination of specialized
technology has created the need for further optimization related to the final assembly steps for the product. This was identified as
we moved towards commercialization for the product line and the need to generate production quantities to support customer orders. This
type of delay is typical with the development of new technology for the healthcare market to ensure the products are safe and effective
for use every time. We are endeavoring to address all obstacles to advance the commercialization of the Provensa product line as soon
as possible.
On
February 3, 2023, the Company completed a securities purchase agreement (“Offering”) with institutional investors and received
net proceeds from the Offering were approximately $3.2 million, net of $600,000 in fees relating to the placement agent and other offering
expenses. The Offering was priced at the market under Nasdaq rules. In connection with the Offering, the Company issued 2,248,521 units
at a purchase price of $1.69 per unit. Each unit consists of one share of common stock and one non-tradable warrant exercisable for one
share of common stock at a price of $1.56. The warrants have a term of five years from the issuance date.
Recent
Developments
Nephron
Asset Purchase Agreement
On
September 22, 2023, Sharps entered into a series of agreements with Nephron and Nephron’s wholly owned subsidiary InjectE, LLC.
Sharps entered into an asset purchase agreement (the “Asset Purchase Agreement”) to purchase certain equipment and leasehold
improvements at Nephron’s facility (the “Facility”) in West Columbia, South Carolina. The Asset Purchase Agreement
provides for a cash purchase price of $40,378,594 and the issuance of a five (5) year subordinated promissory note (the “Nephron
Note”) to Nephron in the principal amount of $10.0 million which bears interest at 8% per annum to be paid upon the closing (the
“Closing”) of the transaction. The Nephron Note will be redeemable (25% per quarter) during the first year if Nephron’s
syringe purchase orders result in revenue of at least $7,500,000 per quarter during the first year. The Company will also issue Nephron
warrants to purchase 4% of the Company’s common stock on a fully diluted basis (the “Nephron Warrants”) exercisable
for a five-year period at an exercise price of $1.56 per share.
In
conjunction with the execution of the Asset Purchase Agreement, on September 19, 2023, the Company entered into a ten-year Purchase Agreement
with Nephron whereby Nephron agreed to utilize the Sharps as its exclusive pre-filled COC syringe manufacturer and to purchase a minimum
aggregate of $450.0 million of syringes over the term of the Purchase Agreement. The Purchase Agreement contains specific quantities
of products required to be purchased from the Company during the term of the Purchase Agreement. The Purchase Agreement provides that
Nephron will make an initial purchase order of $32.0 million upon the closing of the Asset Purchase Agreement . The effectiveness of
the Purchase Agreement is subject to the closing of the Asset Purchase Agreement (the “Closing”).
Closing,
At
the closing, Sharps will enter into a 10 year lease for the Facility in which the Assets are located and will be operated by the Company.
The lease provides for four successive five year options, with a right to purchase the Facility, which lease will be effective upon Closing
(the “Lease”). The Lease provides for a monthly rental fee of $40,550, subject to increase after 5 years based on CPI adjustments.
In
addition, Sharps and Nephron, will enter into a two year Shared Services Agreement whereby Nephron will provide certain administrative
services and personnel to the Company in exchange for an agreed upon fee schedule. These services will assist the Company in establishing
its operations in the Facility.
The
closing of the Asset Purchase Agreement is subject to certain closing conditions. There can be no assurance that such closing conditions
will be satisfied but the Company anticipates closing the transaction within 60 days from the date of the Asset Purchase Agreement.
Critical
Accounting Policies and Significant Judgments and Estimates
This
management’s discussion and analysis of our financial condition and results of operations is based on our financial statements,
which we have prepared in accordance with accounting principles generally accepted in the United States. The preparation of our financial
statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure
of contingent assets and liabilities at the date of our financial statements, as well as the reported revenues and expenses during the
reported periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on
various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments
about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions. The FMV adjustments, based on the trading price of outstanding warrants classified
as liabilities, could impact the operating results in the reporting periods.
Nature
of Business
Nature
of Business
Sharps
Technology, Inc. (“Sharps” or the “Company”) is a pre-revenue medical device company that has designed and patented
various safety syringes and is seeking commercialization by manufacturing and distribution of its products.
The
accompanying consolidated financial statements include the accounts of Sharps Technology, Inc. and its wholly owned subsidiary, Safegard
Medical, Inc, collectively referred to as the “Company.” All intercompany transactions and balances have been eliminated.
The
Company’s fiscal year ends on December 31.
On
April 13, 2022, the Company’s Initial Public Offering was deemed effective with trading commencing on April 14, 2022. The Company
received net proceeds of $14.2 million on April 19, 2022. (See Capital Structure and Note 8 to the Consolidated Financial Statements)
In
March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak has adversely
affected workforces, economies, and financial markets globally leading to an economic downturn in certain industries and countries. It
is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s
business or ability to raise funds. Management continues to monitor the situation but has not experienced a significant disruption to
its product development efforts.
Summary
of Significant Accounting Policies
Basis
of Presentation
The
accompanying consolidated financial statements have been prepared by the Company in accordance with generally accepted accounting principles
(“GAAP”) in the United States (“U.S.”) and are expressed in U.S. dollars.
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Cash
and Cash Equivalents
The
Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date
of purchase to be cash equivalents. Cash and cash equivalents are maintained with various financial institutions.
Inventories
The
Company values inventory at the lower of cost (average cost) or net realizable value. Work-in-process and finished goods inventories
consist of material, labor, and manufacturing overhead. Net
realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion,
disposal, and transportation. A reserve is established for any excess or obsolete inventories or they may be written off. At December
31, 2022 and 2021, inventory is comprised of raw materials, components and finished goods.
Fair
Value Measurements
Fair
Value Measurements and Disclosures, require an entity to maximize the use of observable inputs and minimize the use of unobservable inputs
when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding
the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be
used to measure fair value.
Level
1
Level
1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Valuations
are based on quoted prices that are readily and regularly available in an active market and do no entail a significant degree of judgment.
Level
2
Level
2 applied to assets or liabilities for which there are other than Level 1 observable inputs such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market date.
Level
2 instruments require more management judgment and subjectivity as compared to Level 1 instruments. For instance: determining which instruments
are most similar to the instrument being priced requires management to identify a sample of similar securities based on the coupon rates,
maturity, issuer credit rating and instrument type, and subjectively select an individual security or multiple securities that are deemed
most similar to the security being priced; and determining whether a market is considered active requires management judgment.
Level
3
Level
3 applied to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement
of the fair value of the assets or liabilities. The determination for Level 3 instruments requires the most management judgment and subjectivity.
Fixed
Assets
Fixed
assets are stated at cost. Expenditures for maintenance and repairs are charged to operations as incurred. The Company’s fixed
assets consist of land, building, machinery and equipment, molds and website. Depreciation is calculated using the straight-line method
commencing on the date the asset is operating in the way intended by management over the following useful lives: Building – 20
years, Machinery and Equipment – 3 -10 years and Website – 3 years. The expected life for Molds is based lesser of the number
of parts that will be produced based on the expected mold capability or 5 years.
Impairment
of Long-Lived Assets
Long-lived
assets are reviewed annually for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted
cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from
the asset.
Goodwill
and Purchased Identified Intangible Assets
Goodwill
When
applicable, goodwill will be recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the
fair value of the net tangible and identified intangible assets acquired under a business combination. Goodwill also includes acquired
assembled workforce, which does not qualify as an identifiable intangible asset. The Company reviews impairment of goodwill annually
in the third quarter, or more frequently if events or circumstances indicate that the goodwill might be impaired. The Company first assesses
qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. If, after assessing the
totality of events or circumstances, the Company determines that it is not more likely than not that the fair value of a reporting unit
is less than its carrying amount, then the quantitative goodwill impairment test is unnecessary. If, based on the qualitative assessment,
it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the Company
proceeds to perform the quantitative goodwill impairment test. The Company first determines the fair value of a reporting unit using
weighted results derived from an income approach and a market approach. The income approach is estimated through the discounted cash
flow method based on assumptions about future conditions such as future revenue growth rates, new product and technology introductions,
gross margins, operating expenses, discount rates, future economic and market conditions, and other assumptions. The market approach
estimates the fair value of the Company’s equity by utilizing the market comparable method which is based on revenue multiples
from comparable companies in similar lines of business. The Company then compares the derived fair value of a reporting unit with its
carrying amount. If the carrying value of a reporting unit exceeds its fair value, an impairment loss will be recognized in an amount
equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.
Identified
Intangible Assets
When
applicable, the Company’s identified intangible assets are amortized on a straight-line basis over their estimated useful lives.
The Company makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate that
the useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable. If such facts and
circumstances exist, the Company assesses recoverability by comparing the projected undiscounted net cash flows associated with the related
asset or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the
excess of the carrying amount over the fair value of those assets. If the useful life is shorter than originally estimated, the Company
would accelerate the rate of amortization and amortize the remaining carrying value over the new shorter useful life. The Company evaluates
the carrying value of indefinite-lived intangible assets on an annual basis, and an impairment charge would be recognized to the extent
that the carrying amount of such assets exceeds their estimated fair value.
Stock-based
Compensation Expense
The
Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. For
stock option awards, the Company uses the Black-Scholes option-pricing model. The stock-based awards are granted at an exercise price
that represents the fair market value of the underlying common stock based on the stock price, at which the Company sold stock in private
placements completed by the Company, during the period such options were issued. Stock-based compensation expense is recognized over
the requisite service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest.
The Company recognizes forfeitures of stock-based awards as they occur on a prospective basis.
Stock-based
compensation expense for awards granted to non-employees as consideration for services received is measured on the date of performance
at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured.
Derivative
Instruments
The
Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of
the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC 480”), Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815,
Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments
pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification
under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could
potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent
quarterly period end date while the warrants are outstanding.
At
their issuance date and as of December 31, 2022, the warrants were accounted for as liabilities as these instruments did not meet all
of the requirements for equity classification under ASC 815-40 based on the terms of the aforementioned warrants. The resulting warrant
liabilities are re-measured at each balance sheet date until their exercise or expiration, and any change in fair value is recognized
in the Company’s consolidated statement of operations and comprehensive loss (See Notes 7, 8 and 10 to the Consolidated Financial
Statements).
Basic
and Diluted Loss Per Share
The
Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted
earnings per share (EPS) on the face of the consolidated statement of operations and comprehensive loss. Basic EPS is computed by dividing
net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during
the year. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method
and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used
in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all
dilutive potential shares if their effect is anti-dilutive. As at December 31, 2022, there were 10,405,916 stock options and warrants
that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would
have been antidilutive for the periods presented.
Income
Taxes
The
Company must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates
and judgments are used in the calculation of tax credits, tax benefits, tax deductions, and in the calculation of certain deferred taxes
and tax liabilities. Significant changes to these estimates may result in an increase or decrease to the Company’s tax provision
in a subsequent period.
The
provision for income taxes was composed of the Company’s current tax liability and changes in deferred income tax assets and liabilities.
The calculation of the current tax liability involves dealing with uncertainties in the application of complex tax laws and regulations
and in determining the liability for tax positions, if any, taken on the Company’s tax returns in accordance with authoritative
guidance on accounting for uncertainty in income taxes. Deferred income taxes are determined based on the differences between the financial
reporting and tax basis of assets and liabilities. The Company must assess the likelihood that it will be able to recover the Company’s
deferred tax assets. If recovery is not likely on a more-likely-than-not basis, the Company must increase its provision for income taxes
by recording a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. However, should
there be a change in the Company’s ability to recover its deferred tax assets, the provision for income taxes would fluctuate in
the period of such change.
Contingencies
Contingencies
are evaluated and a liability is recorded when the matter is both probable and reasonably estimable. Gain contingencies are evaluated
and not recognized until the gain is realizable or realized.
Off-Balance
Sheet Arrangements
During
the periods presented, we did not have any off-balance sheet arrangements as defined under Regulation S-K Item 303(a)(4).
Results
of Operations - six months ended June 30, 2023 and 2022
| |
June 30, 2023 | | |
June 30, 2022 | | |
Change | | |
Change % | |
| |
| | |
| | |
| | |
| |
Research and development | |
$ | 558,148 | | |
$ | 1,063,243 | | |
$ | (505,095 | ) | |
| -48 | % |
General and administrative | |
| 4,291,987 | | |
| 3,061,710 | | |
| 1,230,277 | | |
| 40 | % |
Interest expense /(income) | |
| (76,871 | ) | |
| 1,345,944 | | |
| (1,422,815 | ) | |
| -106 | % |
Foreign exchange loss & Other | |
| 38,368 | | |
| - | | |
| 38,368 | | |
| - | |
FMV (income) expense adjustment for Contingent Stock & Warrants | |
| (93,977 | ) | |
| (4,078,930 | ) | |
| 3,984,953 | | |
| 100 | % |
Net loss | |
$ | 4,717,655 | | |
$ | 1,391,967 | | |
$ | 3,325,688 | | |
| 239 | % |
Revenue
The
Company has not generated any revenue to date.
Research
and Development
For
the six months ended June 30, 2023, Research and Development (“R&D”) expenses decreased to $558,148 compared to $1,063,243
for the six months ended June 30, 2022. The decrease of $505,095 was primarily due to R&D costs of approximately $575,000 from $575,000
in 2022 to $0 in 2023 paid to Safegard for operating costs to use their facility and the purchase of R&D materials. In the 2022 period,
prior to the acquisition date the facility, had been used for further development, production of current prototype samples and related
testing. The operating costs are primarily related to the use of Safegard’s workforce, utility costs incurred and other services.
We had further decreased in stock compensation expense of approximately $50,000, primarily due to the timing of awards and a decrease
of $12,000 in other R&D costs. Partially offsetting the decreases was an increase in depreciation related to R&D equipment of
$132,000.
General
and Administrative
For
the six months ended June 30, 2023, General and Administrative (“G&A”) expenses were $4,291,987 as compared to $3,061,710
for the six months ended June 30, 2022. The increase of $1,230,277 was primarily attributable to increases in: i) payroll and consulting
fees of $536,000 from $781,546 in 2022 to $1,217,117 in 2023, primarily due to increases in compensation and consulting fees incurred,
and additional headcount increases. ii) increases in stock compensation expense, due to new option awards and timing of award vesting,
of approximately $98,000 from $539,000 in 2022 to $637,000 in 2023. Further, we had increases due, relating to a contract settlement
during the second quarter of 2023 for $375,000 , marketing ($101,000), professional fees ($74,000), insurance ($157,000), rent ($60,000),
computer ($22,000), other operating costs ($186,000) and depreciation ($155,000) partially offset by decreases from patent and registration
fees ($43,000), board fees ($26,000), travel ($55,000) and public company related expenses ($410,000). In 2022, public company costs
were primarily related to the IPO.
Interest
expense (income)
Interest
income was $76,871 for the six months ended June 30, 2023, as compared to interest expense, net of interest income, of $1,345,944 for
the six months ended June 30, 2022. Interest expense decreased by $1,422,815 due to the financing which was in December 2021 which was
repaid at the IPO closing with net proceeds. The interest was payable at an 8% face amount of $47,111 plus accreted interest of $1,299,985
on the $2,000,000 Note Payable.
FMV
Adjustment for Derivatives
The
Warrants require the FMV to be remeasured at each reporting date while recognition of the changes in fair value to income or expense
in the consolidated statement of operations. For the six months ended June 30, 2023, the Company recorded a $93,977 FMV loss to reflect
the increase in the Warrant liability. For the six months ended June 30, 2022, the Company recorded a $4,078,930 FMV gain to reflect
the decrease in the Warrant liability. (See Note 7, 8 and 10 to the Unaudited Condensed Consolidated Financial Statements)
Liquidity
and Capital Resources
At
June 30, 2023 and December 31, 2022, we had a cash balance of $2,924,019 and $4,107,897, respectively. The Company had working capital
of $1,197,575 and $2,416,928 as of June 30, 2023 and December 31, 2022, respectively. The decrease in our working capital was primarily
by uses of cash in operations for the six month ended June 30, 2023 offset by net proceeds from the Offering in February 2023 which resulted
in net proceeds of approximately $3.2M. (See below and Note 8 to the Condensed Consolidated Financial Statements)
On
February 3, 2023, we completed a securities purchase agreement (“Offering”) with institutional investors and received net
proceeds from the Offering were approximately $3.2 million, net of $600,000 in fees relating to the placement agent and other offering
expenses. The Offering was priced at the market under Nasdaq rules. In connection with the Offering, we issued 2,248,521 units at a purchase
price of $1.69 per unit. Each unit consists of one share of common stock and one non-tradable warrant (Offering Warrant) exercisable
for one share of common stock at a price of $1.56. The Offering Warrants have a term of five years from the issuance date. (See Notes
8 to the Condensed Consolidated Financial Statements)
On
April 13, 2022, we completed its IPO which was declared effective by the SEC, and the Company’s common stock and warrants began
trading on the Nasdaq Capital Market or Nasdaq on April 14, 2022 and which closed on April 19, 2022. The net proceeds from the IPO were
approximately $14.2 million of which $5,778,750 was attributed to the warrant liability (See Notes 8 and 10 to the Condensed Consolidated
Financial Statements).
Cash
Flows
Net
Cash Used in Operating Activities
The
Company used cash of $4,131,000 and $3,093,105 in operating activities for the six months ended June 30, 2023 and 2022, respectively.
The increase in cash used of $1,037, 895, was principally due to the Company incurring additional operating expenses during the six months
ended June 30, 2023.
Net
Cash Used in Investing Activities
For
the six months ended June 30, 2023 and 2022, the Company used cash in investing activities of $342,525 and $2,813,355, respectively.
In both periods cash was used to acquire or pay deposits for fixed assets equipment of $342,525 and $463,355, respectively. Further,
in 2022 the Company used $2,350,000 related to escrow payments for the acquisition of Safegard.
Net
Cash Provided by Financing Activities
For
the six months ended June 30, 2023 and 2022, the Company provided cash from financing activities of $3,238,711 and $12,235,475, respectively.
In the 2023 period, the cash provided from the Offering in February 2023. In the 2022 period, the cash provided was primarily from the
IPO net proceeds of $14,202,975, prior to the effect of recording the liability attributed to the warrants from the IPO, less the Notes
repayment of $2,000,000.
Off-Balance
Sheet Arrangements
We
do not have any off-balance sheet arrangements as defined in Regulation S-K Item 303(a)(4).
Results
of Operations
Comparison
of the Years Ended December 31, 2022 and, 2021.
| |
Year Ended | | |
| |
| |
December
31, 2022 | | |
December
31, 2021 | | |
Change | | |
Change % | |
Research and development | |
$ | 2,280,933 | | |
| 1,690,865 | | |
$ | 590,068 | | |
| 35 | % |
General and administrative | |
| 6,457,860 | | |
| 2,806,801 | | |
| 3,651,059 | | |
| 130 | % |
Interest expense (income) | |
| 1,320,416 | | |
| 166,746 | | |
| 1,153,670 | | |
| 692 | % |
FMV gain adjustment for derivatives | |
| (5,392,911 | ) | |
| - | | |
| (5,392,911 | ) | |
| - | |
Foreign currency Loss | |
| 496 | | |
| - | | |
| 496 | | |
| - | |
Other | |
| (27,132 | ) | |
| - | | |
| (27,132 | ) | |
| - | |
Net loss | |
$ | 4,639,662 | | |
$ | 4,664,412 | | |
$ | (24,750 | ) | |
| 1 | % |
Revenue
The
Company has not generated any revenue to date.
Research
and Development
For
the year ended December 31, 2022, Research and Development (“R&D”) expenses increased to $2,280,933 compared to $1,690,865
for the year ended December 31, 2021. The increase of $590,068 was due to increased R&D costs incurred at Safegard for labor $181,000
and other costs $207,000, which commenced after the acquisition on July 6, 2022. In addition, we had increases in depreciation related
to R&D equipment of $597,000 which had commenced in the fourth quarter of 2021. We had increases in stock compensation and consulting
fees of $4,000 from $321,000 in 2021 to $325,000 in 2022, decreases in engineering of $4,000 from $169,000 in 2021 to $165,000 2022 and
decreases in other R&D costs of $119,000 from $331,000 in 2021 to $212,000 in 2022. The aforementioned changes were offset by the
decrease in the Safegard operating cost of $275,000 from $850,000 in 2021 to $575,000 in 2022, incurred prior to acquisition. The operating
costs primarily related to the use of Safegard’s workforce, utility costs incurred and other services. The facility, since June
2020 and following the acquisition, has been used for further development, production of current prototype samples and related testing.
General
and Administrative
For
the year ended December 31, 2022, General and Administrative (“G&A”) expenses were $6,457,860 as compared to $2,806,801
for the year ended December 31, 2021. The increase of $3,651,059 was primarily attributable to increases in payroll and related of: i)
payroll and consulting fees of $805,000 from $918,000 in 2021 to $1,723,000 in 2022, primarily due to increased amounts of payroll and
increased staffing, including fifty-two staff members and $187,000 relating to the Safegard acquisition from date of acquisition and
additional other staff and pay of $618,000 from $918,000 in 2021 to $1,355,000 in 2022 and ii) decrease in stock compensation expense,
due to timing of option awards and vesting, of approximately $175,000 from $1,091,000 in 2021 to $916,000 in 2022. In addition, we had
increases in G&A in the year ended December 31, 2022 of approximately $3,021,000 principally from increased: marketing and promotion
($878,000), professional fees ($178,000), travel ($152,000), board fees ($151,000), insurance ($521,000). public company and investor
relations related ($294,000), issuance costs related to the warrants ($550,000), rent and office expenses ($109,000) and other ($188,000).
Interest
expense (income)
Interest
expense, net of interest income, was $1,320,416 for the year ended December 31, 2022, compared to interest expense of $166,746 for the
year ended December 31, 2021. Interest expense increased by $1,153,670 due to the financing entered into in December 2021 which resulted
in interest payable at the 8% face amount of $47,111 plus accreted interest of $1,299,985 on the $2,000,000 Note Payable which was repaid
at the IPO closing with net proceeds.
FMV
Adjustment for Derivatives
The
value of the Note Warrants requires the Fair Market Value (“FMV”) to be remeasured at each reporting date while outstanding
with recognition of the changes in fair value to other income or expense in the statement of operations and comprehensive loss. For the
year ended December 31, 2022, the Company recorded a $5,392,911 FMV gain to reflect the decrease in the Note Warrants and Warrants liabilities
issued with the IPO. (See Notes 7, 8 and 10 to the Consolidated Financial Statements)
Liquidity
and Capital Resources
On
April 13, 2022, we completed its IPO which was declared effective by the SEC, and the Company’s common stock and warrants began
trading on the Nasdaq Capital Market or Nasdaq on April 14, 2022 and which closed on April 19, 2022. The net proceeds from the IPO were
approximately $14.2 million of which $5,778,750 was attributed to the warrant liability (See Notes 8 and 10 to the Consolidated Financial
Statements).
At
December 31, 2022 and 2021, we had a cash balance of $4,107,897 and $1,479,166, respectively. The Company has working capital of $2,416,928
as of December 31, 2022 vs working capital deficiency of $1,156,998, as of December 31, 2021. The increase in our working capital was
primarily related to net proceeds from our initial public offering of approximately $14.2 million prior to the effect of recording the
liability attributed to the warrants from the IPO, less use of cash in operations, investing in fixed assets purchased, repayment of
the Note Payable of $2.0 million and $2.4 million paid relating to the Safegard acquisition.
On
February 3, 2023, we completed a securities purchase agreement (“Offering”) with institutional investors and received net
proceeds from the Offering were approximately $3.2 million, net of $600,000 in fees relating to the placement agent and other offering
expenses. The Offering was priced at the market under Nasdaq rules. In connection with the Offering, we issued 2,248,521 units at a purchase
price of $1.69 per unit. Each unit consists of one share of common stock and one non-tradable warrant exercisable for one share of common
stock at a price of $1.56. The warrants have a term of five years from the issuance date. (See Notes 16 to the Consolidated Financial
Statements)
Cash
Flows
Net
Cash Used in Operating Activities
The
Company used cash of $6,433,159 and $3,147,736 in operating activities for the year ended December 31, 2022 and 2021, respectively. The
increase in cash used was principally due to the Company incurring additional G&A expenses and R&D activities as described above
during year ended December 31, 2022.
Net
Cash Used in Investing Activities
For
the year ended December 31, 2022 and 2021, the Company used cash in investing activities of $3,117,916 and $2,343,730, respectively.
In both years, cash was used to acquire or pay deposits for machinery and equipment of $542,662 and $2,221,830, respectively. Further,
in the year ended December 31, 2022 and 2021, the Company used $2,365,576 and $75,000, respectively the acquisition of Safegard or related
escrow payments.
Net
Cash Provided by Financing Activities
For
the year ended December 31, 2022 and 2021, the Company provided cash from financing activities of $12,235,475 and $5,180,429 respectively.
In the 2022 period, the cash provided was primarily from the IPO net proceeds of $14,202,975, prior to the effect of recording the liability
attributed to the warrants from the IPO, less the Notes repayment of $2,000,000. In 2021, the cash provided was from stock subscriptions
from a private placement.
Off-Balance
Sheet Arrangements
We
do not have any off-balance sheet arrangements as defined in Regulation S-K Item 303(a)(4).
Emerging
Growth Company Status
We
are an “emerging-growth company”, as defined in the JOBS Act, and, for as long as we continue to be an emerging growth company,
we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging
growth companies, including, but not limited to, not being required to have our independent registered public accounting firm audit our
internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote
on executive compensation and stockholder approval of any golden parachute payments not previously approved. As an emerging growth company,
we can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend
to avail ourselves of these options. Once adopted, we must continue to report on that basis until we no longer qualify as an emerging
growth company.
We
will cease to be an emerging growth company upon the earliest of: (i) the end of the fiscal year following the fifth anniversary of the
initial public offering; (ii) the first fiscal year after our annual gross revenue are $1.235 billion or more; (iii) the date on which
we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) the end of
any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million as of the end of the second
quarter of that fiscal year. We cannot predict if investors will find our common stock less attractive if we choose to rely on these
exemptions. If, as a result of our decision to reduce future disclosure, investors find our common shares less attractive, there may
be a less active trading market for our common shares and the price of our common shares may be more volatile.
We
are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates plus the aggregate
amount of gross proceeds to us as a result of the IPO is less than $700 million and our annual revenue was less than $100 million during
the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock
held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed
fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company
at the time, we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that
are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most
recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller
reporting companies have reduced disclosure obligations regarding executive compensation.
Emerging
Growth Company Status
We
are an “emerging-growth company”, as defined in the JOBS Act, and, for as long as we continue to be an emerging growth company,
we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging
growth companies, including, but not limited to, not being required to have our independent registered public accounting firm audit our
internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote
on executive compensation and stockholder approval of any golden parachute payments not previously approved. As an emerging growth company,
we can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend
to avail ourselves of these options. Once adopted, we must continue to report on that basis until we no longer qualify as an emerging
growth company.
We
will cease to be an emerging growth company upon the earliest of: (i) the end of the fiscal year following the fifth anniversary of the
initial public offering; (ii) the first fiscal year after our annual gross revenue are $1.235 billion or more; (iii) the date on which
we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) the end of
any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million as of the end of the second
quarter of that fiscal year. We cannot predict if investors will find our common stock less attractive if we choose to rely on these
exemptions. If, as a result of our decision to reduce future disclosure, investors find our common shares less attractive, there may
be a less active trading market for our common shares and the price of our common shares may be more volatile.
We
are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates plus the aggregate
amount of gross proceeds to us as a result of the IPO is less than $700 million and our annual revenue was less than $100 million during
the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock
held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed
fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company
at the time, we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that
are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most
recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller
reporting companies have reduced disclosure obligations regarding executive compensation.
BUSINESS
Background
and Overview
Sharps
Technology, Inc. is a medical device company that has designed and patented various safety syringes which we are seeking to commercialize.
We were incorporated under the laws of the State of Wyoming on December 16, 2017. Sharps was incorporated to purchase, develop and commercialize
the intellectual property resulting in a family of smart safety syringe products. We closed the acquisition of this intellectual property
in the fourth quarter of 2017. The intellectual property we purchased consisted of issued patent and patent files, all new designs and
iterations, samples, regulatory files, manufacturing files, product testing files and market research files relating to such safety syringe
products.
In
June 2020, we entered into an asset/share purchase agreement with Safegard Medical and certain other parties and in August 2020, October
2020, and July 2021, we entered into amendments to this agreement (as amended, the “Safegard Agreement”). Under the Safegard
Agreement, we received an option to purchase either the stock of Safegard or certain assets of Safegard, including a manufacturing facility
in Hungary registered with the FDA and CE for the manufacture of safety syringes, for $2.5 million in cash plus additional consideration
of 100,000 shares of common stock and 125,000 stock options with an exercise price of $2.00. Under the Safegard Agreement, we were granted
the right to operate this facility at our expense and continued to do so through the closing date which occurred on July 6, 2022.
Our
safety syringes products, which we refer to as the Sharps Provensa™ and Securgard™, are ultra-low waste and have safety features,
which we believe will provide us a competitive advantage over other syringes. Sharps Provensa is a patented and FDA-cleared safety syringe
addressing the important needs of the global healthcare market. We received FDA clearance for the Sharps Provensa on June 12, 2006, for
subcutaneous and intramuscular injections into the human body.
As
further discussed below, although we currently have some production capacity for our products and thus ability to receive and fulfill
orders, we expect that the September 2023 Private Placement will allow us to increase our production capacity and thus help us
to generate and fulfill orders for our product line and advance our new products in connection with recent collaboration arrangements
with Nephron Pharmaceutical. We anticipate that we will commence receiving orders for and producing commercial quantities of our products.
However, we have not generated sales or received any orders to date and there is no assurance we will receive any orders for our products.
We
anticipate that we will commence receiving orders for and producing commercial quantities of our Sharps products once inventory levels
are available.
Our
Products
Ultra-low
waste space syringes are the preferred syringe for the administration of many vaccines and injectable medications. In addition, passive
safety features are those most requested by clinicians in the field, in order to avoid infectious needlestick injuries. Our suite of
products is designed to work with vials as well as pre-fillable syringes which are largely used by the pharmaceutical industry. Our Sharps
Provensa Ultra - Low Waste, smart safety syringes engage all safety features, automatically, when the injection is given (and are thus
considered to have passive safety features). The needle tip is covered even before removal from the patient - providing a very high level
of safety. Our design is very stingy with using the medication contained in the syringe. Independent testing measured typical waste space
found in commonly used hypodermic syringes to exceed 50 microliters with several resulting in waste space in excess of 100 microliters.
Our Sharps Provensa has approximately 10 microliters of waste space. When some other syringes are used, vials and pre-fillable syringes
are overfilled to anticipate this higher waste. With Sharps Provensa safety syringes, the overfilling can be virtually eliminated. Of
the eleven commercially available syringes tested, only two (BD Integra and Sharps Provensa) had measured waste space which would place
them in a low waste space category. We estimate that over 95% of the market comprise the products tested, other than the Integra. We
have tested the number of doses, as recommended by Pfizer, which can be extracted from a 5 dose vial of Covid 19 vaccine. Using our Sharps
Provensa Ultra Low – Waste smart safety syringe we are able to extract 7 doses from a 5 dose vial. This is accomplished by utilizing
the overfill of the vial, which would be thrown away with an inefficient syringe design.
Sharps
Provensa has the following features and benefits:
|
● |
Traditional one-handed
operation; |
|
|
|
|
● |
Passive safety features,
which engage automatically, when the injection is given providing maximum protection even before withdrawal of the needle from the
patient; |
|
|
|
|
● |
SharpsLock interchangeable
needle heads connect fast from drawing medication to injection; |
|
|
|
|
● |
Orange color plunger tip
contrasts against black color graduation for proper reading of medication; |
|
|
|
|
● |
Reduces costly discarded
medicine from every inefficient injection with our ultra-low waste space syringes; |
|
|
|
|
● |
No leakage or breakage
at the needlehead connection point; |
|
|
|
|
● |
Prevents improper reuse
of needles and syringes |
The
Sharps Provensa needle tip goes through the skin sharp, delivering the medicine or vaccine, and comes out of the body shielded, protecting
the healthcare worker and the public. We believe that with use of Sharps Provensa, with its aforementioned features and benefits, the
instance of needlestick injuries can be dramatically reduced.
Sharps
Provensa Ultra - Low Waste smart safety syringes have been designed to address four primary problems:
1.
Accidental needlestick injuries: These occur when the clinician is stuck with an infected needle. According to the WHO, these
accidents likely take place in excess of 2 million times per year. When a clinician receives an infectious needlestick injury, any blood
borne disease which the patient had, could be transmitted to them.
A
2016 World Health Organization Commission reported that over 16 billion injections are delivered worldwide each year (pre-Covid era).
A recent analysis showed that 55.1% of healthcare workers had sustained a needlestick injury, or NSI, at some point in their career.
Over one million healthcare worker NSIs are documented each year in the US and Europe and over 3 million worldwide with the true incidence
believed to be more than double those numbers as over half of injuries go unreported.
US
data on injury trends disturbingly show recent worsening despite safety campaigns and protocols. In a 2016 study, economic analysis has
placed the average cost of an NSI at $747 (direct plus indirect costs) and strongly supported the use of safety-engineered devices for
injection. Low compliance with recommended safety protocols can be seen upon examination of injury data where a majority of injuries
continue to occur with non-safety devices or before full activation of a safety-protection feature.
There
are over 20 such transmissible blood borne diseases, including AIDS and hepatitis. Safety syringes provide protection by active or passive
safety mechanism. Active safety requires the clinician to activate the safety features of the syringe following an injection to the patient.
This can be done by pushing a hinge or engaging a slide. Compliance is low and some designs require close proximity to the sharp needle,
in order to activate. A 2019 EPInet report demonstrates that over 80% of NSIs from safety devices occurred at a time when their safety
feature not activated or only partially activated. Passive safety occurs simply by giving the injection in the ordinary way and having
the product design engage the safety features automatically.
2.
Waste Space: all needle and syringes have space which permits the accumulation of injectable medications which cannot be accessed
and are thrown away with each injection. Sharps Provensa has approximately 10 microliters of waste space - others have as much as 140
microliters of waste space. Without knowing what syringe is going to be used, pharmaceutical companies must overfill their vials to account
for this loss. For difficult to manufacture injectable medications, this reduces the number of life saving doses which could be available
to the public. When doses are extremely small, waste space can exceed the required dose. That means more medications are being thrown
away than injected into the patient. As an example, certain Covid 19 vaccine injections approved for booster shots and for children require
lower doses. The lower the dose the higher the percentage of wasted medications. Sharps Provensa maximizes the number of doses obtained
from a vial by minimizing the waste space. A growing trend for pharmaceutical companies is to prefill a syringe and sell it with the
desired precise dose. A needlehead assembly is affixed to the syringe and this avoids the need for a vial. Sharps Provensa saves the
pharmaceutical company from overfilling the pre-filled syringe and produces more doses from the same bulk material. Pfizer has approved
Sharps Provensa Ultra - Low Waste smart safety syringes for use with their Covid 19 vaccine. According to a July 2016 Journal of the
American Medical Association article, for a small group of injectable medications, the median value of the wasted medicine per dose was
$5.00 for high-dead-space medications, and about $0.50 for low dead-space medications. Over one year, the cost of the waste for high-dead-space
medications ranged from $558 to $2,329 (a median value of $1,638) compared to $68 to $205 (a median value of $125) for low-dead-space
medication.
3.
Exchangeable needle head assembly: because we don’t have a single needle permanently attached to a syringe, this permits
the clinician to attach the required needle length and gauge to the syringe, while maintaining all safety features and benefits. This
reduces the amount of inventory otherwise required.
4.
Draw needle: Our Sharps Provensa product line has a draw needle, which facilitates very rapid draw of all injectable medications
from a vial into a syringe, including those medications which are viscous and difficult to draw in any other way. A draw needle has a
larger inside diameter which facilitates fast and proper draw. Once the medication has been drawn into the vial, the draw needle is replaced
with the needle size and gauge required for the patient’s injection. If the needle that is to be used on the patient is a high
gauge thin needle, and is first used to draw the medication from the vial (which would not ocurr with the Sharps Provensa draw needle),
the needle tip may be damaged or lose some of its sharp edge. This could result in more pain/discomfort for the patient or an incomplete
injection.
Draw
needles are commonly used. If the clinician wishes to use a very thin needle for injection into the patient, a draw needle would be used
to puncture the septum of the vial. Draw needles are commonly 18 gauge in size, while needle gauges for injection into the patient range
up to 31/32 gauge (the higher the gauge, the thinner the needle). The thinner the needle, the smaller the inside diameter, the greater
the difficulty to draw medication into the syringe, from the vial. A higher gauge needle has a greater chance of damage when puncturing
the septum of the vial. We believe the Sharps Provensa safety syringes will offer the only passive safety syringes that include draw
needles with passive safety and low-waste features.
We
know of no safety syringe on the market with all of these benefits.
The
Sharps Provensa will come in 4 different designs for use in vials and pre-filled syringes. The Sharps Provensa will be usable in all
traditional settings, including hospitals, clinics, physician offices, and pharmacies.
We
are in discussions with pharmaceutical companies and distributors for sales of our Sharps Provensa. We also intend to market the Sharps
Provensa to the US and foreign governments. In certain limited instances, we may also seek to sell the Sharps Provensa to hospitals and
clinician offices.
Securgard
TM has the following features and benefits:
|
● |
Traditional
one-handed operation; |
|
|
|
|
● |
Auto
Disable Function prevents reuse; |
|
|
|
|
● |
Reduces
costly discarded medicine from every inefficient injection with our ultra-low waste space syringes; |
|
|
|
|
● |
No leakage or breakage
at the needlehead connection point; |
|
|
|
|
● |
Prevents
improper reuse of needles and syringes |
Securgard
products facilitate entry into markets not permitted by Sharps Provensa. The products have FDA approval, CE mark and WHO approval.
Manufacturing
and Supply Agreement
On
September 29, 2022, the Company entered into an agreement (the “Nephron Agreement”) with InjectEZ, LLC (“InjectEZ”),
Nephron Pharmaceuticals Corporation (“NPC”), Nephron SC, Inc. (“NSC”), and Nephron Sterile Compounding Center
LLC (“Sterile”) (NPC, NSC, and Sterile are sometimes collectively referred to as “Nephron”), pursuant to which
the Company will provide technical advice and assistance to support manufacturing by InjectEZ, purchase certain quantities of syringes
as the Company may order or require, and collaborate with Nephron on certain related business endeavors.
The
Nephron Agreement is for a period of four (4) years, expiring on September 28, 2026 and continues thereafter for successive one (1)
year periods.
In
connection with the Nephron Agreement, the Company will enter into a manufacturing and supply agreement with InjectEZ regarding
the development and manufacture of high value pre-fillable syringe systems that can be used by the healthcare industry, pharmaceutical
markets and including Nephron on terms agreed upon by the parties. The Nephron Agreement will allow for the supply of the pre-fillable
systems of different sizes and with specialized technology that will be compatible with industry standards and technology beginning in
early 2023. The Agreement also allows for further expansion of manufacturing capabilities by the Company working with InjectEZ to support
future industry and customer demand of pre-fillable systems as detailed in the Agreement.
In
connection with the Nephron Agreement, the Company will enter into a Pharma Services Program (PSP) with Nephron that will create new
business development growth opportunities for both companies. These opportunities will include the development and sale of next generation
drug delivery systems that will be produced by the Company and can be purchased by healthcare Industry, pharmaceutical markets and Nephron.
In
connection with the Nephron Agreement, the Company will enter into a distribution program with Nephron in which the Company can utilize
Nephron’s third party logistics providers in support of distributing, obtaining product qualifications including clinical trials
with Nephron’s healthcare customers for all products developed by the Company.
NPC
is a West Columbia, S.C.-based company that develops and produces safe, affordable generic inhalation solutions and suspension products.
NPC also operates an industry-leading 503B Outsourcing Facility division, which produces pre-filled sterile syringes, luer-lock vials,
IV bottles and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. NPC launched a CLIA-certified diagnostics
lab in 2020 where it tests people for COVID-19 and administers vaccinations.
A
copy of the Nephron Agreement was filed as Exhibit 10.1 to the Current Report on Form 8-K filed on October 4, 2022,
and is also incorporated herein as Exhibit 10.27.
Distribution
Agreement
On
December 8, 2022, Sharps entered into a distribution agreement (the “Distribution Agreement”) with Nephron Pharmaceuticals
pursuant to which the Sharps Technology appointed Nephron as its exclusive distributor for the sale and distribution of the products
subject to the Distribution Agreement in and throughout the United States. Pursuant to the Distribution Agreement, the price of shipping
products will be based on the cost of delivery to Nephron’s warehouse and the Company will pay for the cost of delivery to Nephron.
The Distribution Agreement has a term of two years and will continue in effect unless either party notifies the other party of its desire
to terminate. At any time and for any reason, either party can terminate the Distribution Agreement after thirty (30) days’ notice
and in the event of a breach of any of the Distribution Agreement’s terms and provisions, either party can terminate the Distribution
Agreement by providing 90 days written notice. The Company has the right to terminate the Distribution Agreement with 60 days written
notice if certain conditions are met as set forth in the Distribution Agreement.
A
copy of the Distribution Agreement was filed as Exhibit 10.1 to the Current Report on Form 8-K filed on December 13,
2022, and also incorporated herein as Exhibit 10.28.
Competitive
Environment
We
anticipate our major domestic competitors will include Retractable Technologies, Inc., Becton Dickinson & Company, Medtronic Minimally
Invasive Therapies (“Medtronic,” formerly known as Covidien), Terumo Medical Corp., Smiths Medical, and B Braun. Our competitors
may have greater financial resources, larger and more established sales, marketing, and distribution organizations; and greater market
influence, including long-term and/or exclusive contracts.
We
anticipate that we will compete primarily on the basis of healthcare worker and patient safety, product performance, and quality. We
believe our competitive advantages will include the combination of passive safety and ultra low waste features.
Government
Regulations
In
the United States, the Federal Food, Drug and Cosmetic Act, or FDCA, FDA regulations and other federal and state statutes and regulations
govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval,
registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and
post-market surveillance. The FDA regulates the design, manufacturing, servicing, sale and distribution of medical devices. Failure to
comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal
to approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, civil penalties and criminal prosecution.
Unless
an exemption applies, each medical device we wish to distribute commercially in the United States will require marketing authorization
from the FDA prior to distribution. The two primary types of FDA marketing authorization applicable to a device are premarket notification,
also called 510k clearance, and premarket approval, also called PMA approval. The type of marketing authorization is generally linked
to the classification of the device. The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree
of risk the FDA determines to be associated with a device and the level of regulatory control deemed necessary to ensure the device’s
safety and effectiveness. Devices requiring fewer controls because they are deemed to pose lower risk are placed in Class I or II. Class
I devices are deemed to pose the least risk and are subject only to general controls applicable to all devices, such as requirements
for device labeling, premarket notification and adherence to the FDA’s current Good Manufacturing Practices, or cGMP, known as
the Quality System Regulations, or QSR. Class II devices are intermediate risk devices that are subject to general controls and may also
be subject to special controls such as performance standards, product-specific guidance documents, special labeling requirements, patient
registries or post-market surveillance. Class III devices are those for which insufficient information exists to assure safety and effectiveness
solely through general or special controls and include life sustaining, life-supporting or implantable devices, devices of substantial
importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. Our Sharps
Provensa has been cleared by the FDA under the 510k premarket notification process (Class II).
Outside
of the United States, our ability to market our products will be contingent also upon our receiving marketing authorizations from the
appropriate foreign regulatory authorities, whether or not FDA approval or clearance has been obtained. The foreign regulatory approval
process in most industrialized countries generally encompasses risks similar to those we will encounter in the FDA approval or clearance
process. The requirements governing conduct of clinical trials and marketing authorizations, and the time required to obtain requisite
approvals, may vary widely from country to country and differ from those required for FDA approval or clearance.
The
sale of medical products is subject to laws and regulations pertaining to health care fraud and abuse, including state and federal anti-kickback,
anti-self-referral, and false claims laws in the United States.
Intellectual
Property
Intellectual
property rights, particularly patent rights, are material to our business. We own three patents used in the Sharps Provensa, which expire
between 2035 and 2040. Our issued patents include a design patent (USD743,025) for the ornamental design for a safety syringe, a patent
(US 10,980,950) for an ultra low-waste needle and syringe system that automatically and passively renders a needle safe during the injection
process, and a patent (US 11,154,663) for a pre-filled safety needle and syringe system.
We
have three additional pending patent applications in the United States and one PCT (Patent Cooperation Treaty) patent application. The
patent applications, which we own, have an anticipated expiration date of June 22, 2040. The pending patent applications are for (i)
an ultra-low waste disposable syringe with self-adjusting integrating safety features, (ii) an ultra-low waste disposable safety syringe
for low dose injections, and (iii) a needle and syringe system with automatic safety shield that renders a needle safe. Our pending patent
applications are for utility patents. With respect to the last of these patent applications, we have, in addition to our United States
patent application, also filed a PCT patent application. A PCT application is a single utility patent filing that provides international
patent-pending status. By itself, a PCT application will not lead to foreign patents. To obtain foreign patents for this PCT patent application,
we will need to file individual patent applications at a later time.
We
have certain trademarks for Sharps Provensa, Sharps Provensa Ultra-Low Waste and filed applications to register other trademarks
for use in our Sharps Provensa product line.
Recent
Developments
Nephron
Asset Purchase Agreement
On
September 22, 2023, Sharps entered into a series of agreements with Nephron and Nephron’s wholly owned subsidiary InjectE, LLC.
Sharps entered into an asset purchase agreement (the “Asset Purchase Agreement”) to purchase certain equipment and leasehold
improvements at Nephron’s facility (the “Facility”) in West Columbia, South Carolina. The Asset Purchase Agreement
provides for a cash purchase price of $40,378,594 and the issuance of a five (5) year subordinated promissory note (the “Nephron
Note”) to Nephron in the principal amount of $10.0 million which bears interest at 8% per annum to be paid upon the closing (the
“Closing”) of the transaction. The Nephron Note will be redeemable (25% per quarter) during the first year if Nephron’s
syringe purchase orders result in revenue of at least $7,500,000 per quarter during the first year. The Company will also issue Nephron
warrants to purchase 4% of the Company’s common stock on a fully diluted basis (the “Nephron Warrants”) exercisable
for a five-year period at an exercise price of $1.56 per share.
In
conjunction with the execution of the Asset Purchase Agreement, on September 19, 2023, the Company entered into a ten-year Purchase Agreement
with Nephron whereby Nephron agreed to utilize the Sharps as its exclusive pre-filled COC syringe manufacturer and to purchase a minimum
aggregate of $450.0 million of syringes over the term of the Purchase Agreement. The Purchase Agreement contains specific quantities
of products required to be purchased from the Company during the term of the Purchase Agreement. The Purchase Agreement provides that
Nephron will make an initial purchase order of $32.0 million upon the closing of the Asset Purchase Agreement . The effectiveness of
the Purchase Agreement is subject to the closing of the Asset Purchase Agreement (the “Closing”).
At
the Closing, Sharps will enter into a 10 year lease for the Facility in which the Assets are located and will be operated by the Company.
The lease provides for four successive five year options, with a right to purchase the Facility, which lease will be effective upon Closing
(the “Lease”). The Lease provides for a monthly rental fee of $40,550, subject to increase after 5 years based on CPI adjustments.
In
addition, Sharps and Nephron, will enter into a two year Shared Services Agreement whereby Nephron will provide certain administrative
services and personnel to the Company in exchange for an agreed upon fee schedule. These services will assist the Company in establishing
its operations in the Facility.
The
closing of the Asset Purchase Agreement is subject to certain closing conditions. There can be no assurance that such closing conditions
will be satisfied but the Company anticipates closing the transaction within 60 days from the date of the Asset Purchase Agreement.
Private
Placement
On
September 27, 2023, the Company entered into a Securities Purchase Agreement (the “PIPE Purchase Agreement”) with certain
accredited investors purchasing common stock in this offering for a private placement offering (“Private Placement”) of (i)
2,581,479 unregistered shares of our common stock (the “PIPE Shares”) (or pre-funded warrants in lieu thereof with each pre-funded
warrant exercisable for one share of common stock (the “PIPE Pre-Funded Warrants”)) and (ii) unregistered warrants to purchase
8,750,003 of our common stock (the “SS Warrants” and together with PIPE Shares (PIPE Pre-Funded Warrants in lieu thereof),
the “PIPE Securities”). Pursuant to the PIPE Purchase Agreement, the Company has agreed to issue and sell 2,581,479 PIPE
Shares (or PIPE Pre-Funded Warrants in lieu thereof) together with the SS Warrants to purchase up to 8,750,003 shares of common stock at
a combined offering price of $1.074 per unit (less $0.001 for each PIPE Pre-Funded Warrant). The PIPE Securities were offered pursuant
to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities Act and/or Rule
506(b) of Regulation D promulgated thereunder. The PIPE securities are being registered in this Registration Statement.
The
PIPE Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all
of the PIPE Pre-Funded Warrants are exercised in full. Under the terms of the PIPE Pre-Funded Warrants, the Company may not effect the
exercise of any such warrant, and a holder will not be entitled to exercise any portion of any such warrant, if, upon giving effect to
such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, any other
persons acting as a group together with the holder or any of the holder’s affiliates, and any other persons whose beneficial ownership
of common stock would or could be aggregated with the holder’s for purposes of Section 13(d) or Section 16 of the Securities Exchange
Act of 1934, as amended) would exceed 4.99% of the number of shares of common stock outstanding immediately after giving effect to the
exercise, as such percentage ownership is determined in accordance with the terms of such warrant, which percentage may be increased
or decreased at the holder’s election upon 61 days’ notice to the Company subject to the terms of such warrants, provided
that such percentage may in no event exceed 9.99%
The
SS Warrants have an exercise price of $0.64 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance
and will expire five years from the date of issuance. The SS Warrants contain standard adjustments to the exercise price including
for stock splits, stock dividend, rights offerings and pro rata distributions.
The
gross proceeds to the Company from the private placement, before deducting placement agent fees and other estimated offering expenses
payable by the Company, was approximately $2,8 million. The Company intends to use the net proceeds from the Private Placement for working
capital and other general corporate purposes.
In
connection with the PIPE Purchase Agreement, the Company entered into a registration rights agreement (the “Registration Rights
Agreement”) with the investor. Pursuant to the Registration Rights Agreement, the Company will be required to file a resale registration
statement (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) to register
for resale of the common stock, the shares issuable upon the exercise of the PIPE Pre-Funded Warrants and the shares issuable upon exercise
of the SS Warrants within fifteen (15) days after the closing date (the “Filing Date”). Pursuant to the Registration Rights
Agreement, the Registration Statement shall be declared effective within 30 days after the Filing Date or 60 days following the Filing
Date if the Registration Statement is reviewed by the SEC. The Company will be obligated to pay certain liquidated damages to the investor
if the Company fails to file the resale registration statement when required, fails to cause the Registration Statement to be declared
effective by the SEC when required, of if the Company fails to maintain the effectiveness of the Registration Statement. This Registration
Statement includes the securities issued with the Private Placement in accordance with the Registration Rights Agreement.
Aegis
Capital Corp. acted as the placement agent in connection with the Private Placement. Pursuant to the engagement agreement , we paid
Aegis a commission equal to 8% of the gross proceeds received by the Company in the Private Placement. The Company has also paid Aegis
$100,000 for fees and expenses including attorney fees.
Employees
We
have eighty full-time employees, one of which is our Chief Executive Officer, and retain the services of additional personnel
on an independent contractor basis to support R&D, Finance, Marketing and Regulatory areas. We do not have any part-time employees.
Of the eighty employees, seventy-three work at our facilities in Hungary. We expect to add additional employees in order
to increase production capacity.
Facilities
We
lease office space, on a month-to-month basis, at 105 Maxess Road, Melville, New York 11747. Our monthly rent is $200.
We
operate a manufacturing facility in Hungary acquired in July 2022, which we previously used for development and testing of our products
and we currently use primarily for the manufacture of Sharps Provensa safety syringe. We are prepared to move our owned molds, machinery
and equipment to an alternative manufacturing location if necessary. See “Background and Overview.”
Legal
Proceedings
We
are not a party to any material legal proceeding, nor is our property the subject of any material legal proceedings.
Impact
of COVID-19
In
March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak has adversely
affected workforces, economies, and financial markets globally leading to an economic downturn in certain industries and countries. It
is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s
business or ability to raise funds. Management continues to monitor the situation but has not experienced a significant disruption to
its product development efforts.
MANAGEMENT
The
following table provides information regarding our executive officers and directors as of the date of this prospectus:
Name |
|
Age |
|
Position(s) |
Executive Officers: |
|
|
|
|
Robert M. Hayes |
|
57 |
|
Chief Executive Officer and Director |
Andrew R. Crescenzo |
|
67 |
|
Chief Financial Officer |
Non-Executive Directors and Director Nominees: |
|
|
|
|
Soren Bo Christiansen, MD |
|
68 |
|
Chairman |
Paul K. Danner |
|
66 |
|
Director |
Timothy J. Ruemler |
|
65 |
|
Director |
Brenda Baird Simpson |
|
|
|
Director |
Jason Monroe |
|
37 |
|
Director |
Executive
Officers
Robert
M. Hayes
Robert
M. Hayes has been the Chief Executive Officer and director for Sharps Technology since September 2021. Before joining the Company, he
served as Senior Director of Product Management and Innovation and other roles with Gerresheimer Pharmaceutical Glass from 2010 to 2021
where he led commercial sales and strategic partnerships with top global healthcare companies. He has over 25 years’ experience
in the healthcare, medical device, and pharmaceutical manufacturing industry. Mr. Hayes received his Bachelor of Business Administration
from University of Toledo. Mr. Hayes’ healthcare industry and product management experience qualify him to serve on our board of
directors.
Andrew
R. Crescenzo
Andrew
R. Crescenzo, CPA has been Chief Financial Officer for Sharps Technology since May 2019 under a consulting agreement with CFO Consulting
Partners LLP through September 30, 2022 and as an employee since October 1, 2022. Before joining the Company, Mr. Crescenzo served in
various finance roles from 2006 to 2019 in biotech, manufacturing and distribution, including, CFO of United Metro Energy from 2014 to
2016; Senior VP of Finance of Enzo Biochem (NYSE:ENZ) from 2006 to 2014. Prior to 2006, he was an Executive Director from 2002 to 2006
and a Senior Manager from 1997 to 2002 at Grant Thornton LLP. Mr. Crescenzo is a Certified Public Accountant and received his Bachelor
of Business Administration from Adelphi University.
Non-Executive
Directors
Dr.
Soren Bo Christiansen
Soren
Bo Christiansen, Chairman of the Board for Sharps Technology, joined the team in April 2018 as a Board member, became Chairman of
the Board in December 2018 (and has been co-Chairman since 2021) , and was CEO from April 2019 until he stepped down in September 2021.
Dr. Christiansen worked for Merck & Co. Inc. for 30 years in Denmark, USA and Switzerland. He was Sr. VP Merck Vaccines (head of
the Global Commercial division), President Eastern Europe, Middle East & Africa and during the last four years of his career, he
was President for Europe, Middle East, Africa and Canada. He holds a medical degree from University of Copenhagen Denmark. Dr. Christiansen’s
medical and pharmaceutical knowledge and experience qualifies him to serve on our board of directors.
Paul
K. Danner
Paul
K. Danner, a member of the Board of Directors and Chairperson of the Audit Committee, joined Sharps Technology in September 2021. Since
2013, Mr. Danner has been chief financial and administrative officer of PAY2DAY Solutions, Inc. dba Authvia, a FinTech software developer
that provides merchants and consumers with a cloud-based CPaaS (Communications Platform as a Service) platform capable of providing end-to-end
payment flows, billing, consumer management, payment analytics, and consumer insights. From 2016 to 2018, Mr. Danner was chief executive
officer of Alliance MMA, Inc., which was a mixed martial arts organization offering promotional opportunities for aspiring mixed martial
arts fighters. As a senior business leader, Mr. Danner has served three Nasdaq-listed companies as the senior corporate executive. Additionally,
he has acquired extensive Board of Director expertise through six separate appointments totaling more than twenty-five years with three
Nasdaq and OTCQB listed companies including Chairman, Corporate Secretary and Audit Committee assignments, as well as two development-stage
ventures and one not-for-profit enterprise. Mr. Danner served as a Naval Aviator flying the F-14 Tomcat, and subsequently as an Aerospace
Engineering Duty Officer supporting the Naval Air Systems Command, for 8 years on active duty plus 22 years with the reserve component
of the United States Navy. He retired from the Navy in 2009 with the rank of Captain. Mr. Danner earned a BS degree in Business Finance
from Colorado State University, and he holds an MBA from the Strome College of Business at Old Dominion University. Mr. Danner’s
executive and marketing experience qualify him to serve on our board of directors.
Timothy
J. Ruemler
Timothy
J. Ruemler, a member of the Board of Directors and Chairperson of the Nominating Committee, joined Sharps Technology in September 2021.
He was division President SW Florida for Centex Homes from 1993 to 2007, where he was responsible for all aspects of the Real Estate
division’s activities. Mr. Ruemler has been retired since 2007. While at Centex Homes, Mr. Ruemler also held the positions of Sales
Manager, Construction Manager, Controller, and Assistant Controller for the Naples, Raleigh and Tampa divisions from 1986 until 1993.
Prior to his career at Centex Homes, he held auditor positions. He holds a BS in Accounting from Indiana State University. Mr. Ruemler’s
business operational experience qualify him to serve on our board of directors.
Brenda
Baird Simpson
Brenda
Baird Simpson has served on our board of directors in April 2022. Ms. Simpson has been senior vice president & chief nursing officer
at Centura Health in Centennial, CO since 2021. She was system vice president & chief nursing executive at Northeast Georgia Health
System from 2016 to 2021, and system senior vice president & chief nursing officer at CHI St. Vincent Health System in Little Rock,
AR, from 2007 to 2016. Ms. Simpson received a DNP from the University of South Alabama, an MSN from the University of Tennessee, Knoxville,
a BSN from Tennessee State University, Nashville, and an AND from the University of Tennessee, Martin. Ms. Simpson’s medical experience
qualifies her to serve on our board of directors.
Jason
L. Monroe
Jason
L. Monroe has served on our board of directors in April 2022 and serves as Chairperson of the Compensation Committee Mr. Monroe has been
sales manager at CVS Health since 2016, and was a pharmacy manager at CVS Health from 2014 to 2015. He was Adjunct Professor for Pharmacy
Technician program at Houston Community College from 2017 to 2019. Mr. Monroe received a PharmD from the Texas Southern University College
of Pharmacy & Health Science and a BS from Prairie View A&M University. Mr. Monroe’s healthcare experience qualifies him
to serve on our board of directors.
Board
Composition
Our
board currently consists of five directors, Robert M. Hayes, Soren Bo Christiansen, Paul K. Danner, and Timothy J.
Ruemler. Mr. Ruemler and Mr. Danner, Ms. .Simpson and Mr. Monroe are “independent directors” within the meaning
of the Listing Rules of the Nasdaq Stock Market.
Family
Relationships
No
family relationships exist between any of our officers or directors.
Director
Independence
The
Board evaluates the independence of each nominee for election as a director of our Company in accordance with the Nasdaq Listing Rules.
A majority of our Board Are “independent directors” within the meaning of the Nasdaq Listing Rules, and all directors who
sit on our Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee must also be independent directors.
Board
of Directors Term of Office
Directors
are elected at our annual meeting of shareholders and serve for one year until the next annual meeting of shareholders or
until their successors are elected and qualified.
Committees
of our Board of Directors
We
have established an Audit Committee, a Compensation Committee or a Nominating Committee, or any committees performing similar functions.
We have an audit committee that consists of Paul Danner, Jason Monroe and Brenda Simpson, a compensation committee consists of Timothy
Ruemler, Paul Danner, and Jason Monroe, and a nominating committee that consists of Timothy Ruemler, Jason Monroe, and Paul Danner.
Code
of Business Conduct and Ethics
We
have a Code of Business Conduct and Ethics (the “Code”) which applies to all of our directors, officers and employees.
The full text of our Code will be posted on our website under the Investor Relations section. We intend to disclose future amendments
to, or waivers of, our Code, as and to the extent required by SEC regulations, at the same location on our website identified above or
in public filings. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider
information contained on our website to be part of this prospectus or in deciding whether to purchase our shares of common stock.
Involvement
in Certain Legal Proceedings
Our
directors and executive officers have not been involved in any of the following events during the past ten years:
1. |
any bankruptcy petition
filed by or against such person or any business of which such person was a general partner or executive officer either at the time
of the bankruptcy or within two years prior to that time; |
|
|
2. |
any conviction in a criminal
proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); |
|
|
3. |
being subject to any order,
judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily
enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated
with any person practicing in banking or securities activities; |
|
|
4. |
being found by a court
of competent jurisdiction in a civil action, the SEC or the Commodity Futures Trading Commission to have violated a Federal or state
securities or commodities law, and the judgment has not been reversed, suspended, or vacated; |
|
|
5. |
being subject of, or a
party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended
or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law or regulation
respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection
with any business entity; or |
|
|
6. |
being subject of or party
to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity
or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated
with a member. |
EXECUTIVE
COMPENSATION
The
amounts below represent the compensation awarded to or earned by or paid to our named executive officers who served as our chief executive
officer or had total compensation of at least $100,000 for the years ended December 31, 2022 and 2021.
Summary
Compensation Table
Name and Principal Position | |
Calendar
Year | |
Salary or
Consulting
$ | | |
Bonus
$ | | |
Stock
Awards
$ | | |
Other
Payments
$ | | |
Option
Awards (6)
$ | | |
Total | |
| |
| |
| | |
| | |
| | |
| | |
| | |
| |
Robert M. Hayes, CEO (1) | |
2022 | |
$ | 313,333 | | |
| | | |
| | | |
| | | |
$ | 56,124 | | |
$ | 369,457 | |
| |
2021 | |
$ | 82,750 | | |
| - | | |
| - | | |
| | | |
$ | 541,779 | | |
$ | 624,529 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Dr. Soren Bo Christiansen, Chairman of the Board, former
CEO (2) | |
2021 | |
$ | 170,000 | | |
| - | | |
| - | | |
| | | |
$ | 24,547 | | |
$ | 194,547 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Alan R. Blackman, COO and Co- Chairman of the Board (3)(7) | |
2022 | |
$ | 272,669 | | |
$ | 250,000 | | |
$ | | | |
| 37,000 | | |
$ | 40,088 | | |
$ | 599,757 | |
| |
2021 | |
$ | 257,000 | | |
| - | | |
| - | | |
| | | |
$ | 187,096 | | |
$ | 444,096 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Barry Berler, CTO (4) | |
2022 | |
| 216,000 | | |
| | | |
$ | | | |
| 30,000 | | |
| 40,088 | | |
$ | 286,088 | |
| |
2021 | |
$ | 216,000 | | |
| - | | |
| - | | |
| | | |
$ | 187,096 | | |
$ | 403,096 | |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Andrew R. Crescenzo, CFO (5) | |
2022 | |
$ | 146,250 | | |
| | | |
| | | |
| | | |
| 12,026 | | |
$ | 158,276 | |
| |
2021 | |
$ | 73,375 | | |
| - | | |
| - | | |
| | | |
$ | 68,209 | | |
$ | 141,584 | |
(1) |
Mr. Hayes was appointed our chief executive officer on September
15, 2021. |
(2) |
Compensation relates to Dr. Christiansen serving as chief executive
officer and chairman of the Board from April 2019 to September 15, 2021. |
(3) |
Reflects consulting fees and/or salary earned, including accrued
and unpaid compensation of $91,667 and $54,000 at December 31, 2022 and 2021, respectively. Other payments represent tax differential
payments of $29,000 and expense allowance of $8,000. |
(4) |
Other compensation reflects travel allowances. |
(5) |
Reflects 2022 compensation as employee from October 1, 2022
to December 31, 2022 and consulting fees paid by CFO Consulting Partners LLC from January 1, 2022 to September 30, 2022 and in 2021 consulting
fees from CFO Consulting Partners, LLC, including $7,875 accrued and unpaid, as of December 31, 2021. |
(6) |
See note 9 to the audited financial statements for assumptions
used in valuation. |
(7) |
Effective July 27, 2023, Alan R. Blackman resigned from
the Board of Directors of the “Company, including his resignation as Co-Chairman of the Board, in which the Company and Mr. Blackman
entered into a Separation Agreement, as further described in Executive Employment Agreements. |
Executive
Employment Agreements
We
are party to an employment agreement, dated September 9, 2021, with Robert M. Hayes, our chief executive officer. Under the agreement,
we pay Mr. Hayes an annual salary of $270,000, and Mr. Hayes will be entitled to a performance bonus if the Company achieves certain
revenue amounts. Mr. Hayes also received options to purchase 114,286 shares of common stock at an exercise price of $7.00 per share,
vesting over 3 years. In 2022, Mr. Hayes was granted options to purchase 70,000, shares of common stock at an exercise price of $1.21,
vesting over 2 years. In August 2022, the agreement was amended to increase Mr. Hayes annual salary to $400,000. The agreement can be
terminated by either party for any reason upon 60 days’ written notice.
We
were party to a consulting agreement, dated December 2020 and through July 31 2022, with Alan Blackman, our co-founder, chief operating
officer and chief investment officer. Under the agreement. Mr. Blackman was entitled to compensation of $18,000 per month. The agreement
provided for an annual bonus in the target amount of $216,000, commensurate with the Company’s results and subject to the approval
of the board. Effective August 1, 2022, we are a party to an employment agreement (2022 Agreement) with a 24 month term with Mr., Blackman
in which he received an initial annual salary of $256,000 increased to $320,000, based on an adjustment formula, and payment for tax
differential. The 2022 Agreement provides for performance bonus at stated periods based on stated criteria with the bonus amount approved
by the Company’s compensation committee. Mr. Blackman also received options: a) in 2021, to purchase 38,571 shares of common stock
with an exercise price of $7.00 per share, vesting over 3 years and b) in 2022, to purchase 50,000 shares of common stock with an exercise
price of $1.21per share vesting over 2 years. The agreement can be terminated by either party for any reason upon 30 days’ written
notice. The Company terminated Mr. Blackman’s Employment Agreement effective May 1, 2023. Mr. Blackman continued to serve as
the Co-Chairman and a member of the Board of Directors. The parties were having preliminary settlement discussions. Subsequent to June
30, 2023, the Company and Mr. Blackman entered into a separation agreement whereby, Mr. Blackman will be paid severance payments of approximately
$346,000, which was recorded as an expense and an accrued expense as of June 30, 2023, over thirteen months, continue his medical benefits
for such period of approximately $29,000 which has been accrued at June 30, 2023. Further, all unvested options were fully vested. In
connection with the separation agreement, Mr. Blackman no longer serves as Co-Chairman or Board member and has agreed to vote his Series
A Preferred Stock in favor of the election, reelection, and/or designation of each individual nominated to serve as a director on the
Board of Director as shall be identified in an applicable proxy statement filed by the Company for such election of directors. Once the
payments due Mr. Blackman are fully paid, the Series A Preferred Stock shall be deemed immediately cancelled and forfeited and without
further consideration. The Series A Preferred shall at such time be returned to the status of an authorized but unissued share of preferred
stock of the Company once the payments are satisfied, Mr. Blackman shall return the Series A Preferred Stock to the Company for cancellation.
We
entered into to a consulting agreement, dated May 28, 2019, with Barry Berler, our chief technology officer. Under the agreement. Mr.
Berler was entitled to compensation of $10,000 per month. The agreement had a term of five years commencing June 1, 2019. In December
2020, we entered into a new consulting agreement with Mr. Berler, under which Mr. Berler is entitled to compensation of $18,000 per month
and provides for an annual bonus in the target amount of $216,000, commensurate with the Company’s results and subject to the approval
of the board. Mr. Berler also received options: a) in 2021, to purchase 38,571 shares of common stock with an exercise price of $7.00
per share, vesting over 3 years and b) in 2022, to purchase 50,000 shares of common stock with an exercise price of $1.21 per share vesting
over 2 years. The agreement can be terminated by either party for any reason upon 90 days’ written notice.
We
are party to an employment agreement, dated September 9, 2021, with Andrew R. Crescenzo, our chief financial officer. Under the agreement,
we pay Mr. Crescenzo an annual salary of $225,000 and was awarded, a one-time $18,750 incentive payment upon the commencement of the
Agreement. In 2021, Mr. Crescenzo, while serving as the Company’s CFO through a consulting arrangement with CFO Consulting Partners
received options to purchase 15,089 shares of common stock at an exercise price of $7.00 per share, vesting over 1 year. In 2022, Mr.
Crescenzo was granted options to purchase 15,000, shares of common stock at an exercise price of $1.21, vesting over 2 years. The agreement
can be terminated by either party for any reason upon 90 days’ written notice.
Compensation
of Directors
The
following table sets forth compensation we paid to our directors during the year ended December 31, 2022 (excluding compensation under
the Summary Compensation table above).
| |
Fees Earned or Paid in Cash | | |
Stock Awards | | |
Option Awards | | |
All Other Compensation | | |
Total | |
Name | |
($) | | |
($) | | |
($) | | |
($) | | |
($) | |
Timothy J. Ruemler (1) | |
| 26,000 | | |
| - | | |
| 8,018 | | |
| - | | |
| 34,018 | |
Paul K. Danner (1,4) | |
| 28,000 | | |
| - | | |
| 8,018 | | |
| 2,400- | | |
| 38,418 | |
Dr Soren Bo. Christiansen (2,4) | |
| 44,000 | | |
| - | | |
| 12,026 | | |
| 25,000- | | |
| 81,026 | |
Brenda Simpson (3) | |
| 14,000 | | |
| - | | |
| 8,018 | | |
| - | | |
| 22,018 | |
Jason Monroe (3) | |
| 17,500 | | |
| - | | |
| 8,018 | | |
| | | |
| 22,018 | |
|
(1) |
Appointed
as Directors in September 2021 |
|
(2) |
Served
as CEO and Chairman of the Board through September 15, 2021. Effective September 16, 2021, serves as Co-Chairman of the Board. Effective
July 27, 2023, Dr. Soren Bo. Christiansen is serving as the Chairman of the Board. |
|
(3) |
Appointed
as Directors in April 2022
|
|
(4) |
Non-director
services performed |
Outstanding
Equity Awards at Fiscal Year-End
The
following table discloses information regarding outstanding equity awards granted or accrued as of December 31, 2022, for our named executive
officers.
| |
Option Awards | | |
Stock Awards |
Name | |
Number of
Securities
Underlying Unexercised Options (#) Vested | | |
Number of Securities Underlying Unexercised Options (#) Unvested | | |
Option Exercise Price ($) | | |
Option Expiration Date | |
Number of Shares or Units of Stock (#) that Vested | | |
Market value of Shares or Units of Stock (#) that have not Vested | |
| |
| | |
| | |
| | |
| |
| | |
| |
Robert M. Hayes | |
| 38,848 | | |
| 31,152 | | |
| 1.21 | | |
5/2/2027 | |
| | | |
| | |
| |
| 65,346 | | |
| 48,939 | | |
| 7.00 | | |
9/9/2026 | |
| - | | |
| - | |
| |
| | | |
| | | |
| | | |
| |
| | | |
| - | |
Alan R. Blackman | |
| 27,749 | | |
| 22,251 | | |
| 1.21 | | |
5/2/2027 | |
| | | |
| | |
| |
| 5,143 | | |
| | | |
| 7.00 | | |
9/30/2026 | |
| - | | |
| - | |
| |
| 38,571 | | |
| | | |
| 7.00 | | |
1/1/2026 | |
| - | | |
| - | |
| |
| | | |
| | | |
| | | |
| |
| | | |
| | |
Barry B. Berler | |
| 27,749 | | |
| 22,251 | | |
| 1.21 | | |
5/2/2027 | |
| | | |
| | |
| |
| 5,143 | | |
| | | |
| 7.00 | | |
9/30/2026 | |
| - | | |
| - | |
| |
| 38,571 | | |
| | | |
| 7.00 | | |
1/1/2026 | |
| - | | |
| - | |
| |
| | | |
| | | |
| | | |
| |
| | | |
| | |
Andrew R. Crescenzo | |
| 8,325 | | |
| 6,675 | | |
| 1.21 | | |
5/2/2027 | |
| | | |
| | |
| |
| 14,285 | | |
| | | |
| 7.00 | | |
9/30/2026 | |
| - | | |
| - | |
| |
| 7,143 | | |
| | | |
| 4.37 | | |
12/31/2024 | |
| - | | |
| - | |
| |
| 15,089 | | |
| | | |
| 4.37 | | |
10/1//2025 | |
| - | | |
| - | |
Equity
Incentive Plan
On
March 28, 2022, the Company adopted the Sharps Technology, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), pursuant
to which up to an aggregate of 779,000 shares of common stock are available for issuance. Awards under the 2022 Plan may include options
(including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, restricted stock units,
performance share awards, or other equity-based awards, each as defined under the 2022 Plan.
On
January 25, 2023, the Company’s Board of Directors adopted the 2023 Equity Incentive Plan (the “2023 Plan”). The 2023
Plan provides for the issuance of up to 1,400,000 options and/or shares of restricted stock to be available for issuance to officers,
directors, employees and consultants. The 2023 plan will be submitted to the Company’s shareholders for approval.
On
January 25, 2023, the Company granted five-year options (the “Options”)
to purchase a total of 950,000 shares of the Company’s Common Stock to its directors, management and employees pursuant to the Sharps
Technology, Inc. 2022 and 2023 Equity Incentive Plans. Of the Options granted, 595,000 were issued pursuant to the 2023 Plan and 355,000
were issued pursuant to the 2022 Plan, with 57,000 shares of common available under the 2022 Plan.
Subsequent to June 30, 2023,
the Company granted five-year Options to purchase 40,000 shares of the Company’s Common Stock to an employee and a consultant pursuant
to the Sharps 2023 Equity Incentive Plan.
A
copy of the 2023 Plan was filed as Exhibit 10.1 to the Current Report on Form 8-K filed on January 27, 2023, and is also incorporated
herein as Exhibit 10.33.
CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Other
than as set forth below and compensation arrangements, including employment, there have been no transactions since January 1, 2020, in
which the amount involved in the transaction exceeded or will exceed the lesser of $120,000 or one percent of the average of our total
assets as at the year-end for the last two completed fiscal years, and to which any of our directors, executive officers or beneficial
holders of more than 5% of our capital stock, or any immediate family member of, or person sharing the household with, any of these individuals,
had or will have a direct or indirect material interest.
As of June 30, 2023 and
December 31, 2022, accounts payable and accrued liabilities include $31,000 and $105,667, respectively, payable to officers and directors
of the Company. The amounts are unsecured, non-interest bearing and are due on demand.
In
connection with the purchase of certain intellectual property in July 2017, Barry Berler, our chief technology officer, and Alan R. Blackman,
our chief investment officer and chief operating officer, entered into a royalty agreement which provided that Barry Berler would be
entitled to a royalty of four percent (4%) of net sales derived from the use, sale, lease, rent and export of products related to the
intellectual property. The royalty continues until the patent expires or is no longer used in the Company’s product. The royalty
agreement was assumed by the Company in December 2017.
In
September 2018, the Royalty Agreement was amended to reduce the royalty to 2% and further provided for a single payment of $500,000 to
Barry Berler within three years in return for cancellation of all further royalty obligations of the Company. In May 2019, the Royalty
Agreement was further amended to change the date the payment will be due to on or before May 31, 2021, or during the term of the amended
Royalty Agreement should the Company be acquired or a controlling interest be acquired. The Company has not made the aforementioned payment
or incurred any change in control. As such the 2% royalty remains in place.
Policies
and Procedures for Related Party Transactions
In
connection with this offering, we expect to adopt a written related party transactions policy that will provide that transactions with
directors, officers and holders of five percent or more of our voting securities and their affiliates, each a related party must be approved
by our audit committee. This policy will become effective on the date on which the registration statement of which this prospectus is
part is declared effective by the SEC. Pursuant to this policy, the audit committee will have the primary responsibility for reviewing
and approving or disapproving “related party transactions,” which are transactions between us and related persons in which
the aggregate amount involved exceeds or may be expected to exceed the lesser of (i) $120,000 or (ii) one percent of the average of our
total assets for the last two completed fiscal years, and in which a related person has or will have a direct or indirect material interest.
For purposes of this policy, a related person will be defined as a director, executive officer, nominee for director, or greater than
5% beneficial owner of our common stock, in each case since the beginning of the most recently completed year, and their immediate family
members.
In
considering related-person transactions, our audit committee or another independent body of our board of directors will take into account
the relevant available facts and circumstances including, but not limited to:
|
● |
the
risks, costs and benefits to us; |
|
● |
the
impact on a director’s independence in the event the related person is a director, immediate family member of a director or
an entity with which a director is affiliated; |
|
● |
the
terms of the transaction; |
|
● |
the
availability of other sources for comparable services or products; and |
|
● |
the
terms available to or from, as the case may be, unrelated third parties under the same or similar circumstances. |
The
audit committee or other independent body of our board of directors will not approve any related party transaction unless it is on the
same basis as an arms’ length transaction and approved by a majority of the disinterested directors.
PRINCIPAL
STOCKHOLDERS
The
following table sets forth certain information, as of September 30, 2023, with respect to the beneficial ownership of the outstanding
common stock by (i) any holder of more than ten (10%) percent; (ii) each of our executive officers and directors; and (iii) our directors
and executive officers as a group.
The
table lists applicable percentage ownership based on 15,274,457 shares of common stock outstanding as of October 16. In addition, under the rules beneficial ownership
include shares of our common stock issuable pursuant to the exercise of stock options and warrants that are either immediately exercisable
or exercisable within 60 days of September 30, 2023. These shares are deemed to be outstanding and beneficially owned by the person
holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding
for the purpose of computing the percentage ownership of any other person.
We
have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of
securities to persons who possess sole or shared voting power or investment power with respect to those securities. Unless otherwise
indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as
beneficially owned by them, subject to applicable community property laws. Except as otherwise noted below, the address for persons listed
in the table is c/o Sharps Technology, Inc, 105 Maxess Road, Ste. 124, Melville, New York 11747.
Name and address of beneficial owner | |
Number of shares of common stock beneficially owned | | |
Percentage of common stock beneficially owned | |
Directors and Executive Officers: | |
| | | |
| | |
Robert M. Hayes (1) | |
| 384,625 | | |
| 2.5 | |
Andrew R. Crescenzo (2) | |
| 72,665 | | |
| * | |
Dr. Soren Bo Christiansen (3) | |
| 391,182 | | |
| 2.5 | |
Paul K. Danner (4) | |
| 87,790 | | |
| * | |
Timothy J. Ruemler (5) | |
| 1,129,853 | | |
| 7.3 | |
Brenda Baird Simpson (6) | |
| 59,219 | | |
| * | |
Jason Monroe (7) | |
| 62,076 | | |
| * | |
All Directors and Officers as a Group (7 persons) | |
| 2,188,409 | | |
| 14.1 | |
(1) |
Represents
314,043 shares underlying options. |
|
|
(2) |
Includes
60,665 shares underlying options. |
|
|
(3) |
Includes
235,039 shares underlying options. |
|
|
(4) |
Includes
87,790 shares underlying options. |
|
|
(5) |
Includes
230,647 shares underlying options.
|
(6)
|
Includes
59,219 shares underlying options. |
|
|
(7)
|
Includes
59,219 shares underlying options. |
(1) |
Represents
100,531 shares underlying options. |
|
|
(2) |
Includes 262,286 shares
owned by spouse and 75,463 shares underlying options. Mr. Blackman also owns our 1 outstanding share of Series A Preferred Stock,
which will provide him with 29.5% of the voting power of our stockholders with respect to the election of directors. |
|
|
(3) |
Includes 45,842 shares
underlying options. |
|
|
(4) |
Includes 186,668 shares
underlying options. |
|
|
(5) |
Includes 29,493 shares
underlying options. |
|
|
(6) |
Includes
172,350 shares underlying options.
|
(7) |
Includes
6,350 shares underlying options. |
|
|
(8) |
Includes 6,350 shares underlying
options. |
DESCRIPTION
OF SECURITIES
General
Our
authorized capital stock consists of 100,000,000 shares of common stock, par value of $0.0001 per share, and 1,000,000 shares of preferred
stock, par value $0.0001 per share. 1 share of our preferred stock is designated as Series A Preferred Stock and is held by Alan Blackman,
our co-chairman and chief operating officer.
Upon
completion of this offering, 15,274,457 shares of common stock and 1 share of Series A Preferred Stock will be issued and outstanding,
which assumes no exercise of:
|
● |
8,625,000
shares underlying warrants offered per the IPO declared effective by the SEC on April 13,
2022;
782,795 shares underlying warrants issued to other parties after the
IPO;
|
|
● |
2,248,521
shares underlying warrants offered by the Selling Shareholders relating to the offering on February 3, 2023; |
|
● |
360,000 warrants issued to an advisor; |
|
● |
8,750,003
shares underlying warrants offered by the Selling Shareholders per this offering;
|
|
● |
3,381,479 pre funded warrants. |
Common
Stock
Holders
of our common stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of common stock do
not have cumulative voting rights. Therefore, holders of a majority of the voting power of our stockholders for the election of directors
can elect all of the directors. Holders of the majority of the voting power of the Company’s stockholders, outstanding and entitled
to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of stockholders. A vote by the holders
of a majority of the voting power of the Company’s stockholders is required to effectuate certain fundamental corporate changes
such as liquidation, merger or an amendment to the Company’s articles of incorporation.
Holders
of our common stock are entitled to share in all dividends that the board of directors, in its discretion, declares from legally available
funds. In the event of a liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in
all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common
stock. The Company’s common stock has no pre-emptive rights, no conversion rights and there are no withdrawal provisions applicable
to the Company’s common stock.
IPO
Warrants
The
following summary of certain terms and provisions of the warrants included in the initial public offering (“IPO Warrants”) hereby is not complete and is
subject to, and qualified in its entirety by the provisions of the form of Warrant, which is filed as an exhibit to the registration
statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the
form of Warrant.
Exercisability.
The IPO Warrants are exercisable at any time after their original issuance and at any time up to the date that is five years after their
original issuance. The IPO Warrants are be exercisable, at the option of each holder, in whole or in part by delivering to us
a duly executed exercise notice and, at any time a registration statement registering the issuance of the shares of common stock underlying
the IPO Warrants under the Securities Act is effective and available for the issuance of such shares, or an exemption from registration
under the Securities Act is available for the issuance of such shares, by payment in full in immediately available funds for the number
of shares of common stock purchased upon such exercise. If a registration statement registering the issuance of the shares of common
stock underlying the IPO Warrants under the Securities Act is not effective or available and an exemption from registration under the
Securities Act is not available for the issuance of such shares, the holder may elect to exercise the IPO Warrants through a cashless
exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to
the formula set forth in the warrant. No fractional shares of common stock will be issued in connection with the exercise of the IPO
Warrants. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise
price.
Exercise
Limitation. A holder will not have the right to exercise any portion of the IPO Warrants if the holder (together with its
affiliates) would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. However, any
holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such
percentage shall not be effective until 61 days following notice from the holder to us.
Exercise
Price. The exercise price per whole share of common stock purchasable upon exercise of the IPO Warrants is $4.25 and adjusted
to $.64 with this offering. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets,
including cash, stock or other property to our stockholders. The exercise price is also subject to adjustment in the event of subsequent
sales of our common stock (or securities exercisable for convertible into common stock) at a purchase price (or conversion or exercise
price, as applicable) less than the then-effective exercise price. In the event of such a subsequent sale, the exercise price will be
reduced to such lower price, subject to certain exceptions and subject to a minimum exercise price set forth in the IPO Warrants.
Forced
Exercise and Redemption. The IPO Warrants will be subject to forced exercise commencing six months from issuance subject to the condition
that the volume weighted average price of the Company’s common stock exceeds 200% of the initial exercise price ($4.25)
for twenty consecutive trading days and subject to certain other conditions set forth in the Warrants. In the event that a holder fails
to exercise the IPO Warrants within 30 days of notice of a forced exercise in accordance with the terms of the IPO Warrants, the Company
may redeem the IPO Warrants at a redemption price of $0.01 per Warrant.
Transferability.
Subject to applicable laws, the IPO Warrants may be offered for sale, sold, transferred or assigned without our consent.
Exchange
Listing. The IPO Warrants are currently listed on the Nasdaq Capital Market under the symbol “STSSW”.
Warrant
Agent. The IPO Warrants will be issued in registered form under a warrant agency agreement between VStock Transfer LLC, as
warrant agent, and us. The IPO Warrants shall initially be represented only by one or more global warrants deposited with the
warrant agent, as custodian on behalf of The Depository Trust Company (DTC) and registered in the name of Cede & Co., a nominee
of DTC, or as otherwise directed by DTC.
Fundamental
Transactions. In the event of a fundamental transaction, as described in the IPO Warrants and generally including any
reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or
substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than
50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by
our outstanding common stock, the holders of the warrants will be entitled to receive upon exercise of the warrants the kind and
amount of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior
to such fundamental transaction.
Rights
as a Stockholder. Except as otherwise provided in the warrants or by virtue of such holder’s ownership of shares of our common
stock, the holder of IPO Warrants does not have the rights or privileges of a holder of our common stock, including any voting rights, until
the holder exercises the IPO Warrants.
Governing
Law. The IPO Warrants and the warrant agency agreement are governed by New York law.
Selling
Stockholders’ Warrants
On
September 27, 2023, Sharps Technology, Inc., (the “Company”) entered into a Securities Purchase Agreement (the “PIPE
Agreement”), with certain purchasers (the “Purchasers”), for the issuance of (i) 2,581,479 shares of our common stock
issuable upon exercise of pre-funded warrants, and (ii) 8,750,003 shares of common stock issuable upon the exercise of outstanding warrants.
The purchase price of each share is $0.64 share priced at-the-market under NASDAQ rules. The purchase price for the pre-funded warrants
is identical to the purchase price for shares, less the exercise price of $0.001 per share.
Each unit consists of
one pre-funded warrant and one non-tradable warrant (the “Selling Stockholders’ Warrants” or “SS Warrants”)
to purchase one share of common stock with an exercise price of $0.64 per share. The Warrants are immediately exercisable and
will expire five and a half years from the issuance date.
The
PIPE Offering closed on September 29, 2023. The aggregate gross proceeds to the Company were approximately $5.6 million before deducting
fees to the placement agent and other offering expenses payable by the Company.
The
following summary of certain terms and provisions of the SS Warrants included in the Common
Units offered hereby is not complete and is subject to, and qualified in its entirety by the provisions of the form of Warrant, which
is filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review
the terms and provisions set forth in the form of Warrant.
Exercisability.
The SS Warrants are exercisable at any time after their original issuance and at any time
up to the date that is five and a half years after their original issuance. The SS Warrants
will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and,
at any time a registration statement registering the issuance of the shares of common stock underlying the SS
Warrants under the Securities Act is effective and available for the issuance of such shares, or an exemption from registration
under the Securities Act is available for the issuance of such shares, by payment in full in immediately available funds for the number
of shares of common stock purchased upon such exercise. If a registration statement registering the issuance of the shares of common
stock underlying the SS Warrants under the Securities Act is not effective or available
and an exemption from registration under the Securities Act is not available for the issuance of such shares, the holder may elect to
exercise the SS Warrants through a cashless exercise, in which case the holder would receive
upon such exercise the net number of shares of common stock determined according to the formula set forth in the warrant. No fractional
shares of common stock will be issued in connection with the exercise of the SS Warrants.
In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.
Exercise
Limitation. A holder will not have the right to exercise any portion of the SS Warrants
if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants.
However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase
in such percentage shall not be effective until 61 days following notice from the holder to us.
Exercise
Price. The exercise price per whole share of common stock purchasable upon exercise of the SS
Warrants is $0.64. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and
distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions
of assets, including cash, stock or other property to our stockholders. The exercise price is also subject to adjustment in the event
of subsequent sales of our common stock (or securities exercisable for convertible into common stock) at a purchase price (or conversion
or exercise price, as applicable) less than the then-effective exercise price. In the event of such a subsequent sale, the exercise price
will be reduced to such lower price, subject to certain exceptions and subject to a minimum exercise price set forth in the SS
Warrants.
Transferability.
Subject to applicable laws, the SS Warrants may be offered for sale, sold, transferred or
assigned without our consent.
Warrant
Agent. The SS Warrants will be issued in registered form under a warrant agency agreement
between VStock Transfer LLC, as warrant agent, and us. The SS Warrants shall initially be
represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository Trust Company
(DTC) and registered in the name of Cede & Co., a nominee of DTC, or as otherwise directed by DTC.
Fundamental
Transactions. In the event of a fundamental transaction, as described in the SS Warrants
and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition
of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of
more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented
by our outstanding common stock, the holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount
of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior to such
fundamental transaction.
Rights
as a Stockholder. Except as otherwise provided in the warrants or by virtue of such holder’s ownership of shares of our common
stock, the holder of an SS Warrants does not have the rights or privileges of a holder of
our common stock, including any voting rights, until the holder exercises the SS Warrants.
Governing
Law. The SS Warrants and the warrant agency agreement are governed by New York law.
Blank
Check Preferred Stock
Our
articles of incorporation authorize the issuance of up to 1,000,000 shares of preferred stock, par value $0.0001 per share, in one or
more series, subject to any limitations prescribed by law, without further vote or action by the stockholders. Each such series of preferred
stock shall have such number of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges
as shall be determined by our board of directors, which may include, among others, dividend rights, voting rights, liquidation preferences,
conversion rights and preemptive rights.
Series
A Preferred Stock
One
share of our authorized preferred stock has been designated Series A Preferred Stock and is outstanding and held by our co-chairman and
chief operating officer, Alan Blackman.
The
Series A Preferred Stock entitles the holder to 29.5% of the voting power of the Company’s stockholders with respect to the election
of directors. Further, the Series A Preferred Stock is not convertible to common stock, has no rights to dividends, and has no liquidation
rights.
On
December 22, 2022, the Company filed a Certificate of Amendment to Designation with the Secretary
of State of Nevada to amend the voting rights for the holder of the Company’s Series A Preferred Stock to be entitled to twenty-nine
and one-half percent (29.5%) vote from twenty-five percent (25%) vote. The amendment was provided for in the employment agreement of
the Company’s Chief Operating Officer, Alan Blackman who is the holder of the Series A Preferred Stock.
In
the event the Company is sold during the two year period following completion of this offering at a price per share of more than 500%
of the initial offering price per Common Unit in this offering, the Series A Preferred Stock, as in effect upon completion of this offering,
will entitle the holder to 10% of the total purchase price. Pursuant to an arrangement with
Alan Blackman effective July 27, 2023, Mr. Blackman has granted the board the right to vote such shares during the period that the Company
is making certain payments to him. Once the Company makes the necessary payments, the share of Series A Preferred Stock will be surrendered
for cancellation.
Transfer
Agent and Registrar
VStock
Transfer LLC is transfer agent and registrar for our common stock.
Limitations
of Liability and Indemnification
Our
articles of incorporation and bylaws limit the liability of our officers and directors and provide that we will indemnify our officers
and directors, in each case, to the fullest extent permitted by the Nevada Revised Statutes, or the NRS.
NRS
Section 78.7502 provides that a corporation shall indemnify any director, officer, employee or agent of a corporation against expenses,
including attorneys’ fees, actually and reasonably incurred by him in connection with any defense to the extent that a director,
officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding
referred to in Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue or matter therein.
NRS
78.7502(1) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in
the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is
or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement
actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138;
or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation,
and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.
NRS
Section 78.7502(2) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason
of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses,
including amounts paid in settlement and attorneys’ fees actually and reasonably incurred by him in connection with the defense
or settlement of the action or suit if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which
he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim,
issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there
from, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court
in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the
circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.
NRS
Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually
liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court
as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.
The
indemnification provisions in our bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary
duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful,
might provide a benefit to us and our stockholders. Our results of operations and financial condition may be harmed to the extent we
pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
At
present, there is no pending litigation or proceeding involving any of our directors or officers as to which indemnification is required
or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.
Listing
We
have applied to list our common stock and warrants on the Nasdaq Capital Market under the symbols “SSTS” and “SSTSW”,
respectively.
Disclosure
of Commission Position on Indemnification for Securities Act Liabilities
Insofar
as indemnification for liabilities under the Securities Act may be permitted to officers, directors or persons controlling the Company
pursuant to the foregoing provisions, the Company has been informed that is it is the opinion of the SEC that such indemnification is
against public policy as expressed in such Securities Act and is, therefore, unenforceable.
PRIVATE
PLACEMENT OF PRE-FUNDED WARRANTS AND WARRANTS
PIPE
Agreement
On September 27, 2023, the Company entered into
a Securities Purchase Agreement (the “PIPE Purchase Agreement”) with certain accredited investors purchasing common stock
in this offering for a Private Placement offering of (i) 2,581,479 unregistered shares of our common stock (the “PIPE Shares”)
(or pre-funded warrants in lieu thereof with each pre-funded warrant exercisable for one share of common stock (the “PIPE Pre-Funded
Warrants”)) and (ii) unregistered warrants to purchase 8,750,003 of our common stock (the “SS Warrants” and together
with PIPE Shares (PIPE Pre-Funded Warrants in lieu thereof), the “PIPE Securities”). Pursuant to the PIPE Purchase Agreement,
the Company has issued and sold 2,581,479 PIPE Shares (or PIPE Pre-Funded Warrants in lieu thereof) together with SS Warrants to purchase
up to 8,750,003 shares of common stock at a combined offering price of $1.074 per unit (less $0.001 for each PIPE Pre-Funded Warrant).
The PIPE Securities are not being registered under the Securities Act The PIPE Securities are being offered pursuant to an exemption
from the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation
D promulgated thereunder.
The PIPE Pre-Funded Warrants are immediately exercisable,
at a nominal exercise price of $0.001, and may be exercised at any time until all of the PIPE Pre-Funded Warrants are exercised in full.
Under the terms of the PIPE Pre-Funded Warrants, the Company may not effect the exercise of any such warrant, and a holder will not be
entitled to exercise any portion of any such warrant, if, upon giving effect to such exercise, the aggregate number of shares of common
stock beneficially owned by the holder (together with its affiliates, any other persons acting as a group together with the holder or
any of the holder’s affiliates, and any other persons whose beneficial ownership of common stock would or could be aggregated with
the holder’s for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) would exceed 4.99%
of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is
determined in accordance with the terms of such warrant, which percentage may be increased or decreased at the holder’s election
upon 61 days’ notice to the Company subject to the terms of such warrants, provided that such percentage may in no event exceed
9.99%
The SS Warrants have an exercise price of $0.64 per share (subject to adjustment
as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance. The SS Warrants contain
standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions.
The Private Placement closed on September 29, 2023, subject to the satisfaction
of customary closing conditions. The gross proceeds to the Company from the private placement, before deducting placement agent fees
and other estimated offering expenses payable by the Company, were approximately $2,8 million. The Company intends to use the net
proceeds from the Private Placement for working capital and other general corporate purposes].
Registration
Rights Agreement
In
connection with the PIPE Agreement, the Company entered
into a Registration Rights Agreement with the Purchasers (the “Registration Rights Agreement”) dated September 27, 2023,
requiring the Company to file a resale registration statement (the “Registration Statement”)
with the U.S. Securities and Exchange Commission (the “SEC”) to register the shares and shares underlying the Warrants
issued under the PIPE Agreement within fifteen (15) days after the closing date (the “Filing
Date”) . Pursuant to the Registration Rights Agreement, the Registration Statement shall be declared effective the sooner of (a)
two Trading Days (as defined therein) following receipt of a notice of no review from the SEC, provided that the Company’s financial
statements are current at such time or (b) within thirty (30) days after the Filing Date (or, in the event of a full review by the
Commission, sixty (60) calendar days following the Filing Date). The Company will be obligated to pay certain liquidated damages
to the Purchasers if the Company fails to file the Registration Statement when required, fails to cause the Registration Statement to
be declared effective by the SEC when required, of if the Company fails to maintain the effectiveness of the Registration Statement.
This Registration Statement covers the securities in the Registration Rights Agreement.
Placement
Agent Agreement
Aegis
Capital Corp. (“Aegis”) acted as the exclusive placement agent in connection with the PIPE Offering under a Placement Agent
Agreement, dated as of September 27, 2023, between the Company and Aegis (the “Placement Agent Agreement”). Pursuant
to the Placement Agent Agreement, Aegis was paid a commission equal to 8.0% of the gross
proceeds received by the Company in the PIPE Offering. The Company also paid Aegis non-accountable expenses of 1% of the gross proceeds
and reimbursed Aegis $100,000 for certain fees and expenses incurred by them, including attorney fees. The Company also agreed to
pay Aegis 10.0% of the proceeds from the exercise of the Warrants issued in the PIPE Offering.
The
PIPE Agreement, the Registration Rights Agreement, the Placement Agent Agreement and the Warrant are filed as Exhibits 10.1, 10.2, 10.3
and 10.4, respectively, to the Current Report on Form 8-K filed on October 3, 2023, and also incorporated herein as Exhibits 10.29,
10.30, 10.31 and 10.32, respectively.
SELLING
STOCKHOLDERS
The
shares of common stock being offered by the selling stockholders are those issuable to the investors upon exercise of the warrants and
pre-funded warrants issued to the investors in the September 2023 Private Placement. For additional information regarding the issuances
of those warrants and pre-funded warrants, see “Private Placement of Pre-funded Warrants and Warrants” above. We are registering
the shares of common stock in order to permit the selling stockholders to offer the shares for resale from time to time. Except for the
ownership of the shares of common stock and warrants, the selling stockholders have not had any material relationship with us within
the past 2 years.
The
table below lists the selling stockholders and other information regarding the beneficial ownership of the shares of common stock by
the selling stockholders. The first numerical column lists the number of shares of common stock beneficially owned by each of the
selling stockholders, based on its ownership of shares of common stock, pre-funded warrants, and other warrants, as of October 16,
2023, assuming exercise of the warrants and pre-funded warrants held by the selling stockholders on that date, without regard to any
limitations on exercises. The second numerical column lists the maximum number of shares of common stock to be sold pursuant to this
Registration Statement. The third numerical column lists the number of shares of Common Stock to be owned following the sale of shares registered
herein. As of October 16, 2023, 15,274,457 shares of
the Company’s’ common stock were issued and outstanding.
This
prospectus generally covers the resale of the sum of the maximum number of shares of common stock issuable upon exercise of the related
warrants and pre-funded warrants, determined as if the outstanding warrants and pre-funded warrants were exercised in full as of the
trading day immediately preceding the date this registration statement was initially filed with the SEC, each as of the trading day immediately
preceding the applicable date of determination and all subject to adjustment as provided in the registration right agreement, without
regard to any limitations on the exercise of the warrants.
Under
the terms of the warrants, the investor may not exercise the warrants or pre-funded warrants to the extent such exercise would cause
such investor, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would
exceed 4.99%, or, 9.99%, as provided in the warrant or pre-funded warrant, of our then outstanding common stock following such exercise,
excluding for purposes of such determination shares of common stock issuable upon exercise of the warrants or pre-funded warrants which
have not been exercised (the “Beneficial Ownership Limitation”). The number of shares in the first and third numerical columns do not reflect this limitation. The
selling stockholder may sell all, some or none of their shares in this offering. See “Plan of Distribution.”
Name of Selling Stockholder | |
Number of shares of Common Stock
Owned Prior to Offering (1) | | |
Maximum Number of shares of Common
Stock to be Sold Pursuant to this Prospectus | | |
Number of shares of Common Stock
Owned After Offering (2) | |
Walleye Opportunities Master Fund Ltd. | |
| 7,575,242 | | |
| 4,532,590 | (3) | |
| 3,042,652 | |
Empery Asset Master, LTD.
(4) | |
| 5,110,734 | (5)(6) | |
| 3,045,925 | (5) | |
| 2,064,809 | (6) |
Empery Tax Efficient, LP
(7) | |
| 1,457,349 | (8)(9) | |
| 859,044 | (8) | |
| 598,305 | (9) |
Empery Tax Efficient III,
LP (10) | |
| 1,740,721 | (11)(12) | |
| 1,153,731 | (11) | |
| 586,990
| (12) |
District 2 Capital Fund
LP (13) | |
| 2,009,163 | | |
| 870,098 | | |
| 1,139,065 | |
Bigger Capital Fund LP
(14) | |
| 2,031,188 | | |
| 870,094 | | |
| 1,161,094 | |
(1) |
This column lists the number of shares of common stock beneficially
owned by each of the selling stockholders, based on its ownership of the shares of common stock, pre-funded warrants, and warrants,
as of October 13, 2023, assuming exercise of the warrants and pre-funded warrants held by the selling stockholders on that date,
without regard to any limitations on exercises. |
(2) |
This column assumes the sale of all of the shares offered
by the selling stockholders pursuant to this prospectus. |
(3) |
Includes 3,499,999 shares of Common Stock underlying warrants and
1,032,991 shares of Common Stock underlying pre-funded warrants issued under the September 2023 Private Placement without giving
effect to limitations on beneficial ownership set forth therein. The shares may be deemed to be indirectly beneficially owned by
William England, as the authorized signatory of Walleye Opportunities Master Fund Ltd. |
(4) |
Empery Asset Management LP, the authorized agent of Empery Asset
Master Ltd (“EAM”), has discretionary authority to vote and dispose of the shares held by EAM and may be deemed to be
the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management
LP, may also be deemed to have investment discretion and voting power over the shares held by EAM. EAM, Mr. Hoe and Mr. Lane each
disclaim any beneficial ownership of these shares. |
(5) |
Includes 2,352,018 shares of Common Stock underlying warrants and
693,907 shares of Common Stock underlying pre-funded warrants, each issued under the September 2023 Private Placement without giving
effect to the Beneficial Ownership Limitation. The Beneficial Ownership Limitation in each of the (i) warrants is 4.99% and (ii)
pre-funded warrants is 9.99%. |
(6) |
Includes (i) 807,058 shares of registered Common Stock, (ii) 956,693
shares of Common Stock underlying other warrants and (iii) 301,058 shares of Common Stock underlying other pre-funded warrants. The
Beneficial Ownership Limitation in each of the (i) warrants is 4.99% and (ii) pre-funded warrants is 9.99%. |
(7) |
Empery Asset Management LP, the authorized agent of Empery Tax Efficient,
LP (“ETE”), has discretionary authority to vote and dispose of the shares held by ETE and may be deemed to be the beneficial
owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also
be deemed to have investment discretion and voting power over the shares held by ETE. ETE, Mr. Hoe and Mr. Lane each disclaim any
beneficial ownership of these shares. |
(8) |
Includes 663,341 shares of Common Stock underlying warrants and
195,703 shares of Common Stock underlying pre-funded warrants, each issued under the September 2023 Private Placement without giving
effect to the Beneficial Ownership Limitation. The Beneficial Ownership Limitation in each of the (i) warrants is 4.99% and (ii)
pre-funded warrants is 9.99%. |
(9) |
Includes (i) 227,616 shares of registered Common Stock, (ii) 285,781
shares of Common Stock underlying other warrants and (iii) 84,908 shares of Common Stock underlying other pre-funded warrants. The
Beneficial Ownership Limitation in each of the (i) warrants is 4.99% and (ii) pre-funded warrants is 9.99%. |
(10) |
Empery Asset Management LP, the authorized agent of Empery Tax Efficient
III, LP (“ETE III”), has discretionary authority to vote and dispose of the shares held by ETE III and may be deemed
to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management
LP, may also be deemed to have investment discretion and voting power over the shares held by ETE III. ETE III, Mr. Hoe and Mr. Lane
each disclaim any beneficial ownership of these shares |
(11) |
Includes 890,894 shares of Common Stock underlying warrants and
262,837 shares of Common Stock underlying pre-funded warrants, each issued under the September 2023 Private Placement without giving
effect to the Beneficial Ownership Limitation. |
(12) |
Includes (i) 305,697 shares of registered Common Stock, (ii) 167,259
shares of Common Stock underlying other warrants and (iii) 114,034 shares of Common Stock underlying other pre-funded warrants. The
Beneficial Ownership Limitation in each of the (i) warrants is 4.99% and (ii) pre-funded warrants is 9.99%. . |
(13) |
Includes 671,877 shares of Common Stock underlying warrants and
198,221 shares of Common Stock underlying pre-funded warrants issued under the September 2023 Private Placement without
giving effect to limitations on beneficial ownership set forth therein, as well as an additional 824,681 shares from warrants that
can be exercised within 180 days The shares may be deemed to be indirectly beneficially owned by Michael Bigger, as the managing
member of District 2 Capital Fund LP. |
(14) |
Includes 671,874 shares of Common Stock underlying warrants and
198,220 shares of Common Stock underlying pre-funded warrants issued under the September 2023 Private Placement without giving effect
to limitations on beneficial ownership set forth therein, as well as an additional 824,681 shares from warrants that can be exercised
within 180 days The shares may be deemed to be indirectly beneficially owned by Michael Bigger, as the managing member of Bigger
Capital Fund, LP. |
PLAN
OF DISTRIBUTION
Each
selling stockholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any
or all of their securities covered hereby on the principal Trading Market or any other stock exchange, market or trading facility on
which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling stockholder may
use any one or more of the following methods when selling securities:
|
● |
ordinary
brokerage transactions and transactions in which the broker dealer solicits purchasers; |
|
|
|
|
● |
block
trades in which the broker dealer will attempt to sell the securities as agent but may position and resell a portion of the
block as principal to facilitate the transaction; |
|
|
|
|
● |
purchases
by a broker dealer as principal and resale by the broker dealer for its account; |
|
|
|
|
● |
an
exchange distribution in accordance with the rules of the applicable exchange; |
|
|
|
|
● |
privately
negotiated transactions; |
|
|
|
|
● |
settlement
of short sales; |
|
|
|
|
● |
in
transactions through broker dealers that agree with the selling stockholders to sell a specified number of such securities
at a stipulated price per security; |
|
|
|
|
● |
through
the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |
|
|
|
|
● |
a
combination of any such methods of sale; or |
|
|
|
|
● |
any
other method permitted pursuant to applicable law. |
The
selling stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available,
rather than under this prospectus.
Broker
dealers engaged by the selling stockholders may arrange for other brokers dealers to participate in sales. Broker dealers may receive
commissions or discounts from the selling stockholders (or, if any broker dealer acts as agent for the purchaser of securities, from
the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction
not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup
or markdown in compliance with FINRA IM-2440.
In
connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The selling stockholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The
selling stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each selling stockholder has informed the Company that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.
The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company
has agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under
the Securities Act.
We
agreed to keep this registration statement effective until the earlier of (i) the date on which the securities may be resold by the selling
stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement
for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of
similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other
rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.
Under
applicable rules and regulations under the Securities Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the selling stockholders will be subject to applicable provisions of the
Securities Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of
the common stock by the selling stockholders or any other person. We will make copies of this prospectus available to the selling stockholders
and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).
LEGAL
MATTERS
The
validity of the securities offered by this prospectus will be passed upon for us by Sichenzia Ross Ference Carmel LLP, New York,
New York.
EXPERTS
The
financial statements included in this registration statement as of December 31, 2022 and 2021, and for each of the years
in the two-year period ended December 31, 2022, have been included
herein in reliance upon the report of Manning Elliott LLP, independent registered public accounting firm, appearing elsewhere herein,
and upon the authority of said firm as experts in accounting and auditing.
WHERE
YOU CAN FIND ADDITIONAL INFORMATION
We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities offered by this
prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth
in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations
of the SEC. For further information with respect to us and our securities, we refer you to the registration statement, including the
exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract
or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement,
please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document
filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an Internet website that contains reports, proxy
statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.
We
are subject to the information and reporting requirements of the Exchange Act and, in accordance with this law, will file periodic reports,
proxy statements and other information with the SEC. We also maintain a website at sharpstechnology.com. Upon completion of this offering,
you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished
to, the SEC. Information contained on our website is not a part of this prospectus and the inclusion of our website address in this prospectus
is an inactive textual reference only.
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the Stockholders and the Board of Directors of Sharps Technology Inc.
Opinion
on the Consolidated Financial Statements
We
have audited the accompanying consolidated balance sheets of Sharps Technology Inc. and its subsidiary (the “Company”) as
of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders’ equity and
cash flows for the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”).
In
our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as
of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended in conformity with accounting
principles generally accepted in the United States of America.
Basis
for Opinion
These
consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion
on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.
/s/
Manning Elliott LLP
CHARTERED
PROFESSIONAL ACCOUNTANTS
Vancouver,
Canada
March
30, 2023
PCAOB ID:1524
We
have served as the Company’s auditor since 2018.
SHARPS
TECHNOLOGY, INC.
CONSOLIDATED
BALANCE SHEETS
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Assets: | |
| | | |
| | |
Current Assets | |
| | | |
| | |
Cash | |
$ | 4,170,897 | | |
$ | 1,479,166 | |
Prepaid expenses and other current assets | |
| 66,749 | | |
| 7,995 | |
Inventories (Note 3) | |
| 185,804 | | |
| 121,994 | |
Current Assets | |
| 4,423,450 | | |
| 1,609,155 | |
| |
| | | |
| | |
Fixed Assets, net of
accumulated depreciation (Notes 4 and 5) | |
| 7,004,890 | | |
| 3,763,332 | |
Other Assets (Notes 5 and 6) | |
| 411,316 | | |
| 529,863 | |
TOTAL ASSETS | |
$ | 11,839,656 | | |
$ | 5,902,350 | |
| |
| | | |
| | |
Liabilities: | |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Accounts payable (Note 4) | |
| 543,226 | | |
| | |
Accounts payable and accrued liabilities (Note 4) | |
$ | 854,684 | | |
$ | 804,138 | |
Notes payable, net of discount (Note 7) | |
| - | | |
| 700,015 | |
Contingent stock liability (Notes 7 and 8) | |
| - | | |
| 677,000 | |
Contingent warrant liability (Notes 7, 8 and 10) | |
| - | | |
| 585,000 | |
Accrued and other current liabilities (Note 15) | |
| 311,458 | | |
| | |
Warrant liability (Notes 8 and 10) | |
| 1,151,838 | | |
| - | |
Total Current Liabilities | |
| 2,006,522 | | |
| 2,766,153 | |
| |
| - | | |
| - | |
Deferred
Tax Liability | |
| 192,000 | | |
| - | |
Total
Liabilities | |
| 2,198,522 | | |
| 2,766,153 | |
| |
| | | |
| | |
Commitments and Contingencies
(Note 15) | |
| - | | |
| - | |
Subsequent Events (Note
16) | |
| - | | |
| - | |
| |
| | | |
| | |
Stockholders’ Equity: | |
| | | |
| | |
Preferred stock, $.0001 par value; 1,000,000 shares authorized; 1 share issued and outstanding | |
| - | | |
| - | |
Common stock, $.0001 par value; 100,000,000, shares authorized; 9,407,415 shares issued and outstanding and (2021: 5,187,062) | |
| 941 | | |
| 519 | |
Common stock subscription receivable | |
| - | | |
| (32,500 | ) |
Additional paid-in capital | |
| 24,733,306 | | |
| 13,835,882 | |
Accumulated other comprehensive income | |
| 214,253 | | |
| - | |
Accumulated deficit | |
| (15,307,366 | ) | |
| (10,667,704 | ) |
Total Stockholders’ Equity | |
| 9,641,134 | | |
| 3,136,197 | |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | |
$ | 11,839,656 | | |
$ | 5,902,350 | |
The
accompanying notes are an integral part of these financial statements.
SHARPS
TECHNOLOGY, INC.
CONSOLIDATED
STATEMENTS OF OPERATIONS
| |
For the year ended | | |
For the year ended | |
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Revenue, net | |
$ | - | | |
$ | - | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
Research and development (Note 5) | |
| 2,280,933 | | |
| 1,690,865 | |
General and administrative | |
| 6,457,860 | | |
| 2,806,801 | |
Total operating expenses | |
| (8,738,793 | ) | |
| (4,497,666 | ) |
Loss from operations | |
| (8,738,793 | ) | |
| (4,497,666 | ) |
| |
| | | |
| | |
Other income (expense) | |
| | | |
| | |
Interest income (expense) | |
| (1,320,416 | ) | |
| (166,746 | ) |
FMV adjustment on contingent stock & warrants | |
| 5,392,911 | | |
| - | |
Foreign currency and other | |
| 26,636 | | |
| - | |
Total Other Income (Expense) | |
| | | |
| | |
Net loss | |
$ | (4,639,662 | ) | |
$ | (4,664,412 | ) |
| |
| | | |
| | |
Net loss per share, basic and diluted | |
$ | (0.57 | ) | |
$ | (0.96 | ) |
Weighted average shares used to compute net loss per share, basic and diluted | |
| 8,100,410 | | |
| 4,876,899 | |
The
accompanying notes are an integral part of these financial statements.
SHARPS
TECHNOLOGY, INC.
CONSOLIDATED
STATEMENTS OF COMPREHENSIVE LOSS
| |
For the year ended | | |
For the year ended | |
| |
December 31, 2022 | | |
December 31, 2021 | |
Net loss | |
$ | (4,639,662 | ) | |
$ | (4,664,412 | ) |
| |
| | | |
| | |
Other comprehensive income: | |
| | | |
| | |
| |
| | | |
| | |
Foreign currency translation adjustments | |
| 214,253 | | |
| - | |
| |
| | | |
| | |
Comprehensive loss | |
$ | (4,425,409 | ) | |
$ | (4,664,412 | ) |
The
accompanying notes are an integral part of these financial statements.
SHARPS
TECHNOLOGY, INC.
CONSOLIDATED
STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Receivable | | |
Capital | |
|
Income |
| |
Deficit | | |
Equity | |
| |
Preferred
Stock | | |
Common
Stock | | |
Common
Stock Subscription | | |
Additional
Paid-in | |
|
Accumulated
Other Comprehensive |
| |
Accumulated | | |
Total
Stockholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Receivable | | |
Capital | |
|
Income |
| |
Deficit | | |
Equity | |
| |
| | |
| | |
| | |
| | |
| | |
| |
|
|
|
| |
| | |
| |
Balance
– December 31, 2020 | |
| 1 | | |
$ | - | | |
| 4,597,000 | | |
$ | 460 | | |
$ | - | | |
$ | 8,133,655 | |
|
$ |
- |
| |
$ | (6,003,292 | ) | |
$ | 2,130,823 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | | |
| | |
Net
loss for the year ended December 31, 2021 | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
|
|
- |
| |
| (4,664,412 | ) | |
| (4,664,412 | ) |
Share-based
compensation charges | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,571,857 | |
|
|
- |
| |
| - | | |
| 1,571,857 | |
Issuance
of common stock for services | |
| - | | |
| - | | |
| 2,857 | | |
| - | | |
| - | | |
| 20,000 | |
|
|
- |
| |
| - | | |
| 20,000 | |
Issuance
of common stock from subscriptions | |
| - | | |
| - | | |
| 487,205 | | |
| 49 | | |
| (32,500 | ) | |
| 3,410,380 | |
|
|
- |
| |
| - | | |
| 3,377,929 | |
Issuance
of common stock for acquisition | |
| - | | |
| - | | |
| 28,571 | | |
| 3 | | |
| - | | |
| 199,997 | |
|
|
- |
| |
| - | | |
| 200,000 | |
Issuance
of common stock for equipment order | |
| - | | |
| - | | |
| 71,429 | | |
| 7 | | |
| - | | |
| 499,993 | |
|
|
- |
| |
| - | | |
| 500,000 | |
Balance
– December 31, 2021 | |
| 1 | | |
$ | - | | |
| 5,187,062 | | |
| 519 | | |
$ | (32,500 | ) | |
$ | 13,835,882 | |
|
$ |
- |
| |
$ | (10,667,704 | ) | |
$ | 3,136,197 | |
Balance,
value | |
| 1 | | |
$ | - | | |
| 5,187,062 | | |
| 519 | | |
$ | (32,500 | ) | |
$ | 13,835,882 | |
|
$ |
- |
| |
$ | (10,667,704 | ) | |
$ | 3,136,197 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | | |
| | |
Net
loss for the year ended December 31, 2022 | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
|
|
- |
| |
| (4,639,662 | ) | |
| (4,639,662 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
|
|
|
| |
| | | |
| | |
Shares
issued in Initial Public Offering | |
| - | | |
| | | |
| 3,750,000 | | |
| 375 | | |
| - | | |
| 8,974,282 | |
|
|
- |
| |
| - | | |
| 8,974,657 | |
Issuance
of shares for contingent stock liability | |
| - | | |
| | | |
| 235,294 | | |
| 24 | | |
| - | | |
| 495,976 | |
|
|
- |
| |
| - | | |
| 496,000 | |
Share-based
compensation charges | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,136,638 | |
|
|
- |
| |
| - | | |
| 1,136,638 | |
Fractional
share adjustment | |
| - | | |
| - | | |
| 59 | | |
| - | | |
| - | | |
| - | |
|
|
- |
| |
| - | | |
| - | |
Issuance
of common stock for services | |
| - | | |
| - | | |
| 235,000 | | |
| 23 | | |
| - | | |
| 290,528 | |
|
|
- |
| |
| - | | |
| 290,551 | |
Foreign
currency translation | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
|
|
214,253 |
| |
| - | | |
| 214,253 | |
Collection
of stock subscription | |
| - | | |
| - | | |
| - | | |
| - | | |
| 32,500 | | |
| - | |
|
|
- |
| |
| - | | |
| 32,500 | |
Balance
– December 31, 2022 | |
| 1 | | |
$ | - | | |
| 9,407,415 | | |
| 941 | | |
$ | - | | |
$ | 24,733,306 | |
|
$ |
214,253 |
| |
$ | (15,307,366 | ) | |
$ | 9,641,134 | |
Balance,
value | |
| 1 | | |
$ | - | | |
| 9,407,415 | | |
| 941 | | |
$ | - | | |
$ | 24,733,306 | |
|
$ |
214,253 |
| |
$ | (15,307,366 | ) | |
$ | 9,641,134 | |
The
accompanying notes are an integral part of these financial statements.
SHARPS
TECHNOLOGY, INC.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
| |
For the year ended | | |
For the year ended | |
| |
December 31, 2022 | | |
December 31, 2021 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | | |
| | |
Net loss | |
$ | (4,639,662 | ) | |
$ | (4,664,412 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 654,572 | | |
| 28,699 | |
Stock-based compensation | |
| 1,012,592 | | |
| 1,195,819 | |
| |
| | | |
| | |
Issuance of common stock for services | |
| 290,551 | | |
| 20,000 | |
Accretion of debt discount | |
| 1,299,985 | | |
| 159,615 | |
FMV for adjustment for contingent stock | |
| (181,000 | ) | |
| - | |
FMV adjustment for Contingent warrants and warrants | |
| (5,211,911 | ) | |
| - | |
IPO issuance costs relating to warrants | |
| 550,433 | | |
| - | |
Foreign exchange loss | |
| 496 | | |
| - | |
Changes in operating assets | |
| | | |
| | |
Prepaid expenses | |
| (58,754 | ) | |
| 42,005 | ) |
Inventory | |
| (34,109 | ) | |
| (121,994 | ) |
Other assets | |
| (12,000 | ) | |
| (10,262 | ) |
Accounts payable and accrued liabilities | |
| (104,352 | ) | |
| 202,894 | |
Net cash used in operating activities | |
| (6,433,159 | ) | |
| (3,147,736 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Deposits paid on fixed assets and components | |
| (209,678 | ) | |
| (46,900 | ) |
Purchase of fixed assets | |
| (542,662 | ) | |
| (2,221,830 | ) |
Other assets – escrow deposit | |
| - | | |
| (75,000 | ) |
Asset acquisition | |
| (2,365,576 | ) | |
| - | |
Net cash used in investing activities | |
| (3,117,916 | ) | |
| (2,343,730 | ) |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Proceeds from common stock issued, net of subscription receivable | |
| - | | |
| 3,377,929 | |
Net proceeds from Initial Public Offering Units | |
| 14,202,975 | | |
| - | |
Net proceeds from notes payable, contingent stock liability, contingent warrant liability | |
| - | | |
| 1,802,500 | |
Net proceeds from Initial Public Offering and additional offering | |
| | | |
| | |
Repayment of note payable | |
| (2,000,000 | ) | |
| - | |
Proceeds from subscriptions receivable | |
| 32,500 | | |
| - | |
Net cash provided by financing activities | |
| 12,235,475 | | |
| 5,180,429 | |
| |
| | | |
| | |
Effect of exchange rate changes on cash | |
| 7,331 | | |
| - | |
| |
| | | |
| | |
NET INCREASE (DECREASE) IN CASH | |
| 2,691,731 | | |
| (311,037 | ) |
CASH — BEGINNING OF YEAR | |
| 1,479,166 | | |
| 1,790,203 | |
CASH — END OF YEAR | |
$ | 4,170,897 | | |
$ | 1,479,166 | |
| |
| | | |
| | |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | |
| | | |
| | |
Cash paid for interest | |
$ | 47,111 | | |
$ | 4,000 | |
Cash paid for taxes | |
$ | - | | |
$ | - | |
| |
| | | |
| | |
Non-cash investing and financing activity: | |
| | | |
| | |
FMV for Common stock issued for contingent shares | |
$ | 496,000 | | |
| - | |
FMV for Warrants issued for contingent warrants | |
$ | 554,312 | | |
| | |
Common stock issued and vested stock options for fixed assets acquired | |
$ | 63,612 | | |
$ | 753,336 | |
Common stock issued and vested stock options issued as consideration for acquisition | |
$ | 60,435 | | |
$ | 322,701 | |
The
accompanying notes are an integral part of these financial statements.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
1. Description of Business
Nature
of Business
Sharps
Technology, Inc. (“Sharps” or the “Company”) is a pre-revenue medical device company that has designed and patented
various safety syringes and is seeking commercialization by manufacturing and distribution of its products.
The
accompanying consolidated financial statements include the accounts of Sharps Technology, Inc. and its wholly owned subsidiary,
Safegard Medical (Hungary) KFT, collectively referred to as the “Company.” All intercompany transactions and balances have been
eliminated.
The
Company’s fiscal year ends on December 31.
On
April 13, 2022, the Company’s Initial Public Offering was deemed effective with trading commencing on April 14, 2022. The Company
received net proceeds of $14.2 million on April 19, 2022 (See Note 8).
Note
2. Summary of Significant Accounting Policies
Basis
of Presentation
The
accompanying consolidated financial statements have been prepared by the Company in accordance with generally accepted accounting principles
(“GAAP”) in the United States (“U.S.”) and are expressed in U.S. dollars.
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As
of December 31, 2022, the most significant estimates relate to derivative liabilities and stock-based compensation.
Cash
and Cash Equivalents
The
Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date
of purchase to be cash equivalents. Cash and cash equivalents are maintained with various financial institutions.
Inventories
The
Company values inventory at the lower of cost (average cost) or net realizable value. Work-in-process and finished goods inventories
consist of material, labor, and manufacturing overhead. Net realizable value is the estimated selling price in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. A reserve is established for any excess
or obsolete inventories or they may be written off. At December 31, 2022 and 2021, inventory is comprised of raw materials,
components and finished goods.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
Fair
Value Measurements
ASC
820, Fair Value Measurements and Disclosures, require an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding
the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be
used to measure fair value.
The
Company’s outstanding warrants are fair valued on a recurring basis with the trading price which could cause fluctuations in
operating results at the reporting periods.
Level
1
Level
1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Valuations
are based on quoted prices that are readily and regularly available in an active market and do not entail a significant degree of judgment.
Level
2
Level
2 applied to assets or liabilities for which there are other than Level 1 observable inputs such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market data.
Level
2 instruments require more management judgment and subjectivity as compared to Level 1 instruments. For instance: determining which instruments
are most similar to the instrument being priced requires management to identify a sample of similar securities based on the coupon rates,
maturity, issuer credit rating and instrument type, and subjectively select an individual security or multiple securities that are deemed
most similar to the security being priced; and determining whether a market is considered active requires management judgment.
Level
3
Level
3 applied to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement
of the fair value of the assets or liabilities. The determination for Level 3 instruments requires the most management judgment and subjectivity.
Fixed
Assets
Fixed
assets are stated at cost. Expenditures for maintenance and repairs are charged to operations as incurred. The Company’s fixed
assets consist of land, building, machinery and equipment, molds and website. Depreciation is calculated using the straight-line
method commencing on the date the asset is operating in the way intended by management over the following useful lives: Building
– 20 years, Machinery and Equipment – 3 -10 years and Website – 3 years. The expected life for Molds is based
lesser of the number of parts that will be produced based on the expected mold capability or 5 years.
Impairment
of Long-Lived Assets
Long-lived
assets are reviewed annually for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted
cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from
the asset.
There
were no impairment losses recognized during the years ended December 31, 2022 and 2021.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
Goodwill
and Purchased Identified Intangible Assets
Goodwill
When
applicable, goodwill will be recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the
fair value of the net tangible and identified intangible assets acquired under a business combination. Goodwill also includes acquired
assembled workforce, which does not qualify as an identifiable intangible asset. The Company reviews impairment of goodwill annually
in the third quarter, or more frequently if events or circumstances indicate that the goodwill might be impaired. The Company first assesses
qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. If, after assessing the
totality of events or circumstances, the Company determines that it is not more likely than not that the fair value of a reporting unit
is less than its carrying amount, then the quantitative goodwill impairment test is unnecessary. If, based on the qualitative assessment,
it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the Company
proceeds to perform the quantitative goodwill impairment test. The Company first determines the fair value of a reporting unit using
weighted results derived from an income approach and a market approach. The income approach is estimated through the discounted cash
flow method based on assumptions about future conditions such as future revenue growth rates, new product and technology introductions,
gross margins, operating expenses, discount rates, future economic and market conditions, and other assumptions. The market approach
estimates the fair value of the Company’s equity by utilizing the market comparable method which is based on revenue multiples
from comparable companies in similar lines of business. The Company then compares the derived fair value of a reporting unit with its
carrying amount. If the carrying value of a reporting unit exceeds its fair value, an impairment loss will be recognized in an amount
equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.
Identified
Intangible Assets
The
Company’s identified intangible assets are amortized on a straight-line basis over their estimated useful lives of 5 years.
The Company makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate
that the useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable. If such
facts and circumstances exist, the Company assesses recoverability by comparing the projected undiscounted net cash flows associated
with the related asset or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any,
are based on the excess of the carrying amount over the fair value of those assets. If the useful life is shorter than originally
estimated, the Company would accelerate the rate of amortization and amortize the remaining carrying value over the new shorter
useful life. The Company evaluates the carrying value of indefinite-lived intangible assets on an annual basis, and an impairment
charge would be recognized to the extent that the carrying amount of such assets exceeds their estimated fair value.
Stock-based
Compensation Expense
The
Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. For
stock option awards, the Company uses the Black-Scholes option-pricing model. For restricted stock awards, the estimated fair value is
generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite
service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company
recognizes forfeitures of stock-based awards as they occur on a prospective basis.
Stock-based
compensation expense for awards granted to non-employees as consideration for services received is measured on the date of performance
at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured.
Derivative
Instruments
The
Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of
the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC 480”), Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815,
Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments
pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification
under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could
potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent
quarterly period end date while the warrants are outstanding.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
At
their issuance date and as of December 31, 2022, the warrants (see Notes 8 and 10) were accounted for as liabilities as these instruments
did not meet all of the requirements for equity classification under ASC 815-40 based on the terms of the aforementioned warrants. The
resulting warrant liabilities are re-measured at each balance sheet date until their exercise or expiration, and any change in fair value
is recognized in the Company’s consolidated statements of operations and comprehensive loss.
Foreign
Currency Translation/Transactions
The
Company has determined that the functional currency for its foreign subsidiary is the local currency. For financial reporting
purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss
accounts are translated at weighted average exchange rates. Resulting translation gains and losses are included as a separate
component of stockholders’ equity as accumulated other comprehensive income or loss. Gains or losses resulting from
transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the
consolidated statements of operations and comprehensive loss.
Comprehensive
income (loss)
Comprehensive
income (loss) consists of the Company’s consolidated net loss and foreign currency translation adjustments related to its subsidiary. Foreign currency
translation adjustments included in comprehensive loss were not tax effected as the Company has a full valuation allowance at
December, 2022 and 2021. Accumulated other comprehensive income (loss) is a separate component of stockholders’ equity and
consists of the cumulative foreign currency translation adjustments.
Basic
and Diluted Loss Per Share
The
Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted
earnings per share (EPS) on the face of the consolidated statement of operations and comprehensive loss. Basic EPS is computed by dividing
net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during
the year. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method
and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used
in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all
dilutive potential shares if their effect is anti-dilutive. As at December 31, 2022, there were 10,405,916 stock options and warrants
that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would
have been antidilutive for the periods presented.
Income
Taxes
The
Company must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates
and judgments are used in the calculation of tax credits, tax benefits, tax deductions, and in the calculation of certain deferred taxes
and tax liabilities. Significant changes to these estimates may result in an increase or decrease to the Company’s tax provision
in a subsequent period.
The
provision for income taxes was comprised of the Company’s current tax liability and changes in deferred income tax assets and liabilities.
The calculation of the current tax liability involves dealing with uncertainties in the application of complex tax laws and regulations
and in determining the liability for tax positions, if any, taken on the Company’s tax returns in accordance with authoritative
guidance on accounting for uncertainty in income taxes. Deferred income taxes are determined based on the differences between the financial
reporting and tax basis of assets and liabilities. The Company must assess the likelihood that it will be able to recover the Company’s
deferred tax assets. If recovery is not likely on a more-likely-than-not basis, the Company must increase its provision for income taxes
by recording a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. However, should
there be a change in the Company’s ability to recover its deferred tax assets, the provision for income taxes would fluctuate in
the period of such change.
Research
and Development Costs
Research
and development costs are expensed as incurred.
Advance
payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized.
Such amounts are recognized as an expense as the related goods are delivered or the services are performed.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
Contingencies
Liabilities for loss
contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized when it is probable
that a liability has been incurred and the amount of the assessment can be reasonably estimated. Gain contingencies are evaluated and
not recognized until the gain is realizable or realized.
Recent
Accounting Pronouncements
In
March 2020, the FASB issued ASC Topic 848, Reference Rate Reform. ASC Topic 848 provides relief for impacted areas as it relates
to impending reference rate reform. ASC Topic 848 contains optional expedients and exceptions for applying GAAP to debt arrangements,
contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective
upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance.
On
August 5, 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40), which simplifies the accounting for certain financial
instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own
equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU
2020-06 simplifies the guidance in U.S. GAAP on the issuer’s accounting for convertible debt instruments, requires entities to
provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been
reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification
and amends certain guidance in ASC 260, Earnings per Share, on the computation of EPS for convertible instruments and contracts
on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance.
The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company
continues to assess all potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.
The
Company does not expect the adoption of any accounting pronouncements to have a material impact on the consolidated financial statements.
We
reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant
to the accounting for our operations.
Note
3. Inventories
Inventories,
net consisted of the following at December 31, 2022 and 2021:
Schedule of Inventories
|
|
December 31, 2022 |
|
|
December 31, 2021 |
|
Raw materials |
|
$ |
106,088 |
|
|
$ |
121,994 |
|
Work in process |
|
|
49,144 |
|
|
|
- |
|
Finished goods |
|
|
30,572 |
|
|
|
- |
|
Total |
|
$ |
185,804 |
|
|
$ |
121,994 |
|
Note
4. Fixed Assets
Fixed
asset, net, as of December 31, 2022 and 2021, are summarized as follows:
Schedule of Property, Plant and Equipment
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Land | |
$ | 242,240 | | |
$ | - | |
Building | |
| 2,824,481 | | |
| - | |
Machinery and Equipment | |
| 4,601,293 | | |
| 3,778,766 | |
Website | |
| 16,600 | | |
| 16,600 | |
Fixed asset, gross | |
| 7,684,614 | | |
| 3,795,366 | |
Less: accumulated depreciation | |
| (679,724 | ) | |
| (32,034 | ) |
Fixed asset, net | |
$ | 7,004,890 | | |
$ | 3,763,332 | |
Depreciation
expense of fixed assets for the year ended December 31, 2022 and 2021 was $647,690
and $28,699,
respectively. Substantially, all of the Company’s fixed assets are located at the Company’s Hungary location.
During
the year ended December 2022, the Company recorded $63,612 in fixed asset costs relating to the estimated fair market value for options
granted in 2021 for the acquired machinery. As of December 31, 2022, the Company has $100,000 in remaining payments for machinery purchased,
which is included in accounts payable.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
5. Asset Acquisition
In
June 2020, the Company entered into a Share Purchase Agreement (“Agreement”) with Safegard Medical
(“Safegard”) and amendments to the Agreement, collectively, the Agreements, to purchase either the stock or certain
assets of a manufacturing facility for $2.5M
in cash, plus additional consideration of 28,571
shares of common stock with an estimated fair market value of $7.00, 35,714
stock options with an exercise price of $7.00
and 50,000
stock options with an exercise price of $4.25.
The purchase price includes the fair market value of the common stock of $200,000
and the vested options of $183,135.
The Agreements provided the Company various periods for due diligence and post due diligence, requirements for escrow payments
through the closing date (“Closing Date”).
Through
the Closing Date, the Agreements provided the Company with the exclusive use of the facility in exchange for payment of the facility’s
operating costs. The monthly fee (“Operating Costs”), which primarily covered the facility’s operating costs, was mainly
comprised of the seller’s workforce costs, materials and other recurring monthly operating cost.
During
the year ended December 31, 2022 and 2021, the Company had remitted $594,000 and $770,000, respectively for the aforementioned Operating
Costs. The remittance of operating costs was discontinued after the Closing Date. These costs were included in research and development
expense in the consolidated statement of operations and comprehensive loss as the activities at the facility in 2022 and 2021 were related
to design and testing of the Company’s products.
The
acquisition of Safegard, which closed on July 6, 2022, did not meet the definition of a business pursuant to ASC 805-10,
and accordingly was accounted for as an asset acquisition in accordance with ASC 805-50. The cost of the
acquisition was $2,936,712,
including transaction costs of $53,576,
with the allocation to the assets acquired on a relative fair value basis. The intangibles relate to permits and a limited workforce
acquired. Under ASC 805-50, no goodwill is recognized. The operating results for Safegard are included in the consolidated balance
sheet and consolidated statements of operations and comprehensive loss for the period beginning after the closing on July 6,
2022.
The
relative fair value of the assets acquired and related deferred tax liability is as follows:
Schedule of Fair Value of the Assets Acquisition
| |
| | |
Land | |
$ | 226,000 | |
Building and affixed assets | |
| 2,648,000 | |
Machinery | |
| 158,000 | |
Inventory | |
| 32,000 | |
Intangibles | |
| 64,712 | |
Deferred tax liability | |
| (192,000 | ) |
| |
| | |
Total | |
$ | 2,936,712 | |
The
useful lives for the acquired assets is Building - 20 years; Machinery – 5 to 10 years; Intangibles – 5 years. The related
depreciation and amortization is being recorded on a straight-line basis.
Note
6. Other Assets
Other
assets as of December 31, 2022 and 2021 are summarized as follows:
Schedule of Other Assets
| |
December 31, | | |
December 31, | |
| |
2022 | | |
2021 | |
Acquisition (see Note 5) | |
$ | - | | |
$ | 472,701 | |
Intangibles, net | |
| 62,480 | | |
| - | |
Deposits or advance payments on machinery, molds and components (see Note 15) | |
| 336,466 | | |
| - | |
Other | |
| 12,370 | | |
| 57,162 | |
Other assets | |
$ | 411,316 | | |
$ | 529,863 | |
Intangibles
are related to the Asset Acquisition (see Note 5) and consist of an acquired workforce and permits. Amortization for the year ended December
31, 2022 was $6,882.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
7. Note Purchase Agreement
On
December 14, 2021, the Company entered into a Note Purchase Agreement (“NPA”) with three unrelated third-party
purchasers (“Purchasers”). The Purchasers provided financing to the Company in the form of bridge financing, aggregating
principal of $2,000,000
(the “Notes”). The principal under the Notes shall be payable on the earlier of (i) December 14, 2022, and (ii) the date
on which the Company consummates an initial public offering (“IPO”), herein referred to as the “Maturity
Date”. The Notes bore interest at 8%
with interest payments due monthly. The Company and the Purchasers had entered into a Security Agreement whereby the Notes were
collateralized by substantially all the assets of the Company, both tangible and intangible both currently owned with stated
exclusions, as defined, and any future acquired with stated exclusions, as defined.
The
NPA provided for covenants that until all of the Notes have been converted, exchanged, redeemed or otherwise satisfied in accordance
with their terms, the Company shall not, and the Company shall not permit any of its subsidiaries without the prior written consent of
the Purchasers: a) incur or guarantee any new debt, b) issue any securities that would cause a breach or default under the NPA, c) incur
any liens other than permitted, d) redeem or repurchase shares, e) declare or pay any cash dividend or distribution, e) sell, lease or
dispose of assets other than in the ordinary course of business, or f) engage in different line of business.
As
additional consideration to the Purchasers for providing the financing, the Company also agreed to a) issue each Purchaser a number
of shares of the Company’s Common Stock equal to 50% of the original principal amount of each Purchaser’s Note (the
“Contingent Stock”) and b) issue each Purchaser a number of warrants, which would allow the Purchasers to purchase
additional shares of the Company’s Common Stock, equal to 50% of the original principal amount each Purchaser’s Note for
a term of 5.0 years (the “Contingent Warrants”).
For
both the Contingent Stock and the Contingent Warrants, the number of shares and warrants that each Purchaser will be issued was unknown
at the time of the NPA and was determined based on a formula of 50% of the original principal amount divided by a “Subsequent
Offering Price” based on the valuation in a future offering of Common stock or other equity interest in the Company (such offering
referred to as a “Consummated Offering”) during the period beginning on December 14, 2021 through and including the date
the Company consummates an initial public offering (“IPO”) (such period referred to as the “Subsequent Offering Period”).
In
accordance with ASC 480-10-25-14, a fixed monetary amount exists at inception for the total value of Contingent Stock that may be issued
to each Purchaser. The Contingent Stock is not considered outstanding at inception, as it will only be issued upon the consummation of
a Consummated Offering, and accordingly, is a conditional obligation. As such the fair market value (“FMV”) of the Contingent
Stock at inception was $677,000, which was recorded as debt discount. Similarly, a fixed monetary amount further exists at inception
for the total value of Contingent Warrants that may be issued to each Purchaser. Accordingly, a conditional obligation exists and as
such the FMV of Contingent Warrants at inception was $585,000, which was recorded as debt discount. The Company incurred $197,500
of debt issuance costs associated with the NPA. The debt issuance costs were allocated between the Notes, Contingent Stock and Contingent
Warrants in a manner that was consistent with the allocation of the proceeds of the Notes. The portion of the debt issuance costs which
were allocated to the Contingent Stock and Contingent Warrants, which was $124,460, was expensed during the year ended December 31, 2021.
The debt issuance costs allocated to the Notes were recorded as a debt discount.
The
Contingent Stock and Contingent Warrant liabilities were measured at FMV on the date of issuance (based on the Black-Scholes valuation
model).
At
inception, the Notes were recorded at the net amount of approximately $665,000,
after adjusting for debt discounts of approximately $1,335,000
relating to the debt issuance costs, Contingent Stock and Contingent Warrants. Management calculates the effective interest rate
(“EIR”) to consider the potential repayment at redemption date by reference to the face value amount after taking into
account the stated 8%
interest rate. In 2022, through the repayment date, the Company recorded interest expense of $39,111
(2021 - $nil)
and accreted interest of $1,299,895
(2021 - $nil)
and repaid the $2,000,000
in Notes with proceeds from the IPO that closed on April 19, 2022.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
7. Note Purchase Agreement (continued)
The
value of the Contingent Stock and Contingent Warrants is required to be re-measured at FMV at each reporting date, using either the
Black-Scholes valuation model or other valuation method, if deemed more appropriate, with recognition of the changes in fair value
to other income or expense in the consolidated statement of operations in accordance with ASC 480, Debt and Equity. On April 19,
2022, the Company issued 235,295
shares of Common Stock to settle the Contingent Stock liability, re-measured the liability at its estimated FMV based on the
stock’s trading price and reclassified $496,000
to Common Stock Par Value and Additional Paid in Capital.
In
connection with the closing of the IPO, 235,295
warrants were issued to settle the Contingent Warrant liability (“Note Warrants”) with an exercise price of $4.25. The terms of the Note Warrants continue to require classification as a liability under ASC 815 with recognition of the
changes in fair value to other income or expense in the consolidated statement of operations in accordance with ASC 480 Debt and
Equity. During the year ended December 31, 2022, the Company recorded a FMV income adjustment of $554,412
to reduce the Warrant liability from $585,000
at December 31, 2021 to $30,588
at December 31, 2022. (See Notes 8 and 10)
Note
8. Stockholders’ Equity
Capital
Structure
On
December 11, 2017, the Company was incorporated in Wyoming with 20,000,000 shares of common stock authorized with a $0.0001 par value.
Effective, April 18, 2019, the Company’s authorized common stock was increased to 50,000,000 shares of common stock. The articles
of incorporation also authorized 10,000 preferred shares with a $0.001 par value.
Effective
March 22, 2022, the Company completed a plan and agreement of merger with Sharps Technology, Inc., a Nevada corporation (“Sharps
Nevada”). Pursuant to the merger agreement, (i) the Company merged with and into Sharps Nevada, (ii) each 3.5 shares of common
stock of the Company were converted into one share of common stock of Sharps Nevada and (iii) the articles of incorporation and bylaws
of Sharps Nevada, became the articles of incorporation and bylaws of the surviving corporation. The Company’s authorized common
stock and preferred stock increased from 50,000,000 to 100,000,000 and 10,000 to 1,000,000 shares, respectively. The par value of preferred
stock decreased from $0.001 to $0.0001 per share.
Common
Stock
On
April 13, 2022, the Company’s initial public offering (“IPO”) was declared effective by the SEC pursuant to which the
Company issued and sold an aggregate of 3,750,000 units (“Units”), each consisting of one share of common stock and two warrants,
to purchase one share of common stock for each whole warrant, with an initial exercise price of $4.25 per share and a term of five years.
In addition, the Company granted Aegis Capital Corp., as underwriter a 45-day over-allotment option to purchase up to 15% of the number
of shares included in the units sold in the offering, and/or additional warrants equal to 15% of the number of Warrants included in the
units sold in the offering, in each case solely to cover over-allotments, which the Aegis Capital Corp. partially exercised with respect
to 1,125,000 warrants on April 19, 2022.
The
Company’s common stock and warrants began trading on the Nasdaq Capital Market or Nasdaq on April 14, 2022. The net proceeds
from the IPO, prior to payments of certain listing and professional fees were approximately $14.2
million. The net proceeds, after reflecting par value, has been recorded in Additional Paid in Capital of $9.0 million and with
respect to the Warrants as a liability under ASC 815 of $5.2M. (See Note 10)
During
the year ended December 31, 2022, the Company issued 235,000 shares of common stock at the trading stock price in connection with services
provided to the Company and recorded a charge of $290,551, In addition, the Company issued 235,295 common shares relating to the Note
Purchase agreement. (See Note 7)
During
2021, the Company completed stock subscriptions through a private placement for 487,204 shares of common stock at $7.00 per share. The
Company received cash proceeds of $3,377,929 and had a subscription receivable of $32,500 which was received in January 2022. In addition,
the Company issued 71,429 shares with an estimated fair value of $500,000 to a vendor for engineering and design services provided for
equipment and for partial payments for equipment begin manufactured (See Note 4), 28,571 shares related to an acquisition (See Note 5)
and 2,857 shares for services with an estimated fair value of $20,000.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
8. Stockholders’ Equity (continued)
Warrants
|
a) |
In
connection with the IPO in April 2022, the Company issued 7,500,000
warrants (Trading Warrants) as a component of
the Units and 1,125,000
warrants to the underwriter (Overallotment Warrants),
as noted in Common Stock above. The Trading and Overallotment Warrants were recorded at the FMV, being the trading price of the warrants,
on the IPO effective date and the Warrants are classified as a Liability based on ASC 815. The Warrant liability requires remeasurement
at each reporting period. At the IPO, the liability was $5,778,750
and at December 31, 2022 the liability was $1,121,250.
During year ended December 31, 2022, the Company recorded a FMV gain adjustment of $4,657,500,
(See Note 10). |
|
|
|
|
b) |
The Company has issued
235,295 Warrants (“Note Warrants”) to the Purchasers of the Notes on April 19, 2022. The Note Warrants have an exercise
price of $4.25 and a term of five years. At the issuance date, the liability was $157,647 During the year ended December 31, 2022,
the Company recorded a FMV gain of 127,058. (See Note 10) |
|
|
|
|
c) |
The underwriter received
187,500 warrants in connection with the IPO for a nominal cost of $11,250. The Warrants have an exercise price of $5.32 and are exercisable
after October 9, 2022. The FMV at the date of issuance was $228,750 computed using the Black Sholes valuation model with the following
assumptions: a) volatility of 93.47%, five-year term, risk free interest rate 2.77% and 0% dividend rate. The estimated FMV was classified
as additional issuance costs. |
Note
9. Preferred Stock
In
February 2018, the Company Board of Directors issued one share of Series A Preferred Stock to Alan Blackman, the Company’s co-founder
and Director. The Series A Preferred Stock entitles the holder to vote on any matters related to the election of directors and was reduced
from 50.1% at December 31, 2021 to 29.5%, effective with the IPO. The Series A Preferred Stock has no right to dividends, or distributions
in the event of a liquidation and is not convertible into common stock. In the event the Company is sold during the two-year period following
completion of IPO at a price per share of more than 500% of the initial offering price per Unit in the IPO, the Series A Preferred Stock,
as in effect upon completion of the IPO, will entitle the holder to 10% of the total purchase price.
Note
10. Warrant Liability
The
Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented as a Warrant liability in the accompanying
consolidated balance sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in
fair value presented within the consolidated statement of operations and comprehensive loss. (See Notes 7 and 8)
The
Warrant liability at December 31, 2022 was as follows:
Schedule
of Warrant Liability
| |
| | |
Note Warrants | |
$ | 30,588 | |
Trading and Overallotment Warrants | |
| 1,121,250 | |
Total | |
$ | 1,151,838 | |
Warrant liability | |
$ | 1,151,838 | |
The
Warrants outstanding at December 31, 2022 were as follows:
Schedule
of Warrant Outstanding
| |
| | |
Note warrants | |
| 235,295 | |
Trading and Overallotment Warrants | |
| 8,812,500 | |
Total | |
| 9,047,795 | |
Warrant outstanding | |
| 9,047,795 | |
The
following table presents the changes in the Warrant liability of the Level 1 warrants issued on April 14, 2022, the effective date of
the IPO measured at fair value:
Schedule
of Changes in the Warrant Liability
| |
Total | |
| |
| |
FMV of Note Warrants, at issuance | |
$ | 157,647 | |
| |
| | |
FMV of Trading and Overallotment Warrants, at issuance | |
| 5,778,750 | |
| |
| | |
Change in fair value of warrant liability, issuance through December 31, 2022 | |
| (4,784,559 | ) |
| |
| | |
Fair Value at December 31, 2022 | |
$ | 1,151,838 | |
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
11. Stock Options
A
summary of options granted and outstanding is presented below.
Schedule
of Stock Options Granted and Outstanding
| |
2022 | | |
2021 | |
| |
Options | | |
Weighted Average Exercise Price | | |
Options | | |
Weighted Average Exercise Price | |
Outstanding at Beginning of year | |
| 1,137,479 | | |
$ | 5.18 | | |
| 792,857 | | |
$ | 3.64 | |
Granted | |
| 367,500 | | |
| 1.63 | | |
| 511,764 | | |
| 7.00 | |
Cancelled | |
| (3,571 | ) | |
| (4.38 | ) | |
| (21,875 | ) | |
| (4.38 | ) |
Forfeited | |
| (143,286 | ) | |
$ | (3.77 | ) | |
| (145,157 | ) | |
$ | (2.57 | ) |
| |
| | | |
| | | |
| | | |
| | |
Outstanding at end of year | |
| 1,358,122 | | |
$ | 4.37 | | |
| 1,137,479 | | |
$ | 5.18 | |
| |
| | | |
| | | |
| | | |
| | |
Exercisable at end of year | |
| 1,132,861 | | |
$ | 4.59 | | |
| 825,847 | | |
$ | 5.38 | |
During
the years ended December 31, 2022 and 2021, the estimated weighted-average grant-date fair value of options granted was $1.63 per share
and $4.55 per share, respectively. As of December 31, 2022 and 2021, there was $475,097 and $1,260,990, respectively, of unrecognized
stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period sixteen
months as of December 31, 2022.
The
following table summarizes information about options outstanding at December 31, 2022:
Schedule
of Information About Options Outstanding
Exercise Prices | | |
Options Outstanding | | |
Aggregate Intrinsic Value | | |
Weighted Average Remaining Contractual Life | | |
Options Exercisable | | |
Aggregate Intrinsic Value on Exercisable Shares | |
| | |
| | |
| | |
| | |
| | |
| |
$ | 1.21 | | |
| 307,500 | | |
| - | | |
| 4.42 | | |
| 168,551 | | |
$ | - | |
$ | 1.39 | | |
| 10,000 | | |
| - | | |
| 4.67 | | |
| 10,000 | | |
$ | - | |
$ | 1.75 | | |
| 68,571 | | |
| - | | |
| .25 | | |
| 68,571 | | |
$ | - | |
$ | 2.80 | | |
| 141,429 | | |
| - | | |
| .50 | | |
| 141,429 | | |
$ | - | |
$ | 4.25 | | |
| 50,000 | | |
| - | | |
| 4.50 | | |
| 37,500 | | |
$ | - | |
$ | 4.38 | | |
| 244,286 | | |
| - | | |
| 2.25 | | |
| 244,286 | | |
$ | - | |
$ | 7.00 | | |
| 536,336 | | |
| - | | |
| 3.00 | | |
| 462,524 | | |
$ | - | |
The
aggregate intrinsic values of stock options outstanding and exercised December 31, 2022 were calculated as the difference between the
exercise price of the options and the fair value of the Company’s common stock on December 31, 2022.
In
2022 and 2021, the Company recognized stock-based compensation expense of $1,012,592, of which $915,796 and $96,795 was recorded in general
and administrative and research and development expenses, respectively and $1,195,819, of which $1,091,227 and $105,592 was recorded
in general and administrative and research and development expenses, respectively. Further, in 2022, the Company recorded stock-based
charges of $63,612 relating to purchase of machinery (See Note 4) and $60,435 relating to an Acquisition. (See Note 5) and in 2021, the
Company recorded stock-based charges relating to consideration for purchase of machinery of $253,337 (see Note 4) and relating to an
Acquisition for $122,701 (see Note 5).
The
fair value of stock option awards accounted for under ASC 718 was estimated at the date of grant using a Black-Scholes option-pricing
model with the following assumptions:
Schedule
of Fair Value of Stock Option Awards
|
|
Year
Ended
December 31, 2022 |
|
|
Year
Ended
December 31, 2021 |
|
Expected
term (years) |
|
|
2.50
to 3.00 |
|
|
|
2.50
to 3.25 |
|
Expected
volatility |
|
|
100.81%
to 110.74 |
% |
|
|
97.26%
to 116.06 |
%
|
Risk-free
interest rate |
|
|
2.90%
to 3.47 |
% |
|
|
0.18%
- .81 |
% |
Dividend
rate |
|
|
0 |
% |
|
|
0 |
% |
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
12. Income Taxes
A
reconciliation of the Federal statutory rate (28%) to the total effective rate applicable to income (loss) is as follows:
Schedule
of Reconciliation of Federal Statutory Rate to Total Effective Rate
| |
| | |
| |
| |
Year Ended | | |
Year Ended | |
| |
December 31, 2022 | | |
December 31,
2021 | |
| |
| | |
| |
Expected benefit at statutory federal tax rate | |
$ | (974,329 | ) | |
$ | (979,527 | ) |
Permanent differences – net | |
| (859,515 | ) | |
| - | |
State and local taxes, net of federal tax benefit | |
| (265,607 | ) | |
| (311,373 | ) |
Other | |
| (21,965 | ) | |
| (57,563 | ) |
Change in valuation allowance | |
| 2,121,416 | | |
| 1,348,463 | |
Income tax Expense (Benefit)
Total | |
$ | - | | |
$ | - | |
The
components of the Company’s deferred tax assets (liabilities) are as follows:
Schedule
of Components of Deferred tax Assets
| |
Year Ended December 31, 2022 | | |
Year Ended December 31, 2021 | |
Deferred tax assets (liabilities): | |
| | | |
| | |
Fixed assets | |
$ | (268,594 | ) | |
$ | 3,837 | |
Interest | |
| 62,310 | | |
| 46,361 | |
Research and development expenses | |
| 454,942 | | |
| - | |
Stock-based compensation | |
| 917,351 | | |
| 637,112 | |
Net operating losses - federal | |
| 2,898,411 | | |
| 1,687,053 | |
Net operating losses – state and local | |
| 921,350 | | |
| 536,282 | |
Net operating losses - foreign | |
| 37,686 | | |
| - | |
Research credit | |
| 28,985 | | |
| 28,985 | |
Deferred tax assets gross | |
| 5,052,441 | | |
| 2,939,630 | |
Less valuation allowance | |
| (5,244,441 | ) | |
| (2,939,630 | ) |
Net deferred tax liability | |
$ | (192,000 | ) | |
$ | - | |
The
authoritative guidance, requires the asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities
are determined based on the difference between the financial statement and tax bases of assets and liabilities. Deferred tax assets or
liabilities at the end of each period are determined using the tax rate expected to be in effect when taxes are actually paid or recovered.
The
guidance also requires that a valuation allowance be established when it is more likely than not that all or a portion of a deferred
tax asset will not be realized. A review of all available positive and negative evidence needs to be considered, including a
company’s current and past performance, the market environment in which the company operates, length of carryback and
carryforward periods and existing contracts that will result in future profits. After reviewing all the evidence, the company has
recorded a full valuation allowance.
Note
13. Related Party Transactions and Balances
As
of December 31, 2022 and 2021, accounts payable and accrued liabilities include $105,667
and $59,375,
respectively, payable to officers and directors of the Company. The amounts are unsecured, non-interest bearing and are due on
demand (See Note 15).
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEAR ENDED DECEMBER 31, 2022 AND 2021
Note
14. Fair Value Measurements
The
Company’s financial instruments include cash, accounts payable, notes payable, contingent stock and warrant liability and warrant
liability. Cash, contingent stock liability, contingent warrant liability and warrant liability are measured at fair value. Accounts
payable and notes payable are measured at amortized cost and approximates fair value due to their short duration and market rate for
similar instruments, respectively.
As
of December 31, 2022, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the
Company’s consolidated balance sheet:
Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
Fair Value Measurements Using | | |
| |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
| | |
| | |
| | |
| |
Assets | |
| | | |
| | | |
| | | |
| | |
Cash | |
$ | 4,170,897 | | |
| - | | |
| - | | |
$ | 4,170,897 | |
| |
| - | | |
| - | | |
| - | | |
| | |
Total assets measured at fair value | |
$ | 4,170,897 | | |
| - | | |
| | | |
$ | 4,170,897 | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Warrant liability | |
$ | 1,151,838 | | |
| - | | |
| - | | |
$ | 1,151,838 | |
| |
| | | |
| | | |
| | | |
| | |
Total liabilities measured at fair value | |
$ | 1,151,838 | | |
| - | | |
| - | | |
$ | 1,151,838 | |
Note
15. Commitments and Contingencies
Fixed
Assets and Other
At
December 31, 2022, the Company has outstanding orders to purchase equipment, molds and component parts for research and development of
$609,953 of which advance payments of $209,678 have been made and recorded in Other Assets (See Note 6).
Contingencies
At
each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably
estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company is currently not
involved in any material litigation or other loss contingencies.
Royalty
Agreement
In
connection with the purchase of certain intellectual property in July 2017, Barry Berler and Alan Blackman entered into a royalty agreement
which provides that Barry Berler will be entitled to a royalty of four percent (4%) of net sales derived from the use, sale, lease, rent
and export of products related to the intellectual property. The royalty continues until the patent expires or is no longer used in the
Company’s product. The royalty agreement was assumed by the Company in December 2017.
In
September 2018, the Royalty Agreement was amended to reduce the royalty to 2% and further provided for a single payment of $500,000 to
Barry Berler within three years in return for cancellation of all further royalty obligations of the Company. In May 2019, the Royalty
Agreement was further amended to change the payment date to on or before May 31, 2021 or during the term of the amended Royalty Agreement
should the Company be acquired or a controlling interest be acquired. The Company has not made the aforementioned payment or incur any
change in control as such the 2% royalty remains in place.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEAR ENDED DECEMBER 31, 2022 AND 2021
Note
15. Commitments and Contingencies (continued)
Employment
Agreements
On
August 1, 2022, the Company cancelled the consulting agreement with Alan Blackman, Co- Chairman and Chief Operating Officer and entered
into an Employment Agreement which provides for annual salary of $256,000,
which provides for increases, and provisions compensation adjustments, expense and tax differential reimbursements, benefits and bonuses.
As of September 1, 2022, the annual salary is $320,000.
At June 30, 2022, the Company approved and accrued a $250,000
bonus to Mr. Blackman for services provided in
2022, of which $65,000
was paid subsequent to December 31, 2022.
On
September 30, 2022, the Company entered into a formal employment agreement, effective on such date and will continue until
terminated by either party, subject to the terms of the agreement, with Andrew R. Crescenzo who has been serving as the
Company’s Chief Financial Officer on a contract services basis for the last three years. The agreement provided for annual
compensation of $225,000 and plus a one-time $18,750 incentive payment upon the commencement of the agreement. During the course of
the term, Mr. Crescenzo will be eligible for (i) performance bonuses to be granted at the discretion of the Company’s
Compensation Committee and (ii) to participate in the Company’s 2022 Equity Incentive Plan. The agreement contains customary
employment terms and conditions.
In
October 2022, the Company entered into a service agreement (“Service Agreement”) with an unrelated third-party for
marketing and investor relations services. The Service Agreement, which has a term of one year, has various deliverables and
provides payments to the third party as follows; a) an initial fee of $90,000,
b) monthly fees through the term of $12,500,
c) 200,000
shares of restricted common stock and d) $300,000
specifically related to digital marketing activities. As stated in Note 8, the 200,000
shares of restricted common stock were valued at $230,000,
representative of the trading price on the issuance.
Note
16. Subsequent Events
On
January 25, 2023, the Company granted five-year options (the “Options”) to purchase a total of 975,000
shares of the Company’s common stock, par
value $0.0001
per share (the “Common Stock”) to
its directors, executive officers, employee and consultants pursuant to the Company’s. 2022 and 2023 Equity Incentive Plans. The
Options are exercisable at $1.37
per share which was the closing price on January
25, 2023. Of the Options granted, Options to purchase an aggregate of 495,000
shares of Common Stock were issued to executive
officers Options to purchase an aggregate of 455,000
shares of Common Stock were issued to directors
and Options to purchase an aggregate of 75,000
shares of Common Stock to employees and a consultant.
On
January 25, 2023, the Company’s Board of Directors adopted the 2023 Equity Incentive Plan (the “2023 Plan”). The 2023
Plan provides for the issuance of up to 1,400,000
options and/or shares of restricted stock to
be available for issuance to officers, directors, employees and consultants. The 2023 Plan is subject to shareholder approval at
the annual meeting.
On
February 09, 2023, the Company, appointed Justin Paige, as Vice President
of Technical Operations with a start date of February 15, 2023. The agreement provides for annual compensation of $235,000
and Options to purchase 50,000
shares of Common Stock at the exercise price of $1.30,
the closing price on the grant date. During the course of the term, Mr. Paige will be eligible for (i) performance bonuses to be granted
at the discretion of the Company’s Compensation Committee and (ii) to participate in the Company’s Equity Incentive Plan.
The agreement contains customary employment terms and conditions and provides for severance of six months if a change in control occurs,
as defined.
On
February 3, 2023, the Company completed a securities purchase agreement (“Offering”) with institutional investors and
received net proceeds from the Offering were approximately $3.2
million, net of $600,000
in fees relating to the placement agent and other offering expenses. The Offering was priced at the market under Nasdaq rules. In
connection with the Offering, the Company issued 2,248,521
units at a purchase price of $1.69
per unit. Each unit consists of one share of common stock and one non-tradable warrant exercisable for one share of common stock at
a price of $1.56.
The warrants have a term of five
years from the issuance date. On February 13, 2023, the Company filed an S-1 (Resale) Registration Statement in connection with the Offering.
SHARPS TECHNOLOGY, INC.
CONDENSED
CONSOLIDATED BALANCE SHEETS
| |
June 30, 2023 | | |
December 31, 2022 | |
| |
(Unaudited) | | |
(Audited) | |
Assets: | |
| | | |
| | |
Current Assets | |
| | | |
| | |
Cash | |
$ | 2,924,019 | | |
$ | 4,170,897 | |
Prepaid expenses and other current assets | |
| 193,875 | | |
| 66,749 | |
Inventories (Note 3) | |
| 992,547 | | |
| 185,804 | |
Current Assets | |
| 4,110,441 | | |
| 4,423,450 | |
| |
| | | |
| | |
Fixed Assets, net of accumulated depreciation (Notes 4 and 5) | |
| 7,092,954 | | |
| 7,004,890 | |
Other Assets (Notes 5 and 6) | |
| 590,740 | | |
| 411,316 | |
TOTAL ASSETS | |
$ | 11,794,135 | | |
$ | 11,839,656 | |
| |
| | | |
| | |
Liabilities: | |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Accounts payable (Note 4) | |
$ | 825,622 | | |
$ | 543,226 | |
Accrued and other current liabilities (Note 15) | |
| 574,057 | | |
| 311,458 | |
Warrant liability (Notes 8 and 10) | |
| 1,513,187 | | |
| 1,151,838 | |
Total Current Liabilities | |
| 2,912,866 | | |
| 2,006,522 | |
| |
| | | |
| | |
Deferred Tax Liability | |
| 192,000 | | |
| 192,000 | |
Total Liabilities | |
| 3,104,866 | | |
| 2,198,522 | |
| |
| | | |
| | |
Commitments and Contingencies (Note 15) | |
| - | | |
| - | |
Subsequent Events (Note 16) | |
| - | | |
| | |
| |
| | | |
| | |
Stockholders’ Equity: | |
| | | |
| | |
Preferred stock, $.0001 par value; 1,000,000 shares authorized; 1 share issued and outstanding | |
| - | | |
| - | |
Common stock, $.0001 par value; 100,000,000, shares authorized; 11,655,936 shares issued and outstanding (2022: 9,407,415) | |
| 1,166 | | |
| 941 | |
Additional paid-in capital | |
| 28,154,012 | | |
| 24,733,306 | |
Accumulated other comprehensive income | |
| 559,112 | | |
| 214,253 | |
Accumulated deficit | |
| (20,025,021 | ) | |
| (15,307,366 | ) |
Total Stockholders’ Equity | |
| 8,689,269 | | |
| 9,641,134 | |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | |
$ | 11,794,135 | | |
$ | 11,839,656 | |
The
accompanying notes are an integral part of these financial statements.
SHARPS
TECHNOLOGY, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR
THE THREE AND SIX MONTHS ENDED JUNE
(UNAUDITED)
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
THREE MONTHS ENDED JUNE 30, | | |
SIX MONTHS ENDED JUNE 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue, net | |
$ | - | | |
$ | - | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development (Note 5) | |
| 224,260 | | |
| 556,868 | | |
| 558,148 | | |
| 1,063,243 | |
General and administrative | |
| 2,308,075 | | |
| 2,230,801 | | |
| 4,291,987 | | |
| 3,061,710 | |
Total operating expenses | |
| 2,532,335 | | |
| 2,787,669 | | |
| 4,850,135 | | |
| 4,124,953 | |
Loss from operations | |
| (2,532,335 | ) | |
| (2,787,669 | ) | |
| (4,850,135 | ) | |
| (4,124,953 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | |
Interest income (expense) | |
| 40,079 | | |
| (1,100,507 | ) | |
| 76,871 | | |
| (1,345,944 | ) |
FMV adjustment on contingent stock & warrants | |
| (90,108 | ) | |
| 4,365,930 | | |
| 93,977 | | |
| 4,078,930 | |
Foreign currency and other | |
| (23,461 | ) | |
| - | | |
| (38,368 | ) | |
| - | |
Total Other Income (Expense) | |
| (73,490 | ) | |
| 3,265,423 | | |
| 132,480 | | |
| 2,732,986 | |
Net (loss) / Gain | |
$ | (2,605,825 | ) | |
$ | 477,754 | | |
| (4,717,655 | ) | |
| (1,391,967 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share, basic and diluted | |
$ | (0.22 | ) | |
$ | 0.06 | | |
| (0.42 | ) | |
| (0.20 | ) |
Weighted average shares used to compute net loss per share, basic and diluted | |
| 11,655,936 | | |
| 8,669,372 | | |
| 11,193,740 | | |
| 6,928,217 | |
The
accompanying notes are an integral part of these financial statements.
SHARPS
TECHNOLOGY, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
FOR
THE THREE AND SIX MONTHS ENDED JUNE 30
(UNAUDITED)
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
THREE MONTHS ENDED JUNE 30, | | |
SIX MONTHS ENDED JUNE 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Net loss | |
$ | (2,605,825 | ) | |
$ | 477,754 | | |
| (4,717,655 | ) | |
| (1,391,967 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other comprehensive income: | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Foreign currency translation adjustments gain/(loss) | |
| 73,786 | | |
| - | | |
| 344,859 | | |
| - | |
| |
| | | |
| | | |
| | | |
| | |
Comprehensive loss | |
$ | (2,532,039 | ) | |
$ | 477,754 | | |
| (4,372,796 | ) | |
| (1,391,967 | ) |
The
accompanying notes are an integral part of these financial statements.
SHARPS
TECHNOLOGY, INC.
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2023
(Unaudited)
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Receivable |
|
|
Capital |
|
|
Income |
|
|
Deficit |
|
|
Equity |
|
|
|
Preferred
Stock |
|
|
Common
Stock |
|
|
Common
Stock Subscription |
|
|
Additional
Paid in |
|
|
Accumulated
Other Comprehensive |
|
|
Accumulated |
|
|
Total
Stockholders |
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Receivable |
|
|
Capital |
|
|
Income |
|
|
Deficit |
|
|
Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
-December 31, 2022 |
|
|
1 |
|
|
$ |
- |
|
|
|
9,407,415 |
|
|
$ |
941 |
|
|
|
- |
|
|
$ |
24,733,306 |
|
|
$ |
214,253 |
|
|
$ |
(15,307,366 |
) |
|
$ |
9,641,134 |
|
Beginning
balance |
|
|
1 |
|
|
$ |
- |
|
|
|
9,407,415 |
|
|
$ |
941 |
|
|
|
- |
|
|
$ |
24,733,306 |
|
|
$ |
214,253 |
|
|
$ |
(15,307,366 |
) |
|
$ |
9,641,134 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss for the three months ended March 31, 2023 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(2,111,830 |
) |
|
|
(2,111,830 |
) |
Shares
issued in Offering |
|
|
|
|
|
|
- |
|
|
|
2,248,521 |
|
|
|
225 |
|
|
|
|
|
|
|
2,783,160 |
|
|
|
- |
|
|
|
|
|
|
|
2,783,385 |
|
Share-based
compensation charges |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
383,100 |
|
|
|
- |
|
|
|
- |
|
|
|
383,100 |
|
Foreign
Currency Translation |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
270,983 |
|
|
|
- |
|
|
|
270,983 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
- March 31, 2023 |
|
|
1 |
|
|
$ |
- |
|
|
|
11,655,936 |
|
|
$ |
1,166 |
|
|
|
- |
|
|
$ |
27,899,566 |
|
|
$ |
485,236 |
|
|
$ |
(17,419,196 |
) |
|
$ |
10,966,772 |
|
Beginning
balance |
|
|
1 |
|
|
$ |
- |
|
|
|
11,655,936 |
|
|
$ |
1,166 |
|
|
|
- |
|
|
$ |
27,899,566 |
|
|
$ |
485,236 |
|
|
$ |
(17,419,196 |
) |
|
$ |
10,966,772 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss for the three months ended June 30, 2023 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(2,605,825 |
) |
|
|
(2,605,825 |
) |
Share-based
compensation charges |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
254,446 |
|
|
|
- |
|
|
|
- |
|
|
|
254,446 |
|
Foreign
Currency Translation |
|
|
- |
|
|
- |
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
73,876 |
|
|
|
- |
|
|
|
73,876 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
- June 30, 2023 |
|
|
1 |
|
|
$ |
- |
|
|
|
11,655,936 |
|
|
$ |
1,166 |
|
|
|
- |
|
|
$ |
28,154,012 |
|
|
$ |
559,112 |
|
|
$ |
(20,025,021 |
) |
|
$ |
8,689,269 |
|
Ending
balance |
|
|
1 |
|
|
$ |
- |
|
|
|
11,655,936 |
|
|
$ |
1,166 |
|
|
|
- |
|
|
$ |
28,154,012 |
|
|
$ |
559,112 |
|
|
$ |
(20,025,021 |
) |
|
$ |
8,689,269 |
|
SHARPS
TECHNOLOGY, INC.
CONDENSED
STATEMENT OF STOCKHOLDERS’ EQUITY
FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2022
(Unaudited)
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Receivable | | |
Capital | | |
Deficit | | |
Equity | |
| |
Preferred
Stock | | |
Common
Stock | | |
Common Stock Subscription | | |
Additional Paid
in | | |
Accumulated | | |
Total Stockholder’s | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Receivable | | |
Capital | | |
Deficit | | |
Equity | |
| |
| | |
| | |
| | |
| |
Balance -December 31, 2021 | |
| 1 | | |
$ | - | | |
| 5,187,062 | | |
$ | 519 | | |
$ | (32,500 | ) | |
$ | 13,835,882 | | |
$ | (10,667,704 | ) | |
| 3,136,197 | |
Beginning balance | |
| 1 | | |
$ | - | | |
| 5,187,062 | | |
$ | 519 | | |
$ | (32,500 | ) | |
$ | 13,835,882 | | |
$ | (10,667,704 | ) | |
| 3,136,197 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net loss for the three months ended March 31, 2022 | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (1,869,721 | ) | |
| (1,869721 | ) |
Share-based compensation charges | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 328,460 | | |
| - | | |
| 328,460 | |
Collections of common stock subscriptions | |
| - | | |
| - | | |
| | | |
| | | |
| 32,500 | | |
| - | | |
| - | | |
| 32,500 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance - March 31, 2022 | |
| 1 | | |
$ | - | | |
| 5,187,062 | | |
$ | 519 | | |
$ | - | | |
$ | 14,164,342 | | |
$ | (12,537,425 | ) | |
$ | 1,627,436 | |
Balance | |
| 1 | | |
$ | - | | |
| 5,187,062 | | |
$ | 519 | | |
$ | - | | |
$ | 14,164,342 | | |
$ | (12,537,425 | ) | |
$ | 1,627,436 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net income for the three months ended June 30, 2022 | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 477,754 | | |
| 477,754 | |
Net income (loss) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 477,754 | | |
| 477,754 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Shares issued in Initial Public Offering | |
| - | | |
| - | | |
| 3,750,000 | | |
| 375 | | |
| - | | |
| 8,974,282 | | |
| - | | |
| 8,974,657 | |
Issuance of shares for contingent stock liability | |
| - | | |
| - | | |
| 235,294 | | |
| 24 | | |
| - | | |
| 495,976 | | |
| - | | |
| 496,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Fractional share adjustment | |
| - | | |
| - | | |
| 59 | | |
| - | | |
| | | |
| - | | |
| - | | |
| | |
Share-based compensation charges | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 365,606 | | |
| - | | |
| 365,606 | |
Shares issued for services | |
| - | | |
| - | | |
| 35,000 | | |
| 4 | | |
| - | | |
| 60,547 | | |
| - | | |
| 60,551 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance – June 30, 2022 | |
| 1 | | |
$ | - | | |
| 9,207,415 | | |
$ | 922 | | |
$ | - | | |
$ | 24,060,753 | | |
$ | (12,059,671 | ) | |
$ | 12,002,004 | |
Balance | |
| 1 | | |
$ | - | | |
| 9,207,415 | | |
$ | 922 | | |
$ | - | | |
$ | 24,060,753 | | |
$ | (12,059,671 | ) | |
$ | 12,002,004 | |
The
accompanying notes are an integral part of these financial statements.
SHARPS
TECHNOLOGY, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR
THE SIX MONTHS ENDED JUNE 30
(UNAUDITED)
| |
2023 | | |
2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | | |
| | |
Net loss | |
$ | (4,717,655 | ) | |
$ | (1,391,967 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 448,657 | | |
| 156,100 | |
Stock-based compensation | |
| 637,547 | | |
| 650,104 | |
Accretion of debt discount | |
| | | |
| 1,299,985 | |
FMV adjustment for Contingent Stock | |
| | | |
| (181,000 | ) |
FMV adjustment for Warrants | |
| (93,977 | ) | |
| (3,897,930 | ) |
IPO Issuance costs relating to Warrants | |
| | | |
| 550,433 | |
Foreign exchange gain | |
| 30,141 | | |
| - | |
Changes in operating assets: | |
| | | |
| | |
Prepaid expenses and other current assets | |
| (119,761 | ) | |
| (27,542 | ) |
Inventory | |
| (769,088 | ) | |
| (5,448 | ) |
Other assets | |
| - | | |
| - | |
Accounts payable and accrued liabilities | |
| 453,136 | | |
| (245,840 | ) |
Net cash used in operating activities | |
| (4,131,000 | ) | |
| (3,093,105 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Acquistion of fixed assets or deposits paid | |
| (342,525 | ) | |
| (463,355 | ) |
Other assets – escrow and other | |
| - | | |
| (2,350,000 | ) |
Net cash used in investing activities | |
| (342,525 | ) | |
| (2,813,355 | ) |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Net proceeds from Initial Public Offering and additional offering | |
| 3,238,711 | | |
| 14,202,975 | |
Repayment of Note Payable | |
| - | | |
| (2,000,000 | ) |
Proceeds from subscriptions receivable | |
| - | | |
| 32,500 | |
Net cash provided by financing activities | |
| 3,238,711 | | |
| 12,235,475 | |
| |
| | | |
| | |
Effect of exchange rate changes on cash | |
| (12,064 | ) | |
| - | |
| |
| | | |
| | |
NET INCREASE (DECREASE) IN CASH | |
| (1,246,878 | ) | |
| 6,329,015 | |
CASH — BEGINNING OF YEAR | |
| 4,170,897 | | |
| 1,479,166 | |
CASH — END OF PERIOD | |
$ | 2,924,019 | | |
$ | 7,808,181 | |
| |
| | | |
| | |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | |
| | | |
| | |
Cash paid for interest | |
$ | - | | |
$ | 47,111 | |
| |
| | | |
| | |
Non-cash investing and financing activity: | |
| | | |
| | |
FMV for Common Stock Issued for Contingent Shares | |
| | | |
| 496,000 | |
Common stock issued and vested stock options for fixed assets acquired | |
$ | - | | |
$ | 63,612 | |
Common stock issued and vested stock options issued as consideration for acquisition | |
$ | - | | |
$ | 40,901 | |
The
accompanying notes are an integral part of these financial statements.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
Note
1. Description of Business
Nature
of Business
Sharps
Technology, Inc. (“Sharps” or the “Company”) is a pre-revenue medical device company that has designed and patented
various safety syringes and is seeking commercialization by manufacturing and distribution of its products.
The
accompanying condensed consolidated financial statements include the accounts of Sharps Technology, Inc. and its wholly owned subsidiary,
Safegard Medical, Inc. collectively referred to as the “Company.” The condensed consolidated balance sheet as of June 30,
2023 and the condensed consolidated statements of operations, statements of comprehensive loss and statements of stockholders’
equity s for the three and six months ended June 30, 2023 and 2022 and the statements of cash flow for the six months ended June
30, 2023 (the “interim statements”) are unaudited. All intercompany transactions and balances have been eliminated. In the
opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position
and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual
financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or
omitted. The interim statements should be read in conjunction with the consolidated financial statements for the year ended December
31, 2022 and notes thereto contained in the Company’s Form 10-K filed with the Securities and Exchange Commission. The condensed
consolidated balance sheet at December 31, 2022 has been derived from the audited financial statements at that date. The results of operations
for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year
ending December 31, 2023.
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has not
generated revenue or cash flow from operations since inception. As of June 30, 2023, the Company had a working capital of $1,197,575 which
is not expected to be sufficient to fund the Company’s planned operations for the next 12 months. These factors raise substantial
doubt regarding the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern
is dependent upon the Company’s ability to raise sufficient financing to acquire or commercialize its products into a profitable
business. The Company intends to finance its commercialization activities and its working capital needs largely from the sale of equity
securities and/or with additional funding from other traditional financing sources until such time that funds provided by operations
are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating
to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary
should the Company be unable to continue as a going concern.
The
Company’s fiscal year ends on December 31.
On
April 13, 2022, the Company’s Initial Public Offering was deemed effective with trading commencing on April 14, 2022. The Company
received net proceeds of $14.2 million on April 19, 2022 (See Note 8).
Note
2. Summary of Significant Accounting Policies
Basis
of Presentation
The
accompanying condensed consolidated financial statements have been prepared by the Company in accordance with generally accepted accounting
principles (“GAAP”) in the United States (“U.S.”) and are expressed in U.S. dollars.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As
of June 30, 2023, the most significant estimates relate to derivative liabilities and stock-based compensation.
Cash
and Cash Equivalents
The
Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date
of purchase to be cash equivalents. Cash and cash equivalents are maintained with various financial institutions.
Inventories
The
Company values inventory at the lower of cost (average cost) or net realizable value. Work-in-process and finished goods inventories
consist of material, labor, and manufacturing overhead. Net realizable value is the estimated selling price in the ordinary course of
business, less reasonably predictable costs of completion, disposal, and transportation. A reserve is established for any excess or obsolete
inventories or they may be written off. At June 30, 2023 and December 31, 2022, inventory is comprised of raw materials, including packaging,
work in process (components) and finished goods.
Fair
Value Measurements
ASC
820, Fair Value Measurements and Disclosures, require an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding
the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be
used to measure fair value.
The
Company’s outstanding warrants are fair valued on a recurring basis with the trading price which could cause fluctuations in operating
results at the reporting periods.
Level
1
Level
1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Valuations
are based on quoted prices that are readily and regularly available in an active market and do not entail a significant degree of judgment.
Level
2
Level
2 applied to assets or liabilities for which there are other than Level 1 observable inputs such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market data.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
Level
2 instruments require more management judgment and subjectivity as compared to Level 1 instruments. For instance: determining which instruments
are most similar to the instrument being priced requires management to identify a sample of similar securities based on the coupon rates,
maturity, issuer credit rating and instrument type, and subjectively select an individual security or multiple securities that are deemed
most similar to the security being priced; and determining whether a market is considered active requires management judgment.
Level
3
Level
3 applied to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement
of the fair value of the assets or liabilities. The determination for Level 3 instruments requires the most management judgment and subjectivity.
Fixed
Assets
Fixed
assets are stated at cost. Expenditures for maintenance and repairs are charged to operations as incurred. The Company’s fixed
assets consist of land, building, machinery and equipment, molds and website. Depreciation is calculated using the straight-line method
commencing on the date the asset is operating in the way intended by management over the following useful lives: Building – 20
years, Machinery and Equipment – 3 -10 years and Website – 3 years. The expected life for Molds is based on the lesser of
the number of parts that will be produced based on the expected mold capability or 5 years.
Impairment
of Long-Lived Assets
Long-lived
assets are reviewed for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash
flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.
There
were no impairment losses recognized during the six months ended June 30, 2023.
Purchased
Identified Intangible Assets
The
Company’s identified intangible assets are amortized on a straight-line basis over their estimated useful lives of 5 years. The
Company makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate that the
useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable. If such facts and circumstances
exist, the Company assesses recoverability by comparing the projected undiscounted net cash flows associated with the related asset or
group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the excess of
the carrying amount over the fair value of those assets. If the useful life is shorter than originally estimated, the Company would accelerate
the rate of amortization and amortize the remaining carrying value over the new shorter useful life. The Company evaluates the carrying
value of indefinite-lived intangible assets whenever events or changes in circumstances indicate that the carrying amount of an
asset may not be recoverable, and an impairment charge would be recognized to the extent that the carrying amount of such assets exceeds
their estimated fair value.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
Stock-based
Compensation Expense
The
Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. For
stock option awards, the Company uses the Black-Scholes option-pricing model. For restricted stock awards, the estimated fair value is
generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite
service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company
recognizes forfeitures of stock-based awards as they occur on a prospective basis.
Stock-based
compensation expense for awards granted to non-employees as consideration for services received is measured on the date of performance
at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured.
Derivative
Instruments
The
Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of
the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC 480”), Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815,
Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments
pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification
under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could
potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent
quarterly period end date while the warrants are outstanding.
At
their issuance date and as of June 30, 2023, the warrants (see Notes 8 and 10) were accounted for as liabilities as these instruments
did not meet all of the requirements for equity classification under ASC 815-40 based on the terms of the aforementioned warrants. The
resulting warrant liabilities are re-measured at each balance sheet date until their exercise or expiration, and any change in fair value
is recognized in the Company’s condensed consolidated statements of operations and comprehensive loss.
Foreign
Currency Translation/Transactions
The
Company has determined that the functional currency for its foreign subsidiary is the local currency. For financial reporting purposes,
assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated
at weighted average exchange rates. Resulting translation gains and losses are included as a separate component of stockholders’
equity as accumulated other comprehensive income or loss. Gains or losses resulting from transactions entered into in other than the
functional currency are recorded as foreign exchange gains and losses in the consolidated statements of operations and comprehensive
loss.
Comprehensive
income (loss)
Comprehensive
income (loss) consists of the Company’s consolidated net loss and foreign currency translation adjustments related to its subsidiary.
Foreign currency translation adjustments included in comprehensive loss were not tax effected as the Company has a full valuation allowance
at June 30, 2023 and December 31, 2022. Accumulated other comprehensive income (loss) is a separate component of stockholders’
equity and consists of the cumulative foreign currency translation adjustments.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
Basic
and Diluted Loss Per Share
The
Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted
earnings per share (EPS) on the face of the consolidated statement of operations and comprehensive loss. Basic EPS is computed by dividing
net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during
the year. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method
and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used
in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all
dilutive potential shares if their effect is anti-dilutive. As of June 30, 2023, there were 13,788,724 stock options and warrants
that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would
have been antidilutive for the periods presented.
Income
Taxes
The
Company must make certain estimates and judgments in determining income tax expenses for financial statement purposes. These estimates
and judgments are used in the calculation of tax credits, tax benefits, tax deductions, and in the calculation of certain deferred taxes
and tax liabilities. Significant changes to these estimates may result in an increase or decrease to the Company’s tax provision
in a subsequent period.
The
provision for income taxes was comprised of the Company’s current tax liability and changes in deferred income tax assets and liabilities.
The calculation of the current tax liability involves dealing with uncertainties in the application of complex tax laws and regulations
and in determining the liability for tax positions, if any, taken on the Company’s tax returns in accordance with authoritative
guidance on accounting for uncertainty in income taxes. Deferred income taxes are determined based on the differences between the financial
reporting and tax basis of assets and liabilities. The Company must assess the likelihood that it will be able to recover the Company’s
deferred tax assets. If recovery is not likely on a more-likely-than-not basis, the Company must increase its provision for income taxes
by recording a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. However, should
there be a change in the Company’s ability to recover its deferred tax assets, the provision for income taxes would fluctuate in
the period of such change.
Research
and Development Costs
Research
and development costs are expensed as incurred.
Advance
payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized.
Such amounts are recognized as an expense as the related goods are delivered or the services are performed.
Contingencies
Liabilities
for loss contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized when it is
probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Gain contingencies are evaluated
and not recognized until the gain is realizable or realized.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
Recent
Accounting Pronouncements
In
March 2020, the FASB issued ASC Topic 848, Reference Rate Reform. ASC Topic 848 provides relief for impacted areas as it relates
to impending reference rate reform. ASC Topic 848 contains optional expedients and exceptions for applying GAAP to debt arrangements,
contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective
upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance.
On
August 5, 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40), which simplifies the accounting for certain financial
instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own
equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU
2020-06 simplifies the guidance in U.S. GAAP on the issuer’s accounting for convertible debt instruments, requires entities to
provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been
reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification
and amends certain guidance in ASC 260, Earnings per Share, on the computation of EPS for convertible instruments and contracts
on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance.
The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company
continues to assess all potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.
In
June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject
to Contractual Sale Restrictions”, intended to clarify that a contractual restriction on the sale of an equity security is not
considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendment
also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. ASU No. 2022-03
is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December
15, 2023. Early adoption is permitted. For all other entities, it is effective for fiscal years, including interim periods within those
fiscal years beginning after December 15, 2024. Early adoption is permitted for both interim and annual financial statements that have
not yet been issued or made available for issuance. The Company is evaluating the adoption of the amendments and the potential impact
it may have, if any, on its financial statements.
The
Company does not expect the adoption of any accounting pronouncements to have a material impact on the condensed consolidated financial
statements.
We
reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant
to the accounting for our operations.
Note
3. Inventories
Inventories,
net consisted of the following at:
Schedule of Inventories
| |
June 30, 2023 | | |
December 31, 2022 | |
Raw materials | |
$ | 226,062 | | |
$ | 106,088 | |
Work in process | |
| 86,831 | | |
| 49,144 | |
Finished goods | |
| 679,654 | | |
| 30,572 | |
Total | |
$ | 992,547 | | |
$ | 185,804 | |
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
4. Fixed Assets
Fixed
asset, net, is summarized as follows as of:
Schedule of Property, Plant and Equipment
| |
June 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Land | |
$ | 264,736 | | |
$ | 242,240 | |
Building | |
| 3,068,950 | | |
| 2,824,481 | |
Machinery and Equipment | |
| 4,863,882 | | |
| 4,601,293 | |
Website | |
| 20,363 | | |
| 16,600 | |
Fixed asset, gross | |
| 8,217,930 | | |
| 7,684,614 | |
Less: accumulated depreciation | |
| (1,124,976 | ) | |
| (679,724 | ) |
Fixed asset, net | |
$ | 7,092,954 | | |
$ | 7,004,890 | |
Depreciation
expense of fixed assets for the six months ended June 30, 2023 and 2022 was $445,252 net of foreign currency impacts and $156,100
respectively. Substantially, all the Company’s fixed assets are located at the Company’s Hungary location.
During
the six months ended June 30, 2022 , the Company recorded $63,612 in fixed asset costs relating to the estimated fair market value
for options granted in 2021 for the acquired machinery. As of June 30, 2023, the Company has $100,000 in remaining payments for machinery
purchased, which is included in accounts payable.
Note
5. Asset Acquisition
In
June 2020, the Company entered into a Share Purchase Agreement (“Agreement”) with Safegard Medical (“Safegard”)
and amendments to the Agreement, collectively, the Agreements, to purchase either the stock or certain assets of a manufacturing facility
for $2.5M in cash, plus additional consideration of 28,571 shares of common stock with an estimated fair market value of $7.00, 35,714
stock options with an exercise price of $7.00 and 50,000 stock options with an exercise price of $4.25. The purchase price includes the
fair market value of the common stock of $200,000 and the vested options of $183,135. The Agreements provided the Company various periods
for due diligence and post due diligence, requirements for escrow payments through the closing date (“Closing Date”).
Through
the Closing Date, the Agreements provided the Company with the exclusive use of the facility in exchange for payment of the facility’s
operating costs. The monthly fee (“Operating Costs”), which primarily covered the facility’s operating costs, was mainly
comprised of the seller’s workforce costs, materials and other recurring monthly operating cost.
During
the three and six months ended June 30, 2022, the Company had remitted $275,000 and $300,000, respectively for the forementioned Operating
Costs. The remittance of operating costs was discontinued after the Closing Date. These costs were included in research and development
expense in the condensed consolidated statement of operations as the activities at the facility in 2022 were related to design and testing
of the Company’s products.
The
acquisition of Safegard, which closed on July 6, 2022, did not meet the definition of a business pursuant to ASC 805-10, and accordingly
was accounted for as an asset acquisition in accordance with ASC 805-50. The cost of the acquisition was $2,936,712, including transaction
costs of $53,576, with the allocation to the assets acquired on a relative fair value basis. The intangibles relate to permits and a
limited workforce acquired. Under ASC 805-50, no goodwill is recognized. The operating results for Safegard are included in the consolidated
balance sheet and consolidated statements of operations and comprehensive loss for the period beginning after the closing on July 6,
2022.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
5. Asset Acquisition (continued)
The
relative fair value of the assets acquired and related deferred tax liability is as follows:
Schedule of Fair Value of the Assets Acquisition
| |
| | |
Land | |
$ | 226,000 | |
Building and affixed assets | |
| 2,648,000 | |
Machinery | |
| 158,000 | |
Inventory | |
| 32,000 | |
Intangibles | |
| 64,712 | |
Deferred tax liability | |
| (192,000 | ) |
| |
| | |
Total | |
$ | 2,936,712 | |
The
useful lives for the acquired assets is Building - 20 years; Machinery – 5 to 10 years; Intangibles – 5 years. The related
depreciation and amortization is being recorded on a straight-line basis.
Note
6. Other Assets
Other
assets as of June 30, 2023 and December 31, 2022 are summarized as follows:
Schedule of Other Assets
| |
2023 | | |
2022 | |
Intangibles, net | |
| 60,993 | | |
| 62,480 | |
Deposits or advance payments on machinery, molds, components or technology (see Note 15) | |
| 517,377 | | |
| 336,466 | |
Other | |
| 12,370 | | |
| 12,370 | |
Other assets | |
$ | 590,740 | | |
$ | 411,316 | |
Intangibles
are related to the Asset Acquisition (see Note 5) and consist of an acquired workforce and permits. Amortization for the six months ended
June 30, 2023 and 2022 was 7,928 and $1,487 respectively.
Note
7. Note Purchase Agreement
On
December 14, 2021, the Company entered into a Note Purchase Agreement (“NPA”) with three unrelated third-party purchasers
(“Purchasers”). The Purchasers provided financing to the Company in the form of bridge financing, aggregating principal of
$2,000,000 (the “Notes”). The principal under the Notes shall be payable on the earlier of (i) December 14, 2022, and (ii)
the date on which the Company consummates an initial public offering (“IPO”), herein referred to as the “Maturity Date”.
The Notes bore interest at 8% with interest payments due monthly. The Company and the Purchasers had entered into a Security Agreement
whereby the Notes were collateralized by substantially all the assets of the Company, both tangible and intangible both currently owned
with stated exclusions, as defined, and any future acquired with stated exclusions, as defined.
The
NPA provided for covenants that until all of the Notes have been converted, exchanged, redeemed or otherwise satisfied in accordance
with their terms, the Company shall not, and the Company shall not permit any of its subsidiaries without the prior written consent of
the Purchasers: a) incur or guarantee any new debt, b) issue any securities that would cause a breach or default under the NPA, c) incur
any liens other than permitted, d) redeem or repurchase shares, e) declare or pay any cash dividend or distribution, e) sell, lease or
dispose of assets other than in the ordinary course of business, or f) engage in different line of business.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
7. Note Purchase Agreement (continued)
As
additional consideration to the Purchasers for providing the financing, the Company also agreed to a) issue each Purchaser a number of
shares of the Company’s Common Stock equal to 50% of the original principal amount of each Purchaser’s Note (the “Contingent
Stock”) and b) issue each Purchaser a number of warrants, which would allow the Purchasers to purchase additional shares of the
Company’s Common Stock, equal to 50% of the original principal amount each Purchaser’s Note for a term of 5.0 years (the
“Contingent Warrants”).
For
both the Contingent Stock and the Contingent Warrants, the number of shares and warrants that each Purchaser will be issued was unknown
at the time of the NPA and was determined based on a formula of 50% of the original principal amount divided by a “Subsequent Offering
Price” based on the valuation in a future offering of Common stock or other equity interest in the Company (such offering referred
to as a “Consummated Offering”) during the period beginning on December 14, 2021 through and including the date the Company
consummates an initial public offering (“IPO”) (such period referred to as the “Subsequent Offering Period”).
In
accordance with ASC 480-10-25-14, a fixed monetary amount exists at inception for the total value of Contingent Stock that may be issued
to each Purchaser. The Contingent Stock is not considered outstanding at inception, as it will only be issued upon the consummation of
a Consummated Offering, and accordingly, is a conditional obligation. As such the fair market value (“FMV”) of the Contingent
Stock at inception was $677,000, which was recorded as debt discount. Similarly, a fixed monetary amount further exists at inception
for the total value of Contingent Warrants that may be issued to each Purchaser. Accordingly, a conditional obligation exists and as
such the FMV of Contingent Warrants at inception was $585,000, which was recorded as debt discount. The Company incurred $197,500 of
debt issuance costs associated with the NPA. The debt issuance costs were allocated between the Notes, Contingent Stock and Contingent
Warrants in a manner that was consistent with the allocation of the proceeds of the Notes. The portion of the debt issuance costs which
were allocated to the Contingent Stock and Contingent Warrants, which was $124,460, was expensed during the year ended December 31, 2021.
The debt issuance costs allocated to the Notes were recorded as a debt discount.
The
Contingent Stock and Contingent Warrant liabilities were measured at FMV on the date of issuance (based on the Black-Scholes valuation
model).
At
inception, the Notes were recorded at the net amount of approximately $665,000, after adjusting for debt discounts of approximately $1,335,000
relating to the debt issuance costs, Contingent Stock and Contingent Warrants. Management calculates the effective interest rate (“EIR”)
to consider the potential repayment at redemption date by reference to the face value amount after taking into account the stated 8%
interest rate. In 2022, through for the three months ended March 31, 2022, the Company recorded interest expense of $39,111 and accreted
interest of $206,417 The Company repaid the $2,000,000 in Notes with proceeds from the IPO that closed on April 19, 2022.
The
value of the Contingent Stock and Contingent Warrants was required to be re-measured at FMV at each reporting date, using either the
Black-Scholes valuation model or other valuation method, if deemed more appropriate, with recognition of the changes in fair value to
other income or expense in the consolidated statement of operations in accordance with ASC 480, Debt and Equity. For the three months
ended March 31, 2022, the Company recorded a $287,000 fair market (FMV) charge to reflect the increase in the Contingent Stock and Contingent
Warrants. On April 19, 2022, the Company issued 235,295 shares of Common Stock to settle the Contingent Stock liability, re-measured
the liability at its estimated FMV based on the stock’s trading price and reclassified $496,000 to Common Stock Par Value and Additional
Paid in Capital.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
7. Note Purchase Agreement (continued)
In
connection with the closing of the IPO, 235,295 warrants were issued to settle the Contingent Warrant liability (“Note Warrants”)
with an exercise price of $4.25. The terms of the Note Warrants continue to require classification as a liability under ASC 815 with
recognition of the changes in fair value to other income or expense in the consolidated statement of operations in accordance with ASC
480 Debt and Equity. (See Note 8 and 10).
Note
8. Stockholders’ Equity
Capital
Structure
On
December 11, 2017, the Company was incorporated in Wyoming with 20,000,000 shares of common stock authorized with a $0.0001 par value.
Effective, April 18, 2019, the Company’s authorized common stock was increased to 50,000,000 shares of common stock. The articles
of incorporation also authorized 10,000 preferred shares with a $0.001 par value.
Effective
March 22, 2022, the Company completed a plan and agreement of merger with Sharps Technology, Inc., a Nevada corporation (“Sharps
Nevada”). Pursuant to the merger agreement, (i) the Company merged with and into Sharps Nevada, (ii) each 3.5 shares of common
stock of the Company were converted into one share of common stock of Sharps Nevada and (iii) the articles of incorporation and bylaws
of Sharps Nevada, became the articles of incorporation and bylaws of the surviving corporation. The Company’s authorized common
stock and preferred stock increased from 50,000,000 to 100,000,000 and 10,000 to 1,000,000 shares, respectively. The par value of preferred
stock decreased from $0.001 to $0.0001 per share.
Common
Stock
On
February 3, 2023, the Company completed a securities purchase agreement (“Offering”) with institutional investors and received
net proceeds from the Offering were approximately $3.2 million, net of $600,000 in fees relating to the placement agent and other offering
expenses. The Offering was priced at the market under Nasdaq rules. In connection with the Offering, the Company issued 2,248,521 units
at a purchase price of $1.69 per unit. Each unit consists of one share of common stock and one non-tradable warrant (“Offering
Warrants”) exercisable for one share of common stock at a price of $1.56. The Offering Warrants have a term of five years from
the issuance date. On February 13, 2023, the Company filed an S-1 (Resale) Registration Statement in connection with the Offering and
on April 14, 2023, an Amendment to the S-1 was filed and went effective. The net proceeds, after reflecting par value, has been recorded
in Additional Paid in Capital of $2.8 million and with respect to the Warrants as a liability under ASC 815 of $455,326. (See Notes 8
and 10)
On
April 13, 2022, the Company’s initial public offering (“IPO”) was declared effective by the SEC pursuant to which the
Company issued and sold an aggregate of 3,750,000 units (“Units”), each consisting of one share of common stock and two warrants,
to purchase one share of common stock for each whole warrant, with an initial exercise price of $4.25 per share, adjusted to $1.56 at
February 3, 2023 based on the warrant terms, and a term of five years. In addition, the Company granted Aegis Capital Corp., as underwriter
a 45-day over-allotment option to purchase up to 15% of the number of shares included in the units sold in the offering, and/or additional
warrants equal to 15% of the number of Warrants included in the units sold in the offering, in each case solely to cover over-allotments,
which the Aegis Capital Corp. partially exercised with respect to 1,125,000 warrants on April 19, 2022.
The
Company’s common stock and warrants began trading on the Nasdaq Capital Market or Nasdaq on April 14, 2022. The net proceeds from
the IPO, prior to payments of certain listing and professional fees were approximately $14.2 million. The net proceeds, after reflecting
par value, has been recorded in Additional Paid in Capital of $9.0 million and with respect to the Warrants as a liability under ASC
815 of $5.2M. (See Note 10)
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
8. Stockholders’ Equity (continued)
During
the period April 1, 2022 through December 31, 2022, the Company issued 235,000 shares of common stock at the trading stock price in connection
with services provided to the Company and recorded a charge of $290,551, In addition, the Company issued 235,295 common shares relating
to the Note Purchase agreement. (See Note 7)
Warrants
|
a) |
In
connection with an advisory services arrangement entered into in April 2023, the Company issued 135,000 warrants during the three
months ended June 30, 2023 at an exercise price of $1.56. The warrants have a three-year term and were fully vested on issuance.
The FMV of the warrants was $19,836 computed using the Black Sholes valuation model with the following assumptions: a) volatility
of 37.45%, three-year term, risk free interest rate 3.58% and 0% dividend rate. |
|
|
|
|
(b) |
In
connection with the Offering in February 2023, the Company issued 2,248,521 non-trading warrants Offering Warrants as a component
of the Unit as noted in Common Stock above. The Offering Warrants were recorded at the FMV, computed using the Black Sholes valuation
method with the following assumptions: volatility of 41.24%, five-year term, risk free interest rate 3.71% and 0% dividend rate.
The Offering Warrant’s liability requires remeasurement at each reporting period. The Offering Warrants are classified as a
liability based on ASC 815. At the issuance date the liability was $455,326 and at June 30, 2023 the liability was $272,746. During
the three and six months ended June 30, 2023, the Company recorded a FMV gain (loss) adjustment of $1,505 and $182,580. (See Note
10). |
|
|
|
|
(c) |
In
connection with the IPO in April 2022, the Company issued 7,500,000 warrants (Trading Warrants) as a component of the Units and 1,125,000
warrants to the underwriter (Overallotment Warrants), as noted in Common Stock above. The Trading and Overallotment Warrants were
recorded at the FMV, being the trading price of the warrants, on the IPO effective date and the Warrants are classified as a Liability
based on ASC 815. The Warrant liability requires remeasurement at each reporting period. At the IPO, the liability was $5,778,750
and at December 31, 2022 the liability was $1,121,250. During the three and six months ended June 30, 2023, the Company recorded
an FMV loss adjustment of $86,250. During the three and six months ended June 30, 2022, the Company recorded a FMV gain adjustment
of $3,378,412. (See Note 10). |
|
|
|
|
(d) |
The
Company has issued 235,295 Warrants (“Note Warrants”) to the Purchasers of the Notes on April 19, 2022. The Note Warrants
have an exercise price of $4.25 and a term of five years. At the issuance date, the liability was $157,647 and through the year ended
December 31, 2022, the Company recorded a FMV gain of $127,059. During the three and six months ended June 30, 2023, the Company
recorded a FMV loss adjustment of $2,353 and the warrant liability was $32,941 at June 30, 2023. During the three and six months
ended June 30, 2022, the Company recorded a FMV gain adjustment of $520,000. (See Note 8 and 10).
|
|
|
|
|
(e) |
The
underwriter received 187,500 warrants in connection with the IPO for a nominal cost of $11,250. The Warrants have an exercise price
of $5.32 and are exercisable after October 9, 2022. The FMV at the date of issuance was $228,750 computed using the Black Sholes
valuation model with the following assumptions: a) volatility of 93.47%, five-year term, risk free interest rate 2.77% and 0% dividend
rate. The estimated FMV was classified as additional issuance costs. |
Note
9. Preferred Stock
In
February 2018, the Company Board of Directors issued one share of Series A Preferred Stock to Alan Blackman, the Company’s co-founder
and Director. The Series A Preferred Stock entitles the holder to vote on any matters related to the election of directors and was reduced
from 50.1% at December 31, 2021 to 29.5%, effective with the IPO. The Series A Preferred Stock has no right to dividends, or distributions
in the event of a liquidation and is not convertible into common stock. In the event the Company is sold during the two-year period following
completion of IPO at a price per share of more than 500% of the initial offering price per Unit in the IPO, the Series A Preferred Stock,
as in effect upon completion of the IPO, will entitle the holder to 10% of the total purchase price. (See Note 15)
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
10. Warrant Liability
The
Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented as a Warrant liability in the accompanying
condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with
changes in fair value presented within the condensed consolidated statements of operations. (See Notes 7 and 8)
The
Warrant liability at June 30, 2023 was as follows:
Schedule
of Warrant Liability
| |
| | |
Trading and Overallotment Warrants | |
$ | 1,207,500 | |
Note Warrants | |
| 32,941 | |
Offering Warrants | |
| 272,746 | |
Total | |
$ | 1,513,187 | |
Warrant liability | |
$ | 1,513,187 | |
The
Warrants outstanding at June 30, 2023 are as follows:
Schedule
of Warrant Outstanding
| |
| | |
Trading and Overallotment Warrants | |
| 8,812,500 | |
Note warrants | |
| 235,295 | |
Offering Warrants | |
| 2,248,521 | |
Warrants issued for services arrangement | |
| 135,000 | |
Total | |
| 11,431,316 | |
Warrant outstanding | |
| 11,431,316 | |
The
following table presents the changes in the Warrant liability of the Level 1 warrants issued on April 14, 2022, the effective date of
the IPO measured at fair value from December 31, 2022 and the changes in the Offering Warrants liability of the Level 2 warrants issued
on February 6, 2023 through June 30, 2023.
Schedule
of Changes in the Warrant Liability
| |
Total | |
| |
| |
FMV of Note Warrants | |
$ | 30,588 | |
FMV of Trading and Overallotment Warrants | |
| 1,121,250 | |
FMV of Offering Warrants, at issuance | |
| 455,326 | |
Change in fair value of warrant liability for the six months ended June 30,2023 | |
| (93,977 | ) |
| |
| | |
Fair Value at June 30, 2023 | |
$ | 1,513,187 | |
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
11. Stock Options
A
summary of options granted and outstanding is presented below.
Schedule
of Stock Options Granted and Outstanding
| |
June 30, 2023 | |
| |
Options | | |
Weighted Average Exercise
Price | |
Outstanding at Beginning of year | |
| 1,358,122 | | |
$ | 4.37 | |
Granted | |
| 1,025,000 | | |
| 1.37 | |
Forfeited | |
| (25,714 | ) | |
| 1.75 | |
Outstanding at end of period | |
| 2,357,408 | | |
$ | 3.08 | |
| |
| | | |
| | |
Exercisable at end of period | |
| 1,665,378 | | |
$ | 3.63 | |
During
the six months ended June 30, 2023 , the Company granted five-year options (the “Options”) to purchase a total of 975,000
shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) to its directors, executive
officers, employees and consultants pursuant to the Company’s. 2022 and 2023 Equity Incentive Plans. The Options are exercisable
at $1.37 per share which was the closing price on January 25, 2023. Of the Options granted, Options to purchase an aggregate of 495,000
shares of Common Stock were issued to executive officers Options to purchase an aggregate of 455,000 shares of Common Stock were issued
to directors and Options to purchase an aggregate of 25,000 shares of Common Stock to employees and a consultant. In connection with
an employment agreement the Company granted five-year options to purchase 50,000 shares of common stock in February 2023 under the 2022
Equity Incentive Plan. (See Note 15).
On
January 25, 2023, the Company’s Board of Directors adopted the 2023 Equity Incentive Plan (the “2023 Plan”). The 2023
Plan provides for the issuance of up to 1,400,000 options and/or shares of restricted stock to be available for issuance to officers,
directors, employees and consultants. The 2023 Plan is subject to shareholder approval at the annual meeting.
As
of June 30, 2023, there was $725,355 in unrecognized stock-based compensation related to unvested stock options, which is expected to
be recognized over a weighted average period of forty months.
The
following table summarizes information about options outstanding at June 30, 2023:
Schedule
of Information about Options Outstanding
Exercise
Prices |
|
|
Shares
Outstanding |
|
|
Weighted
Average Remaining Contractual Life |
|
|
Shares
Exercisable |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1.21 |
|
|
|
307,500 |
|
|
|
4.42 |
|
|
|
233,719 |
|
$ |
1.30 |
|
|
|
50,000 |
|
|
|
4.71 |
|
|
|
18,750 |
|
$ |
1.37 |
|
|
|
975,000 |
|
|
|
4.67 |
|
|
|
437,032 |
|
$ |
1.39 |
|
|
|
10,000 |
|
|
|
4.17 |
|
|
|
10,000 |
|
$ |
1.75 |
|
|
|
42,857 |
|
|
|
2.75 |
|
|
|
42,857 |
|
$ |
2.80 |
|
|
|
141,429 |
|
|
|
1.00 |
|
|
|
141,429 |
|
$ |
4.25 |
|
|
|
50,000 |
|
|
|
4.00 |
|
|
|
50,000 |
|
$ |
4.38 |
|
|
|
244,286 |
|
|
|
1.75 |
|
|
|
244,286 |
|
$ |
7.00 |
|
|
|
536,336 |
|
|
|
2.50 |
|
|
|
477,305 |
|
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
11. Stock Options (continued)
For
the three and six months ended June 30, 2023, the Company recognized stock-based compensation expense of $234,610 and $617,711
respectively, recorded in general and administrative. For the three and six months ended June 30, 2022, the recognized stock-based compensation
expense of $365,606 and $589,553 respectively, of which $39,870 and $50,182 was recorded in general and administrative and research and
development expenses, respectively. Further, for the three months ended March 31, 2022, the Company recorded stock-based charges relating
to consideration for purchase of machinery of $63,512 (see Note 4) and $40,901 relating to an Acquisition (see Note 5).
The
fair value of stock option awards accounted for under ASC 718 was estimated at the date of grant using a Black-Scholes option-pricing
model with the following assumptions for the options granted during the six months ended June 30, 2023.
Schedule
of Fair Value of Stock Option Awards
Expected term (years) | |
2.88 to 3.25 | |
Expected volatility | |
75.40% to 89.93 | % |
Risk-free interest rate | |
3.71% to 4.27 | % |
Dividend rate | |
| 0 | % |
Note
12. Income Taxes
At
the end of each interim reporting period, the Company estimates its effective tax rate expected to be applied for the full year. This
estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods.
Accordingly, the Company’s effective tax rate for the three and six months ended , June 30, 2023 was 0%, compared to the
effective tax rate of 0% for the three and six months ended June 30, 2022. The Company’s effective tax rates for both periods were
affected primarily by a full valuation allowance on domestic net deferred tax assets.
Note
13. Related Party Transactions and Balances
As
of June 30, 2023 and December 31, 2022, accounts payable and accrued liabilities include $31,000 and $105,667, respectively, payable
to officers and directors of the Company. The amounts are unsecured, non-interest bearing and are due on demand (See Note 15).
Note
14. Fair Value Measurements
The
Company’s financial instruments include cash, accounts payable, notes payable, contingent stock and warrant liability and warrant
liability. Cash, contingent stock liability, contingent warrant liability and warrant liability are measured at fair value. Accounts
payable and notes payable are measured at amortized cost and approximates fair value due to their short duration and market rate for
similar instruments, respectively.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
14. Fair Value Measurements (continued)
As
of June 30, 2023, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the Company’s
consolidated balance sheet:
Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis
|
|
Level
1 |
|
|
Level
2 |
|
|
Level
3 |
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash |
|
$ |
2,924,019 |
|
|
|
- |
|
|
|
- |
|
|
$ |
2,924,019 |
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
Total
assets measured at fair value |
|
$ |
2,924,019 |
|
|
|
- |
|
|
|
|
|
|
$ |
2,924,019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant
liability |
|
$ |
1,240,441 |
|
|
|
272,276 |
|
|
|
- |
|
|
$ |
1,513,187 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
liabilities measured at fair value |
|
$ |
1,240,441 |
|
|
|
272,276 |
|
|
|
- |
|
|
$ |
1,513,187 |
|
Note
15. Commitments and Contingencies
Fixed
Assets and Other
At
June 30, 2023, the Company has outstanding orders to purchase equipment, mold and component parts for research and development of $490,651
of which advance payments of $280,349 have been made and recorded in Other Assets (See Note 6).
Contingencies
At
each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably
estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company is currently not
involved in any material litigation or other loss contingencies.
Royalty
Agreement
In
connection with the purchase of certain intellectual property in July 2017, Barry Berler and Alan Blackman entered into a royalty agreement
which provides that Barry Berler will be entitled to a royalty of four percent (4%) of net sales derived from the use, sale, lease, rent
and export of products related to the intellectual property. The royalty continues until the patent expires or is no longer used in the
Company’s product. The royalty agreement was assumed by the Company in December 2017.
In
September 2018, the Royalty Agreement was amended to reduce the royalty to 2% and further provided for a single payment of $500,000 to
Barry Berler within three years in return for cancellation of all further royalty obligations of the Company. In May 2019, the Royalty
Agreement was further amended to change the payment date to on or before May 31, 2021 or during the term of the amended Royalty Agreement
should the Company be acquired or a controlling interest be acquired. The Company has not made the aforementioned payment or incur any
change in control as such the 2% royalty remains in place.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
15. Commitments and Contingencies (continued)
Employment
Agreements and Other
On
August 1, 2022, the Company cancelled the consulting agreement with Alan Blackman, Co- Chairman and Chief Operating Officer and
entered into an Employment Agreement which provides for annual salary of $256,000,
which provides for increases, and provisions compensation adjustments, expense and tax differential reimbursements, benefits and
bonuses. As of September 1, 2022, the annual salary is $320,000.
At June 30, 2022, the Company approved and accrued a $250,000
bonus to Mr. Blackman for services provided in 2022, of which $65,000
was paid subsequent to December 31, 2022. The Company terminated Mr. Blackman’s Employment Agreement effective May 1, 2023.
Mr. Blackman continued to serve as the Co-Chairman and a member of the Board of Directors. The parties were having preliminary
settlement discussions. Subsequent to June 30, 2023, the Company and Mr. Blackman entered into a separation agreement whereby, Mr.
Blackman will be paid severance payments of approximately $346,000,
which was recorded as an expense and an accrued expense as of June 30, 2023, over thirteen months, continue his medical benefits for
such period with a cost of approximately $29,000
which has been accrued at June 30, 2023. Further, all unvested options were fully vested. In connection with the separation
agreement, Mr. Blackman no longer serves as Co-Chairman or Board member and has agreed to vote his Series A Preferred Stock in favor
of the election, reelection, and/or designation of each individual nominated to serve as a director on the Board of Director as
shall be identified in an applicable proxy statement filed by the Company for such election of directors. Once the payments due Mr.
Blackman are fully paid, the Series A Preferred Stock shall be deemed immediately cancelled and forfeited and without further
consideration. The Series A Preferred shall at such time be returned to the status of an authorized but unissued share of preferred
stock of the Company.
On
September 30, 2022, the Company entered into a formal employment agreement, effective on such date and will continue until terminated
by either party, subject to the terms of the agreement, with Andrew R. Crescenzo who has been serving as the Company’s Chief Financial
Officer on a contract services basis for the last three years. The agreement provided for annual compensation of $225,000 and plus a
one-time $18,750 incentive payment upon the commencement of the agreement. During the course of the term, Mr. Crescenzo will be eligible
for (i) performance bonuses to be granted at the discretion of the Company’s Compensation Committee and (ii) to participate in
the Company’s 2022 Equity Incentive Plan. The agreement contains customary employment terms and conditions.
In
October 2022, the Company entered into a service agreement (“Service Agreement”) with an unrelated third-party for marketing
and investor relations services. The Service Agreement, which has a term of one year, has various deliverables and provides payments
to the third party as follows; a) an initial fee of $90,000, b) monthly fees through the term of $12,500, c) 200,000 shares of restricted
common stock and d) $300,000 specifically related to digital marketing activities. As stated in Note 8, the 200,000 shares of restricted
common stock were valued at $230,000, representative of the trading price on the issuance.
On
February 09, 2023, the Company, appointed Justin Page,
as Vice President of Technical Operations with a start date of February 15, 2023. The agreement
provides for annual compensation of $235,000 and options to purchase 50,000 shares of common stock at the exercise price of $1.30, the
closing price on the grant date. During the course of the term, Mr. Paige will be eligible for (i) performance bonuses to be granted
at the discretion of the Company’s Compensation Committee and (ii) to participate in the Company’s Equity Incentive Plan.
The agreement contains customary employment terms and conditions and provides for severance of six months if a change in control occurs,
as defined.
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
13. Other Expenses of Issuance and Distribution.
The
following table sets forth all expenses to be paid by the registrant in connection with the issuance and distribution of the securities
to be registered, other than underwriting discounts and commissions. All amounts shown are estimates except for the SEC registration
fee:
SEC registration fee | |
$ | | |
Legal fees and expenses | |
$ | 40,000 | |
Accounting fees and expenses | |
$ | 10,000 | |
Placement agent non-accountable expense reimbursement | |
| - | |
Miscellaneous fees and expenses | |
$ | 0 | |
Total | |
$ | | |
Item
14. Indemnification of Directors and Officers.
Our
articles of incorporation and bylaws limit the liability of our officers and directors and provide that we will indemnify our officers
and directors, in each case, to the fullest extent permitted by the Nevada Revised Statutes, or the NRS.
NRS
Section 78.7502 provides that a corporation shall indemnify any director, officer, employee or agent of a corporation against expenses,
including attorneys’ fees, actually and reasonably incurred by him in connection with any defense to the extent that a director,
officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding
referred to in Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue or matter therein.
NRS
78.7502(1) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in
the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is
or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement
actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138;
or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation,
and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.
NRS
Section 78.7502(2) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason
of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses,
including amounts paid in settlement and attorneys’ fees actually and reasonably incurred by him in connection with the defense
or settlement of the action or suit if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which
he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim,
issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there
from, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court
in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the
circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.
NRS
Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually
liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court
as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to the Registrant’s directors, officers and
controlling persons pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission,
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
Item
15. Recent Sale of Unregistered Securities
On
September 27, 2023, the Company entered into a Securities Purchase Agreement with certain accredited investors purchasing common stock
in this offering for a private placement offering of (i) 2,581,479 unregistered shares of our common stock (or pre-funded warrants in
lieu thereof with each pre-funded warrant exercisable for one share of common stock and (ii) unregistered warrants to purchase 8,750,003
of our common stock. Pursuant to the PIPE Purchase Agreement, the Company has agreed to issue and sell 2,581,479 PIPE Shares (or PIPE
Pre-Funded Warrants in lieu thereof) together with SS Warrants to purchase up to 8,750,003 shares of common stock at a combined offering
price of $1.074 per unit (less $0.001 for each PIPE Pre-Funded Warrant). The PIPE Securities are not being registered under the Securities
Act and are not being offered pursuant to this prospectus supplement and the accompanying base prospectus. The PIPE Securities are being
offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities
Act and/or Rule 506(b) of Regulation D promulgated thereunder.
During
2022, the Company issued 367,500 stock options at exercise prices ranging from $1.08 to $4.25.
During
2021, the Company completed stock subscriptions through a private placement for 487,204 shares of common stock at $7.00 per share. In
addition, the Company issued 71,429 shares to a vendor for engineering and design services provided for equipment and for partial payments
for equipment being manufactured, 28,571 shares related to an acquisition and 2,857 shares for services.
During
2021, the Company granted 511,764 stock options at an exercise price of $7.00, including 71,248 stock options granted to a vendor relating
to an equipment purchase, 114,285 stock options under an executive employment agreement and 35,714 options relating to an acquisition
agreement.
The
offers, sales, and issuances of the above securities were exempt from registration under the Securities Act by virtue of Section 4(a)(2)
of the Securities Act as transactions by an issuer not involving any public offering, or in reliance on Rule 701 promulgated under Section
3(b) of the Securities Act because the transactions were pursuant to compensatory benefit plans or contracts relating to compensation
as provided under Rule 701.
Item
16. Exhibits and Financial Statement Schedules.
Exhibits
See
the Exhibit Index immediately preceding the signature page hereto for a list of exhibits filed as part of this registration statement
on Form S-1, which Exhibit Index is incorporated herein by reference.
Financial
Statement Schedules
All
financial statement schedules are omitted because the information called for is not required or is shown either in the financial statements
or in the notes thereto.
Item
17. Undertakings.
The
undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements certificates
in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit, or proceeding)
is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the
final adjudication of such issue.
The
undersigned registrant hereby undertakes that:
|
(1) |
For
purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part
of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the
time it was declared effective. |
|
|
|
|
(2) |
For
the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof. |
EXHIBIT
INDEX
Exhibit
Number |
|
Description |
3.1 |
|
Articles of Incorporation of Registrant (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
3.2 |
|
Certificate of Designation of Series A Preferred Stock (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
3.3 |
|
Bylaws of Registrant (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
3.4 |
|
Certificate of Amendment to Designation, filed on December 22, 2022 (incorporated by reference to 8-K filed on December 22, 2022) |
5.1 |
|
Legal Opinion of Sichenzia Ross Ference LLP* |
10.1 |
|
Asset/Share Purchase Agreement, dated June 10, 2020, among the Company, Safegard Medical (Hungary) Ktf,, Numan Holding Ltd, Cortrus Services SA and Latitude Investments Limited (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.2 |
|
Amendment No. 1 to Asset/Share Purchase Agreement, dated June 24, 2020 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.3 |
|
Amendment No. 2 to Asset/Share Purchase Agreement, dated August 27, 2020 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.4 |
|
Amendment No. 3 to Asset/Share Purchase Agreement, dated October 28, 2020 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.5 |
|
Amendment No. 4 to Asset/Share Purchase Agreement, dated July 19, 2021 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.6 |
|
Amendment No. 5 to Asset/Share Purchase Agreement, dated February 28, 2022 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.7 |
|
Letter, dated September 23, 2021, from Numan Holding Ltd (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.8 |
|
Employment Agreement, dated September 9, 2021, between the Company and Robert Hayes (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.9 |
|
Consulting Agreement between the Company and Alan Blackman (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.10 |
|
Amended Consulting Agreement, dated May 28, 2019, between the Company and Barry Berler (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.11
|
|
Royalty Agreement, dated July 11, 2017, between Alan Blackman and Barry Berler (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.12 |
|
Amendment to Royalty Agreement, dated September 4, 2018 (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.13 |
|
Consulting Agreement, dated January 1, 2021, between the Company and Berry Berler (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.14 |
|
Note Purchase Agreement, dated December 14, 2021, among the Company and the purchasers named therein (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.15 |
|
Form of Note (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.16 |
|
Security Agreement among the Company and the secured parties named therein (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.17 |
|
Consent to be named as a director nominee of Jason Monroe (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.18 |
|
Consent to be named as a director nominee of Brenda Baird Simpson (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.19 |
|
Form of Warrant for this offering (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.20 |
|
Form of Pre-Funded Warrant for this offering (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.21 |
|
Form of Warrant Agent Agreement (Pre-Funded Warrants) (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.22
|
|
2022 Equity Incentive Plan (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.23
|
|
Plan and Agreement of Merger, dated March 22, 2022, between Sharps Technology, Inc., a Wyoming corporation, and Sharps Technology, Inc., a Nevada corporation (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.24
|
|
Form of Warrant Agent Agreement (Warrants) (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.25
|
|
Form of Representative’s Warrant (incorporated by reference to the Form S-1/ Amendment 4 filed on April 12, 2022; registration number 333-263715) |
10.26 |
|
Amendment No. 6 to Asset/Share Purchase Agreement, dated April 13, 2022 (incorporated by reference to 8-K filed on April 19, 2022) |
10.27 |
|
Agreement, dated September 29, 2022, by and among Sharps Technology, Inc., InjectEZ, LLC, Nephron Pharmaceuticals Corporation, Nephron SC, Inc. and Nephron Sterile Compounding Center LLC (incorporated by reference to 8-K filed on October 4, 2022) |
10.28 |
|
Distribution Agreement, dated December 8, 2022, by and among Sharps Technology, Inc., Nephron Pharmaceuticals Corporation and Nephron SC, Inc. (incorporated by reference to 8-K filed on December 13, 2022) |
10.29 |
|
PIPE Agreement, dated September 27, 2023 (incorporated by reference to 8-K filed on October 3, 2023)
Rd Agreement, dated September 27, 2023 (incorporated by reference to 8-K filed on October 3, 2023) |
10.30
|
|
Registration Rights Agreement, dated September 27, 2023 (incorporated by reference to 8-K filed on October 3, 2023)
|
10.31 |
|
Placement Agent Agreement, dated September 27, 2023 (incorporated by reference to 8-K filed on October 3, 2023) |
10.32 |
|
Form of Warrant (incorporated by reference to 8-K filed on October 3, 2023) |
10.33 |
|
Form
of RD Pre-Funded Warrant (incorporated by reference to 8-K filed on October 3, 2023) |
10.34 |
|
Form
of PIPE Pre-Funded Warrant (incorporated by reference to 8-K filed on October 3, 2023) |
10.35 |
|
2023
Equity Incentive Plan (incorporated by reference to 8-K filed on January 27, 2023) |
23.1 |
|
Consent of Manning Elliott LLP |
23 |
|
Consent of Sichenzia Ross Ference LLP (included in Exhibit 5.1) |
24.1 |
|
Power of Attorney |
107 |
|
Filing Fees Exhibit |
*
To be filed by amendment.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement on Form S-1 to be signed
on its behalf by the undersigned, thereunto duly authorized, in the city of Melville, State of New York, on the 16th day of October,
2023.
|
SHARPS
TECHNOLOGY, INC |
|
|
|
By: |
/s/
Robert M. Hayes |
|
|
Robert
M. Hayes |
|
|
Chief
Executive Officer and Director |
Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/
Robert M. Hayes |
|
Chief
Executive Officer and Director |
|
October
16, 2023 |
Robert
M. Hayes |
|
(Principal
Executive Officer) |
|
|
|
|
|
|
|
/s/
Andrew R. Crescenzo |
|
Chief
Financial Officer |
|
October
16, 2023 |
Andrew
R. Crescenzo |
|
(Principal
Financial and Accounting Officer) |
|
|
|
|
|
|
|
/s/
Alan R. Blackman* |
|
Co-Chairman, Chief
Investment Officer |
|
October
16, 2023 |
Alan
R. Blackman |
|
and
Chief Operating Officer |
|
|
|
|
|
|
|
/s/
Dr. Soren Bo Christiansen* |
|
Co-Chairman |
|
October
16, 2023 |
Dr
Soren Bo Christiansen |
|
|
|
|
|
|
|
|
|
/s/
Paul K. Danner* |
|
Director |
|
October
16, 2023 |
Paul
K. Danner |
|
|
|
|
|
|
|
|
|
/s/
Timothy J. Ruemler* |
|
Director |
|
October
16, 2023 |
Timothy
J. Ruemler |
|
|
|
|
*
By: |
/s/
Robert M. Hayes |
|
|
Attorney-in-fact
|
|
Exhibit 5.1
October
16, 2023
Sharps
Technology, Inc.
105
Maxess Road, Ste. 124
Melville,
New York 11747
Re:
Registered Direct Offering and Concurrent Private Placement Pursuant to Registration Statement on Form S-3
Ladies
and Gentlemen:
We
have acted as counsel to Sharps Technology, Inc., a Nevada corporation (the “Company”), in connection with the Placement
Agent Agreement dated September 27, 2023 (the “Placement Agent Agreement”), by and between the Company and Aegis
Capital Corp., acting as the placement agent on a best efforts basis in connection with the t private placement (the “Placement”),
which includes (i) 2,581,479 shares of our common stock issuable upon exercise of pre-funded warrants (“Pre-Funded Warrants”),
and (ii) 8,750,003 shares of common stock issuable upon the exercise of the warrants issued in the Private Placement. Herein, we refer
to the Shares and Warrants, as the “Securities.”
This
opinion is being delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act of 1933,
as amended (the “Securities Act”).
In
connection with this opinion, we have examined originals or copies, certified or otherwise identified to our satisfaction, of the following:
|
1. |
The Certificate of Incorporation
of the Company, as amended; |
|
|
|
|
2. |
The Amended and Restated
Bylaws of the Company; |
|
|
|
|
3. |
The Placement Agent Agreement; |
|
|
|
|
4. |
The Form of the Warrant; |
|
|
|
|
5. |
The Form of the RD Pre-Funded
Warrant; |
|
|
|
|
6. |
Form of the PIPE Pre-Funded
Warrant; |
|
|
|
|
7. |
Registration Statement
on Form S-3 ((File No. 333-274146) filed by the Company with the Securities and Exchange Commission (the “Commission”)
on June 23, 2023, in the form in which it became effective on September 5, 2023 (the “Registration Statement”) pursuant
to the Securities Act; |
|
|
|
|
8. |
A draft of the prospectus
supplement dated September 27, 2023, filed with the Commission pursuant to Rule 424(b)(5) promulgated under the Securities Act (the
“Prospectus Supplement”), together with the base prospectus dated September 27, 2023; and |
|
|
|
|
9. |
Written consent of the
Board of Directors of the Company approving the Placement Agent Agreement. |
|
|
|
1185
AVENUE OF THE AMERICAS | 31ST FLOOR | NEW YORK, NY | 10036
T
(212) 930-9700 | F (212) 930-9725 | WWW.SRFC.LAW
We
have also examined originals or copies, certified or otherwise identified to our satisfaction, of such records of the Company and such
agreements, certificates and receipts of public officials, certificates of officers or other representatives of the Company and others,
and such other documents as we have deemed necessary or appropriate as a basis for the opinions stated below.
In
our examination, we have assumed the genuineness of all signatures, including endorsements, the legal capacity and competency of all
natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents
submitted to us as facsimile, electronic, certified or photostatic copies, and the authenticity of the originals of such copies. In making
our examination of executed documents, we have assumed (i) that the parties thereto, other than the Company, had the power, corporate
or other, to enter into and perform all obligations thereunder and (ii) the due authorization by all requisite action, corporate or other,
and the execution and delivery by such parties of such documents, and the validity and binding effect thereof on such parties.
The
opinion expressed below is limited to the federal securities laws of the United States of America and the corporate laws of the State
of Delaware and we express no opinion as to the effect on the matters covered by the laws of any other jurisdiction.
Based
upon and subject to the foregoing, we are of the opinion that (i) when the Shares issuable upon exercise of the pre-funded Warrants have
been delivered to and paid for by the underwriters as contemplated by the Placement Agent Agreement, the Shares will be duly authorized,
validly issued, fully paid and non-assessable, (ii) the pre-funded Warrants are valid and legally binding obligations of the Company,
(iii) the Warrants as described in the Prospectus Supplement have been duly authorized, and, provided that the Warrants have been duly
executed by the Company and delivered to and paid for by as contemplated by the Placement Agent Agreement and the Warrants, will be valid
and legally binding obligations of the Company, enforceable against the Company in accordance with their terms, and (iv) the Warrant
Shares have been duly authorized and when issued and delivered by the Company against payment therefor in accordance with the terms of
such Warrants, will be duly authorized, validly issued, fully paid and non-assessable.
We
hereby consent to the filing of this opinion with the Commission as an exhibit to the Company’s Current Report on Form 8-K being
filed on the date hereof and incorporated by reference into the Registration Statement. We also hereby consent to the reference to our
firm under the caption “Legal Matters” in the Prospectus Supplement. In giving this consent, we do not thereby admit that
we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of
the Commission promulgated thereunder. This opinion is expressed as of the date hereof unless otherwise expressly stated, and we disclaim
any undertaking to advise you of any subsequent changes in the facts stated or assumed herein or of any subsequent changes in applicable
laws.
Very truly yours, |
|
|
|
/s/ Sichenzia
Ross Ference Carmel LLP |
|
|
|
Sichenzia Ross Ference
Carmel LLP |
|
Exhibit
23.1
CONSENT
OF INDEPENDENT AUDITOR
We
consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 30, 2023, with
respect to the consolidated financial statements of Sharps Technology, Inc. and its subsidiary as of December 31, 2022 and 2021 included
in the Form S-1 Registration Statement.
/s/
Manning Elliott LLP
CHARTERED
PROFESSIONAL ACCOUNTANTS
Vancouver,
Canada
October
16, 2023
Exhibit
107
Calculation
of Filing Fee Table
FORM
S-1
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
(Form
Type)
Sharps
Technology Inc.
(Exact
Name of Registrant As Specified in its Charter)
Table
1: Newly Registered Securities
|
|
Security
Type |
|
Security
Class
Title |
|
|
Fee
Calculation
Rule |
|
|
Amount
Registered (1) |
|
|
Proposed
Maximum
Offering Price
Per Share |
|
|
Maximum
Aggregate
Offering
Price |
|
|
Fee
Rate |
|
|
|
Amount
of
Registration
Fee |
|
Newly
Registered Securities |
|
Fees
to Be Paid |
|
Equity |
|
Common
Stock underlying pre-funded warrants, $0.0001 par value per share |
|
|
|
457(c) |
|
|
|
2,581,479 |
|
|
$ |
0.44 |
(2) |
|
$ |
1,135,850.76 |
|
|
|
0.00014760 |
|
|
$ |
167.66 |
|
|
|
Equity |
|
Common
Stock exercisable upon exercise of the Warrants |
|
|
|
457(g) |
|
|
|
8,750,003
|
|
|
$ |
0.64 |
|
|
$ |
5,600,001.92 |
|
|
|
0.00014760 |
|
|
|
826.56 |
|
Fees
Previously Paid |
|
- |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Total
Offering Amounts |
|
|
$ |
6,735,852.68 |
|
|
|
|
|
|
$ |
994.22 |
|
Total
Fees Previously Paid |
|
|
$ |
- |
|
|
|
|
|
|
$ |
- |
|
Total
Fee Offsets |
|
|
|
- |
|
|
|
|
|
|
$ |
- |
|
Net
Fees Due |
|
|
$ |
- |
|
|
|
|
|
|
$ |
994.22 |
|
|
(1) |
Pursuant
to Rule 416(a) promulgated under the U.S. Securities Act of 1933, as amended (the “Securities Act”), there are also being
registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock
dividends, or similar transactions. |
|
|
|
|
(2) |
Estimated
solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, as amended, based on
the average of the high and low reported trading prices of the Registrant’s Common Stock as reported on the Nasdaq Capital
Market on October 12, 2023, such date being within five business days of the date that this Registration Statement was filed with
the SEC. |
|
|
|
|
(3) |
No
separate registration fee is required pursuant to Rule 457(g) under the Securities Act. |
v3.23.3
Cover
|
6 Months Ended |
Jun. 30, 2023 |
Entity Addresses [Line Items] |
|
Document Type |
S-1
|
Amendment Flag |
false
|
Entity Registrant Name |
Sharps
Technology, Inc.
|
Entity Central Index Key |
0001737995
|
Entity Tax Identification Number |
82-3751728
|
Entity Incorporation, State or Country Code |
NV
|
Entity Address, Address Line One |
105
Maxess Road
|
Entity Address, Address Line Two |
Ste. 124
|
Entity Address, City or Town |
Melville
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
11747
|
City Area Code |
(631)
|
Local Phone Number |
574 -4436
|
Entity Filer Category |
Non-accelerated Filer
|
Entity Small Business |
true
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Business Contact [Member] |
|
Entity Addresses [Line Items] |
|
Entity Address, Address Line One |
105
Maxess Road
|
Entity Address, Address Line Two |
Ste. 124
|
Entity Address, City or Town |
Melville
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
11747
|
City Area Code |
(631)
|
Local Phone Number |
574 -4436
|
Contact Personnel Name |
Robert
M. Hayes
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
dei_EntityAddressesLineItems |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Current Assets |
|
|
|
Cash |
$ 2,924,019
|
$ 4,170,897
|
$ 1,479,166
|
Prepaid expenses and other current assets |
193,875
|
66,749
|
7,995
|
Inventories (Note 3) |
992,547
|
185,804
|
121,994
|
Current Assets |
4,110,441
|
4,423,450
|
1,609,155
|
Fixed Assets, net of accumulated depreciation (Notes 4 and 5) |
7,092,954
|
7,004,890
|
3,763,332
|
Other Assets (Notes 5 and 6) |
590,740
|
411,316
|
529,863
|
TOTAL ASSETS |
11,794,135
|
11,839,656
|
5,902,350
|
Current Liabilities |
|
|
|
Accounts payable (Note 4) |
825,622
|
543,226
|
|
Accounts payable and accrued liabilities (Note 4) |
|
854,684
|
804,138
|
Notes payable, net of discount (Note 7) |
|
|
700,015
|
Contingent stock liability (Notes 7 and 8) |
|
|
677,000
|
Contingent warrant liability (Notes 7, 8 and 10) |
|
|
585,000
|
Accrued and other current liabilities (Note 15) |
574,057
|
311,458
|
|
Warrant liability (Notes 8 and 10) |
1,513,187
|
1,151,838
|
|
Total Current Liabilities |
2,912,866
|
2,006,522
|
2,766,153
|
Deferred Tax Liability |
192,000
|
192,000
|
|
Total Liabilities |
3,104,866
|
2,198,522
|
2,766,153
|
Commitments and Contingencies (Note 15) |
|
|
|
Subsequent Events (Note 16) |
|
|
|
Stockholders’ Equity: |
|
|
|
Preferred stock, $.0001 par value; 1,000,000 shares authorized; 1 share issued and outstanding |
|
|
|
Common stock, $.0001 par value; 100,000,000, shares authorized; 11,655,936 shares issued and outstanding (2022: 9,407,415) |
1,166
|
941
|
519
|
Common stock subscription receivable |
|
|
(32,500)
|
Additional paid-in capital |
28,154,012
|
24,733,306
|
13,835,882
|
Accumulated other comprehensive income |
559,112
|
214,253
|
|
Accumulated deficit |
(20,025,021)
|
(15,307,366)
|
(10,667,704)
|
Total Stockholders’ Equity |
8,689,269
|
9,641,134
|
3,136,197
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
$ 11,794,135
|
$ 11,839,656
|
$ 5,902,350
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
+ Details
Name: |
STSS_AccountsPayableAndAccruedLiabilities |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAccrued and other current liabilities.
+ References
+ Details
Name: |
STSS_AccruedAndOtherCurrentLiabilities |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCommon stock subscription receivable.
+ References
+ Details
Name: |
STSS_CommonStockSubscriptionReceivable |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContingent stock liability.
+ References
+ Details
Name: |
STSS_ContingentStockLiability |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContingent warrant liability.
+ References
+ Details
Name: |
STSS_ContingentWarrantLiability |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommitmentsAndContingencies |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Statement of Financial Position [Abstract] |
|
|
|
Preferred stock, par value |
$ 0.0001
|
$ 0.0001
|
$ 0.0001
|
Preferred stock, shares authorized |
1,000,000
|
1,000,000
|
1,000,000
|
Preferred stock, shares issued |
1
|
1
|
1
|
Preferred stock, shares outstanding |
1
|
1
|
1
|
Common stock, par value |
$ 0.0001
|
$ 0.0001
|
$ 0.0001
|
Common stock, shares authorized |
100,000,000
|
100,000,000
|
100,000,000
|
Common stock, shares issued |
11,655,936
|
9,407,415
|
5,187,062
|
Common stock, shares outstanding |
11,655,936
|
9,407,415
|
5,187,062
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfFinancialPositionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
|
3 Months Ended |
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Income Statement [Abstract] |
|
|
|
|
|
|
Revenue, net |
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
Research and development (Note 5) |
224,260
|
556,868
|
$ 558,148
|
$ 1,063,243
|
2,280,933
|
1,690,865
|
General and administrative |
2,308,075
|
2,230,801
|
4,291,987
|
3,061,710
|
6,457,860
|
2,806,801
|
Total operating expenses |
2,532,335
|
2,787,669
|
4,850,135
|
4,124,953
|
(8,738,793)
|
(4,497,666)
|
Loss from operations |
(2,532,335)
|
(2,787,669)
|
(4,850,135)
|
(4,124,953)
|
(8,738,793)
|
(4,497,666)
|
Other income (expense) |
|
|
|
|
|
|
Interest income (expense) |
40,079
|
(1,100,507)
|
76,871
|
(1,345,944)
|
(1,320,416)
|
(166,746)
|
FMV adjustment on contingent stock & warrants |
(90,108)
|
4,365,930
|
93,977
|
4,078,930
|
5,392,911
|
|
Foreign currency and other |
(23,461)
|
|
(38,368)
|
|
26,636
|
|
Total Other Income (Expense) |
(73,490)
|
3,265,423
|
132,480
|
2,732,986
|
|
|
Net (loss) / Gain |
$ (2,605,825)
|
$ 477,754
|
$ (4,717,655)
|
$ (1,391,967)
|
$ (4,639,662)
|
$ (4,664,412)
|
Net loss per share, basic |
$ (0.22)
|
$ 0.06
|
$ (0.42)
|
$ (0.20)
|
$ (0.57)
|
$ (0.96)
|
Net loss per share, diluted |
$ (0.22)
|
$ 0.06
|
$ (0.42)
|
$ (0.20)
|
$ (0.57)
|
$ (0.96)
|
Weighted average shares used to compute net loss per share, basic |
11,655,936
|
8,669,372
|
11,193,740
|
6,928,217
|
8,100,410
|
4,876,899
|
Weighted average shares used to compute net loss per share, diluted |
11,655,936
|
8,669,372
|
11,193,740
|
6,928,217
|
8,100,410
|
4,876,899
|
X |
- References
+ Details
Name: |
STSS_ForeignCurrencyAndOtherNonOperatingIncomeExpenses |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.13(h)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_GainLossOnSaleOfDerivatives |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net amount of operating interest income (expense).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.10) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_InterestIncomeExpenseNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
|
3 Months Ended |
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Income Statement [Abstract] |
|
|
|
|
|
|
Net loss |
$ (2,605,825)
|
$ 477,754
|
$ (4,717,655)
|
$ (1,391,967)
|
$ (4,639,662)
|
$ (4,664,412)
|
Other comprehensive income: |
|
|
|
|
|
|
Foreign currency translation adjustments gain/(loss) |
73,786
|
|
344,859
|
|
214,253
|
|
Comprehensive loss |
$ (2,532,039)
|
$ 477,754
|
$ (4,372,796)
|
$ (1,391,967)
|
$ (4,425,409)
|
$ (4,664,412)
|
X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossTaxAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
|
Preferred Stock [Member] |
Common Stock [Member] |
Common Stock Subscription Receivable [Member] |
Additional Paid-in Capital [Member] |
AOCI Attributable to Parent [Member] |
Retained Earnings [Member] |
Total |
Balance at Dec. 31, 2020 |
|
$ 460
|
|
$ 8,133,655
|
|
$ (6,003,292)
|
$ 2,130,823
|
Balance, shares at Dec. 31, 2020 |
1
|
4,597,000
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
(4,664,412)
|
(4,664,412)
|
Share-based compensation charges |
|
|
|
1,571,857
|
|
|
1,571,857
|
Shares issued for services |
|
|
|
20,000
|
|
|
20,000
|
Shares issued for services, shares |
|
2,857
|
|
|
|
|
|
Issuance of common stock from subscriptions |
|
$ 49
|
(32,500)
|
3,410,380
|
|
|
3,377,929
|
Issuance of common stock from subscriptions, shares |
|
487,205
|
|
|
|
|
|
Issuance of common stock for acquisition |
|
$ 3
|
|
199,997
|
|
|
200,000
|
Issuance of common stock for acquisition, shares |
|
28,571
|
|
|
|
|
|
Shares issued in Offering |
|
$ 7
|
|
499,993
|
|
|
500,000
|
Shares issued in Offering, shares |
|
71,429
|
|
|
|
|
|
Balance at Dec. 31, 2021 |
|
$ 519
|
(32,500)
|
13,835,882
|
|
(10,667,704)
|
3,136,197
|
Balance, shares at Dec. 31, 2021 |
1
|
5,187,062
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
(1,869,721)
|
(1,869,721)
|
Share-based compensation charges |
|
|
|
328,460
|
|
|
328,460
|
Collections of common stock subscriptions |
|
|
32,500
|
|
|
|
32,500
|
Balance at Mar. 31, 2022 |
|
$ 519
|
|
14,164,342
|
|
(12,537,425)
|
1,627,436
|
Balance, shares at Mar. 31, 2022 |
1
|
5,187,062
|
|
|
|
|
|
Balance at Dec. 31, 2021 |
|
$ 519
|
(32,500)
|
13,835,882
|
|
(10,667,704)
|
3,136,197
|
Balance, shares at Dec. 31, 2021 |
1
|
5,187,062
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
|
(1,391,967)
|
Balance at Jun. 30, 2022 |
|
$ 922
|
|
24,060,753
|
|
(12,059,671)
|
12,002,004
|
Balance, shares at Jun. 30, 2022 |
1
|
9,207,415
|
|
|
|
|
|
Balance at Dec. 31, 2021 |
|
$ 519
|
(32,500)
|
13,835,882
|
|
(10,667,704)
|
3,136,197
|
Balance, shares at Dec. 31, 2021 |
1
|
5,187,062
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
(4,639,662)
|
(4,639,662)
|
Share-based compensation charges |
|
|
|
1,136,638
|
|
|
1,136,638
|
Shares issued for services |
|
$ 23
|
|
290,528
|
|
|
290,551
|
Shares issued for services, shares |
|
235,000
|
|
|
|
|
|
Shares issued in Initial Public Offering |
|
$ 375
|
|
8,974,282
|
|
|
8,974,657
|
Shares issued in Initial Public Offering, shares |
|
3,750,000
|
|
|
|
|
|
Issuance of shares for contingent stock liability |
|
$ 24
|
|
495,976
|
|
|
496,000
|
Issuance of shares for contingent stock liability, shares |
|
235,294
|
|
|
|
|
|
Fractional share adjustment |
|
|
|
|
|
|
|
Fractional share adjustment, shares |
|
59
|
|
|
|
|
|
Foreign Currency Translation |
|
|
|
|
214,253
|
|
214,253
|
Collections of common stock subscriptions |
|
|
32,500
|
|
|
|
32,500
|
Balance at Dec. 31, 2022 |
|
$ 941
|
|
24,733,306
|
214,253
|
(15,307,366)
|
9,641,134
|
Balance, shares at Dec. 31, 2022 |
1
|
9,407,415
|
|
|
|
|
|
Balance at Mar. 31, 2022 |
|
$ 519
|
|
14,164,342
|
|
(12,537,425)
|
1,627,436
|
Balance, shares at Mar. 31, 2022 |
1
|
5,187,062
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
477,754
|
477,754
|
Share-based compensation charges |
|
|
|
365,606
|
|
|
365,606
|
Shares issued for services |
|
$ 4
|
|
60,547
|
|
|
60,551
|
Shares issued for services, shares |
|
35,000
|
|
|
|
|
|
Shares issued in Initial Public Offering |
|
$ 375
|
|
8,974,282
|
|
|
8,974,657
|
Shares issued in Initial Public Offering, shares |
|
3,750,000
|
|
|
|
|
|
Issuance of shares for contingent stock liability |
|
$ 24
|
|
495,976
|
|
|
496,000
|
Issuance of shares for contingent stock liability, shares |
|
235,294
|
|
|
|
|
|
Fractional share adjustment |
|
|
|
|
|
|
|
Fractional share adjustment, shares |
|
59
|
|
|
|
|
|
Balance at Jun. 30, 2022 |
|
$ 922
|
|
24,060,753
|
|
(12,059,671)
|
12,002,004
|
Balance, shares at Jun. 30, 2022 |
1
|
9,207,415
|
|
|
|
|
|
Balance at Mar. 31, 2022 |
|
$ 519
|
|
14,164,342
|
|
(12,537,425)
|
1,627,436
|
Balance, shares at Mar. 31, 2022 |
1
|
5,187,062
|
|
|
|
|
|
Shares issued for services |
|
|
|
|
|
|
$ 290,551
|
Shares issued for services, shares |
|
|
|
|
|
|
235,000
|
Balance at Dec. 31, 2022 |
|
$ 941
|
|
24,733,306
|
214,253
|
(15,307,366)
|
$ 9,641,134
|
Balance, shares at Dec. 31, 2022 |
1
|
9,407,415
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
(2,111,830)
|
(2,111,830)
|
Share-based compensation charges |
|
|
|
383,100
|
|
|
383,100
|
Shares issued in Offering |
|
$ 225
|
|
2,783,160
|
|
|
2,783,385
|
Shares issued in Offering, shares |
|
2,248,521
|
|
|
|
|
|
Foreign Currency Translation |
|
|
|
|
270,983
|
|
270,983
|
Balance at Mar. 31, 2023 |
|
$ 1,166
|
|
27,899,566
|
485,236
|
(17,419,196)
|
10,966,772
|
Balance, shares at Mar. 31, 2023 |
1
|
11,655,936
|
|
|
|
|
|
Balance at Dec. 31, 2022 |
|
$ 941
|
|
24,733,306
|
214,253
|
(15,307,366)
|
9,641,134
|
Balance, shares at Dec. 31, 2022 |
1
|
9,407,415
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
|
(4,717,655)
|
Balance at Jun. 30, 2023 |
|
$ 1,166
|
|
28,154,012
|
559,112
|
(20,025,021)
|
8,689,269
|
Balance, shares at Jun. 30, 2023 |
1
|
11,655,936
|
|
|
|
|
|
Balance at Mar. 31, 2023 |
|
$ 1,166
|
|
27,899,566
|
485,236
|
(17,419,196)
|
10,966,772
|
Balance, shares at Mar. 31, 2023 |
1
|
11,655,936
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
(2,605,825)
|
(2,605,825)
|
Share-based compensation charges |
|
|
|
254,446
|
|
|
254,446
|
Foreign Currency Translation |
|
|
|
|
73,876
|
|
73,876
|
Balance at Jun. 30, 2023 |
|
$ 1,166
|
|
$ 28,154,012
|
$ 559,112
|
$ (20,025,021)
|
$ 8,689,269
|
Balance, shares at Jun. 30, 2023 |
1
|
11,655,936
|
|
|
|
|
|
X |
- DefinitionStock issued during period collections of common stock subscriptions value.
+ References
+ Details
Name: |
STSS_StockIssuedDuringPeriodCollectionsOfCommonStockSubscriptionsValue |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period issuance of common stock from subscriptions shares.
+ References
+ Details
Name: |
STSS_StockIssuedDuringPeriodIssuanceOfCommonStockFromSubscriptionsShares |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period issuance of common stock from subscriptions value.
+ References
+ Details
Name: |
STSS_StockIssuedDuringPeriodIssuanceOfCommonStockFromSubscriptionsValue |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares contingent stock liability.
+ References
+ Details
Name: |
STSS_StockIssuedDuringPeriodSharesContingentStockLiability |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during shares fractional share adjustment.
+ References
+ Details
Name: |
STSS_StockIssuedDuringPeriodSharesFractionalShareAdjustment |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares initial public offering.
+ References
+ Details
Name: |
STSS_StockIssuedDuringPeriodSharesInitialPublicOffering |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value contingent stock liability.
+ References
+ Details
Name: |
STSS_StockIssuedDuringPeriodValueContingentStockLiability |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value fractional share adjustment.
+ References
+ Details
Name: |
STSS_StockIssuedDuringPeriodValueFractionalShareAdjustment |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value initial public offering.
+ References
+ Details
Name: |
STSS_StockIssuedDuringPeriodValueInitialPublicOffering |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of stock issued during the period pursuant to acquisitions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued pursuant to acquisitions during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
Net loss |
$ (4,717,655)
|
$ (1,391,967)
|
$ (4,639,662)
|
$ (4,664,412)
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
Depreciation and amortization |
448,657
|
156,100
|
654,572
|
28,699
|
Stock-based compensation |
637,547
|
650,104
|
1,012,592
|
1,195,819
|
Issuance of common stock for services |
|
|
290,551
|
20,000
|
Accretion of debt discount |
|
1,299,985
|
1,299,985
|
159,615
|
FMV adjustment for Contingent Stock |
|
(181,000)
|
(181,000)
|
|
FMV adjustment for Warrants |
(93,977)
|
(3,897,930)
|
(5,211,911)
|
|
IPO Issuance costs relating to Warrants |
|
550,433
|
550,433
|
|
Foreign exchange gain |
30,141
|
|
496
|
|
Changes in operating assets: |
|
|
|
|
Prepaid expenses and other current assets |
(119,761)
|
(27,542)
|
(58,754)
|
42,005
|
Inventory |
(769,088)
|
(5,448)
|
(34,109)
|
(121,994)
|
Other assets |
|
|
(12,000)
|
(10,262)
|
Accounts payable and accrued liabilities |
453,136
|
(245,840)
|
(104,352)
|
202,894
|
Net cash used in operating activities |
(4,131,000)
|
(3,093,105)
|
(6,433,159)
|
(3,147,736)
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
Acquistion of fixed assets or deposits paid |
(342,525)
|
(463,355)
|
(209,678)
|
(46,900)
|
Purchase of fixed assets |
|
|
(542,662)
|
(2,221,830)
|
Other assets – escrow and other |
|
(2,350,000)
|
|
(75,000)
|
Asset acquisition |
|
|
(2,365,576)
|
|
Net cash used in investing activities |
(342,525)
|
(2,813,355)
|
(3,117,916)
|
(2,343,730)
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
Proceeds from common stock issued, net of subscription receivable |
|
|
|
3,377,929
|
Net proceeds from Initial Public Offering Units |
|
|
14,202,975
|
|
Net proceeds from notes payable, contingent stock liability, contingent warrant liability |
|
|
|
1,802,500
|
Net proceeds from Initial Public Offering and additional offering |
3,238,711
|
14,202,975
|
|
|
Repayment of Note Payable |
|
(2,000,000)
|
(2,000,000)
|
|
Proceeds from subscriptions receivable |
|
32,500
|
32,500
|
|
Net cash provided by financing activities |
3,238,711
|
12,235,475
|
12,235,475
|
5,180,429
|
Effect of exchange rate changes on cash |
(12,064)
|
|
7,331
|
|
NET INCREASE (DECREASE) IN CASH |
(1,246,878)
|
6,329,015
|
2,691,731
|
(311,037)
|
CASH — BEGINNING OF YEAR |
4,170,897
|
1,479,166
|
1,479,166
|
1,790,203
|
CASH — END OF PERIOD |
2,924,019
|
7,808,181
|
4,170,897
|
1,479,166
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: |
|
|
|
|
Cash paid for interest |
|
47,111
|
47,111
|
4,000
|
Cash paid for taxes |
|
|
|
|
Non-cash investing and financing activity: |
|
|
|
|
FMV for Common Stock Issued for Contingent Shares |
|
496,000
|
496,000
|
|
FMV for Warrants issued for contingent warrants |
|
|
554,312
|
|
Common stock issued and vested stock options for fixed assets acquired |
|
63,612
|
63,612
|
753,336
|
Common stock issued and vested stock options issued as consideration for acquisition |
|
$ 40,901
|
$ 60,435
|
$ 322,701
|
X |
- DefinitionCommon stock issued and vested stock options for fixed assets acquired.
+ References
+ Details
Name: |
STSS_CommonStockIssuedAndVestedStockOptionsForFixedAssetsAcquired |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionCommon stock issued and vested stock options issued as consideration for acquisition.
+ References
+ Details
Name: |
STSS_CommonStockIssuedAndVestedStockOptionsIssuedAsConsiderationForAcquisition |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair market value for adjustment for contingent warrants.
+ References
+ Details
Name: |
STSS_FairMarketValueAdjustmentForContingentWarrants |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFair market valuea djustment for Contingent Warrants and Warrants.
+ References
+ Details
Name: |
STSS_FairMarketValueAdjustmentForContingentWarrantsAndWarrants |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFMV for common stock issued for cintingent shares.
+ References
+ Details
Name: |
STSS_FmvForCommonStockIssuedForContingentShares |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFmv for warrants issued for contingent warrants.
+ References
+ Details
Name: |
STSS_FmvForWarrantsIssuedForContingentWarrants |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIPO issuance cost relating to warrants.
+ References
+ Details
Name: |
STSS_IpoIssuanceCostsRelatingToWarrants |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNet proceeds from Initial Public Offering and additional offering.
+ References
+ Details
Name: |
STSS_NetProceedsFromInitialPublicOfferingAndAdditionalOffering |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPayments to acquire other assets escrow deposit.
+ References
+ Details
Name: |
STSS_PaymentsToAcquireOtherAssetsEscrowDeposit |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPayments to asset acquisition.
+ References
+ Details
Name: |
STSS_PaymentsToAssetAcquisition |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionProceeds from subscriptions receivable.
+ References
+ Details
Name: |
STSS_ProceedsFromSubscriptionsReceivable |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_DepreciationAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17
+ Details
Name: |
us-gaap_ForeignCurrencyTransactionGainLossBeforeTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInInventories |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in operating assets classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherOperatingAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details
Name: |
us-gaap_InterestPaidNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NoncashInvestingAndFinancingItemsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash (inflow) outflow from investing activities classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12
+ Details
Name: |
us-gaap_PaymentsForProceedsFromOtherInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceInitialPublicOffering |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.3
Description of Business
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Accounting Policies [Abstract] |
|
|
Description of Business |
Note
1. Description of Business
Nature
of Business
Sharps
Technology, Inc. (“Sharps” or the “Company”) is a pre-revenue medical device company that has designed and patented
various safety syringes and is seeking commercialization by manufacturing and distribution of its products.
The
accompanying condensed consolidated financial statements include the accounts of Sharps Technology, Inc. and its wholly owned subsidiary,
Safegard Medical, Inc. collectively referred to as the “Company.” The condensed consolidated balance sheet as of June 30,
2023 and the condensed consolidated statements of operations, statements of comprehensive loss and statements of stockholders’
equity s for the three and six months ended June 30, 2023 and 2022 and the statements of cash flow for the six months ended June
30, 2023 (the “interim statements”) are unaudited. All intercompany transactions and balances have been eliminated. In the
opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position
and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual
financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or
omitted. The interim statements should be read in conjunction with the consolidated financial statements for the year ended December
31, 2022 and notes thereto contained in the Company’s Form 10-K filed with the Securities and Exchange Commission. The condensed
consolidated balance sheet at December 31, 2022 has been derived from the audited financial statements at that date. The results of operations
for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year
ending December 31, 2023.
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has not
generated revenue or cash flow from operations since inception. As of June 30, 2023, the Company had a working capital of $1,197,575 which
is not expected to be sufficient to fund the Company’s planned operations for the next 12 months. These factors raise substantial
doubt regarding the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern
is dependent upon the Company’s ability to raise sufficient financing to acquire or commercialize its products into a profitable
business. The Company intends to finance its commercialization activities and its working capital needs largely from the sale of equity
securities and/or with additional funding from other traditional financing sources until such time that funds provided by operations
are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating
to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary
should the Company be unable to continue as a going concern.
The
Company’s fiscal year ends on December 31.
On
April 13, 2022, the Company’s Initial Public Offering was deemed effective with trading commencing on April 14, 2022. The Company
received net proceeds of $14.2 million on April 19, 2022 (See Note 8).
|
Note
1. Description of Business
Nature
of Business
Sharps
Technology, Inc. (“Sharps” or the “Company”) is a pre-revenue medical device company that has designed and patented
various safety syringes and is seeking commercialization by manufacturing and distribution of its products.
The
accompanying consolidated financial statements include the accounts of Sharps Technology, Inc. and its wholly owned subsidiary,
Safegard Medical (Hungary) KFT, collectively referred to as the “Company.” All intercompany transactions and balances have been
eliminated.
The
Company’s fiscal year ends on December 31.
On
April 13, 2022, the Company’s Initial Public Offering was deemed effective with trading commencing on April 14, 2022. The Company
received net proceeds of $14.2 million on April 19, 2022 (See Note 8).
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//275/tableOfContent
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent
+ Details
Name: |
us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Summary of Significant Accounting Policies
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Accounting Policies [Abstract] |
|
|
Summary of Significant Accounting Policies |
Note
2. Summary of Significant Accounting Policies
Basis
of Presentation
The
accompanying condensed consolidated financial statements have been prepared by the Company in accordance with generally accepted accounting
principles (“GAAP”) in the United States (“U.S.”) and are expressed in U.S. dollars.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As
of June 30, 2023, the most significant estimates relate to derivative liabilities and stock-based compensation.
Cash
and Cash Equivalents
The
Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date
of purchase to be cash equivalents. Cash and cash equivalents are maintained with various financial institutions.
Inventories
The
Company values inventory at the lower of cost (average cost) or net realizable value. Work-in-process and finished goods inventories
consist of material, labor, and manufacturing overhead. Net realizable value is the estimated selling price in the ordinary course of
business, less reasonably predictable costs of completion, disposal, and transportation. A reserve is established for any excess or obsolete
inventories or they may be written off. At June 30, 2023 and December 31, 2022, inventory is comprised of raw materials, including packaging,
work in process (components) and finished goods.
Fair
Value Measurements
ASC
820, Fair Value Measurements and Disclosures, require an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding
the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be
used to measure fair value.
The
Company’s outstanding warrants are fair valued on a recurring basis with the trading price which could cause fluctuations in operating
results at the reporting periods.
Level
1
Level
1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Valuations
are based on quoted prices that are readily and regularly available in an active market and do not entail a significant degree of judgment.
Level
2
Level
2 applied to assets or liabilities for which there are other than Level 1 observable inputs such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market data.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
Level
2 instruments require more management judgment and subjectivity as compared to Level 1 instruments. For instance: determining which instruments
are most similar to the instrument being priced requires management to identify a sample of similar securities based on the coupon rates,
maturity, issuer credit rating and instrument type, and subjectively select an individual security or multiple securities that are deemed
most similar to the security being priced; and determining whether a market is considered active requires management judgment.
Level
3
Level
3 applied to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement
of the fair value of the assets or liabilities. The determination for Level 3 instruments requires the most management judgment and subjectivity.
Fixed
Assets
Fixed
assets are stated at cost. Expenditures for maintenance and repairs are charged to operations as incurred. The Company’s fixed
assets consist of land, building, machinery and equipment, molds and website. Depreciation is calculated using the straight-line method
commencing on the date the asset is operating in the way intended by management over the following useful lives: Building – 20
years, Machinery and Equipment – 3 -10 years and Website – 3 years. The expected life for Molds is based on the lesser of
the number of parts that will be produced based on the expected mold capability or 5 years.
Impairment
of Long-Lived Assets
Long-lived
assets are reviewed for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash
flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.
There
were no impairment losses recognized during the six months ended June 30, 2023.
Purchased
Identified Intangible Assets
The
Company’s identified intangible assets are amortized on a straight-line basis over their estimated useful lives of 5 years. The
Company makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate that the
useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable. If such facts and circumstances
exist, the Company assesses recoverability by comparing the projected undiscounted net cash flows associated with the related asset or
group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the excess of
the carrying amount over the fair value of those assets. If the useful life is shorter than originally estimated, the Company would accelerate
the rate of amortization and amortize the remaining carrying value over the new shorter useful life. The Company evaluates the carrying
value of indefinite-lived intangible assets whenever events or changes in circumstances indicate that the carrying amount of an
asset may not be recoverable, and an impairment charge would be recognized to the extent that the carrying amount of such assets exceeds
their estimated fair value.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
Stock-based
Compensation Expense
The
Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. For
stock option awards, the Company uses the Black-Scholes option-pricing model. For restricted stock awards, the estimated fair value is
generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite
service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company
recognizes forfeitures of stock-based awards as they occur on a prospective basis.
Stock-based
compensation expense for awards granted to non-employees as consideration for services received is measured on the date of performance
at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured.
Derivative
Instruments
The
Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of
the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC 480”), Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815,
Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments
pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification
under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could
potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent
quarterly period end date while the warrants are outstanding.
At
their issuance date and as of June 30, 2023, the warrants (see Notes 8 and 10) were accounted for as liabilities as these instruments
did not meet all of the requirements for equity classification under ASC 815-40 based on the terms of the aforementioned warrants. The
resulting warrant liabilities are re-measured at each balance sheet date until their exercise or expiration, and any change in fair value
is recognized in the Company’s condensed consolidated statements of operations and comprehensive loss.
Foreign
Currency Translation/Transactions
The
Company has determined that the functional currency for its foreign subsidiary is the local currency. For financial reporting purposes,
assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated
at weighted average exchange rates. Resulting translation gains and losses are included as a separate component of stockholders’
equity as accumulated other comprehensive income or loss. Gains or losses resulting from transactions entered into in other than the
functional currency are recorded as foreign exchange gains and losses in the consolidated statements of operations and comprehensive
loss.
Comprehensive
income (loss)
Comprehensive
income (loss) consists of the Company’s consolidated net loss and foreign currency translation adjustments related to its subsidiary.
Foreign currency translation adjustments included in comprehensive loss were not tax effected as the Company has a full valuation allowance
at June 30, 2023 and December 31, 2022. Accumulated other comprehensive income (loss) is a separate component of stockholders’
equity and consists of the cumulative foreign currency translation adjustments.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
Basic
and Diluted Loss Per Share
The
Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted
earnings per share (EPS) on the face of the consolidated statement of operations and comprehensive loss. Basic EPS is computed by dividing
net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during
the year. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method
and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used
in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all
dilutive potential shares if their effect is anti-dilutive. As of June 30, 2023, there were 13,788,724 stock options and warrants
that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would
have been antidilutive for the periods presented.
Income
Taxes
The
Company must make certain estimates and judgments in determining income tax expenses for financial statement purposes. These estimates
and judgments are used in the calculation of tax credits, tax benefits, tax deductions, and in the calculation of certain deferred taxes
and tax liabilities. Significant changes to these estimates may result in an increase or decrease to the Company’s tax provision
in a subsequent period.
The
provision for income taxes was comprised of the Company’s current tax liability and changes in deferred income tax assets and liabilities.
The calculation of the current tax liability involves dealing with uncertainties in the application of complex tax laws and regulations
and in determining the liability for tax positions, if any, taken on the Company’s tax returns in accordance with authoritative
guidance on accounting for uncertainty in income taxes. Deferred income taxes are determined based on the differences between the financial
reporting and tax basis of assets and liabilities. The Company must assess the likelihood that it will be able to recover the Company’s
deferred tax assets. If recovery is not likely on a more-likely-than-not basis, the Company must increase its provision for income taxes
by recording a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. However, should
there be a change in the Company’s ability to recover its deferred tax assets, the provision for income taxes would fluctuate in
the period of such change.
Research
and Development Costs
Research
and development costs are expensed as incurred.
Advance
payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized.
Such amounts are recognized as an expense as the related goods are delivered or the services are performed.
Contingencies
Liabilities
for loss contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized when it is
probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Gain contingencies are evaluated
and not recognized until the gain is realizable or realized.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
Recent
Accounting Pronouncements
In
March 2020, the FASB issued ASC Topic 848, Reference Rate Reform. ASC Topic 848 provides relief for impacted areas as it relates
to impending reference rate reform. ASC Topic 848 contains optional expedients and exceptions for applying GAAP to debt arrangements,
contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective
upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance.
On
August 5, 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40), which simplifies the accounting for certain financial
instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own
equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU
2020-06 simplifies the guidance in U.S. GAAP on the issuer’s accounting for convertible debt instruments, requires entities to
provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been
reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification
and amends certain guidance in ASC 260, Earnings per Share, on the computation of EPS for convertible instruments and contracts
on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance.
The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company
continues to assess all potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.
In
June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject
to Contractual Sale Restrictions”, intended to clarify that a contractual restriction on the sale of an equity security is not
considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendment
also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. ASU No. 2022-03
is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December
15, 2023. Early adoption is permitted. For all other entities, it is effective for fiscal years, including interim periods within those
fiscal years beginning after December 15, 2024. Early adoption is permitted for both interim and annual financial statements that have
not yet been issued or made available for issuance. The Company is evaluating the adoption of the amendments and the potential impact
it may have, if any, on its financial statements.
The
Company does not expect the adoption of any accounting pronouncements to have a material impact on the condensed consolidated financial
statements.
We
reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant
to the accounting for our operations.
|
Note
2. Summary of Significant Accounting Policies
Basis
of Presentation
The
accompanying consolidated financial statements have been prepared by the Company in accordance with generally accepted accounting principles
(“GAAP”) in the United States (“U.S.”) and are expressed in U.S. dollars.
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As
of December 31, 2022, the most significant estimates relate to derivative liabilities and stock-based compensation.
Cash
and Cash Equivalents
The
Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date
of purchase to be cash equivalents. Cash and cash equivalents are maintained with various financial institutions.
Inventories
The
Company values inventory at the lower of cost (average cost) or net realizable value. Work-in-process and finished goods inventories
consist of material, labor, and manufacturing overhead. Net realizable value is the estimated selling price in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. A reserve is established for any excess
or obsolete inventories or they may be written off. At December 31, 2022 and 2021, inventory is comprised of raw materials,
components and finished goods.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
Fair
Value Measurements
ASC
820, Fair Value Measurements and Disclosures, require an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding
the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be
used to measure fair value.
The
Company’s outstanding warrants are fair valued on a recurring basis with the trading price which could cause fluctuations in
operating results at the reporting periods.
Level
1
Level
1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Valuations
are based on quoted prices that are readily and regularly available in an active market and do not entail a significant degree of judgment.
Level
2
Level
2 applied to assets or liabilities for which there are other than Level 1 observable inputs such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market data.
Level
2 instruments require more management judgment and subjectivity as compared to Level 1 instruments. For instance: determining which instruments
are most similar to the instrument being priced requires management to identify a sample of similar securities based on the coupon rates,
maturity, issuer credit rating and instrument type, and subjectively select an individual security or multiple securities that are deemed
most similar to the security being priced; and determining whether a market is considered active requires management judgment.
Level
3
Level
3 applied to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement
of the fair value of the assets or liabilities. The determination for Level 3 instruments requires the most management judgment and subjectivity.
Fixed
Assets
Fixed
assets are stated at cost. Expenditures for maintenance and repairs are charged to operations as incurred. The Company’s fixed
assets consist of land, building, machinery and equipment, molds and website. Depreciation is calculated using the straight-line
method commencing on the date the asset is operating in the way intended by management over the following useful lives: Building
– 20 years, Machinery and Equipment – 3 -10 years and Website – 3 years. The expected life for Molds is based
lesser of the number of parts that will be produced based on the expected mold capability or 5 years.
Impairment
of Long-Lived Assets
Long-lived
assets are reviewed annually for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted
cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from
the asset.
There
were no impairment losses recognized during the years ended December 31, 2022 and 2021.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
Goodwill
and Purchased Identified Intangible Assets
Goodwill
When
applicable, goodwill will be recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the
fair value of the net tangible and identified intangible assets acquired under a business combination. Goodwill also includes acquired
assembled workforce, which does not qualify as an identifiable intangible asset. The Company reviews impairment of goodwill annually
in the third quarter, or more frequently if events or circumstances indicate that the goodwill might be impaired. The Company first assesses
qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. If, after assessing the
totality of events or circumstances, the Company determines that it is not more likely than not that the fair value of a reporting unit
is less than its carrying amount, then the quantitative goodwill impairment test is unnecessary. If, based on the qualitative assessment,
it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the Company
proceeds to perform the quantitative goodwill impairment test. The Company first determines the fair value of a reporting unit using
weighted results derived from an income approach and a market approach. The income approach is estimated through the discounted cash
flow method based on assumptions about future conditions such as future revenue growth rates, new product and technology introductions,
gross margins, operating expenses, discount rates, future economic and market conditions, and other assumptions. The market approach
estimates the fair value of the Company’s equity by utilizing the market comparable method which is based on revenue multiples
from comparable companies in similar lines of business. The Company then compares the derived fair value of a reporting unit with its
carrying amount. If the carrying value of a reporting unit exceeds its fair value, an impairment loss will be recognized in an amount
equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.
Identified
Intangible Assets
The
Company’s identified intangible assets are amortized on a straight-line basis over their estimated useful lives of 5 years.
The Company makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate
that the useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable. If such
facts and circumstances exist, the Company assesses recoverability by comparing the projected undiscounted net cash flows associated
with the related asset or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any,
are based on the excess of the carrying amount over the fair value of those assets. If the useful life is shorter than originally
estimated, the Company would accelerate the rate of amortization and amortize the remaining carrying value over the new shorter
useful life. The Company evaluates the carrying value of indefinite-lived intangible assets on an annual basis, and an impairment
charge would be recognized to the extent that the carrying amount of such assets exceeds their estimated fair value.
Stock-based
Compensation Expense
The
Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. For
stock option awards, the Company uses the Black-Scholes option-pricing model. For restricted stock awards, the estimated fair value is
generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite
service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company
recognizes forfeitures of stock-based awards as they occur on a prospective basis.
Stock-based
compensation expense for awards granted to non-employees as consideration for services received is measured on the date of performance
at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured.
Derivative
Instruments
The
Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of
the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC 480”), Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815,
Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments
pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification
under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could
potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent
quarterly period end date while the warrants are outstanding.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
At
their issuance date and as of December 31, 2022, the warrants (see Notes 8 and 10) were accounted for as liabilities as these instruments
did not meet all of the requirements for equity classification under ASC 815-40 based on the terms of the aforementioned warrants. The
resulting warrant liabilities are re-measured at each balance sheet date until their exercise or expiration, and any change in fair value
is recognized in the Company’s consolidated statements of operations and comprehensive loss.
Foreign
Currency Translation/Transactions
The
Company has determined that the functional currency for its foreign subsidiary is the local currency. For financial reporting
purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss
accounts are translated at weighted average exchange rates. Resulting translation gains and losses are included as a separate
component of stockholders’ equity as accumulated other comprehensive income or loss. Gains or losses resulting from
transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the
consolidated statements of operations and comprehensive loss.
Comprehensive
income (loss)
Comprehensive
income (loss) consists of the Company’s consolidated net loss and foreign currency translation adjustments related to its subsidiary. Foreign currency
translation adjustments included in comprehensive loss were not tax effected as the Company has a full valuation allowance at
December, 2022 and 2021. Accumulated other comprehensive income (loss) is a separate component of stockholders’ equity and
consists of the cumulative foreign currency translation adjustments.
Basic
and Diluted Loss Per Share
The
Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted
earnings per share (EPS) on the face of the consolidated statement of operations and comprehensive loss. Basic EPS is computed by dividing
net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during
the year. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method
and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used
in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all
dilutive potential shares if their effect is anti-dilutive. As at December 31, 2022, there were 10,405,916 stock options and warrants
that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would
have been antidilutive for the periods presented.
Income
Taxes
The
Company must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates
and judgments are used in the calculation of tax credits, tax benefits, tax deductions, and in the calculation of certain deferred taxes
and tax liabilities. Significant changes to these estimates may result in an increase or decrease to the Company’s tax provision
in a subsequent period.
The
provision for income taxes was comprised of the Company’s current tax liability and changes in deferred income tax assets and liabilities.
The calculation of the current tax liability involves dealing with uncertainties in the application of complex tax laws and regulations
and in determining the liability for tax positions, if any, taken on the Company’s tax returns in accordance with authoritative
guidance on accounting for uncertainty in income taxes. Deferred income taxes are determined based on the differences between the financial
reporting and tax basis of assets and liabilities. The Company must assess the likelihood that it will be able to recover the Company’s
deferred tax assets. If recovery is not likely on a more-likely-than-not basis, the Company must increase its provision for income taxes
by recording a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. However, should
there be a change in the Company’s ability to recover its deferred tax assets, the provision for income taxes would fluctuate in
the period of such change.
Research
and Development Costs
Research
and development costs are expensed as incurred.
Advance
payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized.
Such amounts are recognized as an expense as the related goods are delivered or the services are performed.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
Contingencies
Liabilities for loss
contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized when it is probable
that a liability has been incurred and the amount of the assessment can be reasonably estimated. Gain contingencies are evaluated and
not recognized until the gain is realizable or realized.
Recent
Accounting Pronouncements
In
March 2020, the FASB issued ASC Topic 848, Reference Rate Reform. ASC Topic 848 provides relief for impacted areas as it relates
to impending reference rate reform. ASC Topic 848 contains optional expedients and exceptions for applying GAAP to debt arrangements,
contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective
upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance.
On
August 5, 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40), which simplifies the accounting for certain financial
instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own
equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU
2020-06 simplifies the guidance in U.S. GAAP on the issuer’s accounting for convertible debt instruments, requires entities to
provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been
reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification
and amends certain guidance in ASC 260, Earnings per Share, on the computation of EPS for convertible instruments and contracts
on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance.
The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company
continues to assess all potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.
The
Company does not expect the adoption of any accounting pronouncements to have a material impact on the consolidated financial statements.
We
reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant
to the accounting for our operations.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
+ Details
Name: |
us-gaap_SignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Inventories
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Inventory Disclosure [Abstract] |
|
|
Inventories |
Note
3. Inventories
Inventories,
net consisted of the following at:
Schedule of Inventories
| |
June 30, 2023 | | |
December 31, 2022 | |
Raw materials | |
$ | 226,062 | | |
$ | 106,088 | |
Work in process | |
| 86,831 | | |
| 49,144 | |
Finished goods | |
| 679,654 | | |
| 30,572 | |
Total | |
$ | 992,547 | | |
$ | 185,804 | |
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
|
Note
3. Inventories
Inventories,
net consisted of the following at December 31, 2022 and 2021:
Schedule of Inventories
|
|
December 31, 2022 |
|
|
December 31, 2021 |
|
Raw materials |
|
$ |
106,088 |
|
|
$ |
121,994 |
|
Work in process |
|
|
49,144 |
|
|
|
- |
|
Finished goods |
|
|
30,572 |
|
|
|
- |
|
Total |
|
$ |
185,804 |
|
|
$ |
121,994 |
|
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent
+ Details
Name: |
us-gaap_InventoryDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Fixed Assets
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Property, Plant and Equipment [Abstract] |
|
|
Fixed Assets |
Note
4. Fixed Assets
Fixed
asset, net, is summarized as follows as of:
Schedule of Property, Plant and Equipment
| |
June 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Land | |
$ | 264,736 | | |
$ | 242,240 | |
Building | |
| 3,068,950 | | |
| 2,824,481 | |
Machinery and Equipment | |
| 4,863,882 | | |
| 4,601,293 | |
Website | |
| 20,363 | | |
| 16,600 | |
Fixed asset, gross | |
| 8,217,930 | | |
| 7,684,614 | |
Less: accumulated depreciation | |
| (1,124,976 | ) | |
| (679,724 | ) |
Fixed asset, net | |
$ | 7,092,954 | | |
$ | 7,004,890 | |
Depreciation
expense of fixed assets for the six months ended June 30, 2023 and 2022 was $445,252 net of foreign currency impacts and $156,100
respectively. Substantially, all the Company’s fixed assets are located at the Company’s Hungary location.
During
the six months ended June 30, 2022 , the Company recorded $63,612 in fixed asset costs relating to the estimated fair market value
for options granted in 2021 for the acquired machinery. As of June 30, 2023, the Company has $100,000 in remaining payments for machinery
purchased, which is included in accounts payable.
|
Note
4. Fixed Assets
Fixed
asset, net, as of December 31, 2022 and 2021, are summarized as follows:
Schedule of Property, Plant and Equipment
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Land | |
$ | 242,240 | | |
$ | - | |
Building | |
| 2,824,481 | | |
| - | |
Machinery and Equipment | |
| 4,601,293 | | |
| 3,778,766 | |
Website | |
| 16,600 | | |
| 16,600 | |
Fixed asset, gross | |
| 7,684,614 | | |
| 3,795,366 | |
Less: accumulated depreciation | |
| (679,724 | ) | |
| (32,034 | ) |
Fixed asset, net | |
$ | 7,004,890 | | |
$ | 3,763,332 | |
Depreciation
expense of fixed assets for the year ended December 31, 2022 and 2021 was $647,690
and $28,699,
respectively. Substantially, all of the Company’s fixed assets are located at the Company’s Hungary location.
During
the year ended December 2022, the Company recorded $63,612 in fixed asset costs relating to the estimated fair market value for options
granted in 2021 for the acquired machinery. As of December 31, 2022, the Company has $100,000 in remaining payments for machinery purchased,
which is included in accounts payable.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//360/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Asset Acquisition
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Business Combination and Asset Acquisition [Abstract] |
|
|
Asset Acquisition |
Note
5. Asset Acquisition
In
June 2020, the Company entered into a Share Purchase Agreement (“Agreement”) with Safegard Medical (“Safegard”)
and amendments to the Agreement, collectively, the Agreements, to purchase either the stock or certain assets of a manufacturing facility
for $2.5M in cash, plus additional consideration of 28,571 shares of common stock with an estimated fair market value of $7.00, 35,714
stock options with an exercise price of $7.00 and 50,000 stock options with an exercise price of $4.25. The purchase price includes the
fair market value of the common stock of $200,000 and the vested options of $183,135. The Agreements provided the Company various periods
for due diligence and post due diligence, requirements for escrow payments through the closing date (“Closing Date”).
Through
the Closing Date, the Agreements provided the Company with the exclusive use of the facility in exchange for payment of the facility’s
operating costs. The monthly fee (“Operating Costs”), which primarily covered the facility’s operating costs, was mainly
comprised of the seller’s workforce costs, materials and other recurring monthly operating cost.
During
the three and six months ended June 30, 2022, the Company had remitted $275,000 and $300,000, respectively for the forementioned Operating
Costs. The remittance of operating costs was discontinued after the Closing Date. These costs were included in research and development
expense in the condensed consolidated statement of operations as the activities at the facility in 2022 were related to design and testing
of the Company’s products.
The
acquisition of Safegard, which closed on July 6, 2022, did not meet the definition of a business pursuant to ASC 805-10, and accordingly
was accounted for as an asset acquisition in accordance with ASC 805-50. The cost of the acquisition was $2,936,712, including transaction
costs of $53,576, with the allocation to the assets acquired on a relative fair value basis. The intangibles relate to permits and a
limited workforce acquired. Under ASC 805-50, no goodwill is recognized. The operating results for Safegard are included in the consolidated
balance sheet and consolidated statements of operations and comprehensive loss for the period beginning after the closing on July 6,
2022.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
5. Asset Acquisition (continued)
The
relative fair value of the assets acquired and related deferred tax liability is as follows:
Schedule of Fair Value of the Assets Acquisition
| |
| | |
Land | |
$ | 226,000 | |
Building and affixed assets | |
| 2,648,000 | |
Machinery | |
| 158,000 | |
Inventory | |
| 32,000 | |
Intangibles | |
| 64,712 | |
Deferred tax liability | |
| (192,000 | ) |
| |
| | |
Total | |
$ | 2,936,712 | |
The
useful lives for the acquired assets is Building - 20 years; Machinery – 5 to 10 years; Intangibles – 5 years. The related
depreciation and amortization is being recorded on a straight-line basis.
|
Note
5. Asset Acquisition
In
June 2020, the Company entered into a Share Purchase Agreement (“Agreement”) with Safegard Medical
(“Safegard”) and amendments to the Agreement, collectively, the Agreements, to purchase either the stock or certain
assets of a manufacturing facility for $2.5M
in cash, plus additional consideration of 28,571
shares of common stock with an estimated fair market value of $7.00, 35,714
stock options with an exercise price of $7.00
and 50,000
stock options with an exercise price of $4.25.
The purchase price includes the fair market value of the common stock of $200,000
and the vested options of $183,135.
The Agreements provided the Company various periods for due diligence and post due diligence, requirements for escrow payments
through the closing date (“Closing Date”).
Through
the Closing Date, the Agreements provided the Company with the exclusive use of the facility in exchange for payment of the facility’s
operating costs. The monthly fee (“Operating Costs”), which primarily covered the facility’s operating costs, was mainly
comprised of the seller’s workforce costs, materials and other recurring monthly operating cost.
During
the year ended December 31, 2022 and 2021, the Company had remitted $594,000 and $770,000, respectively for the aforementioned Operating
Costs. The remittance of operating costs was discontinued after the Closing Date. These costs were included in research and development
expense in the consolidated statement of operations and comprehensive loss as the activities at the facility in 2022 and 2021 were related
to design and testing of the Company’s products.
The
acquisition of Safegard, which closed on July 6, 2022, did not meet the definition of a business pursuant to ASC 805-10,
and accordingly was accounted for as an asset acquisition in accordance with ASC 805-50. The cost of the
acquisition was $2,936,712,
including transaction costs of $53,576,
with the allocation to the assets acquired on a relative fair value basis. The intangibles relate to permits and a limited workforce
acquired. Under ASC 805-50, no goodwill is recognized. The operating results for Safegard are included in the consolidated balance
sheet and consolidated statements of operations and comprehensive loss for the period beginning after the closing on July 6,
2022.
The
relative fair value of the assets acquired and related deferred tax liability is as follows:
Schedule of Fair Value of the Assets Acquisition
| |
| | |
Land | |
$ | 226,000 | |
Building and affixed assets | |
| 2,648,000 | |
Machinery | |
| 158,000 | |
Inventory | |
| 32,000 | |
Intangibles | |
| 64,712 | |
Deferred tax liability | |
| (192,000 | ) |
| |
| | |
Total | |
$ | 2,936,712 | |
The
useful lives for the acquired assets is Building - 20 years; Machinery – 5 to 10 years; Intangibles – 5 years. The related
depreciation and amortization is being recorded on a straight-line basis.
|
X |
- DefinitionThe entire disclosure for asset acquisition.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3
+ Details
Name: |
us-gaap_AssetAcquisitionTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_BusinessCombinationAndAssetAcquisitionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Other Assets
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
|
Other Assets |
Note
6. Other Assets
Other
assets as of June 30, 2023 and December 31, 2022 are summarized as follows:
Schedule of Other Assets
| |
2023 | | |
2022 | |
Intangibles, net | |
| 60,993 | | |
| 62,480 | |
Deposits or advance payments on machinery, molds, components or technology (see Note 15) | |
| 517,377 | | |
| 336,466 | |
Other | |
| 12,370 | | |
| 12,370 | |
Other assets | |
$ | 590,740 | | |
$ | 411,316 | |
Intangibles
are related to the Asset Acquisition (see Note 5) and consist of an acquired workforce and permits. Amortization for the six months ended
June 30, 2023 and 2022 was 7,928 and $1,487 respectively.
|
Note
6. Other Assets
Other
assets as of December 31, 2022 and 2021 are summarized as follows:
Schedule of Other Assets
| |
December 31, | | |
December 31, | |
| |
2022 | | |
2021 | |
Acquisition (see Note 5) | |
$ | - | | |
$ | 472,701 | |
Intangibles, net | |
| 62,480 | | |
| - | |
Deposits or advance payments on machinery, molds and components (see Note 15) | |
| 336,466 | | |
| - | |
Other | |
| 12,370 | | |
| 57,162 | |
Other assets | |
$ | 411,316 | | |
$ | 529,863 | |
Intangibles
are related to the Asset Acquisition (see Note 5) and consist of an acquired workforce and permits. Amortization for the year ended December
31, 2022 was $6,882.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
+ Details
Name: |
us-gaap_OtherAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Note Purchase Agreement
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Note Purchase Agreement |
|
|
Note Purchase Agreement |
Note
7. Note Purchase Agreement
On
December 14, 2021, the Company entered into a Note Purchase Agreement (“NPA”) with three unrelated third-party purchasers
(“Purchasers”). The Purchasers provided financing to the Company in the form of bridge financing, aggregating principal of
$2,000,000 (the “Notes”). The principal under the Notes shall be payable on the earlier of (i) December 14, 2022, and (ii)
the date on which the Company consummates an initial public offering (“IPO”), herein referred to as the “Maturity Date”.
The Notes bore interest at 8% with interest payments due monthly. The Company and the Purchasers had entered into a Security Agreement
whereby the Notes were collateralized by substantially all the assets of the Company, both tangible and intangible both currently owned
with stated exclusions, as defined, and any future acquired with stated exclusions, as defined.
The
NPA provided for covenants that until all of the Notes have been converted, exchanged, redeemed or otherwise satisfied in accordance
with their terms, the Company shall not, and the Company shall not permit any of its subsidiaries without the prior written consent of
the Purchasers: a) incur or guarantee any new debt, b) issue any securities that would cause a breach or default under the NPA, c) incur
any liens other than permitted, d) redeem or repurchase shares, e) declare or pay any cash dividend or distribution, e) sell, lease or
dispose of assets other than in the ordinary course of business, or f) engage in different line of business.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
7. Note Purchase Agreement (continued)
As
additional consideration to the Purchasers for providing the financing, the Company also agreed to a) issue each Purchaser a number of
shares of the Company’s Common Stock equal to 50% of the original principal amount of each Purchaser’s Note (the “Contingent
Stock”) and b) issue each Purchaser a number of warrants, which would allow the Purchasers to purchase additional shares of the
Company’s Common Stock, equal to 50% of the original principal amount each Purchaser’s Note for a term of 5.0 years (the
“Contingent Warrants”).
For
both the Contingent Stock and the Contingent Warrants, the number of shares and warrants that each Purchaser will be issued was unknown
at the time of the NPA and was determined based on a formula of 50% of the original principal amount divided by a “Subsequent Offering
Price” based on the valuation in a future offering of Common stock or other equity interest in the Company (such offering referred
to as a “Consummated Offering”) during the period beginning on December 14, 2021 through and including the date the Company
consummates an initial public offering (“IPO”) (such period referred to as the “Subsequent Offering Period”).
In
accordance with ASC 480-10-25-14, a fixed monetary amount exists at inception for the total value of Contingent Stock that may be issued
to each Purchaser. The Contingent Stock is not considered outstanding at inception, as it will only be issued upon the consummation of
a Consummated Offering, and accordingly, is a conditional obligation. As such the fair market value (“FMV”) of the Contingent
Stock at inception was $677,000, which was recorded as debt discount. Similarly, a fixed monetary amount further exists at inception
for the total value of Contingent Warrants that may be issued to each Purchaser. Accordingly, a conditional obligation exists and as
such the FMV of Contingent Warrants at inception was $585,000, which was recorded as debt discount. The Company incurred $197,500 of
debt issuance costs associated with the NPA. The debt issuance costs were allocated between the Notes, Contingent Stock and Contingent
Warrants in a manner that was consistent with the allocation of the proceeds of the Notes. The portion of the debt issuance costs which
were allocated to the Contingent Stock and Contingent Warrants, which was $124,460, was expensed during the year ended December 31, 2021.
The debt issuance costs allocated to the Notes were recorded as a debt discount.
The
Contingent Stock and Contingent Warrant liabilities were measured at FMV on the date of issuance (based on the Black-Scholes valuation
model).
At
inception, the Notes were recorded at the net amount of approximately $665,000, after adjusting for debt discounts of approximately $1,335,000
relating to the debt issuance costs, Contingent Stock and Contingent Warrants. Management calculates the effective interest rate (“EIR”)
to consider the potential repayment at redemption date by reference to the face value amount after taking into account the stated 8%
interest rate. In 2022, through for the three months ended March 31, 2022, the Company recorded interest expense of $39,111 and accreted
interest of $206,417 The Company repaid the $2,000,000 in Notes with proceeds from the IPO that closed on April 19, 2022.
The
value of the Contingent Stock and Contingent Warrants was required to be re-measured at FMV at each reporting date, using either the
Black-Scholes valuation model or other valuation method, if deemed more appropriate, with recognition of the changes in fair value to
other income or expense in the consolidated statement of operations in accordance with ASC 480, Debt and Equity. For the three months
ended March 31, 2022, the Company recorded a $287,000 fair market (FMV) charge to reflect the increase in the Contingent Stock and Contingent
Warrants. On April 19, 2022, the Company issued 235,295 shares of Common Stock to settle the Contingent Stock liability, re-measured
the liability at its estimated FMV based on the stock’s trading price and reclassified $496,000 to Common Stock Par Value and Additional
Paid in Capital.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
7. Note Purchase Agreement (continued)
In
connection with the closing of the IPO, 235,295 warrants were issued to settle the Contingent Warrant liability (“Note Warrants”)
with an exercise price of $4.25. The terms of the Note Warrants continue to require classification as a liability under ASC 815 with
recognition of the changes in fair value to other income or expense in the consolidated statement of operations in accordance with ASC
480 Debt and Equity. (See Note 8 and 10).
|
Note
7. Note Purchase Agreement
On
December 14, 2021, the Company entered into a Note Purchase Agreement (“NPA”) with three unrelated third-party
purchasers (“Purchasers”). The Purchasers provided financing to the Company in the form of bridge financing, aggregating
principal of $2,000,000
(the “Notes”). The principal under the Notes shall be payable on the earlier of (i) December 14, 2022, and (ii) the date
on which the Company consummates an initial public offering (“IPO”), herein referred to as the “Maturity
Date”. The Notes bore interest at 8%
with interest payments due monthly. The Company and the Purchasers had entered into a Security Agreement whereby the Notes were
collateralized by substantially all the assets of the Company, both tangible and intangible both currently owned with stated
exclusions, as defined, and any future acquired with stated exclusions, as defined.
The
NPA provided for covenants that until all of the Notes have been converted, exchanged, redeemed or otherwise satisfied in accordance
with their terms, the Company shall not, and the Company shall not permit any of its subsidiaries without the prior written consent of
the Purchasers: a) incur or guarantee any new debt, b) issue any securities that would cause a breach or default under the NPA, c) incur
any liens other than permitted, d) redeem or repurchase shares, e) declare or pay any cash dividend or distribution, e) sell, lease or
dispose of assets other than in the ordinary course of business, or f) engage in different line of business.
As
additional consideration to the Purchasers for providing the financing, the Company also agreed to a) issue each Purchaser a number
of shares of the Company’s Common Stock equal to 50% of the original principal amount of each Purchaser’s Note (the
“Contingent Stock”) and b) issue each Purchaser a number of warrants, which would allow the Purchasers to purchase
additional shares of the Company’s Common Stock, equal to 50% of the original principal amount each Purchaser’s Note for
a term of 5.0 years (the “Contingent Warrants”).
For
both the Contingent Stock and the Contingent Warrants, the number of shares and warrants that each Purchaser will be issued was unknown
at the time of the NPA and was determined based on a formula of 50% of the original principal amount divided by a “Subsequent
Offering Price” based on the valuation in a future offering of Common stock or other equity interest in the Company (such offering
referred to as a “Consummated Offering”) during the period beginning on December 14, 2021 through and including the date
the Company consummates an initial public offering (“IPO”) (such period referred to as the “Subsequent Offering Period”).
In
accordance with ASC 480-10-25-14, a fixed monetary amount exists at inception for the total value of Contingent Stock that may be issued
to each Purchaser. The Contingent Stock is not considered outstanding at inception, as it will only be issued upon the consummation of
a Consummated Offering, and accordingly, is a conditional obligation. As such the fair market value (“FMV”) of the Contingent
Stock at inception was $677,000, which was recorded as debt discount. Similarly, a fixed monetary amount further exists at inception
for the total value of Contingent Warrants that may be issued to each Purchaser. Accordingly, a conditional obligation exists and as
such the FMV of Contingent Warrants at inception was $585,000, which was recorded as debt discount. The Company incurred $197,500
of debt issuance costs associated with the NPA. The debt issuance costs were allocated between the Notes, Contingent Stock and Contingent
Warrants in a manner that was consistent with the allocation of the proceeds of the Notes. The portion of the debt issuance costs which
were allocated to the Contingent Stock and Contingent Warrants, which was $124,460, was expensed during the year ended December 31, 2021.
The debt issuance costs allocated to the Notes were recorded as a debt discount.
The
Contingent Stock and Contingent Warrant liabilities were measured at FMV on the date of issuance (based on the Black-Scholes valuation
model).
At
inception, the Notes were recorded at the net amount of approximately $665,000,
after adjusting for debt discounts of approximately $1,335,000
relating to the debt issuance costs, Contingent Stock and Contingent Warrants. Management calculates the effective interest rate
(“EIR”) to consider the potential repayment at redemption date by reference to the face value amount after taking into
account the stated 8%
interest rate. In 2022, through the repayment date, the Company recorded interest expense of $39,111
(2021 - $nil)
and accreted interest of $1,299,895
(2021 - $nil)
and repaid the $2,000,000
in Notes with proceeds from the IPO that closed on April 19, 2022.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
7. Note Purchase Agreement (continued)
The
value of the Contingent Stock and Contingent Warrants is required to be re-measured at FMV at each reporting date, using either the
Black-Scholes valuation model or other valuation method, if deemed more appropriate, with recognition of the changes in fair value
to other income or expense in the consolidated statement of operations in accordance with ASC 480, Debt and Equity. On April 19,
2022, the Company issued 235,295
shares of Common Stock to settle the Contingent Stock liability, re-measured the liability at its estimated FMV based on the
stock’s trading price and reclassified $496,000
to Common Stock Par Value and Additional Paid in Capital.
In
connection with the closing of the IPO, 235,295
warrants were issued to settle the Contingent Warrant liability (“Note Warrants”) with an exercise price of $4.25. The terms of the Note Warrants continue to require classification as a liability under ASC 815 with recognition of the
changes in fair value to other income or expense in the consolidated statement of operations in accordance with ASC 480 Debt and
Equity. During the year ended December 31, 2022, the Company recorded a FMV income adjustment of $554,412
to reduce the Warrant liability from $585,000
at December 31, 2021 to $30,588
at December 31, 2022. (See Notes 8 and 10)
|
X |
- References
+ Details
Name: |
STSS_DisclosureNotePurchaseAgreementAbstract |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNote Purchase Agreement [Text Block]
+ References
+ Details
Name: |
STSS_NotePurchaseAgreementTextBlock |
Namespace Prefix: |
STSS_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Stockholders’ Equity
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Equity [Abstract] |
|
|
Stockholders’ Equity |
Note
8. Stockholders’ Equity
Capital
Structure
On
December 11, 2017, the Company was incorporated in Wyoming with 20,000,000 shares of common stock authorized with a $0.0001 par value.
Effective, April 18, 2019, the Company’s authorized common stock was increased to 50,000,000 shares of common stock. The articles
of incorporation also authorized 10,000 preferred shares with a $0.001 par value.
Effective
March 22, 2022, the Company completed a plan and agreement of merger with Sharps Technology, Inc., a Nevada corporation (“Sharps
Nevada”). Pursuant to the merger agreement, (i) the Company merged with and into Sharps Nevada, (ii) each 3.5 shares of common
stock of the Company were converted into one share of common stock of Sharps Nevada and (iii) the articles of incorporation and bylaws
of Sharps Nevada, became the articles of incorporation and bylaws of the surviving corporation. The Company’s authorized common
stock and preferred stock increased from 50,000,000 to 100,000,000 and 10,000 to 1,000,000 shares, respectively. The par value of preferred
stock decreased from $0.001 to $0.0001 per share.
Common
Stock
On
February 3, 2023, the Company completed a securities purchase agreement (“Offering”) with institutional investors and received
net proceeds from the Offering were approximately $3.2 million, net of $600,000 in fees relating to the placement agent and other offering
expenses. The Offering was priced at the market under Nasdaq rules. In connection with the Offering, the Company issued 2,248,521 units
at a purchase price of $1.69 per unit. Each unit consists of one share of common stock and one non-tradable warrant (“Offering
Warrants”) exercisable for one share of common stock at a price of $1.56. The Offering Warrants have a term of five years from
the issuance date. On February 13, 2023, the Company filed an S-1 (Resale) Registration Statement in connection with the Offering and
on April 14, 2023, an Amendment to the S-1 was filed and went effective. The net proceeds, after reflecting par value, has been recorded
in Additional Paid in Capital of $2.8 million and with respect to the Warrants as a liability under ASC 815 of $455,326. (See Notes 8
and 10)
On
April 13, 2022, the Company’s initial public offering (“IPO”) was declared effective by the SEC pursuant to which the
Company issued and sold an aggregate of 3,750,000 units (“Units”), each consisting of one share of common stock and two warrants,
to purchase one share of common stock for each whole warrant, with an initial exercise price of $4.25 per share, adjusted to $1.56 at
February 3, 2023 based on the warrant terms, and a term of five years. In addition, the Company granted Aegis Capital Corp., as underwriter
a 45-day over-allotment option to purchase up to 15% of the number of shares included in the units sold in the offering, and/or additional
warrants equal to 15% of the number of Warrants included in the units sold in the offering, in each case solely to cover over-allotments,
which the Aegis Capital Corp. partially exercised with respect to 1,125,000 warrants on April 19, 2022.
The
Company’s common stock and warrants began trading on the Nasdaq Capital Market or Nasdaq on April 14, 2022. The net proceeds from
the IPO, prior to payments of certain listing and professional fees were approximately $14.2 million. The net proceeds, after reflecting
par value, has been recorded in Additional Paid in Capital of $9.0 million and with respect to the Warrants as a liability under ASC
815 of $5.2M. (See Note 10)
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
8. Stockholders’ Equity (continued)
During
the period April 1, 2022 through December 31, 2022, the Company issued 235,000 shares of common stock at the trading stock price in connection
with services provided to the Company and recorded a charge of $290,551, In addition, the Company issued 235,295 common shares relating
to the Note Purchase agreement. (See Note 7)
Warrants
|
a) |
In
connection with an advisory services arrangement entered into in April 2023, the Company issued 135,000 warrants during the three
months ended June 30, 2023 at an exercise price of $1.56. The warrants have a three-year term and were fully vested on issuance.
The FMV of the warrants was $19,836 computed using the Black Sholes valuation model with the following assumptions: a) volatility
of 37.45%, three-year term, risk free interest rate 3.58% and 0% dividend rate. |
|
|
|
|
(b) |
In
connection with the Offering in February 2023, the Company issued 2,248,521 non-trading warrants Offering Warrants as a component
of the Unit as noted in Common Stock above. The Offering Warrants were recorded at the FMV, computed using the Black Sholes valuation
method with the following assumptions: volatility of 41.24%, five-year term, risk free interest rate 3.71% and 0% dividend rate.
The Offering Warrant’s liability requires remeasurement at each reporting period. The Offering Warrants are classified as a
liability based on ASC 815. At the issuance date the liability was $455,326 and at June 30, 2023 the liability was $272,746. During
the three and six months ended June 30, 2023, the Company recorded a FMV gain (loss) adjustment of $1,505 and $182,580. (See Note
10). |
|
|
|
|
(c) |
In
connection with the IPO in April 2022, the Company issued 7,500,000 warrants (Trading Warrants) as a component of the Units and 1,125,000
warrants to the underwriter (Overallotment Warrants), as noted in Common Stock above. The Trading and Overallotment Warrants were
recorded at the FMV, being the trading price of the warrants, on the IPO effective date and the Warrants are classified as a Liability
based on ASC 815. The Warrant liability requires remeasurement at each reporting period. At the IPO, the liability was $5,778,750
and at December 31, 2022 the liability was $1,121,250. During the three and six months ended June 30, 2023, the Company recorded
an FMV loss adjustment of $86,250. During the three and six months ended June 30, 2022, the Company recorded a FMV gain adjustment
of $3,378,412. (See Note 10). |
|
|
|
|
(d) |
The
Company has issued 235,295 Warrants (“Note Warrants”) to the Purchasers of the Notes on April 19, 2022. The Note Warrants
have an exercise price of $4.25 and a term of five years. At the issuance date, the liability was $157,647 and through the year ended
December 31, 2022, the Company recorded a FMV gain of $127,059. During the three and six months ended June 30, 2023, the Company
recorded a FMV loss adjustment of $2,353 and the warrant liability was $32,941 at June 30, 2023. During the three and six months
ended June 30, 2022, the Company recorded a FMV gain adjustment of $520,000. (See Note 8 and 10).
|
|
|
|
|
(e) |
The
underwriter received 187,500 warrants in connection with the IPO for a nominal cost of $11,250. The Warrants have an exercise price
of $5.32 and are exercisable after October 9, 2022. The FMV at the date of issuance was $228,750 computed using the Black Sholes
valuation model with the following assumptions: a) volatility of 93.47%, five-year term, risk free interest rate 2.77% and 0% dividend
rate. The estimated FMV was classified as additional issuance costs. |
|
Note
8. Stockholders’ Equity
Capital
Structure
On
December 11, 2017, the Company was incorporated in Wyoming with 20,000,000 shares of common stock authorized with a $0.0001 par value.
Effective, April 18, 2019, the Company’s authorized common stock was increased to 50,000,000 shares of common stock. The articles
of incorporation also authorized 10,000 preferred shares with a $0.001 par value.
Effective
March 22, 2022, the Company completed a plan and agreement of merger with Sharps Technology, Inc., a Nevada corporation (“Sharps
Nevada”). Pursuant to the merger agreement, (i) the Company merged with and into Sharps Nevada, (ii) each 3.5 shares of common
stock of the Company were converted into one share of common stock of Sharps Nevada and (iii) the articles of incorporation and bylaws
of Sharps Nevada, became the articles of incorporation and bylaws of the surviving corporation. The Company’s authorized common
stock and preferred stock increased from 50,000,000 to 100,000,000 and 10,000 to 1,000,000 shares, respectively. The par value of preferred
stock decreased from $0.001 to $0.0001 per share.
Common
Stock
On
April 13, 2022, the Company’s initial public offering (“IPO”) was declared effective by the SEC pursuant to which the
Company issued and sold an aggregate of 3,750,000 units (“Units”), each consisting of one share of common stock and two warrants,
to purchase one share of common stock for each whole warrant, with an initial exercise price of $4.25 per share and a term of five years.
In addition, the Company granted Aegis Capital Corp., as underwriter a 45-day over-allotment option to purchase up to 15% of the number
of shares included in the units sold in the offering, and/or additional warrants equal to 15% of the number of Warrants included in the
units sold in the offering, in each case solely to cover over-allotments, which the Aegis Capital Corp. partially exercised with respect
to 1,125,000 warrants on April 19, 2022.
The
Company’s common stock and warrants began trading on the Nasdaq Capital Market or Nasdaq on April 14, 2022. The net proceeds
from the IPO, prior to payments of certain listing and professional fees were approximately $14.2
million. The net proceeds, after reflecting par value, has been recorded in Additional Paid in Capital of $9.0 million and with
respect to the Warrants as a liability under ASC 815 of $5.2M. (See Note 10)
During
the year ended December 31, 2022, the Company issued 235,000 shares of common stock at the trading stock price in connection with services
provided to the Company and recorded a charge of $290,551, In addition, the Company issued 235,295 common shares relating to the Note
Purchase agreement. (See Note 7)
During
2021, the Company completed stock subscriptions through a private placement for 487,204 shares of common stock at $7.00 per share. The
Company received cash proceeds of $3,377,929 and had a subscription receivable of $32,500 which was received in January 2022. In addition,
the Company issued 71,429 shares with an estimated fair value of $500,000 to a vendor for engineering and design services provided for
equipment and for partial payments for equipment begin manufactured (See Note 4), 28,571 shares related to an acquisition (See Note 5)
and 2,857 shares for services with an estimated fair value of $20,000.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
8. Stockholders’ Equity (continued)
Warrants
|
a) |
In
connection with the IPO in April 2022, the Company issued 7,500,000
warrants (Trading Warrants) as a component of
the Units and 1,125,000
warrants to the underwriter (Overallotment Warrants),
as noted in Common Stock above. The Trading and Overallotment Warrants were recorded at the FMV, being the trading price of the warrants,
on the IPO effective date and the Warrants are classified as a Liability based on ASC 815. The Warrant liability requires remeasurement
at each reporting period. At the IPO, the liability was $5,778,750
and at December 31, 2022 the liability was $1,121,250.
During year ended December 31, 2022, the Company recorded a FMV gain adjustment of $4,657,500,
(See Note 10). |
|
|
|
|
b) |
The Company has issued
235,295 Warrants (“Note Warrants”) to the Purchasers of the Notes on April 19, 2022. The Note Warrants have an exercise
price of $4.25 and a term of five years. At the issuance date, the liability was $157,647 During the year ended December 31, 2022,
the Company recorded a FMV gain of 127,058. (See Note 10) |
|
|
|
|
c) |
The underwriter received
187,500 warrants in connection with the IPO for a nominal cost of $11,250. The Warrants have an exercise price of $5.32 and are exercisable
after October 9, 2022. The FMV at the date of issuance was $228,750 computed using the Black Sholes valuation model with the following
assumptions: a) volatility of 93.47%, five-year term, risk free interest rate 2.77% and 0% dividend rate. The estimated FMV was classified
as additional issuance costs. |
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Preferred Stock
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Equity [Abstract] |
|
|
Preferred Stock |
Note
9. Preferred Stock
In
February 2018, the Company Board of Directors issued one share of Series A Preferred Stock to Alan Blackman, the Company’s co-founder
and Director. The Series A Preferred Stock entitles the holder to vote on any matters related to the election of directors and was reduced
from 50.1% at December 31, 2021 to 29.5%, effective with the IPO. The Series A Preferred Stock has no right to dividends, or distributions
in the event of a liquidation and is not convertible into common stock. In the event the Company is sold during the two-year period following
completion of IPO at a price per share of more than 500% of the initial offering price per Unit in the IPO, the Series A Preferred Stock,
as in effect upon completion of the IPO, will entitle the holder to 10% of the total purchase price. (See Note 15)
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
|
Note
9. Preferred Stock
In
February 2018, the Company Board of Directors issued one share of Series A Preferred Stock to Alan Blackman, the Company’s co-founder
and Director. The Series A Preferred Stock entitles the holder to vote on any matters related to the election of directors and was reduced
from 50.1% at December 31, 2021 to 29.5%, effective with the IPO. The Series A Preferred Stock has no right to dividends, or distributions
in the event of a liquidation and is not convertible into common stock. In the event the Company is sold during the two-year period following
completion of IPO at a price per share of more than 500% of the initial offering price per Unit in the IPO, the Series A Preferred Stock,
as in effect upon completion of the IPO, will entitle the holder to 10% of the total purchase price.
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
+ Details
Name: |
us-gaap_PreferredStockTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Warrant Liability
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Warrant Liability |
|
|
Warrant Liability |
Note
10. Warrant Liability
The
Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented as a Warrant liability in the accompanying
condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with
changes in fair value presented within the condensed consolidated statements of operations. (See Notes 7 and 8)
The
Warrant liability at June 30, 2023 was as follows:
Schedule
of Warrant Liability
| |
| | |
Trading and Overallotment Warrants | |
$ | 1,207,500 | |
Note Warrants | |
| 32,941 | |
Offering Warrants | |
| 272,746 | |
Total | |
$ | 1,513,187 | |
Warrant liability | |
$ | 1,513,187 | |
The
Warrants outstanding at June 30, 2023 are as follows:
Schedule
of Warrant Outstanding
| |
| | |
Trading and Overallotment Warrants | |
| 8,812,500 | |
Note warrants | |
| 235,295 | |
Offering Warrants | |
| 2,248,521 | |
Warrants issued for services arrangement | |
| 135,000 | |
Total | |
| 11,431,316 | |
Warrant outstanding | |
| 11,431,316 | |
The
following table presents the changes in the Warrant liability of the Level 1 warrants issued on April 14, 2022, the effective date of
the IPO measured at fair value from December 31, 2022 and the changes in the Offering Warrants liability of the Level 2 warrants issued
on February 6, 2023 through June 30, 2023.
Schedule
of Changes in the Warrant Liability
| |
Total | |
| |
| |
FMV of Note Warrants | |
$ | 30,588 | |
FMV of Trading and Overallotment Warrants | |
| 1,121,250 | |
FMV of Offering Warrants, at issuance | |
| 455,326 | |
Change in fair value of warrant liability for the six months ended June 30,2023 | |
| (93,977 | ) |
| |
| | |
Fair Value at June 30, 2023 | |
$ | 1,513,187 | |
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
|
Note
10. Warrant Liability
The
Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented as a Warrant liability in the accompanying
consolidated balance sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in
fair value presented within the consolidated statement of operations and comprehensive loss. (See Notes 7 and 8)
The
Warrant liability at December 31, 2022 was as follows:
Schedule
of Warrant Liability
| |
| | |
Note Warrants | |
$ | 30,588 | |
Trading and Overallotment Warrants | |
| 1,121,250 | |
Total | |
$ | 1,151,838 | |
Warrant liability | |
$ | 1,151,838 | |
The
Warrants outstanding at December 31, 2022 were as follows:
Schedule
of Warrant Outstanding
| |
| | |
Note warrants | |
| 235,295 | |
Trading and Overallotment Warrants | |
| 8,812,500 | |
Total | |
| 9,047,795 | |
Warrant outstanding | |
| 9,047,795 | |
The
following table presents the changes in the Warrant liability of the Level 1 warrants issued on April 14, 2022, the effective date of
the IPO measured at fair value:
Schedule
of Changes in the Warrant Liability
| |
Total | |
| |
| |
FMV of Note Warrants, at issuance | |
$ | 157,647 | |
| |
| | |
FMV of Trading and Overallotment Warrants, at issuance | |
| 5,778,750 | |
| |
| | |
Change in fair value of warrant liability, issuance through December 31, 2022 | |
| (4,784,559 | ) |
| |
| | |
Fair Value at December 31, 2022 | |
$ | 1,151,838 | |
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
|
X |
- References
+ Details
Name: |
STSS_DisclosureWarrantLiabilityAbstract |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWarrant Liability [Text Block]
+ References
+ Details
Name: |
STSS_WarrantLiabilityTextBlock |
Namespace Prefix: |
STSS_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Stock Options
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Share-Based Payment Arrangement [Abstract] |
|
|
Stock Options |
Note
11. Stock Options
A
summary of options granted and outstanding is presented below.
Schedule
of Stock Options Granted and Outstanding
| |
June 30, 2023 | |
| |
Options | | |
Weighted Average Exercise
Price | |
Outstanding at Beginning of year | |
| 1,358,122 | | |
$ | 4.37 | |
Granted | |
| 1,025,000 | | |
| 1.37 | |
Forfeited | |
| (25,714 | ) | |
| 1.75 | |
Outstanding at end of period | |
| 2,357,408 | | |
$ | 3.08 | |
| |
| | | |
| | |
Exercisable at end of period | |
| 1,665,378 | | |
$ | 3.63 | |
During
the six months ended June 30, 2023 , the Company granted five-year options (the “Options”) to purchase a total of 975,000
shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) to its directors, executive
officers, employees and consultants pursuant to the Company’s. 2022 and 2023 Equity Incentive Plans. The Options are exercisable
at $1.37 per share which was the closing price on January 25, 2023. Of the Options granted, Options to purchase an aggregate of 495,000
shares of Common Stock were issued to executive officers Options to purchase an aggregate of 455,000 shares of Common Stock were issued
to directors and Options to purchase an aggregate of 25,000 shares of Common Stock to employees and a consultant. In connection with
an employment agreement the Company granted five-year options to purchase 50,000 shares of common stock in February 2023 under the 2022
Equity Incentive Plan. (See Note 15).
On
January 25, 2023, the Company’s Board of Directors adopted the 2023 Equity Incentive Plan (the “2023 Plan”). The 2023
Plan provides for the issuance of up to 1,400,000 options and/or shares of restricted stock to be available for issuance to officers,
directors, employees and consultants. The 2023 Plan is subject to shareholder approval at the annual meeting.
As
of June 30, 2023, there was $725,355 in unrecognized stock-based compensation related to unvested stock options, which is expected to
be recognized over a weighted average period of forty months.
The
following table summarizes information about options outstanding at June 30, 2023:
Schedule
of Information about Options Outstanding
Exercise
Prices |
|
|
Shares
Outstanding |
|
|
Weighted
Average Remaining Contractual Life |
|
|
Shares
Exercisable |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1.21 |
|
|
|
307,500 |
|
|
|
4.42 |
|
|
|
233,719 |
|
$ |
1.30 |
|
|
|
50,000 |
|
|
|
4.71 |
|
|
|
18,750 |
|
$ |
1.37 |
|
|
|
975,000 |
|
|
|
4.67 |
|
|
|
437,032 |
|
$ |
1.39 |
|
|
|
10,000 |
|
|
|
4.17 |
|
|
|
10,000 |
|
$ |
1.75 |
|
|
|
42,857 |
|
|
|
2.75 |
|
|
|
42,857 |
|
$ |
2.80 |
|
|
|
141,429 |
|
|
|
1.00 |
|
|
|
141,429 |
|
$ |
4.25 |
|
|
|
50,000 |
|
|
|
4.00 |
|
|
|
50,000 |
|
$ |
4.38 |
|
|
|
244,286 |
|
|
|
1.75 |
|
|
|
244,286 |
|
$ |
7.00 |
|
|
|
536,336 |
|
|
|
2.50 |
|
|
|
477,305 |
|
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
11. Stock Options (continued)
For
the three and six months ended June 30, 2023, the Company recognized stock-based compensation expense of $234,610 and $617,711
respectively, recorded in general and administrative. For the three and six months ended June 30, 2022, the recognized stock-based compensation
expense of $365,606 and $589,553 respectively, of which $39,870 and $50,182 was recorded in general and administrative and research and
development expenses, respectively. Further, for the three months ended March 31, 2022, the Company recorded stock-based charges relating
to consideration for purchase of machinery of $63,512 (see Note 4) and $40,901 relating to an Acquisition (see Note 5).
The
fair value of stock option awards accounted for under ASC 718 was estimated at the date of grant using a Black-Scholes option-pricing
model with the following assumptions for the options granted during the six months ended June 30, 2023.
Schedule
of Fair Value of Stock Option Awards
Expected term (years) | |
2.88 to 3.25 | |
Expected volatility | |
75.40% to 89.93 | % |
Risk-free interest rate | |
3.71% to 4.27 | % |
Dividend rate | |
| 0 | % |
|
Note
11. Stock Options
A
summary of options granted and outstanding is presented below.
Schedule
of Stock Options Granted and Outstanding
| |
2022 | | |
2021 | |
| |
Options | | |
Weighted Average Exercise Price | | |
Options | | |
Weighted Average Exercise Price | |
Outstanding at Beginning of year | |
| 1,137,479 | | |
$ | 5.18 | | |
| 792,857 | | |
$ | 3.64 | |
Granted | |
| 367,500 | | |
| 1.63 | | |
| 511,764 | | |
| 7.00 | |
Cancelled | |
| (3,571 | ) | |
| (4.38 | ) | |
| (21,875 | ) | |
| (4.38 | ) |
Forfeited | |
| (143,286 | ) | |
$ | (3.77 | ) | |
| (145,157 | ) | |
$ | (2.57 | ) |
| |
| | | |
| | | |
| | | |
| | |
Outstanding at end of year | |
| 1,358,122 | | |
$ | 4.37 | | |
| 1,137,479 | | |
$ | 5.18 | |
| |
| | | |
| | | |
| | | |
| | |
Exercisable at end of year | |
| 1,132,861 | | |
$ | 4.59 | | |
| 825,847 | | |
$ | 5.38 | |
During
the years ended December 31, 2022 and 2021, the estimated weighted-average grant-date fair value of options granted was $1.63 per share
and $4.55 per share, respectively. As of December 31, 2022 and 2021, there was $475,097 and $1,260,990, respectively, of unrecognized
stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period sixteen
months as of December 31, 2022.
The
following table summarizes information about options outstanding at December 31, 2022:
Schedule
of Information About Options Outstanding
Exercise Prices | | |
Options Outstanding | | |
Aggregate Intrinsic Value | | |
Weighted Average Remaining Contractual Life | | |
Options Exercisable | | |
Aggregate Intrinsic Value on Exercisable Shares | |
| | |
| | |
| | |
| | |
| | |
| |
$ | 1.21 | | |
| 307,500 | | |
| - | | |
| 4.42 | | |
| 168,551 | | |
$ | - | |
$ | 1.39 | | |
| 10,000 | | |
| - | | |
| 4.67 | | |
| 10,000 | | |
$ | - | |
$ | 1.75 | | |
| 68,571 | | |
| - | | |
| .25 | | |
| 68,571 | | |
$ | - | |
$ | 2.80 | | |
| 141,429 | | |
| - | | |
| .50 | | |
| 141,429 | | |
$ | - | |
$ | 4.25 | | |
| 50,000 | | |
| - | | |
| 4.50 | | |
| 37,500 | | |
$ | - | |
$ | 4.38 | | |
| 244,286 | | |
| - | | |
| 2.25 | | |
| 244,286 | | |
$ | - | |
$ | 7.00 | | |
| 536,336 | | |
| - | | |
| 3.00 | | |
| 462,524 | | |
$ | - | |
The
aggregate intrinsic values of stock options outstanding and exercised December 31, 2022 were calculated as the difference between the
exercise price of the options and the fair value of the Company’s common stock on December 31, 2022.
In
2022 and 2021, the Company recognized stock-based compensation expense of $1,012,592, of which $915,796 and $96,795 was recorded in general
and administrative and research and development expenses, respectively and $1,195,819, of which $1,091,227 and $105,592 was recorded
in general and administrative and research and development expenses, respectively. Further, in 2022, the Company recorded stock-based
charges of $63,612 relating to purchase of machinery (See Note 4) and $60,435 relating to an Acquisition. (See Note 5) and in 2021, the
Company recorded stock-based charges relating to consideration for purchase of machinery of $253,337 (see Note 4) and relating to an
Acquisition for $122,701 (see Note 5).
The
fair value of stock option awards accounted for under ASC 718 was estimated at the date of grant using a Black-Scholes option-pricing
model with the following assumptions:
Schedule
of Fair Value of Stock Option Awards
|
|
Year
Ended
December 31, 2022 |
|
|
Year
Ended
December 31, 2021 |
|
Expected
term (years) |
|
|
2.50
to 3.00 |
|
|
|
2.50
to 3.25 |
|
Expected
volatility |
|
|
100.81%
to 110.74 |
% |
|
|
97.26%
to 116.06 |
%
|
Risk-free
interest rate |
|
|
2.90%
to 3.47 |
% |
|
|
0.18%
- .81 |
% |
Dividend
rate |
|
|
0 |
% |
|
|
0 |
% |
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
|
X |
- DefinitionThe entire disclosure for share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Income Taxes
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Income Tax Disclosure [Abstract] |
|
|
Income Taxes |
Note
12. Income Taxes
At
the end of each interim reporting period, the Company estimates its effective tax rate expected to be applied for the full year. This
estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods.
Accordingly, the Company’s effective tax rate for the three and six months ended , June 30, 2023 was 0%, compared to the
effective tax rate of 0% for the three and six months ended June 30, 2022. The Company’s effective tax rates for both periods were
affected primarily by a full valuation allowance on domestic net deferred tax assets.
|
Note
12. Income Taxes
A
reconciliation of the Federal statutory rate (28%) to the total effective rate applicable to income (loss) is as follows:
Schedule
of Reconciliation of Federal Statutory Rate to Total Effective Rate
| |
| | |
| |
| |
Year Ended | | |
Year Ended | |
| |
December 31, 2022 | | |
December 31,
2021 | |
| |
| | |
| |
Expected benefit at statutory federal tax rate | |
$ | (974,329 | ) | |
$ | (979,527 | ) |
Permanent differences – net | |
| (859,515 | ) | |
| - | |
State and local taxes, net of federal tax benefit | |
| (265,607 | ) | |
| (311,373 | ) |
Other | |
| (21,965 | ) | |
| (57,563 | ) |
Change in valuation allowance | |
| 2,121,416 | | |
| 1,348,463 | |
Income tax Expense (Benefit)
Total | |
$ | - | | |
$ | - | |
The
components of the Company’s deferred tax assets (liabilities) are as follows:
Schedule
of Components of Deferred tax Assets
| |
Year Ended December 31, 2022 | | |
Year Ended December 31, 2021 | |
Deferred tax assets (liabilities): | |
| | | |
| | |
Fixed assets | |
$ | (268,594 | ) | |
$ | 3,837 | |
Interest | |
| 62,310 | | |
| 46,361 | |
Research and development expenses | |
| 454,942 | | |
| - | |
Stock-based compensation | |
| 917,351 | | |
| 637,112 | |
Net operating losses - federal | |
| 2,898,411 | | |
| 1,687,053 | |
Net operating losses – state and local | |
| 921,350 | | |
| 536,282 | |
Net operating losses - foreign | |
| 37,686 | | |
| - | |
Research credit | |
| 28,985 | | |
| 28,985 | |
Deferred tax assets gross | |
| 5,052,441 | | |
| 2,939,630 | |
Less valuation allowance | |
| (5,244,441 | ) | |
| (2,939,630 | ) |
Net deferred tax liability | |
$ | (192,000 | ) | |
$ | - | |
The
authoritative guidance, requires the asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities
are determined based on the difference between the financial statement and tax bases of assets and liabilities. Deferred tax assets or
liabilities at the end of each period are determined using the tax rate expected to be in effect when taxes are actually paid or recovered.
The
guidance also requires that a valuation allowance be established when it is more likely than not that all or a portion of a deferred
tax asset will not be realized. A review of all available positive and negative evidence needs to be considered, including a
company’s current and past performance, the market environment in which the company operates, length of carryback and
carryforward periods and existing contracts that will result in future profits. After reviewing all the evidence, the company has
recorded a full valuation allowance.
|
X |
- DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//740/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2
+ Details
Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Related Party Transactions and Balances
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Related Party Transactions [Abstract] |
|
|
Related Party Transactions and Balances |
Note
13. Related Party Transactions and Balances
As
of June 30, 2023 and December 31, 2022, accounts payable and accrued liabilities include $31,000 and $105,667, respectively, payable
to officers and directors of the Company. The amounts are unsecured, non-interest bearing and are due on demand (See Note 15).
|
Note
13. Related Party Transactions and Balances
As
of December 31, 2022 and 2021, accounts payable and accrued liabilities include $105,667
and $59,375,
respectively, payable to officers and directors of the Company. The amounts are unsecured, non-interest bearing and are due on
demand (See Note 15).
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEAR ENDED DECEMBER 31, 2022 AND 2021
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//850/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Fair Value Measurements
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Fair Value Disclosures [Abstract] |
|
|
Fair Value Measurements |
Note
14. Fair Value Measurements
The
Company’s financial instruments include cash, accounts payable, notes payable, contingent stock and warrant liability and warrant
liability. Cash, contingent stock liability, contingent warrant liability and warrant liability are measured at fair value. Accounts
payable and notes payable are measured at amortized cost and approximates fair value due to their short duration and market rate for
similar instruments, respectively.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
14. Fair Value Measurements (continued)
As
of June 30, 2023, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the Company’s
consolidated balance sheet:
Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis
|
|
Level
1 |
|
|
Level
2 |
|
|
Level
3 |
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash |
|
$ |
2,924,019 |
|
|
|
- |
|
|
|
- |
|
|
$ |
2,924,019 |
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
Total
assets measured at fair value |
|
$ |
2,924,019 |
|
|
|
- |
|
|
|
|
|
|
$ |
2,924,019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant
liability |
|
$ |
1,240,441 |
|
|
|
272,276 |
|
|
|
- |
|
|
$ |
1,513,187 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
liabilities measured at fair value |
|
$ |
1,240,441 |
|
|
|
272,276 |
|
|
|
- |
|
|
$ |
1,513,187 |
|
|
Note
14. Fair Value Measurements
The
Company’s financial instruments include cash, accounts payable, notes payable, contingent stock and warrant liability and warrant
liability. Cash, contingent stock liability, contingent warrant liability and warrant liability are measured at fair value. Accounts
payable and notes payable are measured at amortized cost and approximates fair value due to their short duration and market rate for
similar instruments, respectively.
As
of December 31, 2022, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the
Company’s consolidated balance sheet:
Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
Fair Value Measurements Using | | |
| |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
| | |
| | |
| | |
| |
Assets | |
| | | |
| | | |
| | | |
| | |
Cash | |
$ | 4,170,897 | | |
| - | | |
| - | | |
$ | 4,170,897 | |
| |
| - | | |
| - | | |
| - | | |
| | |
Total assets measured at fair value | |
$ | 4,170,897 | | |
| - | | |
| | | |
$ | 4,170,897 | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Warrant liability | |
$ | 1,151,838 | | |
| - | | |
| - | | |
$ | 1,151,838 | |
| |
| | | |
| | | |
| | | |
| | |
Total liabilities measured at fair value | |
$ | 1,151,838 | | |
| - | | |
| - | | |
$ | 1,151,838 | |
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//820/tableOfContent
+ Details
Name: |
us-gaap_FairValueMeasurementInputsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Commitments and Contingencies
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Commitments and Contingencies Disclosure [Abstract] |
|
|
Commitments and Contingencies |
Note
15. Commitments and Contingencies
Fixed
Assets and Other
At
June 30, 2023, the Company has outstanding orders to purchase equipment, mold and component parts for research and development of $490,651
of which advance payments of $280,349 have been made and recorded in Other Assets (See Note 6).
Contingencies
At
each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably
estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company is currently not
involved in any material litigation or other loss contingencies.
Royalty
Agreement
In
connection with the purchase of certain intellectual property in July 2017, Barry Berler and Alan Blackman entered into a royalty agreement
which provides that Barry Berler will be entitled to a royalty of four percent (4%) of net sales derived from the use, sale, lease, rent
and export of products related to the intellectual property. The royalty continues until the patent expires or is no longer used in the
Company’s product. The royalty agreement was assumed by the Company in December 2017.
In
September 2018, the Royalty Agreement was amended to reduce the royalty to 2% and further provided for a single payment of $500,000 to
Barry Berler within three years in return for cancellation of all further royalty obligations of the Company. In May 2019, the Royalty
Agreement was further amended to change the payment date to on or before May 31, 2021 or during the term of the amended Royalty Agreement
should the Company be acquired or a controlling interest be acquired. The Company has not made the aforementioned payment or incur any
change in control as such the 2% royalty remains in place.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
15. Commitments and Contingencies (continued)
Employment
Agreements and Other
On
August 1, 2022, the Company cancelled the consulting agreement with Alan Blackman, Co- Chairman and Chief Operating Officer and
entered into an Employment Agreement which provides for annual salary of $256,000,
which provides for increases, and provisions compensation adjustments, expense and tax differential reimbursements, benefits and
bonuses. As of September 1, 2022, the annual salary is $320,000.
At June 30, 2022, the Company approved and accrued a $250,000
bonus to Mr. Blackman for services provided in 2022, of which $65,000
was paid subsequent to December 31, 2022. The Company terminated Mr. Blackman’s Employment Agreement effective May 1, 2023.
Mr. Blackman continued to serve as the Co-Chairman and a member of the Board of Directors. The parties were having preliminary
settlement discussions. Subsequent to June 30, 2023, the Company and Mr. Blackman entered into a separation agreement whereby, Mr.
Blackman will be paid severance payments of approximately $346,000,
which was recorded as an expense and an accrued expense as of June 30, 2023, over thirteen months, continue his medical benefits for
such period with a cost of approximately $29,000
which has been accrued at June 30, 2023. Further, all unvested options were fully vested. In connection with the separation
agreement, Mr. Blackman no longer serves as Co-Chairman or Board member and has agreed to vote his Series A Preferred Stock in favor
of the election, reelection, and/or designation of each individual nominated to serve as a director on the Board of Director as
shall be identified in an applicable proxy statement filed by the Company for such election of directors. Once the payments due Mr.
Blackman are fully paid, the Series A Preferred Stock shall be deemed immediately cancelled and forfeited and without further
consideration. The Series A Preferred shall at such time be returned to the status of an authorized but unissued share of preferred
stock of the Company.
On
September 30, 2022, the Company entered into a formal employment agreement, effective on such date and will continue until terminated
by either party, subject to the terms of the agreement, with Andrew R. Crescenzo who has been serving as the Company’s Chief Financial
Officer on a contract services basis for the last three years. The agreement provided for annual compensation of $225,000 and plus a
one-time $18,750 incentive payment upon the commencement of the agreement. During the course of the term, Mr. Crescenzo will be eligible
for (i) performance bonuses to be granted at the discretion of the Company’s Compensation Committee and (ii) to participate in
the Company’s 2022 Equity Incentive Plan. The agreement contains customary employment terms and conditions.
In
October 2022, the Company entered into a service agreement (“Service Agreement”) with an unrelated third-party for marketing
and investor relations services. The Service Agreement, which has a term of one year, has various deliverables and provides payments
to the third party as follows; a) an initial fee of $90,000, b) monthly fees through the term of $12,500, c) 200,000 shares of restricted
common stock and d) $300,000 specifically related to digital marketing activities. As stated in Note 8, the 200,000 shares of restricted
common stock were valued at $230,000, representative of the trading price on the issuance.
On
February 09, 2023, the Company, appointed Justin Page,
as Vice President of Technical Operations with a start date of February 15, 2023. The agreement
provides for annual compensation of $235,000 and options to purchase 50,000 shares of common stock at the exercise price of $1.30, the
closing price on the grant date. During the course of the term, Mr. Paige will be eligible for (i) performance bonuses to be granted
at the discretion of the Company’s Compensation Committee and (ii) to participate in the Company’s Equity Incentive Plan.
The agreement contains customary employment terms and conditions and provides for severance of six months if a change in control occurs,
as defined.
|
Note
15. Commitments and Contingencies
Fixed
Assets and Other
At
December 31, 2022, the Company has outstanding orders to purchase equipment, molds and component parts for research and development of
$609,953 of which advance payments of $209,678 have been made and recorded in Other Assets (See Note 6).
Contingencies
At
each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably
estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company is currently not
involved in any material litigation or other loss contingencies.
Royalty
Agreement
In
connection with the purchase of certain intellectual property in July 2017, Barry Berler and Alan Blackman entered into a royalty agreement
which provides that Barry Berler will be entitled to a royalty of four percent (4%) of net sales derived from the use, sale, lease, rent
and export of products related to the intellectual property. The royalty continues until the patent expires or is no longer used in the
Company’s product. The royalty agreement was assumed by the Company in December 2017.
In
September 2018, the Royalty Agreement was amended to reduce the royalty to 2% and further provided for a single payment of $500,000 to
Barry Berler within three years in return for cancellation of all further royalty obligations of the Company. In May 2019, the Royalty
Agreement was further amended to change the payment date to on or before May 31, 2021 or during the term of the amended Royalty Agreement
should the Company be acquired or a controlling interest be acquired. The Company has not made the aforementioned payment or incur any
change in control as such the 2% royalty remains in place.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEAR ENDED DECEMBER 31, 2022 AND 2021
Note
15. Commitments and Contingencies (continued)
Employment
Agreements
On
August 1, 2022, the Company cancelled the consulting agreement with Alan Blackman, Co- Chairman and Chief Operating Officer and entered
into an Employment Agreement which provides for annual salary of $256,000,
which provides for increases, and provisions compensation adjustments, expense and tax differential reimbursements, benefits and bonuses.
As of September 1, 2022, the annual salary is $320,000.
At June 30, 2022, the Company approved and accrued a $250,000
bonus to Mr. Blackman for services provided in
2022, of which $65,000
was paid subsequent to December 31, 2022.
On
September 30, 2022, the Company entered into a formal employment agreement, effective on such date and will continue until
terminated by either party, subject to the terms of the agreement, with Andrew R. Crescenzo who has been serving as the
Company’s Chief Financial Officer on a contract services basis for the last three years. The agreement provided for annual
compensation of $225,000 and plus a one-time $18,750 incentive payment upon the commencement of the agreement. During the course of
the term, Mr. Crescenzo will be eligible for (i) performance bonuses to be granted at the discretion of the Company’s
Compensation Committee and (ii) to participate in the Company’s 2022 Equity Incentive Plan. The agreement contains customary
employment terms and conditions.
In
October 2022, the Company entered into a service agreement (“Service Agreement”) with an unrelated third-party for
marketing and investor relations services. The Service Agreement, which has a term of one year, has various deliverables and
provides payments to the third party as follows; a) an initial fee of $90,000,
b) monthly fees through the term of $12,500,
c) 200,000
shares of restricted common stock and d) $300,000
specifically related to digital marketing activities. As stated in Note 8, the 200,000
shares of restricted common stock were valued at $230,000,
representative of the trading price on the issuance.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Subsequent Events
|
12 Months Ended |
Dec. 31, 2022 |
Subsequent Events [Abstract] |
|
Subsequent Events |
Note
16. Subsequent Events
On
January 25, 2023, the Company granted five-year options (the “Options”) to purchase a total of 975,000
shares of the Company’s common stock, par
value $0.0001
per share (the “Common Stock”) to
its directors, executive officers, employee and consultants pursuant to the Company’s. 2022 and 2023 Equity Incentive Plans. The
Options are exercisable at $1.37
per share which was the closing price on January
25, 2023. Of the Options granted, Options to purchase an aggregate of 495,000
shares of Common Stock were issued to executive
officers Options to purchase an aggregate of 455,000
shares of Common Stock were issued to directors
and Options to purchase an aggregate of 75,000
shares of Common Stock to employees and a consultant.
On
January 25, 2023, the Company’s Board of Directors adopted the 2023 Equity Incentive Plan (the “2023 Plan”). The 2023
Plan provides for the issuance of up to 1,400,000
options and/or shares of restricted stock to
be available for issuance to officers, directors, employees and consultants. The 2023 Plan is subject to shareholder approval at
the annual meeting.
On
February 09, 2023, the Company, appointed Justin Paige, as Vice President
of Technical Operations with a start date of February 15, 2023. The agreement provides for annual compensation of $235,000
and Options to purchase 50,000
shares of Common Stock at the exercise price of $1.30,
the closing price on the grant date. During the course of the term, Mr. Paige will be eligible for (i) performance bonuses to be granted
at the discretion of the Company’s Compensation Committee and (ii) to participate in the Company’s Equity Incentive Plan.
The agreement contains customary employment terms and conditions and provides for severance of six months if a change in control occurs,
as defined.
On
February 3, 2023, the Company completed a securities purchase agreement (“Offering”) with institutional investors and
received net proceeds from the Offering were approximately $3.2
million, net of $600,000
in fees relating to the placement agent and other offering expenses. The Offering was priced at the market under Nasdaq rules. In
connection with the Offering, the Company issued 2,248,521
units at a purchase price of $1.69
per unit. Each unit consists of one share of common stock and one non-tradable warrant exercisable for one share of common stock at
a price of $1.56.
The warrants have a term of five
years from the issuance date. On February 13, 2023, the Company filed an S-1 (Resale) Registration Statement in connection with the Offering.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Summary of Significant Accounting Policies (Policies)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Accounting Policies [Abstract] |
|
|
Basis of Presentation |
Basis
of Presentation
The
accompanying condensed consolidated financial statements have been prepared by the Company in accordance with generally accepted accounting
principles (“GAAP”) in the United States (“U.S.”) and are expressed in U.S. dollars.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
|
Basis
of Presentation
The
accompanying consolidated financial statements have been prepared by the Company in accordance with generally accepted accounting principles
(“GAAP”) in the United States (“U.S.”) and are expressed in U.S. dollars.
|
Use of Estimates |
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As
of June 30, 2023, the most significant estimates relate to derivative liabilities and stock-based compensation.
|
Use
of Estimates
The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. As
of December 31, 2022, the most significant estimates relate to derivative liabilities and stock-based compensation.
|
Cash and Cash Equivalents |
Cash
and Cash Equivalents
The
Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date
of purchase to be cash equivalents. Cash and cash equivalents are maintained with various financial institutions.
|
Cash
and Cash Equivalents
The
Company considers all highly liquid investments purchased with an original or remaining maturity of three months or less at the date
of purchase to be cash equivalents. Cash and cash equivalents are maintained with various financial institutions.
|
Inventories |
Inventories
The
Company values inventory at the lower of cost (average cost) or net realizable value. Work-in-process and finished goods inventories
consist of material, labor, and manufacturing overhead. Net realizable value is the estimated selling price in the ordinary course of
business, less reasonably predictable costs of completion, disposal, and transportation. A reserve is established for any excess or obsolete
inventories or they may be written off. At June 30, 2023 and December 31, 2022, inventory is comprised of raw materials, including packaging,
work in process (components) and finished goods.
|
Inventories
The
Company values inventory at the lower of cost (average cost) or net realizable value. Work-in-process and finished goods inventories
consist of material, labor, and manufacturing overhead. Net realizable value is the estimated selling price in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. A reserve is established for any excess
or obsolete inventories or they may be written off. At December 31, 2022 and 2021, inventory is comprised of raw materials,
components and finished goods.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
|
Fair Value Measurements |
Fair
Value Measurements
ASC
820, Fair Value Measurements and Disclosures, require an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding
the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be
used to measure fair value.
The
Company’s outstanding warrants are fair valued on a recurring basis with the trading price which could cause fluctuations in operating
results at the reporting periods.
Level
1
Level
1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Valuations
are based on quoted prices that are readily and regularly available in an active market and do not entail a significant degree of judgment.
Level
2
Level
2 applied to assets or liabilities for which there are other than Level 1 observable inputs such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market data.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
Level
2 instruments require more management judgment and subjectivity as compared to Level 1 instruments. For instance: determining which instruments
are most similar to the instrument being priced requires management to identify a sample of similar securities based on the coupon rates,
maturity, issuer credit rating and instrument type, and subjectively select an individual security or multiple securities that are deemed
most similar to the security being priced; and determining whether a market is considered active requires management judgment.
Level
3
Level
3 applied to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement
of the fair value of the assets or liabilities. The determination for Level 3 instruments requires the most management judgment and subjectivity.
|
Fair
Value Measurements
ASC
820, Fair Value Measurements and Disclosures, require an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding
the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be
used to measure fair value.
The
Company’s outstanding warrants are fair valued on a recurring basis with the trading price which could cause fluctuations in
operating results at the reporting periods.
Level
1
Level
1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Valuations
are based on quoted prices that are readily and regularly available in an active market and do not entail a significant degree of judgment.
Level
2
Level
2 applied to assets or liabilities for which there are other than Level 1 observable inputs such as quoted prices for similar assets
or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent
transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally
from, or corroborated by, observable market data.
Level
2 instruments require more management judgment and subjectivity as compared to Level 1 instruments. For instance: determining which instruments
are most similar to the instrument being priced requires management to identify a sample of similar securities based on the coupon rates,
maturity, issuer credit rating and instrument type, and subjectively select an individual security or multiple securities that are deemed
most similar to the security being priced; and determining whether a market is considered active requires management judgment.
Level
3
Level
3 applied to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement
of the fair value of the assets or liabilities. The determination for Level 3 instruments requires the most management judgment and subjectivity.
|
Fixed Assets |
Fixed
Assets
Fixed
assets are stated at cost. Expenditures for maintenance and repairs are charged to operations as incurred. The Company’s fixed
assets consist of land, building, machinery and equipment, molds and website. Depreciation is calculated using the straight-line method
commencing on the date the asset is operating in the way intended by management over the following useful lives: Building – 20
years, Machinery and Equipment – 3 -10 years and Website – 3 years. The expected life for Molds is based on the lesser of
the number of parts that will be produced based on the expected mold capability or 5 years.
|
Fixed
Assets
Fixed
assets are stated at cost. Expenditures for maintenance and repairs are charged to operations as incurred. The Company’s fixed
assets consist of land, building, machinery and equipment, molds and website. Depreciation is calculated using the straight-line
method commencing on the date the asset is operating in the way intended by management over the following useful lives: Building
– 20 years, Machinery and Equipment – 3 -10 years and Website – 3 years. The expected life for Molds is based
lesser of the number of parts that will be produced based on the expected mold capability or 5 years.
|
Impairment of Long-Lived Assets |
Impairment
of Long-Lived Assets
Long-lived
assets are reviewed for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash
flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset.
There
were no impairment losses recognized during the six months ended June 30, 2023.
Purchased
Identified Intangible Assets
The
Company’s identified intangible assets are amortized on a straight-line basis over their estimated useful lives of 5 years. The
Company makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate that the
useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable. If such facts and circumstances
exist, the Company assesses recoverability by comparing the projected undiscounted net cash flows associated with the related asset or
group of assets over their remaining lives against their respective carrying amounts. Impairments, if any, are based on the excess of
the carrying amount over the fair value of those assets. If the useful life is shorter than originally estimated, the Company would accelerate
the rate of amortization and amortize the remaining carrying value over the new shorter useful life. The Company evaluates the carrying
value of indefinite-lived intangible assets whenever events or changes in circumstances indicate that the carrying amount of an
asset may not be recoverable, and an impairment charge would be recognized to the extent that the carrying amount of such assets exceeds
their estimated fair value.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
|
Impairment
of Long-Lived Assets
Long-lived
assets are reviewed annually for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted
cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from
the asset.
There
were no impairment losses recognized during the years ended December 31, 2022 and 2021.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
|
Goodwill and Purchased Identified Intangible Assets |
|
Goodwill
and Purchased Identified Intangible Assets
Goodwill
When
applicable, goodwill will be recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the
fair value of the net tangible and identified intangible assets acquired under a business combination. Goodwill also includes acquired
assembled workforce, which does not qualify as an identifiable intangible asset. The Company reviews impairment of goodwill annually
in the third quarter, or more frequently if events or circumstances indicate that the goodwill might be impaired. The Company first assesses
qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. If, after assessing the
totality of events or circumstances, the Company determines that it is not more likely than not that the fair value of a reporting unit
is less than its carrying amount, then the quantitative goodwill impairment test is unnecessary. If, based on the qualitative assessment,
it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the Company
proceeds to perform the quantitative goodwill impairment test. The Company first determines the fair value of a reporting unit using
weighted results derived from an income approach and a market approach. The income approach is estimated through the discounted cash
flow method based on assumptions about future conditions such as future revenue growth rates, new product and technology introductions,
gross margins, operating expenses, discount rates, future economic and market conditions, and other assumptions. The market approach
estimates the fair value of the Company’s equity by utilizing the market comparable method which is based on revenue multiples
from comparable companies in similar lines of business. The Company then compares the derived fair value of a reporting unit with its
carrying amount. If the carrying value of a reporting unit exceeds its fair value, an impairment loss will be recognized in an amount
equal to that excess, limited to the total amount of goodwill allocated to that reporting unit.
|
Identified Intangible Assets |
|
Identified
Intangible Assets
The
Company’s identified intangible assets are amortized on a straight-line basis over their estimated useful lives of 5 years.
The Company makes judgments about the recoverability of finite-lived intangible assets whenever facts and circumstances indicate
that the useful life is shorter than originally estimated or that the carrying amount of assets may not be recoverable. If such
facts and circumstances exist, the Company assesses recoverability by comparing the projected undiscounted net cash flows associated
with the related asset or group of assets over their remaining lives against their respective carrying amounts. Impairments, if any,
are based on the excess of the carrying amount over the fair value of those assets. If the useful life is shorter than originally
estimated, the Company would accelerate the rate of amortization and amortize the remaining carrying value over the new shorter
useful life. The Company evaluates the carrying value of indefinite-lived intangible assets on an annual basis, and an impairment
charge would be recognized to the extent that the carrying amount of such assets exceeds their estimated fair value.
|
Stock-based Compensation Expense |
Stock-based
Compensation Expense
The
Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. For
stock option awards, the Company uses the Black-Scholes option-pricing model. For restricted stock awards, the estimated fair value is
generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite
service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company
recognizes forfeitures of stock-based awards as they occur on a prospective basis.
Stock-based
compensation expense for awards granted to non-employees as consideration for services received is measured on the date of performance
at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured.
|
Stock-based
Compensation Expense
The
Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. For
stock option awards, the Company uses the Black-Scholes option-pricing model. For restricted stock awards, the estimated fair value is
generally the fair market value of the underlying stock on the grant date. Stock-based compensation expense is recognized over the requisite
service period and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. The Company
recognizes forfeitures of stock-based awards as they occur on a prospective basis.
Stock-based
compensation expense for awards granted to non-employees as consideration for services received is measured on the date of performance
at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured.
|
Derivative Instruments |
Derivative
Instruments
The
Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of
the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC 480”), Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815,
Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments
pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification
under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could
potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent
quarterly period end date while the warrants are outstanding.
At
their issuance date and as of June 30, 2023, the warrants (see Notes 8 and 10) were accounted for as liabilities as these instruments
did not meet all of the requirements for equity classification under ASC 815-40 based on the terms of the aforementioned warrants. The
resulting warrant liabilities are re-measured at each balance sheet date until their exercise or expiration, and any change in fair value
is recognized in the Company’s condensed consolidated statements of operations and comprehensive loss.
|
Derivative
Instruments
The
Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of
the specific terms of the warrants and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC 480”), Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815,
Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments
pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification
under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could
potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification.
This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent
quarterly period end date while the warrants are outstanding.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
At
their issuance date and as of December 31, 2022, the warrants (see Notes 8 and 10) were accounted for as liabilities as these instruments
did not meet all of the requirements for equity classification under ASC 815-40 based on the terms of the aforementioned warrants. The
resulting warrant liabilities are re-measured at each balance sheet date until their exercise or expiration, and any change in fair value
is recognized in the Company’s consolidated statements of operations and comprehensive loss.
|
Foreign Currency Translation/Transactions |
Foreign
Currency Translation/Transactions
The
Company has determined that the functional currency for its foreign subsidiary is the local currency. For financial reporting purposes,
assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated
at weighted average exchange rates. Resulting translation gains and losses are included as a separate component of stockholders’
equity as accumulated other comprehensive income or loss. Gains or losses resulting from transactions entered into in other than the
functional currency are recorded as foreign exchange gains and losses in the consolidated statements of operations and comprehensive
loss.
|
Foreign
Currency Translation/Transactions
The
Company has determined that the functional currency for its foreign subsidiary is the local currency. For financial reporting
purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss
accounts are translated at weighted average exchange rates. Resulting translation gains and losses are included as a separate
component of stockholders’ equity as accumulated other comprehensive income or loss. Gains or losses resulting from
transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the
consolidated statements of operations and comprehensive loss.
|
Comprehensive income (loss) |
Comprehensive
income (loss)
Comprehensive
income (loss) consists of the Company’s consolidated net loss and foreign currency translation adjustments related to its subsidiary.
Foreign currency translation adjustments included in comprehensive loss were not tax effected as the Company has a full valuation allowance
at June 30, 2023 and December 31, 2022. Accumulated other comprehensive income (loss) is a separate component of stockholders’
equity and consists of the cumulative foreign currency translation adjustments.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
|
Comprehensive
income (loss)
Comprehensive
income (loss) consists of the Company’s consolidated net loss and foreign currency translation adjustments related to its subsidiary. Foreign currency
translation adjustments included in comprehensive loss were not tax effected as the Company has a full valuation allowance at
December, 2022 and 2021. Accumulated other comprehensive income (loss) is a separate component of stockholders’ equity and
consists of the cumulative foreign currency translation adjustments.
|
Basic and Diluted Loss Per Share |
Basic
and Diluted Loss Per Share
The
Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted
earnings per share (EPS) on the face of the consolidated statement of operations and comprehensive loss. Basic EPS is computed by dividing
net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during
the year. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method
and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used
in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all
dilutive potential shares if their effect is anti-dilutive. As of June 30, 2023, there were 13,788,724 stock options and warrants
that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would
have been antidilutive for the periods presented.
|
Basic
and Diluted Loss Per Share
The
Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted
earnings per share (EPS) on the face of the consolidated statement of operations and comprehensive loss. Basic EPS is computed by dividing
net income (loss) available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during
the year. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method
and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used
in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all
dilutive potential shares if their effect is anti-dilutive. As at December 31, 2022, there were 10,405,916 stock options and warrants
that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would
have been antidilutive for the periods presented.
|
Income Taxes |
Income
Taxes
The
Company must make certain estimates and judgments in determining income tax expenses for financial statement purposes. These estimates
and judgments are used in the calculation of tax credits, tax benefits, tax deductions, and in the calculation of certain deferred taxes
and tax liabilities. Significant changes to these estimates may result in an increase or decrease to the Company’s tax provision
in a subsequent period.
The
provision for income taxes was comprised of the Company’s current tax liability and changes in deferred income tax assets and liabilities.
The calculation of the current tax liability involves dealing with uncertainties in the application of complex tax laws and regulations
and in determining the liability for tax positions, if any, taken on the Company’s tax returns in accordance with authoritative
guidance on accounting for uncertainty in income taxes. Deferred income taxes are determined based on the differences between the financial
reporting and tax basis of assets and liabilities. The Company must assess the likelihood that it will be able to recover the Company’s
deferred tax assets. If recovery is not likely on a more-likely-than-not basis, the Company must increase its provision for income taxes
by recording a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. However, should
there be a change in the Company’s ability to recover its deferred tax assets, the provision for income taxes would fluctuate in
the period of such change.
|
Income
Taxes
The
Company must make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates
and judgments are used in the calculation of tax credits, tax benefits, tax deductions, and in the calculation of certain deferred taxes
and tax liabilities. Significant changes to these estimates may result in an increase or decrease to the Company’s tax provision
in a subsequent period.
The
provision for income taxes was comprised of the Company’s current tax liability and changes in deferred income tax assets and liabilities.
The calculation of the current tax liability involves dealing with uncertainties in the application of complex tax laws and regulations
and in determining the liability for tax positions, if any, taken on the Company’s tax returns in accordance with authoritative
guidance on accounting for uncertainty in income taxes. Deferred income taxes are determined based on the differences between the financial
reporting and tax basis of assets and liabilities. The Company must assess the likelihood that it will be able to recover the Company’s
deferred tax assets. If recovery is not likely on a more-likely-than-not basis, the Company must increase its provision for income taxes
by recording a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. However, should
there be a change in the Company’s ability to recover its deferred tax assets, the provision for income taxes would fluctuate in
the period of such change.
|
Research and Development Costs |
Research
and Development Costs
Research
and development costs are expensed as incurred.
Advance
payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized.
Such amounts are recognized as an expense as the related goods are delivered or the services are performed.
|
Research
and Development Costs
Research
and development costs are expensed as incurred.
Advance
payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized.
Such amounts are recognized as an expense as the related goods are delivered or the services are performed.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Note
2. Summary of Significant Accounting Policies (continued)
|
Contingencies |
Contingencies
Liabilities
for loss contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized when it is
probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. Gain contingencies are evaluated
and not recognized until the gain is realizable or realized.
SHARPS
TECHNOLOGY, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE NINE MONTHS ENDED JUNE 30, 2023 AND 2022
Note
2. Summary of Significant Accounting Policies (continued)
|
Contingencies
Liabilities for loss
contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized when it is probable
that a liability has been incurred and the amount of the assessment can be reasonably estimated. Gain contingencies are evaluated and
not recognized until the gain is realizable or realized.
|
Recent Accounting Pronouncements |
Recent
Accounting Pronouncements
In
March 2020, the FASB issued ASC Topic 848, Reference Rate Reform. ASC Topic 848 provides relief for impacted areas as it relates
to impending reference rate reform. ASC Topic 848 contains optional expedients and exceptions for applying GAAP to debt arrangements,
contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective
upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance.
On
August 5, 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40), which simplifies the accounting for certain financial
instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own
equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU
2020-06 simplifies the guidance in U.S. GAAP on the issuer’s accounting for convertible debt instruments, requires entities to
provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been
reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification
and amends certain guidance in ASC 260, Earnings per Share, on the computation of EPS for convertible instruments and contracts
on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance.
The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company
continues to assess all potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.
In
June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject
to Contractual Sale Restrictions”, intended to clarify that a contractual restriction on the sale of an equity security is not
considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendment
also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. ASU No. 2022-03
is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December
15, 2023. Early adoption is permitted. For all other entities, it is effective for fiscal years, including interim periods within those
fiscal years beginning after December 15, 2024. Early adoption is permitted for both interim and annual financial statements that have
not yet been issued or made available for issuance. The Company is evaluating the adoption of the amendments and the potential impact
it may have, if any, on its financial statements.
The
Company does not expect the adoption of any accounting pronouncements to have a material impact on the condensed consolidated financial
statements.
We
reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant
to the accounting for our operations.
|
Recent
Accounting Pronouncements
In
March 2020, the FASB issued ASC Topic 848, Reference Rate Reform. ASC Topic 848 provides relief for impacted areas as it relates
to impending reference rate reform. ASC Topic 848 contains optional expedients and exceptions for applying GAAP to debt arrangements,
contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective
upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance.
On
August 5, 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40), which simplifies the accounting for certain financial
instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own
equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU
2020-06 simplifies the guidance in U.S. GAAP on the issuer’s accounting for convertible debt instruments, requires entities to
provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been
reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification
and amends certain guidance in ASC 260, Earnings per Share, on the computation of EPS for convertible instruments and contracts
on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance.
The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company
continues to assess all potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.
The
Company does not expect the adoption of any accounting pronouncements to have a material impact on the consolidated financial statements.
We
reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant
to the accounting for our operations.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
+ Details
Name: |
us-gaap_BasisOfAccountingPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 450 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480598/954-450-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b),(f(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_CompensationRelatedCostsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for comprehensive income.
+ References
+ Details
Name: |
us-gaap_ComprehensiveIncomePolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for its derivative instruments and hedging activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(n)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7
+ Details
Name: |
us-gaap_DerivativesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2
+ Details
Name: |
us-gaap_EarningsPerSharePolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
+ Details
Name: |
us-gaap_FairValueMeasurementPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//830/tableOfContent
+ Details
Name: |
us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 30 -Topic 350 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4
+ Details
Name: |
us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20
+ Details
Name: |
us-gaap_IncomeTaxPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6
+ Details
Name: |
us-gaap_InventoryPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
+ Details
Name: |
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpensePolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Inventories (Tables)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Inventory Disclosure [Abstract] |
|
|
Schedule of Inventories |
Inventories,
net consisted of the following at:
Schedule of Inventories
| |
June 30, 2023 | | |
December 31, 2022 | |
Raw materials | |
$ | 226,062 | | |
$ | 106,088 | |
Work in process | |
| 86,831 | | |
| 49,144 | |
Finished goods | |
| 679,654 | | |
| 30,572 | |
Total | |
$ | 992,547 | | |
$ | 185,804 | |
|
Inventories,
net consisted of the following at December 31, 2022 and 2021:
Schedule of Inventories
|
|
December 31, 2022 |
|
|
December 31, 2021 |
|
Raw materials |
|
$ |
106,088 |
|
|
$ |
121,994 |
|
Work in process |
|
|
49,144 |
|
|
|
- |
|
Finished goods |
|
|
30,572 |
|
|
|
- |
|
Total |
|
$ |
185,804 |
|
|
$ |
121,994 |
|
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfInventoryCurrentTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Fixed Assets (Tables)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Property, Plant and Equipment [Abstract] |
|
|
Schedule of Property, Plant and Equipment |
Fixed
asset, net, is summarized as follows as of:
Schedule of Property, Plant and Equipment
| |
June 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Land | |
$ | 264,736 | | |
$ | 242,240 | |
Building | |
| 3,068,950 | | |
| 2,824,481 | |
Machinery and Equipment | |
| 4,863,882 | | |
| 4,601,293 | |
Website | |
| 20,363 | | |
| 16,600 | |
Fixed asset, gross | |
| 8,217,930 | | |
| 7,684,614 | |
Less: accumulated depreciation | |
| (1,124,976 | ) | |
| (679,724 | ) |
Fixed asset, net | |
$ | 7,092,954 | | |
$ | 7,004,890 | |
|
Fixed
asset, net, as of December 31, 2022 and 2021, are summarized as follows:
Schedule of Property, Plant and Equipment
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Land | |
$ | 242,240 | | |
$ | - | |
Building | |
| 2,824,481 | | |
| - | |
Machinery and Equipment | |
| 4,601,293 | | |
| 3,778,766 | |
Website | |
| 16,600 | | |
| 16,600 | |
Fixed asset, gross | |
| 7,684,614 | | |
| 3,795,366 | |
Less: accumulated depreciation | |
| (679,724 | ) | |
| (32,034 | ) |
Fixed asset, net | |
$ | 7,004,890 | | |
$ | 3,763,332 | |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Asset Acquisition (Tables)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Business Combination and Asset Acquisition [Abstract] |
|
|
Schedule of Fair Value of the Assets Acquisition |
The
relative fair value of the assets acquired and related deferred tax liability is as follows:
Schedule of Fair Value of the Assets Acquisition
| |
| | |
Land | |
$ | 226,000 | |
Building and affixed assets | |
| 2,648,000 | |
Machinery | |
| 158,000 | |
Inventory | |
| 32,000 | |
Intangibles | |
| 64,712 | |
Deferred tax liability | |
| (192,000 | ) |
| |
| | |
Total | |
$ | 2,936,712 | |
|
The
relative fair value of the assets acquired and related deferred tax liability is as follows:
Schedule of Fair Value of the Assets Acquisition
| |
| | |
Land | |
$ | 226,000 | |
Building and affixed assets | |
| 2,648,000 | |
Machinery | |
| 158,000 | |
Inventory | |
| 32,000 | |
Intangibles | |
| 64,712 | |
Deferred tax liability | |
| (192,000 | ) |
| |
| | |
Total | |
$ | 2,936,712 | |
|
X |
- References
+ Details
Name: |
us-gaap_BusinessCombinationAndAssetAcquisitionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Other Assets (Tables)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
|
Schedule of Other Assets |
Other
assets as of June 30, 2023 and December 31, 2022 are summarized as follows:
Schedule of Other Assets
| |
2023 | | |
2022 | |
Intangibles, net | |
| 60,993 | | |
| 62,480 | |
Deposits or advance payments on machinery, molds, components or technology (see Note 15) | |
| 517,377 | | |
| 336,466 | |
Other | |
| 12,370 | | |
| 12,370 | |
Other assets | |
$ | 590,740 | | |
$ | 411,316 | |
|
Other
assets as of December 31, 2022 and 2021 are summarized as follows:
Schedule of Other Assets
| |
December 31, | | |
December 31, | |
| |
2022 | | |
2021 | |
Acquisition (see Note 5) | |
$ | - | | |
$ | 472,701 | |
Intangibles, net | |
| 62,480 | | |
| - | |
Deposits or advance payments on machinery, molds and components (see Note 15) | |
| 336,466 | | |
| - | |
Other | |
| 12,370 | | |
| 57,162 | |
Other assets | |
$ | 411,316 | | |
$ | 529,863 | |
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
+ Details
Name: |
us-gaap_ScheduleOfOtherAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Warrant Liability (Tables)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Warrant Liability |
|
|
Schedule of Warrant Liability |
The
Warrant liability at June 30, 2023 was as follows:
Schedule
of Warrant Liability
| |
| | |
Trading and Overallotment Warrants | |
$ | 1,207,500 | |
Note Warrants | |
| 32,941 | |
Offering Warrants | |
| 272,746 | |
Total | |
$ | 1,513,187 | |
Warrant liability | |
$ | 1,513,187 | |
|
The
Warrant liability at December 31, 2022 was as follows:
Schedule
of Warrant Liability
| |
| | |
Note Warrants | |
$ | 30,588 | |
Trading and Overallotment Warrants | |
| 1,121,250 | |
Total | |
$ | 1,151,838 | |
Warrant liability | |
$ | 1,151,838 | |
|
Schedule of Warrant Outstanding |
The
Warrants outstanding at June 30, 2023 are as follows:
Schedule
of Warrant Outstanding
| |
| | |
Trading and Overallotment Warrants | |
| 8,812,500 | |
Note warrants | |
| 235,295 | |
Offering Warrants | |
| 2,248,521 | |
Warrants issued for services arrangement | |
| 135,000 | |
Total | |
| 11,431,316 | |
Warrant outstanding | |
| 11,431,316 | |
|
Schedule
of Warrant Outstanding
| |
| | |
Note warrants | |
| 235,295 | |
Trading and Overallotment Warrants | |
| 8,812,500 | |
Total | |
| 9,047,795 | |
Warrant outstanding | |
| 9,047,795 | |
|
Schedule of Changes in the Warrant Liability |
The
following table presents the changes in the Warrant liability of the Level 1 warrants issued on April 14, 2022, the effective date of
the IPO measured at fair value from December 31, 2022 and the changes in the Offering Warrants liability of the Level 2 warrants issued
on February 6, 2023 through June 30, 2023.
Schedule
of Changes in the Warrant Liability
| |
Total | |
| |
| |
FMV of Note Warrants | |
$ | 30,588 | |
FMV of Trading and Overallotment Warrants | |
| 1,121,250 | |
FMV of Offering Warrants, at issuance | |
| 455,326 | |
Change in fair value of warrant liability for the six months ended June 30,2023 | |
| (93,977 | ) |
| |
| | |
Fair Value at June 30, 2023 | |
$ | 1,513,187 | |
|
The
following table presents the changes in the Warrant liability of the Level 1 warrants issued on April 14, 2022, the effective date of
the IPO measured at fair value:
Schedule
of Changes in the Warrant Liability
| |
Total | |
| |
| |
FMV of Note Warrants, at issuance | |
$ | 157,647 | |
| |
| | |
FMV of Trading and Overallotment Warrants, at issuance | |
| 5,778,750 | |
| |
| | |
Change in fair value of warrant liability, issuance through December 31, 2022 | |
| (4,784,559 | ) |
| |
| | |
Fair Value at December 31, 2022 | |
$ | 1,151,838 | |
|
X |
- References
+ Details
Name: |
STSS_DisclosureWarrantLiabilityAbstract |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSchedule of change in warrant liability [Table Text Block]
+ References
+ Details
Name: |
STSS_ScheduleOfChangesInWarrantLiabilityTableTextBlock |
Namespace Prefix: |
STSS_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSchedule of warrant liability [Table Text Block]
+ References
+ Details
Name: |
STSS_ScheduleOfWarrantLiabilityTableTextBlock |
Namespace Prefix: |
STSS_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Stock Options (Tables)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Share-Based Payment Arrangement [Abstract] |
|
|
Schedule of Stock Options Granted and Outstanding |
A
summary of options granted and outstanding is presented below.
Schedule
of Stock Options Granted and Outstanding
| |
June 30, 2023 | |
| |
Options | | |
Weighted Average Exercise
Price | |
Outstanding at Beginning of year | |
| 1,358,122 | | |
$ | 4.37 | |
Granted | |
| 1,025,000 | | |
| 1.37 | |
Forfeited | |
| (25,714 | ) | |
| 1.75 | |
Outstanding at end of period | |
| 2,357,408 | | |
$ | 3.08 | |
| |
| | | |
| | |
Exercisable at end of period | |
| 1,665,378 | | |
$ | 3.63 | |
|
A
summary of options granted and outstanding is presented below.
Schedule
of Stock Options Granted and Outstanding
| |
2022 | | |
2021 | |
| |
Options | | |
Weighted Average Exercise Price | | |
Options | | |
Weighted Average Exercise Price | |
Outstanding at Beginning of year | |
| 1,137,479 | | |
$ | 5.18 | | |
| 792,857 | | |
$ | 3.64 | |
Granted | |
| 367,500 | | |
| 1.63 | | |
| 511,764 | | |
| 7.00 | |
Cancelled | |
| (3,571 | ) | |
| (4.38 | ) | |
| (21,875 | ) | |
| (4.38 | ) |
Forfeited | |
| (143,286 | ) | |
$ | (3.77 | ) | |
| (145,157 | ) | |
$ | (2.57 | ) |
| |
| | | |
| | | |
| | | |
| | |
Outstanding at end of year | |
| 1,358,122 | | |
$ | 4.37 | | |
| 1,137,479 | | |
$ | 5.18 | |
| |
| | | |
| | | |
| | | |
| | |
Exercisable at end of year | |
| 1,132,861 | | |
$ | 4.59 | | |
| 825,847 | | |
$ | 5.38 | |
|
Schedule of Information about Options Outstanding |
The
following table summarizes information about options outstanding at June 30, 2023:
Schedule
of Information about Options Outstanding
Exercise
Prices |
|
|
Shares
Outstanding |
|
|
Weighted
Average Remaining Contractual Life |
|
|
Shares
Exercisable |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1.21 |
|
|
|
307,500 |
|
|
|
4.42 |
|
|
|
233,719 |
|
$ |
1.30 |
|
|
|
50,000 |
|
|
|
4.71 |
|
|
|
18,750 |
|
$ |
1.37 |
|
|
|
975,000 |
|
|
|
4.67 |
|
|
|
437,032 |
|
$ |
1.39 |
|
|
|
10,000 |
|
|
|
4.17 |
|
|
|
10,000 |
|
$ |
1.75 |
|
|
|
42,857 |
|
|
|
2.75 |
|
|
|
42,857 |
|
$ |
2.80 |
|
|
|
141,429 |
|
|
|
1.00 |
|
|
|
141,429 |
|
$ |
4.25 |
|
|
|
50,000 |
|
|
|
4.00 |
|
|
|
50,000 |
|
$ |
4.38 |
|
|
|
244,286 |
|
|
|
1.75 |
|
|
|
244,286 |
|
$ |
7.00 |
|
|
|
536,336 |
|
|
|
2.50 |
|
|
|
477,305 |
|
|
The
following table summarizes information about options outstanding at December 31, 2022:
Schedule
of Information About Options Outstanding
Exercise Prices | | |
Options Outstanding | | |
Aggregate Intrinsic Value | | |
Weighted Average Remaining Contractual Life | | |
Options Exercisable | | |
Aggregate Intrinsic Value on Exercisable Shares | |
| | |
| | |
| | |
| | |
| | |
| |
$ | 1.21 | | |
| 307,500 | | |
| - | | |
| 4.42 | | |
| 168,551 | | |
$ | - | |
$ | 1.39 | | |
| 10,000 | | |
| - | | |
| 4.67 | | |
| 10,000 | | |
$ | - | |
$ | 1.75 | | |
| 68,571 | | |
| - | | |
| .25 | | |
| 68,571 | | |
$ | - | |
$ | 2.80 | | |
| 141,429 | | |
| - | | |
| .50 | | |
| 141,429 | | |
$ | - | |
$ | 4.25 | | |
| 50,000 | | |
| - | | |
| 4.50 | | |
| 37,500 | | |
$ | - | |
$ | 4.38 | | |
| 244,286 | | |
| - | | |
| 2.25 | | |
| 244,286 | | |
$ | - | |
$ | 7.00 | | |
| 536,336 | | |
| - | | |
| 3.00 | | |
| 462,524 | | |
$ | - | |
|
Schedule of Fair Value of Stock Option Awards |
The
fair value of stock option awards accounted for under ASC 718 was estimated at the date of grant using a Black-Scholes option-pricing
model with the following assumptions for the options granted during the six months ended June 30, 2023.
Schedule
of Fair Value of Stock Option Awards
Expected term (years) | |
2.88 to 3.25 | |
Expected volatility | |
75.40% to 89.93 | % |
Risk-free interest rate | |
3.71% to 4.27 | % |
Dividend rate | |
| 0 | % |
|
The
fair value of stock option awards accounted for under ASC 718 was estimated at the date of grant using a Black-Scholes option-pricing
model with the following assumptions:
Schedule
of Fair Value of Stock Option Awards
|
|
Year
Ended
December 31, 2022 |
|
|
Year
Ended
December 31, 2021 |
|
Expected
term (years) |
|
|
2.50
to 3.00 |
|
|
|
2.50
to 3.25 |
|
Expected
volatility |
|
|
100.81%
to 110.74 |
% |
|
|
97.26%
to 116.06 |
%
|
Risk-free
interest rate |
|
|
2.90%
to 3.47 |
% |
|
|
0.18%
- .81 |
% |
Dividend
rate |
|
|
0 |
% |
|
|
0 |
% |
|
X |
- DefinitionTabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2022 |
Income Tax Disclosure [Abstract] |
|
Schedule of Reconciliation of Federal Statutory Rate to Total Effective Rate |
Schedule
of Reconciliation of Federal Statutory Rate to Total Effective Rate
| |
| | |
| |
| |
Year Ended | | |
Year Ended | |
| |
December 31, 2022 | | |
December 31,
2021 | |
| |
| | |
| |
Expected benefit at statutory federal tax rate | |
$ | (974,329 | ) | |
$ | (979,527 | ) |
Permanent differences – net | |
| (859,515 | ) | |
| - | |
State and local taxes, net of federal tax benefit | |
| (265,607 | ) | |
| (311,373 | ) |
Other | |
| (21,965 | ) | |
| (57,563 | ) |
Change in valuation allowance | |
| 2,121,416 | | |
| 1,348,463 | |
Income tax Expense (Benefit)
Total | |
$ | - | | |
$ | - | |
|
Schedule of Components of Deferred tax Assets |
The
components of the Company’s deferred tax assets (liabilities) are as follows:
Schedule
of Components of Deferred tax Assets
| |
Year Ended December 31, 2022 | | |
Year Ended December 31, 2021 | |
Deferred tax assets (liabilities): | |
| | | |
| | |
Fixed assets | |
$ | (268,594 | ) | |
$ | 3,837 | |
Interest | |
| 62,310 | | |
| 46,361 | |
Research and development expenses | |
| 454,942 | | |
| - | |
Stock-based compensation | |
| 917,351 | | |
| 637,112 | |
Net operating losses - federal | |
| 2,898,411 | | |
| 1,687,053 | |
Net operating losses – state and local | |
| 921,350 | | |
| 536,282 | |
Net operating losses - foreign | |
| 37,686 | | |
| - | |
Research credit | |
| 28,985 | | |
| 28,985 | |
Deferred tax assets gross | |
| 5,052,441 | | |
| 2,939,630 | |
Less valuation allowance | |
| (5,244,441 | ) | |
| (2,939,630 | ) |
Net deferred tax liability | |
$ | (192,000 | ) | |
$ | - | |
|
X |
- DefinitionTabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Paragraph 12 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12
+ Details
Name: |
us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Fair Value Measurements (Tables)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Fair Value Disclosures [Abstract] |
|
|
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis |
As
of June 30, 2023, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the Company’s
consolidated balance sheet:
Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis
|
|
Level
1 |
|
|
Level
2 |
|
|
Level
3 |
|
|
Total |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash |
|
$ |
2,924,019 |
|
|
|
- |
|
|
|
- |
|
|
$ |
2,924,019 |
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
Total
assets measured at fair value |
|
$ |
2,924,019 |
|
|
|
- |
|
|
|
|
|
|
$ |
2,924,019 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant
liability |
|
$ |
1,240,441 |
|
|
|
272,276 |
|
|
|
- |
|
|
$ |
1,513,187 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
liabilities measured at fair value |
|
$ |
1,240,441 |
|
|
|
272,276 |
|
|
|
- |
|
|
$ |
1,513,187 |
|
|
As
of December 31, 2022, the following financial assets and liabilities were measured at fair value on a recurring basis presented on the
Company’s consolidated balance sheet:
Schedule
of Assets and Liabilities Measured at Fair Value on Recurring Basis
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
Fair Value Measurements Using | | |
| |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| |
| | |
| | |
| | |
| |
Assets | |
| | | |
| | | |
| | | |
| | |
Cash | |
$ | 4,170,897 | | |
| - | | |
| - | | |
$ | 4,170,897 | |
| |
| - | | |
| - | | |
| - | | |
| | |
Total assets measured at fair value | |
$ | 4,170,897 | | |
| - | | |
| | | |
$ | 4,170,897 | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | | |
| | |
Warrant liability | |
$ | 1,151,838 | | |
| - | | |
| - | | |
$ | 1,151,838 | |
| |
| | | |
| | | |
| | | |
| | |
Total liabilities measured at fair value | |
$ | 1,151,838 | | |
| - | | |
| - | | |
$ | 1,151,838 | |
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Description of Business (Details Narrative) - USD ($)
|
|
|
12 Months Ended |
|
Apr. 19, 2022 |
Apr. 19, 2022 |
Apr. 14, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Jun. 30, 2023 |
Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
Initial public offering |
|
|
|
$ 14,202,975
|
|
|
Working capital |
|
|
|
|
|
$ 1,197,575
|
IPO [Member] |
|
|
|
|
|
|
Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
Initial public offering |
$ 14,200,000
|
$ 14,200,000
|
$ 14,200,000
|
|
|
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceInitialPublicOffering |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_SubsidiarySaleOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] |
|
|
|
Impairment losses |
$ 0
|
$ 0
|
$ 0
|
Stock Options and Warrants [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Antidilutive securities shares |
13,788,724
|
10,405,916
|
|
Building [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Property plant and equipment asset useful life |
20 years
|
20 years
|
|
Machinery and Equipment [Member] | Minimum [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Property plant and equipment asset useful life |
3 years
|
3 years
|
|
Machinery and Equipment [Member] | Maximum [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Property plant and equipment asset useful life |
10 years
|
10 years
|
|
Website [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Property plant and equipment asset useful life |
3 years
|
3 years
|
|
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4
+ Details
Name: |
us-gaap_ImpairmentOfLongLivedAssetsHeldForUse |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=STSS_StockOptionsAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=STSS_WebsiteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Inventories (Details) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Inventory Disclosure [Abstract] |
|
|
|
Raw materials |
$ 226,062
|
$ 106,088
|
$ 121,994
|
Work in process |
86,831
|
49,144
|
|
Finished goods |
679,654
|
30,572
|
|
Total |
$ 992,547
|
$ 185,804
|
$ 121,994
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2
+ Details
Name: |
us-gaap_InventoryFinishedGoodsNetOfReserves |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2
+ Details
Name: |
us-gaap_InventoryRawMaterialsNetOfReserves |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2
+ Details
Name: |
us-gaap_InventoryWorkInProcessNetOfReserves |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.3
Schedule of Property, Plant and Equipment (Details) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] |
|
|
|
Fixed asset, gross |
$ 8,217,930
|
$ 7,684,614
|
$ 3,795,366
|
Less: accumulated depreciation |
(1,124,976)
|
(679,724)
|
(32,034)
|
Fixed asset, net |
7,092,954
|
7,004,890
|
3,763,332
|
Land [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Fixed asset, gross |
264,736
|
242,240
|
|
Building [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Fixed asset, gross |
3,068,950
|
2,824,481
|
|
Machinery and Equipment [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Fixed asset, gross |
4,863,882
|
4,601,293
|
3,778,766
|
Website [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Fixed asset, gross |
$ 20,363
|
$ 16,600
|
$ 16,600
|
X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=STSS_WebsiteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Fixed Assets (Details Narrative) - USD ($)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
|
|
Depreciation |
$ 445,252
|
$ 156,100
|
$ 647,690
|
$ 28,699
|
Balance due on machinery |
$ 100,000
|
|
100,000
|
|
Equity Option [Member] |
|
|
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
|
|
Acquisition of machinery |
|
$ 63,612
|
$ 63,612
|
|
X |
- DefinitionRemaining payments uue on machinery.
+ References
+ Details
Name: |
STSS_RemainingPaymentsDueOnMachinery |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for acquisition of machinery and equipment.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquireMachineryAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_StockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Fair Value of the Assets Acquisition (Details) - Safegard Medical, Inc [Member]
|
Jul. 06, 2022
USD ($)
|
Business Acquisition [Line Items] |
|
Land |
$ 226,000
|
Building and affixed assets |
2,648,000
|
Machinery |
158,000
|
Inventory |
32,000
|
Intangibles |
64,712
|
Deferred tax liability |
(192,000)
|
Total |
$ 2,936,712
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5
+ Details
Name: |
us-gaap_BusinessAcquisitionLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of assets acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of facility held for productive use including, but not limited to, office, production, storage and distribution facilities, acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBuildings |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment, acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of identifiable intangible assets recognized as of the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of inventory recognized as of the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of real estate acquired, at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=STSS_SafegardMedicalIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Asset Acquisition (Details Narrative) - USD ($)
|
|
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
Jul. 06, 2022 |
Jun. 30, 2022 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Jun. 30, 2023 |
Building [Member] |
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
Finite-lived intangible asset, useful life |
|
|
|
20 years
|
|
20 years
|
Machinery and Equipment [Member] | Minimum [Member] |
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
Finite-lived intangible asset, useful life |
|
|
|
5 years
|
|
5 years
|
Machinery and Equipment [Member] | Maximum [Member] |
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
Finite-lived intangible asset, useful life |
|
|
|
10 years
|
|
10 years
|
Finite-Lived Intangible Assets [Member] |
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
Finite-lived intangible asset, useful life |
|
|
|
5 years
|
|
5 years
|
Safegard Medical, Inc [Member] |
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
Acquisition cost |
$ 2,936,712
|
|
|
|
|
|
Fair value of assets acquired |
53,576
|
|
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
Additional consideration, shares |
|
|
|
|
28,571
|
|
Share Purchase Agreement [Member] |
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
Asset acquisition |
$ 2,500,000
|
|
|
|
|
|
Operating costs |
|
$ 275,000
|
$ 300,000
|
$ 594,000
|
$ 770,000
|
|
Share Purchase Agreement [Member] | Equity Option [Member] |
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
Stock options issued |
35,714
|
|
|
|
|
|
Exercise price |
$ 7.00
|
|
|
|
|
|
Vested options |
183,135
|
|
|
|
|
|
Vested options, value |
$ 183,135
|
|
|
|
|
|
Share Purchase Agreement [Member] | Stock Option One [Member] |
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
Stock options issued |
50,000
|
|
|
|
|
|
Exercise price |
$ 4.25
|
|
|
|
|
|
Share Purchase Agreement [Member] | Common Stock [Member] |
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
Additional consideration, shares |
28,571
|
|
|
|
|
|
Share price |
$ 7.00
|
|
|
|
|
|
Fair market value of common stock |
$ 200,000
|
|
|
|
|
|
X |
- DefinitionFair market value of common stock
+ References
+ Details
Name: |
STSS_FairMarketValueOfCommonStock |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2
+ Details
Name: |
us-gaap_AssetAcquisitionConsiderationTransferred |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5
+ Details
Name: |
us-gaap_BusinessAcquisitionLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of assets acquired at the acquisition date.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
+ Details
Name: |
us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe fair value of assets acquired in noncash investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_FairValueOfAssetsAcquired |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.
+ References
+ Details
Name: |
us-gaap_OperatingCostsAndExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNet number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of options vested.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued during the period pursuant to acquisitions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FiniteLivedIntangibleAssetsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=STSS_SafegardMedicalIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=STSS_SharePurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_StockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=STSS_StockOptionOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Other Assets (Details) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
|
|
Acquisition (see Note 5) |
|
|
$ 472,701
|
Intangibles, net |
$ 60,993
|
62,480
|
|
Deposits or advance payments on machinery, molds, components or technology (see Note 15) |
517,377
|
336,466
|
|
Other |
12,370
|
12,370
|
57,162
|
Other assets |
$ 590,740
|
$ 411,316
|
$ 529,863
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DepositsAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1
+ Details
Name: |
us-gaap_IntangibleAssetsNetExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.3
X |
- DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_AdjustmentForAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Note Purchase Agreement (Details Narrative) - USD ($)
|
|
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
Feb. 13, 2023 |
Apr. 19, 2022 |
Apr. 19, 2022 |
Apr. 14, 2022 |
Dec. 14, 2021 |
Apr. 30, 2023 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent stock liability |
|
|
|
|
|
|
|
|
|
|
|
|
$ 677,000
|
Contingent warrants liability |
|
|
|
|
|
|
|
|
|
|
|
|
$ 585,000
|
Common stock, shares issued |
|
|
|
|
|
|
11,655,936
|
|
|
11,655,936
|
|
9,407,415
|
5,187,062
|
Fair market value of warrant |
$ 455,326
|
|
|
$ 5,200,000
|
|
$ 19,836
|
|
|
|
|
|
$ 228,750
|
|
Warrant liability |
|
|
|
|
|
|
$ 1,513,187
|
|
|
$ 1,513,187
|
|
1,151,838
|
|
Gain loss on sale of derivatives |
|
|
|
|
|
|
$ (90,108)
|
$ 4,365,930
|
|
$ 93,977
|
$ 4,078,930
|
$ 5,392,911
|
|
Exercise price |
|
|
|
|
|
|
|
|
|
|
|
$ 4.38
|
$ 4.38
|
Note Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair market value of warrant |
|
|
|
|
|
|
|
|
|
|
$ 3,378,412
|
$ 127,058
|
|
Exercise price |
|
$ 4.25
|
$ 4.25
|
|
|
|
$ 1.56
|
|
|
$ 1.56
|
|
$ 4.25
|
|
Note Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
|
|
|
8.00%
|
|
|
8.00%
|
8.00%
|
|
Contingent stock liability |
|
|
|
|
$ 677,000
|
|
|
|
|
|
|
|
|
Contingent warrants liability |
|
|
|
|
585,000
|
|
|
|
|
|
|
|
|
Allocation of debt issuance cost to contingent stock and contingent warrants |
|
|
|
|
124,460
|
|
|
|
|
|
|
|
$ 124,460
|
Notes payable |
|
|
|
|
|
|
|
$ 665,000
|
|
|
$ 665,000
|
$ 665,000
|
|
Debt discount |
|
|
|
|
|
|
|
$ 1,335,000
|
|
|
$ 1,335,000
|
1,335,000
|
|
Interest expense |
|
|
|
|
|
|
|
|
$ 39,111
|
|
|
39,111
|
0
|
Accreted interest |
|
|
|
|
|
|
|
|
206,417
|
|
|
1,299,895
|
0
|
Notes payable |
|
|
$ 2,000,000
|
|
|
|
|
|
|
|
|
2,000,000
|
|
Common stock, shares issued |
|
235,295
|
235,295
|
|
|
|
|
|
|
|
|
|
|
Fair market value of warrant |
|
$ 496,000
|
$ 496,000
|
|
|
|
|
|
|
|
|
|
|
Gain loss on sale of derivatives |
|
|
|
|
|
|
|
|
$ 287,000
|
|
|
|
|
Note Purchase Agreement [Member] | Note Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair market value of warrant |
|
|
|
|
|
|
|
|
|
|
|
$ 554,412
|
|
Contingent warrant |
|
|
|
|
|
|
|
|
|
235,295
|
|
235,295
|
|
Exercise price |
|
|
|
|
|
|
|
|
|
|
|
$ 4.25
|
|
Warrant liability |
|
|
|
|
|
|
|
|
|
|
|
$ 30,588
|
$ 585,000
|
Exercise price |
|
|
|
|
|
|
|
|
|
$ 4.25
|
|
|
|
Note Purchase Agreement [Member] | Unrelated Third Party Purchasers [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument face amount |
|
|
|
|
$ 2,000,000
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
|
|
8.00%
|
|
|
|
|
|
|
|
|
Debt issuance costs |
|
|
|
|
$ 197,500
|
|
|
|
|
|
|
|
|
Debt description |
|
|
|
|
As
additional consideration to the Purchasers for providing the financing, the Company also agreed to a) issue each Purchaser a number of
shares of the Company’s Common Stock equal to 50% of the original principal amount of each Purchaser’s Note (the “Contingent
Stock”) and b) issue each Purchaser a number of warrants, which would allow the Purchasers to purchase additional shares of the
Company’s Common Stock, equal to 50% of the original principal amount each Purchaser’s Note for a term of 5.0 years (the
“Contingent Warrants”)
|
|
|
|
|
|
|
|
|
X |
- DefinitionAllocation of debt issuance cost to contingent stock and contingent warrants.
+ References
+ Details
Name: |
STSS_AllocationOfDebtIssuanceCostToContingentStockAndContingentWarrants |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionContingent stock liability.
+ References
+ Details
Name: |
STSS_ContingentStockLiability |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContingent warrant liability.
+ References
+ Details
Name: |
STSS_ContingentWarrantLiability |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIdentification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3
+ Details
Name: |
us-gaap_DebtInstrumentDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.13(h)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_GainLossOnSaleOfDerivatives |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InterestPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_NotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_PaymentsOfDebtIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=STSS_NotePurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Stockholders’ Equity (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
9 Months Ended |
12 Months Ended |
|
|
|
Feb. 13, 2023 |
Feb. 03, 2023 |
Apr. 30, 2022 |
Apr. 19, 2022 |
Apr. 19, 2022 |
Apr. 19, 2022 |
Apr. 14, 2022 |
Apr. 13, 2022 |
Mar. 22, 2022 |
Apr. 30, 2023 |
Feb. 28, 2023 |
Apr. 30, 2022 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Mar. 21, 2022 |
Apr. 18, 2019 |
Dec. 11, 2017 |
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, share authorized |
|
|
|
|
|
|
|
|
50,000,000
|
|
|
|
100,000,000
|
|
|
100,000,000
|
|
100,000,000
|
100,000,000
|
100,000,000
|
|
50,000,000
|
20,000,000
|
Common stock, par value |
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
$ 0.0001
|
|
$ 0.0001
|
$ 0.0001
|
$ 0.0001
|
|
|
$ 0.0001
|
Preferred stock, shares authorized |
|
|
|
|
|
|
|
|
10,000
|
|
|
|
1,000,000
|
|
|
1,000,000
|
|
1,000,000
|
1,000,000
|
1,000,000
|
10,000
|
10,000
|
|
Preferred stock, par value |
|
|
|
|
|
|
|
|
$ 0.001
|
|
|
|
$ 0.0001
|
|
|
$ 0.0001
|
|
$ 0.0001
|
$ 0.0001
|
$ 0.0001
|
$ 0.001
|
$ 0.001
|
|
Conversion of stock, description |
|
|
|
|
|
|
|
|
Pursuant to the merger agreement, (i) the Company merged with and into Sharps Nevada, (ii) each 3.5 shares of common
stock of the Company were converted into one share of common stock of Sharps Nevada and (iii) the articles of incorporation and bylaws
of Sharps Nevada, became the articles of incorporation and bylaws of the surviving corporation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants received |
|
|
|
|
|
|
|
|
|
|
|
|
11,431,316
|
|
|
11,431,316
|
|
9,047,795
|
9,047,795
|
|
|
|
|
Net proceeds from IPO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 14,202,975
|
|
|
|
|
Additional paid in capital |
$ 2,800,000
|
|
|
|
|
|
$ 9,000,000.0
|
|
|
|
|
|
$ 28,154,012
|
|
|
$ 28,154,012
|
|
$ 24,733,306
|
24,733,306
|
13,835,882
|
|
|
|
Fair value adjustment of warrants |
$ 455,326
|
|
|
|
|
|
5,200,000
|
|
|
$ 19,836
|
|
|
|
|
|
|
|
|
228,750
|
|
|
|
|
Common stock issued for services, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
235,000
|
|
|
|
|
|
Common stock issued for services, value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 60,551
|
|
|
$ 290,551
|
290,551
|
20,000
|
|
|
|
Issuance of common stock for equipment order |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,783,385
|
|
|
|
|
|
500,000
|
|
|
|
Warrant liability |
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,513,187
|
|
|
$ 1,513,187
|
|
$ 1,151,838
|
1,151,838
|
|
|
|
|
Payments for Repurchase of Initial Public Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,121,250
|
|
|
|
|
Volatility |
|
|
|
|
|
|
|
|
|
37.45%
|
|
|
|
|
|
|
|
|
93.47%
|
|
|
|
|
Risk free interest rate |
|
|
|
|
|
|
|
|
|
3.58%
|
|
|
|
|
|
|
|
|
2.77%
|
|
|
|
|
Dividend rate |
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
0.00%
|
|
|
0.00%
|
0.00%
|
|
|
|
Exercise price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.38
|
$ 4.38
|
|
|
|
Note Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
$ 496,000
|
|
$ 496,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for services, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
235,295
|
235,295
|
|
|
|
|
Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price |
|
$ 1.56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant term |
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of warrants |
|
2,248,521
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued price per share |
|
$ 1.69
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net proceeds from offering |
|
$ 3,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Offering expenses |
|
$ 600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price |
|
|
|
|
|
|
|
|
|
|
|
|
$ 5.32
|
|
|
$ 5.32
|
|
$ 5.32
|
$ 5.32
|
|
|
|
|
Warrants received |
|
|
|
|
|
|
|
|
|
|
|
|
187,500
|
|
|
187,500
|
|
187,500
|
187,500
|
|
|
|
|
Net proceeds from IPO |
|
|
|
$ 14,200,000
|
|
$ 14,200,000
|
$ 14,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 228,750
|
|
|
|
|
|
|
|
Warrant liability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,778,750
|
$ 5,778,750
|
|
|
|
|
Warrants cost |
|
|
|
|
|
|
|
|
|
|
|
|
$ 11,250
|
|
|
$ 11,250
|
|
11,250
|
11,250
|
|
|
|
|
Volatility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
93.47%
|
|
|
|
|
|
|
|
Risk free interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.77%
|
|
|
|
|
|
|
|
Dividend rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
Expected term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
Trading Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
$ 86,250
|
|
3,378,412
|
$ 86,250
|
|
|
|
|
|
|
|
Issuance of warrants |
|
|
7,500,000
|
|
|
|
|
|
|
|
|
7,500,000
|
|
|
|
|
|
|
|
|
|
|
|
Warrants cost |
|
|
$ 5,778,750
|
|
|
|
|
|
|
|
|
$ 5,778,750
|
|
|
|
|
|
$ 1,121,250
|
$ 1,121,250
|
|
|
|
|
Over Allotment Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of warrants |
|
|
1,125,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price |
|
|
|
$ 4.25
|
$ 4.25
|
$ 4.25
|
|
|
|
|
|
|
$ 1.56
|
|
|
$ 1.56
|
|
$ 4.25
|
$ 4.25
|
|
|
|
|
Warrant term |
|
|
|
5 years
|
5 years
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
5 years
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,378,412
|
|
$ 127,058
|
|
|
|
|
Issuance of warrants |
|
|
|
|
235,295
|
235,295
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of liability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 157,647
|
|
|
|
|
Note Warrant [Member] | Note Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.25
|
$ 4.25
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 554,412
|
|
|
|
|
Warrant liability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 30,588
|
$ 30,588
|
$ 585,000
|
|
|
|
Exercise price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.25
|
|
|
|
|
|
|
|
Non Trading Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,505
|
|
|
$ 182,580
|
|
|
|
|
|
|
|
Issuance of warrants |
|
|
|
|
|
|
|
|
|
135,000
|
2,248,521
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants cost |
|
|
|
|
|
|
|
|
|
|
$ 455,326
|
|
$ 272,746
|
|
|
$ 272,746
|
|
|
|
|
|
|
|
Volatility |
|
|
|
|
|
|
|
|
|
|
41.24%
|
|
|
|
|
|
|
|
|
|
|
|
|
Risk free interest rate |
|
|
|
|
|
|
|
|
|
|
3.71%
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividend rate |
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
Over-Allotment Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of warrants |
|
|
|
|
|
|
|
|
|
|
|
1,125,000
|
|
|
|
|
|
|
|
|
|
|
|
Note Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants received |
|
|
|
|
|
|
|
|
|
|
|
|
235,295
|
|
|
235,295
|
|
235,295
|
235,295
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,353
|
|
$ 520,000
|
$ 2,353
|
$ 520,000
|
|
|
|
|
|
|
Warrant liability |
|
|
|
|
|
|
|
|
|
|
|
|
32,941
|
|
|
32,941
|
|
$ 30,588
|
$ 30,588
|
|
|
|
|
Warrants cost |
|
|
|
|
|
|
|
|
|
|
|
|
$ 32,941
|
|
|
$ 32,941
|
|
|
|
|
|
|
|
Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Initial public offering |
|
|
|
|
|
|
|
3,750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price |
|
|
|
|
|
|
|
$ 4.25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant term |
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants received |
|
|
|
1,125,000
|
1,125,000
|
1,125,000
|
|
1,125,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,657,500
|
|
|
|
|
Exercise price |
|
|
|
|
|
|
|
$ 4.25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant [Member] | Note Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 127,059
|
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Initial public offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,750,000
|
|
|
|
3,750,000
|
|
|
|
|
Common stock issued for services, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35,000
|
|
|
|
235,000
|
2,857
|
|
|
|
Common stock issued for services, value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4
|
|
|
|
$ 23
|
|
|
|
|
Issuance of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
2,248,521
|
|
|
|
|
|
71,429
|
|
|
|
Issuance of common stock for equipment order |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 225
|
|
|
|
|
|
$ 7
|
|
|
|
Issuance of common stock for acquisition, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28,571
|
|
|
|
Common Stock [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
487,204
|
|
|
|
Shares issued price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 7.00
|
|
|
|
Proceeds from issuance of private placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,377,929
|
|
|
|
Subscription receivable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 32,500
|
|
|
|
X |
- DefinitionNet Proceeds From Issuance Initial Public Offering.
+ References
+ Details
Name: |
STSS_NetProceedsFromIssuanceInitialPublicOffering |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPayments for repurchase of liability.
+ References
+ Details
Name: |
STSS_PaymentsForRepurchaseOfLiability |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares initial public offering.
+ References
+ Details
Name: |
STSS_StockIssuedDuringPeriodSharesInitialPublicOffering |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of warrants or rights outstanding.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of subscription receivable from investors who have been allocated common stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionA unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIncludes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.14) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NoninterestExpenseOfferingCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_PaymentsForRepurchaseOfInitialPublicOffering |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceInitialPublicOffering |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfPrivatePlacement |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRate of weighted-average expected volatility for award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer share or per unit amount of equity securities issued.
+ References
+ Details
Name: |
us-gaap_SharesIssuedPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of stock issued during the period pursuant to acquisitions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=STSS_NotePurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=STSS_PurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=STSS_TradingWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=STSS_OverAllotmentWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=STSS_NonTradingWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=STSS_NoteWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
+ Details
Name: |
us-gaap_EquityMethodInvestmentOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=STSS_AlanBlackmanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_DirectorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Warrant Liability (Details) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Subsidiary, Sale of Stock [Line Items] |
|
|
|
Warrant liability |
$ 1,513,187
|
$ 1,151,838
|
|
Note Warrants [Member] |
|
|
|
Subsidiary, Sale of Stock [Line Items] |
|
|
|
Warrant liability |
32,941
|
30,588
|
|
Trading And Overallotment Warrants [Member] |
|
|
|
Subsidiary, Sale of Stock [Line Items] |
|
|
|
Warrant liability |
1,207,500
|
$ 1,121,250
|
|
Offering Warrants [Member] |
|
|
|
Subsidiary, Sale of Stock [Line Items] |
|
|
|
Warrant liability |
$ 272,746
|
|
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_SubsidiarySaleOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=STSS_NoteWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=STSS_TradingAndOverallotmentWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=STSS_OfferingWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Warrant Outstanding (Details) - shares
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Subsidiary, Sale of Stock [Line Items] |
|
|
Warrant outstanding |
11,431,316
|
9,047,795
|
Note Warrants [Member] |
|
|
Subsidiary, Sale of Stock [Line Items] |
|
|
Warrant outstanding |
235,295
|
235,295
|
Trading And Overallotment Warrants [Member] |
|
|
Subsidiary, Sale of Stock [Line Items] |
|
|
Warrant outstanding |
8,812,500
|
8,812,500
|
Offering Warrants [Member] |
|
|
Subsidiary, Sale of Stock [Line Items] |
|
|
Warrant outstanding |
2,248,521
|
|
Warrants Issued For Service Management [Member] |
|
|
Subsidiary, Sale of Stock [Line Items] |
|
|
Warrant outstanding |
135,000
|
|
X |
- DefinitionNumber of warrants or rights outstanding.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_SubsidiarySaleOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=STSS_NoteWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=STSS_TradingAndOverallotmentWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=STSS_OfferingWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=STSS_WarrantsIssuedForServiceManagementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Changes in the Warrant Liability (Details) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Warrant Liability |
|
|
|
FMV of Note Warrants |
$ 30,588
|
$ 157,647
|
|
FMV of Trading and Overallotment Warrants |
1,121,250
|
5,778,750
|
|
Change in fair value of warrant liability for the six months ended June 30,2023 |
(93,977)
|
(4,784,559)
|
|
Fair Value at June 30, 2023 |
1,513,187
|
$ 1,151,838
|
|
FMV of Offering Warrants, at issuance |
$ 455,326
|
|
|
X |
- References
+ Details
Name: |
STSS_DisclosureWarrantLiabilityAbstract |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFair market value of change in fair value of warrant liability.
+ References
+ Details
Name: |
STSS_FairMarketValueOfChangeInFairValueOfWarrantLiability |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFair market value of note warrants.
+ References
+ Details
Name: |
STSS_FairMarketValueOfNoteWarrants |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFair market value of trading and overall warrants.
+ References
+ Details
Name: |
STSS_FairMarketValueOfTradingAndOverallWarrants |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFair market value of trading and overall warrants issuance.
+ References
+ Details
Name: |
STSS_FairMarketValueOfTradingAndOverallWarrantsIssuance |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
Schedule of Stock Options Granted and Outstanding (Details) - $ / shares
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Share-Based Payment Arrangement [Abstract] |
|
|
|
Stock option, beginning balance |
1,358,122
|
1,137,479
|
792,857
|
Weighted average exercise price, beginning balance |
$ 4.37
|
$ 5.18
|
$ 3.64
|
Shares, options granted |
1,025,000
|
367,500
|
511,764
|
Weighted average exercise price, options granted |
$ 1.37
|
$ 1.63
|
$ 7.00
|
Options, cancelled |
|
(3,571)
|
(21,875)
|
Weighted average exercise price, options Cancelled |
|
$ (4.38)
|
$ (4.38)
|
Options, forfeited |
|
(143,286)
|
(145,157)
|
Weighted average exercise price, options forfeited |
$ (1.75)
|
$ (3.77)
|
$ (2.57)
|
Stock option, ending balance |
2,357,408
|
1,358,122
|
1,137,479
|
Weighted average exercise price, ending balance |
$ 3.08
|
$ 4.37
|
$ 5.18
|
Stock option, exercisable |
1,665,378
|
1,132,861
|
825,847
|
Weighted average exercise price, exercisable |
$ 3.63
|
$ 4.59
|
$ 5.38
|
Shares, options granted |
(25,714)
|
|
|
Weighted average exercise price, options granted |
$ 1.75
|
$ 3.77
|
$ 2.57
|
X |
- DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of non-vested options forfeited.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Schedule of Information About Options Outstanding (Details) - USD ($)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Exercise Price Range One [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 1.21
|
$ 1.21
|
Options, shares outstanding |
307,500
|
307,500
|
Stock option, aggregate intrinsic value |
|
|
Stock option, weighted average remaining contractual life |
4 years 5 months 1 day
|
4 years 5 months 1 day
|
Options, shares exercisable |
233,719
|
168,551
|
Stock option, aggregate intrinsic value on exercisable shares |
|
|
Exercise Price Range Two [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 1.30
|
$ 1.39
|
Options, shares outstanding |
50,000
|
10,000
|
Stock option, aggregate intrinsic value |
|
|
Stock option, weighted average remaining contractual life |
4 years 8 months 15 days
|
4 years 8 months 1 day
|
Options, shares exercisable |
18,750
|
10,000
|
Stock option, aggregate intrinsic value on exercisable shares |
|
|
Exercise Price Range Three [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 1.37
|
$ 1.75
|
Options, shares outstanding |
975,000
|
68,571
|
Stock option, aggregate intrinsic value |
|
|
Stock option, weighted average remaining contractual life |
4 years 8 months 1 day
|
3 months
|
Options, shares exercisable |
437,032
|
68,571
|
Stock option, aggregate intrinsic value on exercisable shares |
|
|
Exercise Price Range Four [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 1.39
|
$ 2.80
|
Options, shares outstanding |
10,000
|
141,429
|
Stock option, aggregate intrinsic value |
|
|
Stock option, weighted average remaining contractual life |
4 years 2 months 1 day
|
6 months
|
Options, shares exercisable |
10,000
|
141,429
|
Stock option, aggregate intrinsic value on exercisable shares |
|
|
Exercise Price Range Five [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 1.75
|
$ 4.25
|
Options, shares outstanding |
42,857
|
50,000
|
Stock option, aggregate intrinsic value |
|
|
Stock option, weighted average remaining contractual life |
2 years 9 months
|
4 years 6 months
|
Options, shares exercisable |
42,857
|
37,500
|
Stock option, aggregate intrinsic value on exercisable shares |
|
|
Exercise Price Range Six [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 2.80
|
$ 4.38
|
Options, shares outstanding |
141,429
|
244,286
|
Stock option, aggregate intrinsic value |
|
|
Stock option, weighted average remaining contractual life |
1 year
|
2 years 3 months
|
Options, shares exercisable |
141,429
|
244,286
|
Stock option, aggregate intrinsic value on exercisable shares |
|
|
Exercise Price Range Seven [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 4.25
|
$ 7.00
|
Options, shares outstanding |
50,000
|
536,336
|
Stock option, aggregate intrinsic value |
|
|
Stock option, weighted average remaining contractual life |
4 years
|
3 years
|
Options, shares exercisable |
50,000
|
462,524
|
Stock option, aggregate intrinsic value on exercisable shares |
|
|
X |
- DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeFiveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeSixMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeSevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRate of weighted-average expected volatility for award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Stock Options (Details Narrative) - USD ($)
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
Feb. 09, 2023 |
Feb. 28, 2023 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Jan. 25, 2023 |
Dec. 11, 2017 |
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Weighted-average grant-date fair value of options granted |
|
|
|
|
|
|
|
$ 1.63
|
$ 4.55
|
|
|
Unrecognized stock based compensation |
|
|
$ 725,355
|
|
|
$ 725,355
|
|
$ 475,097
|
$ 1,260,990
|
|
|
Share based compensation |
|
|
|
|
|
$ 637,547
|
$ 650,104
|
1,012,592
|
1,195,819
|
|
|
Stock based charges relating to purchase of machinery |
|
|
|
|
$ 63,512
|
|
|
63,612
|
253,337
|
|
|
Stock based charges relating to acquisition |
|
|
|
|
$ 40,901
|
|
|
$ 60,435
|
$ 122,701
|
|
|
Stock option purchase shares |
50,000
|
|
|
|
|
|
|
|
|
|
|
Ciommon stock, par value |
|
|
$ 0.0001
|
|
|
$ 0.0001
|
|
$ 0.0001
|
$ 0.0001
|
|
$ 0.0001
|
Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Stock option purchase shares |
|
|
|
|
|
495,000
|
|
|
|
|
|
Director [Member] |
|
|
|
|
|
|
|
|
|
|
|
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Stock option purchase shares |
|
|
|
|
|
455,000
|
|
|
|
|
|
Employees and Consultant [Member] |
|
|
|
|
|
|
|
|
|
|
|
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Stock option purchase shares |
|
|
|
|
|
25,000
|
|
|
|
|
|
2023 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Expected term |
|
|
|
|
|
5 years
|
|
|
|
|
|
Stock option purchase shares |
|
|
|
|
|
975,000
|
|
|
|
|
|
Ciommon stock, par value |
|
|
0.0001
|
|
|
$ 0.0001
|
|
|
|
|
|
Options exercisable |
|
|
$ 1.37
|
|
|
$ 1.37
|
|
|
|
|
|
Stock available for issuance |
|
|
|
|
|
|
|
|
|
1,400,000
|
|
2022 Equity Incentive Plan [Member] | Employment Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Expected term |
|
5 years
|
|
|
|
|
|
|
|
|
|
Stock option purchase shares |
|
50,000
|
|
|
|
|
|
|
|
|
|
General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Share based compensation |
|
|
$ 234,610
|
$ 365,606
|
|
$ 617,711
|
589,553
|
$ 915,796
|
$ 1,091,227
|
|
|
Research and Development Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
Share based compensation |
|
|
|
$ 39,870
|
|
|
$ 50,182
|
$ 96,795
|
$ 105,592
|
|
|
X |
- DefinitionShare Based Compensation Options Exercisable Weighted Average Exercise Price.
+ References
+ Details
Name: |
STSS_ShareBasedCompensationOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
STSS_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionStock based charges relating to acquisition
+ References
+ Details
Name: |
STSS_StockBasedChargesRelatingToAcquisition |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionStock based charges relating to purchase of machinery.
+ References
+ Details
Name: |
STSS_StockBasedChargesRelatingToPurchaseOfMachinery |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_DirectorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=STSS_EmployeesAndConsultantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=STSS_TwoThousandTwentyThreeEquityIncentivePlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=STSS_TwoThousandTwentyTwoEquityIncentivePlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=STSS_EmploymentAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Reconciliation of Federal Statutory Rate to Total Effective Rate (Details) - USD ($)
|
12 Months Ended |
Dec. 31, 2022 |
Dec. 31, 2021 |
Income Tax Disclosure [Abstract] |
|
|
Expected benefit at statutory federal tax rate |
$ (974,329)
|
$ (979,527)
|
Permanent differences – net |
(859,515)
|
|
State and local taxes, net of federal tax benefit |
(265,607)
|
(311,373)
|
Other |
(21,965)
|
(57,563)
|
Change in valuation allowance |
2,121,416
|
1,348,463
|
Income tax Expense (Benefit) Total |
|
|
v3.23.3
Schedule of Components of Deferred tax Assets (Details) - USD ($)
|
Dec. 31, 2022 |
Dec. 31, 2021 |
Income Tax Disclosure [Abstract] |
|
|
Fixed assets |
$ (268,594)
|
$ 3,837
|
Interest |
62,310
|
46,361
|
Research and development expenses |
454,942
|
|
Stock-based compensation |
917,351
|
637,112
|
Net operating losses - federal |
2,898,411
|
1,687,053
|
Net operating losses – state and local |
921,350
|
536,282
|
Net operating losses - foreign |
37,686
|
|
Research credit |
28,985
|
28,985
|
Deferred tax assets gross |
5,052,441
|
2,939,630
|
Less valuation allowance |
(5,244,441)
|
(2,939,630)
|
Net deferred tax liability |
$ (192,000)
|
|
X |
- DefinitionDeferred tax assets property plant and equipments.
+ References
+ Details
Name: |
STSS_DeferredTaxAssetsPropertyPlantAndEquipments |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
+ Details
Name: |
us-gaap_DeferredTaxAssetInterestCarryforward |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_DeferredTaxAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3
+ Details
Name: |
us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_DeferredTaxAssetsValuationAllowance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6
+ Details
Name: |
us-gaap_DeferredTaxLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
v3.23.3
X |
- DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(1),(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=STSS_OfficersAndDirectorsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Assets |
|
|
|
Cash |
$ 2,924,019
|
$ 4,170,897
|
|
Total assets measured at fair value |
2,924,019
|
4,170,897
|
|
Liabilities |
|
|
|
Warrant liability |
1,513,187
|
1,151,838
|
|
Total liabilities measured at fair value |
1,513,187
|
1,151,838
|
|
Fair Value, Inputs, Level 1 [Member] |
|
|
|
Assets |
|
|
|
Cash |
2,924,019
|
4,170,897
|
|
Total assets measured at fair value |
2,924,019
|
4,170,897
|
|
Liabilities |
|
|
|
Warrant liability |
1,240,441
|
1,151,838
|
|
Total liabilities measured at fair value |
1,240,441
|
1,151,838
|
|
Fair Value, Inputs, Level 2 [Member] |
|
|
|
Assets |
|
|
|
Cash |
|
|
|
Total assets measured at fair value |
|
|
|
Liabilities |
|
|
|
Warrant liability |
272,276
|
|
|
Total liabilities measured at fair value |
272,276
|
|
|
Fair Value, Inputs, Level 3 [Member] |
|
|
|
Assets |
|
|
|
Cash |
|
|
|
Liabilities |
|
|
|
Warrant liability |
|
|
|
Total liabilities measured at fair value |
|
|
|
X |
- DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_AssetsFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
+ Details
Name: |
us-gaap_CashAndCashEquivalentsFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFair value of financial and nonfinancial obligations.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_LiabilitiesFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.3
Commitments and Contingencies (Details Narrative) - USD ($)
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
Feb. 09, 2023 |
Jan. 01, 2023 |
Sep. 30, 2022 |
Sep. 01, 2022 |
Aug. 01, 2022 |
Oct. 31, 2022 |
May 31, 2019 |
Sep. 30, 2018 |
Jul. 31, 2017 |
Mar. 26, 2023 |
Jun. 30, 2023 |
Dec. 31, 2022 |
Jun. 30, 2022 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total order costs to purchase equipment, molds and component parts for research and development |
|
|
|
|
|
|
|
|
|
|
|
$ 609,953
|
|
Progress payments |
|
|
|
|
|
|
|
|
|
|
$ 280,349
|
209,678
|
|
Total order costs to purchase equipment and molds |
|
|
|
|
|
|
|
|
|
|
490,651
|
|
|
Severance costs |
|
|
|
|
|
|
|
|
|
|
346,000
|
|
|
Medical benefit cost |
|
|
|
|
|
|
|
|
|
|
$ 29,000
|
|
|
Compensation cost |
$ 235,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Options to purchase shares |
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock option, exercise price |
$ 1.30
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensation cost |
$ 235,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Options to purchase shares |
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock option, exercise price |
$ 1.30
|
|
|
|
|
|
|
|
|
|
|
|
|
Mr. Blackman [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued Bonuses |
|
|
|
|
|
|
|
|
|
|
|
|
$ 250,000
|
Payment for bonuses |
|
$ 65,000
|
|
|
|
|
|
|
|
|
|
|
|
Mr. Blackman [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Payment for bonuses |
|
|
|
|
|
|
|
|
|
$ 65,000
|
|
|
|
Royalty Agreement [Member] | Barry Berler [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalty percentage |
|
|
|
|
|
|
2.00%
|
2.00%
|
4.00%
|
|
|
|
|
Single payment obligation |
|
|
|
|
|
|
|
$ 500,000
|
|
|
|
|
|
Employment Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Salaries and wages |
|
|
|
$ 320,000
|
$ 256,000
|
|
|
|
|
|
|
|
|
Annual compensation |
|
|
$ 225,000
|
|
|
|
|
|
|
|
|
225,000
|
|
Payment for incentive fee |
|
|
$ 18,750
|
|
|
|
|
|
|
|
|
$ 18,750
|
|
Service Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Initial fee |
|
|
|
|
|
$ 90,000
|
|
|
|
|
|
|
|
Monthly fee |
|
|
|
|
|
$ 12,500
|
|
|
|
|
|
|
|
Shares of restricted common stock |
|
|
|
|
|
200,000
|
|
|
|
|
|
|
|
Value of digital marketing activities |
|
|
|
|
|
$ 300,000
|
|
|
|
|
|
|
|
Value of restricted common stock |
|
|
|
|
|
$ 230,000
|
|
|
|
|
|
|
|
X |
- DefinitionTotal order costs to purchase equipment and molds.
+ References
+ Details
Name: |
STSS_OrderCostsToPurchaseEquipmentAndMolds |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionOrder costs to purchase equipment molds and component parts for research and development.
+ References
+ Details
Name: |
STSS_OrderCostsToPurchaseEquipmentMoldsAndComponentPartsForResearchAndDevelopment |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionSingle payment obligation.
+ References
+ Details
Name: |
STSS_SinglePaymentObligation |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionValue of digital marketing activities.
+ References
+ Details
Name: |
STSS_ValueOfDigitalMarketingActivities |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_AccruedBonusesCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for employee benefit and equity-based compensation.
+ References
+ Details
Name: |
us-gaap_EmployeeBenefitsAndShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount paid for incentive rights held by the managing member or general partner, of limited liability company (LLC) or limited partnership (LP).
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17
+ Details
Name: |
us-gaap_PaymentForIncentiveFee |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_SalariesAndWages |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_SeveranceCosts1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=STSS_Mr.BlackmanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=STSS_RoyaltyAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=STSS_BarryBerlerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=STSS_EmploymentAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=STSS_ServiceAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Schedule of Information about Options Outstanding (Details) - $ / shares
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Dec. 31, 2022 |
Exercise Price Range One [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 1.21
|
$ 1.21
|
Stock option, shares outstanding |
307,500
|
307,500
|
Stock option, weighted average remaining contractual life |
4 years 5 months 1 day
|
4 years 5 months 1 day
|
Stock option, shares exercisable |
233,719
|
168,551
|
Exercise Price Range Two [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 1.30
|
$ 1.39
|
Stock option, shares outstanding |
50,000
|
10,000
|
Stock option, weighted average remaining contractual life |
4 years 8 months 15 days
|
4 years 8 months 1 day
|
Stock option, shares exercisable |
18,750
|
10,000
|
Exercise Price Range Three [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 1.37
|
$ 1.75
|
Stock option, shares outstanding |
975,000
|
68,571
|
Stock option, weighted average remaining contractual life |
4 years 8 months 1 day
|
3 months
|
Stock option, shares exercisable |
437,032
|
68,571
|
Exercise Price Range Four [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 1.39
|
$ 2.80
|
Stock option, shares outstanding |
10,000
|
141,429
|
Stock option, weighted average remaining contractual life |
4 years 2 months 1 day
|
6 months
|
Stock option, shares exercisable |
10,000
|
141,429
|
Exercise Price Range Five [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 1.75
|
$ 4.25
|
Stock option, shares outstanding |
42,857
|
50,000
|
Stock option, weighted average remaining contractual life |
2 years 9 months
|
4 years 6 months
|
Stock option, shares exercisable |
42,857
|
37,500
|
Exercise Price Range Six [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 2.80
|
$ 4.38
|
Stock option, shares outstanding |
141,429
|
244,286
|
Stock option, weighted average remaining contractual life |
1 year
|
2 years 3 months
|
Stock option, shares exercisable |
141,429
|
244,286
|
Exercise Price Range Seven [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 4.25
|
$ 7.00
|
Stock option, shares outstanding |
50,000
|
536,336
|
Stock option, weighted average remaining contractual life |
4 years
|
3 years
|
Stock option, shares exercisable |
50,000
|
462,524
|
Exercise Price Range Eight [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 4.38
|
|
Stock option, shares outstanding |
244,286
|
|
Stock option, weighted average remaining contractual life |
1 year 9 months
|
|
Stock option, shares exercisable |
244,286
|
|
Exercise Price Range Nine [Member] |
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] |
|
|
Stock option, exercise price |
$ 7.00
|
|
Stock option, shares outstanding |
536,336
|
|
Stock option, weighted average remaining contractual life |
2 years 6 months
|
|
Stock option, shares exercisable |
477,305
|
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeFiveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeSixMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeSevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeEightMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=STSS_ExercisePriceRangeNineMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.3
Subsequent Events (Details Narrative) - USD ($)
|
|
|
|
6 Months Ended |
|
|
|
Feb. 09, 2023 |
Feb. 03, 2023 |
Jan. 25, 2023 |
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 11, 2017 |
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture |
50,000
|
|
|
|
|
|
|
Common Stock, Par or Stated Value Per Share |
|
|
|
$ 0.0001
|
$ 0.0001
|
$ 0.0001
|
$ 0.0001
|
Employee Benefits and Share-Based Compensation |
$ 235,000
|
|
|
|
|
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price |
$ 1.30
|
|
|
|
|
|
|
Purchase Agreement [Member] |
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Net proceeds from offering |
|
$ 3,200,000
|
|
|
|
|
|
Offering expenses |
|
$ 600,000
|
|
|
|
|
|
Shares issued |
|
2,248,521
|
|
|
|
|
|
Shares issued price per share |
|
$ 1.69
|
|
|
|
|
|
Warrant exerice price |
|
$ 1.56
|
|
|
|
|
|
Warrant term |
|
5 years
|
|
|
|
|
|
2023 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture |
|
|
|
975,000
|
|
|
|
Common Stock, Par or Stated Value Per Share |
|
|
|
$ 0.0001
|
|
|
|
Options exercisable |
|
|
|
$ 1.37
|
|
|
|
Stock available for issuance |
|
|
1,400,000
|
|
|
|
|
Chief Executive Officer [Member] |
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture |
|
|
|
495,000
|
|
|
|
Director [Member] |
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture |
|
|
|
455,000
|
|
|
|
Subsequent Event [Member] |
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture |
50,000
|
|
|
|
|
|
|
Employee Benefits and Share-Based Compensation |
$ 235,000
|
|
|
|
|
|
|
Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price |
$ 1.30
|
|
|
|
|
|
|
Subsequent Event [Member] | Purchase Agreement [Member] |
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Net proceeds from offering |
|
$ 3,200,000
|
|
|
|
|
|
Offering expenses |
|
$ 600,000
|
|
|
|
|
|
Shares issued |
|
2,248,521
|
|
|
|
|
|
Shares issued price per share |
|
$ 1.69
|
|
|
|
|
|
Warrant exerice price |
|
$ 1.56
|
|
|
|
|
|
Warrant term |
|
5 years
|
|
|
|
|
|
Subsequent Event [Member] | 2023 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Stock available for issuance |
|
|
1,400,000
|
|
|
|
|
Subsequent Event [Member] | Chief Executive Officer And Director [Member] |
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture |
|
|
975,000
|
|
|
|
|
Common Stock, Par or Stated Value Per Share |
|
|
$ 0.0001
|
|
|
|
|
Options exercisable |
|
|
$ 1.37
|
|
|
|
|
Subsequent Event [Member] | Chief Executive Officer [Member] |
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture |
|
|
495,000
|
|
|
|
|
Subsequent Event [Member] | Executive Officer [Member] |
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture |
|
|
455,000
|
|
|
|
|
Subsequent Event [Member] | Director [Member] |
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture |
|
|
75,000
|
|
|
|
|
X |
- DefinitionNet Proceeds From Issuance Initial Public Offering.
+ References
+ Details
Name: |
STSS_NetProceedsFromIssuanceInitialPublicOffering |
Namespace Prefix: |
STSS_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionShare Based Compensation Options Exercisable Weighted Average Exercise Price.
+ References
+ Details
Name: |
STSS_ShareBasedCompensationOptionsExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
STSS_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense for employee benefit and equity-based compensation.
+ References
+ Details
Name: |
us-gaap_EmployeeBenefitsAndShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIncludes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.14) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NoninterestExpenseOfferingCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i)-(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPer share or per unit amount of equity securities issued.
+ References
+ Details
Name: |
us-gaap_SharesIssuedPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=STSS_PurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=STSS_TwoThousandTwentyThreeEquityIncentivePlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_DirectorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=STSS_ChiefExecutiveOfficerAndDirectorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Sharps Technology (NASDAQ:STSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sharps Technology (NASDAQ:STSS)
Historical Stock Chart
From Oct 2023 to Oct 2024